0001628280-24-005055.txt : 20240215 0001628280-24-005055.hdr.sgml : 20240215 20240215161742 ACCESSION NUMBER: 0001628280-24-005055 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 80 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240215 DATE AS OF CHANGE: 20240215 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CORCEPT THERAPEUTICS INC CENTRAL INDEX KEY: 0001088856 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 770487658 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-50679 FILM NUMBER: 24644036 BUSINESS ADDRESS: STREET 1: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650.688.8803 MAIL ADDRESS: STREET 1: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 10-K 1 cort-20231231.htm 10-K cort-20231231
false2023FY000108885600010888562023-01-012023-12-3100010888562023-06-30iso4217:USD00010888562024-02-06xbrli:shares00010888562023-12-3100010888562022-12-31iso4217:USDxbrli:shares00010888562022-01-012022-12-3100010888562021-01-012021-12-310001088856cort:TenderOfferMember2023-01-012023-12-310001088856cort:TenderOfferMember2022-01-012022-12-310001088856cort:TenderOfferMember2021-01-012021-12-310001088856cort:StockRepurchaseProgramMember2023-01-012023-12-310001088856cort:StockRepurchaseProgramMember2022-01-012022-12-310001088856cort:StockRepurchaseProgramMember2021-01-012021-12-3100010888562021-12-3100010888562020-12-310001088856us-gaap:CommonStockMember2020-12-310001088856us-gaap:AdditionalPaidInCapitalMember2020-12-310001088856us-gaap:TreasuryStockCommonMember2020-12-310001088856us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001088856us-gaap:RetainedEarningsMember2020-12-310001088856us-gaap:CommonStockMember2021-01-012021-12-310001088856us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310001088856us-gaap:TreasuryStockCommonMember2021-01-012021-12-310001088856us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310001088856cort:StockRepurchaseProgramMemberus-gaap:CommonStockMember2021-01-012021-12-310001088856us-gaap:TreasuryStockCommonMembercort:StockRepurchaseProgramMember2021-01-012021-12-310001088856cort:TenderOfferMemberus-gaap:CommonStockMember2021-01-012021-12-310001088856us-gaap:TreasuryStockCommonMembercort:TenderOfferMember2021-01-012021-12-310001088856us-gaap:RetainedEarningsMember2021-01-012021-12-310001088856us-gaap:CommonStockMember2021-12-310001088856us-gaap:AdditionalPaidInCapitalMember2021-12-310001088856us-gaap:TreasuryStockCommonMember2021-12-310001088856us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001088856us-gaap:RetainedEarningsMember2021-12-310001088856us-gaap:CommonStockMember2022-01-012022-12-310001088856us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310001088856us-gaap:TreasuryStockCommonMember2022-01-012022-12-310001088856us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310001088856us-gaap:RetainedEarningsMember2022-01-012022-12-310001088856us-gaap:CommonStockMember2022-12-310001088856us-gaap:AdditionalPaidInCapitalMember2022-12-310001088856us-gaap:TreasuryStockCommonMember2022-12-310001088856us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001088856us-gaap:RetainedEarningsMember2022-12-310001088856us-gaap:CommonStockMember2023-01-012023-12-310001088856us-gaap:AdditionalPaidInCapitalMember2023-01-012023-12-310001088856us-gaap:TreasuryStockCommonMember2023-01-012023-12-310001088856cort:TenderOfferMemberus-gaap:CommonStockMember2023-01-012023-12-310001088856us-gaap:TreasuryStockCommonMembercort:TenderOfferMember2023-01-012023-12-310001088856us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310001088856us-gaap:RetainedEarningsMember2023-01-012023-12-310001088856us-gaap:CommonStockMember2023-12-310001088856us-gaap:AdditionalPaidInCapitalMember2023-12-310001088856us-gaap:TreasuryStockCommonMember2023-12-310001088856us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001088856us-gaap:RetainedEarningsMember2023-12-31cort:seriescort:compound0001088856us-gaap:CustomerConcentrationRiskMembercort:SpecialtyDistributorMemberus-gaap:SalesRevenueNetMember2023-01-012023-12-31xbrli:pure0001088856us-gaap:CustomerConcentrationRiskMembercort:SpecialtyDistributorMemberus-gaap:SalesRevenueNetMember2022-01-012022-12-310001088856us-gaap:CustomerConcentrationRiskMembercort:SpecialtyDistributorMemberus-gaap:SalesRevenueNetMember2021-01-012021-12-310001088856cort:ChargebacksMember2020-12-310001088856cort:GovernmentRebatesMember2020-12-310001088856cort:ChargebacksMember2021-01-012021-12-310001088856cort:GovernmentRebatesMember2021-01-012021-12-310001088856cort:ChargebacksMember2021-12-310001088856cort:GovernmentRebatesMember2021-12-310001088856cort:ChargebacksMember2022-01-012022-12-310001088856cort:GovernmentRebatesMember2022-01-012022-12-310001088856cort:ChargebacksMember2022-12-310001088856cort:GovernmentRebatesMember2022-12-310001088856cort:ChargebacksMember2023-01-012023-12-310001088856cort:GovernmentRebatesMember2023-01-012023-12-310001088856cort:ChargebacksMember2023-12-310001088856cort:GovernmentRebatesMember2023-12-31cort:segment0001088856cort:ESPPMembercort:RestrictedStockAwardsRSAsMember2023-01-012023-12-310001088856cort:OptimeCareIncMember2017-08-012017-08-310001088856us-gaap:CashEquivalentsMember2023-12-310001088856us-gaap:CashEquivalentsMember2022-12-310001088856cort:ShortTermMarketableSecuritiesMember2023-12-310001088856cort:ShortTermMarketableSecuritiesMember2022-12-310001088856cort:LongTermMarketableSecuritiesMember2023-12-310001088856cort:LongTermMarketableSecuritiesMember2022-12-310001088856us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310001088856us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001088856us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:CommercialPaperMember2023-12-310001088856us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:CommercialPaperMember2022-12-310001088856us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001088856us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310001088856us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:AssetBackedSecuritiesMember2023-12-310001088856us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:AssetBackedSecuritiesMember2022-12-310001088856us-gaap:USTreasurySecuritiesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Member2023-12-310001088856us-gaap:USTreasurySecuritiesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Member2022-12-310001088856us-gaap:MoneyMarketFundsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Member2023-12-310001088856us-gaap:MoneyMarketFundsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Member2022-12-310001088856us-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310001088856us-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001088856srt:MinimumMember2023-01-012023-12-310001088856srt:MaximumMember2023-01-012023-12-310001088856us-gaap:AccountingStandardsUpdate201602Member2023-12-310001088856cort:TenderOfferMemberus-gaap:CommonStockMember2023-03-310001088856cort:TenderOfferMemberus-gaap:CommonStockMember2023-04-052023-04-050001088856cort:TenderOfferMemberus-gaap:CommonStockMember2021-11-300001088856cort:TenderOfferMemberus-gaap:CommonStockMember2021-11-082021-12-150001088856cort:StockRepurchaseProgramMemberus-gaap:CommonStockMember2020-11-300001088856cort:StockRepurchaseProgramMemberus-gaap:CommonStockMember2021-01-012021-12-310001088856us-gaap:EmployeeStockOptionMember2023-01-012023-12-310001088856us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001088856us-gaap:EmployeeStockOptionMember2021-01-012021-12-310001088856cort:StockOptionsFiscalTwentyTwelvePlanMember2023-01-012023-12-31cort:plan0001088856srt:MinimumMembercort:StockOptionsFiscalTwentyTwelvePlanMember2023-01-012023-12-310001088856cort:StockOptionsFiscalTwentyTwelvePlanMembersrt:MaximumMember2023-01-012023-12-310001088856cort:StockOptionsFiscalTwentyTwelvePlanMember2023-12-310001088856cort:EmployeeAndDirectorStockOptionMember2023-12-310001088856cort:EmployeeAndDirectorStockOptionMember2023-01-012023-12-310001088856cort:StockOptionsFiscalTwentyTwelvePlanMemberus-gaap:RestrictedStockMember2022-12-310001088856cort:StockOptionsFiscalTwentyTwelvePlanMemberus-gaap:RestrictedStockMember2023-01-012023-12-310001088856cort:StockOptionsFiscalTwentyTwelvePlanMemberus-gaap:RestrictedStockMember2023-12-310001088856us-gaap:RestrictedStockMember2023-01-012023-12-310001088856us-gaap:EmployeeStockMember2023-12-310001088856cort:RestrictedStockAwardsRSAsMember2023-01-012023-12-310001088856cort:RestrictedStockAwardsRSAsMember2022-01-012022-12-310001088856us-gaap:CostOfSalesMember2023-01-012023-12-310001088856us-gaap:CostOfSalesMember2022-01-012022-12-310001088856us-gaap:CostOfSalesMember2021-01-012021-12-310001088856us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-12-310001088856us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-12-310001088856us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-12-310001088856us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-12-310001088856us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-12-310001088856us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-12-310001088856us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001088856us-gaap:EmployeeStockOptionMember2021-01-012021-12-310001088856us-gaap:StateAndLocalJurisdictionMember2023-12-310001088856cort:OtherStatesMember2023-12-310001088856us-gaap:SubsequentEventMember2024-01-310001088856us-gaap:SettledLitigationMembercort:MelucciMember2023-02-082023-02-080001088856us-gaap:SettledLitigationMembercort:MelucciMember2022-10-012022-12-310001088856us-gaap:SettledLitigationMembercort:MelucciMember2023-12-310001088856us-gaap:SettledLitigationMembercort:MelucciMemberus-gaap:SubsequentEventMember2024-01-042024-01-040001088856cort:StockRepurchaseProgramMemberus-gaap:SubsequentEventMemberus-gaap:CommonStockMember2024-01-08

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2023
or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission File Number: 000-50679
CORCEPT THERAPEUTICS INCORPORATED
(Exact Name of Corporation as Specified in Its Charter)
Delaware77-0487658
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
149 Commonwealth Drive
Menlo Park, CA 94025
(Address of principal executive offices) (zip code)
(650) 327-3270
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12 (b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 par valueCORTThe Nasdaq Stock Market
Securities registered pursuant to Section 12 (g) of the Act:
None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Acts. Yes ☒ No ☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐


Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.:
Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐  Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
The aggregate market value of voting and non-voting common equity held by non-affiliates of the Registrant as of June 30, 2023 was $1,827,006,147, based on the closing price of $22.25 for shares of the Registrant’s common stock as reported on the Nasdaq Stock Market on June 30, 2023. Shares of common stock beneficially owned by each executive officer, director and holder of more than 10% of our common stock have been excluded, in that such persons may be deemed to be affiliates. This calculation does not reflect a determination that certain persons are affiliates of the Registrant for any other purpose.
On February 6, 2024 there were 103,517,388 shares of common stock outstanding at a par value of $0.001 per share.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the Registrant’s definitive proxy statement for its 2024 Annual Meeting of Stockholders are incorporated by reference in Items 10, 11, 12, 13 and 14 of Part III.


TABLE OF CONTENTS
Form 10-K
For the year ended December 31, 2023
    Page
     
  PART I  
     
ITEM 1.  
     
ITEM 1A.  
     
ITEM 1B.  
     
ITEM 1C.
ITEM 2.  
     
ITEM 3.  
     
ITEM 4.  
     
  PART II  
     
ITEM 5.  
     
ITEM 6.  
     
ITEM 7.  
     
ITEM 7A.  
     
ITEM 8.  
     
ITEM 9.  
     
ITEM 9A.  
     
ITEM 9B.  
ITEM 9C.
     
  PART III  
     
ITEM 10.  
     
ITEM 11.  
     
ITEM 12.  
     
ITEM 13.  
     
ITEM 14.  
     
  PART IV  
     
ITEM 15.  
     
ITEM 16.
     
   


PART I
This Annual Report on Form 10-K (“Form 10-K”) contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and Section 27A of the Securities Act of 1933, as amended (“Securities Act”). All statements contained in this Form 10-K, other than statements of historical fact, are forward-looking statements. When used in this report, the words “believe,” “anticipate,” “intend,” “plan,” “estimate,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek” and similar expressions are forward-looking statements based on management’s current expectations. The absence of these words does not mean that a statement is not forward-looking. Forward-looking statements include, but are not limited to, statements about:
•our ability to manufacture, market and sell Korlym® (mifepristone) 300 mg Tablets (“Korlym”);
•the impact of possible future competition for Korlym, including generic versions of Korlym, or our product candidates;
•our estimates regarding enrollment in and the completion dates of our clinical trials and the anticipated results of these trials;
•the timing of regulatory submissions seeking approval of product candidates and the commercialization of any product candidates that are approved;
•the progress and timing of our research and development programs and the regulatory activities associated with them;
•our estimates for future performance, including revenue, income and capital requirements;
•our ability to manufacture, market, commercialize and achieve market acceptance for our product candidates; and
•uncertainties associated with obtaining and enforcing patents.
Forward-looking statements involve risks and uncertainties and are not guarantees of future performance. Actual events or results may differ materially for many reasons. For a more detailed discussion of the risks and uncertainties that may affect the accuracy of our forward-looking statements, see the “Risk Factors,” “Overview” and “Liquidity and Capital Resources” sections of the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of this Form 10-K. You should also carefully consider the other reports and documents we file with the Securities and Exchange Commission (“SEC”).
Forward-looking statements in this Form 10-K reflect our view only as of the date of this report. Except as required by law, we undertake no obligation to update forward-looking statements.
Unless stated otherwise, all references in this document to “we,” “us,” “our,” “Corcept,” the “Company,” “our company” and similar words and phrases refer to Corcept Therapeutics Incorporated.
ITEM 1. BUSINESS
Overview
We are a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol.
Cortisol plays a significant role in the body’s response to stress and is essential for survival. Cortisol influences metabolism and the immune system and contributes to emotional stability. Cortisol levels follow a diurnal rhythm that is essential to health, peaking upon awakening and decreasing during the day. Insufficient cortisol activity may lead to dehydration, hypotension, shock, fatigue and hypoglycemia. Excessive cortisol activity, known as hypercortisolism, may lead to a suppressed immune response, impaired glucose tolerance, diabetes, obesity, fatty liver disease, depressed mood, psychosis, wasting of the arms and legs, edema, fatigue, hypertension and other problems.
Pre-clinical and clinical data suggest that cortisol reduces a patient’s immune response to oncogenesis, shields certain cancer cells from the apoptotic effects of chemotherapy and facilitates the growth of others. Pre-clinical and clinical data also indicate that modulating cortisol activity may improve outcomes in patients with fatty liver disease and non-alcoholic steatohepatitis (“NASH”), which are precursors of liver fibrosis and cirrhosis, and in patients at risk of weight gain caused by antipsychotic medications (referred to as antipsychotic induced weight gain, or “AIWG”). Pre-clinical data also suggest that modulating cortisol activity may lead to treatments for patients with amyotrophic lateral sclerosis (“ALS”).
1

Since 2012, we have marketed Korlym® in the United States for the treatment of patients suffering from hypercortisolism (“Cushing’s syndrome”). The challenge in treating a patient with Cushing’s syndrome is modulating cortisol’s effects without either inappropriately suppressing them or disrupting cortisol’s normal diurnal rhythm. Simply reducing or destroying the ability of the body to make cortisol can cause serious harm. Cortisol activity can be modulated effectively by a drug that competes with cortisol, binding to the glucocorticoid receptor (“GR”).
Because Korlym’s active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisol’s healthy functions and rhythms. However, mifepristone also binds to the progesterone receptor (“PR”), thereby terminating pregnancy and causing other adverse effects, including endometrial thickening and vaginal bleeding, a debilitating condition suffered by a significant portion of women who take Korlym.
We have discovered more than 1,000 proprietary cortisol modulators that bind to the GR but have no affinity for the PR and so do not cause Korlym’s PR-related side effects. These novel molecules are “selective” cortisol modulators: they share Korlym’s affinity for the GR, but, unlike Korlym, do not bind to the PR and therefore do not cause effects arising from antagonism of progesterone activity, such as termination of pregnancy, endometrial thickening and vaginal bleeding. The composition of our selective cortisol modulators and their methods of use in a wide range of indications are covered by U.S. and foreign patents.
Our lead compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders – Cushing’s syndrome, advanced ovarian cancer, adrenal cancer with cortisol excess, prostate cancer, ALS and NASH.
COVID-19 Pandemic
Public health restrictions and measures voluntarily undertaken by patients, physicians, hospitals and health clinics to reduce the impact of COVID-19 reduced our revenue growth and made it difficult to grow our Korlym business.
The pandemic’s impact on our clinical development programs was variable. Some of our trials of indications not considered immediately life-threatening, such as Cushing’s syndrome, experienced slower enrollment and difficulty retaining patients. In addition, some clinical sites reduced the frequency with which physicians were able to examine study participants. Trials in patients with immediately life-threatening diseases, such as our Phase 2 trial in women with platinum-resistant ovarian cancer, did not encounter delays.
Although the impact of COVID-19 on our business is now significantly reduced, some physicians and hospitals continue to limit interactions with sales representatives and medical science liaisons, which makes growing our business more difficult.
Cushing’s Syndrome
Background. An estimated 10 to 15 of every one million people are diagnosed with Cushing’s syndrome each year, resulting in approximately 3,000 new patients per year and a patient population in the United States of about 20,000, approximately half of whom are cured by surgery. Cushing’s syndrome most often affects adults between the ages of 20 and 50.
Most people with Cushing’s syndrome have one or more of the following symptoms: high blood sugar, diabetes, high blood pressure, upper body obesity, rounded face, increased fat around the neck, thinning arms and legs, severe fatigue and weak muscles. Irritability, anxiety, cognitive disturbances and depression are also common. Cushing’s syndrome can affect every organ system in the body and can be lethal if not treated. The preferred treatment is surgery, which, if successful, can cure the disease. In approximately half of patients, surgery is not successful because the tumor cannot be located or removed completely. Depending on the type of tumor, surgery can result in a range of complications.
Korlym. We sell Korlym in the United States, using experienced sales representatives to call on physicians caring for patients with Cushing’s syndrome (also called “hypercortisolism”). We also have a field-based force of medical science liaisons. We use one specialty pharmacy and one specialty distributor to distribute Korlym and provide logistical support to physicians and patients. Our policy is that no patient with Cushing’s syndrome will be denied access to Korlym for financial reasons. To help us achieve that goal, we fund our own patient support programs and donate money to independent charitable foundations that help patients pay for all aspects of their Cushing’s syndrome care, whether or not that care includes taking Korlym.
Because many people who suffer from Cushing’s syndrome are undiagnosed or inadequately treated, we have developed and continue to refine and expand programs to educate physicians and patients about screening for hypercortisolism and the role Korlym can play in treating patients with the disorder. We have initiated a Phase 4 study (“CATALYST”), to determine the prevalence of Cushing’s syndrome in patients with difficult-to-control diabetes (HbA1c of 7.5 percent or higher) despite receiving standard treatment. In CATALYST’s first phase, 1,000 patients will be evaluated. Those found to have Cushing’s
2

syndrome may elect to enter the second phase of the study, in which patients will be randomized to receive either Korlym or placebo for 24 weeks. We expect that data from CATALYST will help physicians better identify patients with Cushing’s syndrome and determine their optimal treatment.
Relacorilant. We are conducting two Phase 3 trials (“GRACE” and “GRADIENT”) of our proprietary, selective cortisol modulator, relacorilant, as a treatment for patients with Cushing’s syndrome. Relacorilant was well-tolerated in its Phase 1 and Phase 2 trials. Patients in the Phase 2 trial exhibited meaningful improvements in glucose control, hypertension, weight, liver function, coagulopathy, cognition, mood, insulin resistance and quality of life measures. Relacorilant shares Korlym’s affinity for the GR, but, unlike Korlym, has no affinity for the PR, and so is not the “abortion pill.” It does not cause other effects associated with PR affinity, including endometrial thickening and vaginal bleeding. There is no evidence that relacorilant causes hypokalemia (low potassium), a potentially serious condition that is a leading cause of patients stopping treatment with Korlym. Forty-four percent of patients in Korlym’s pivotal trial experienced hypokalemia. Unlike all other medications used to treat Cushing's syndrome, relacorilant does not prolong the heart's QT interval, a potentially deadly off-target effect.
In the GRACE trial, each patient receives relacorilant for 22 weeks. Patients who exhibit pre-specified improvements in hypertension and/or glucose metabolism enter a 12-week, double-blind, “randomized withdrawal” phase, in which half of the patients continue receiving relacorilant and half receive placebo. The trial’s primary endpoint is the rate and degree of relapse of hypertension in patients receiving placebo measured against the rate and degree of relapse of hypertension in those continuing relacorilant. GRACE has enrolled 152 patients at sites in the United States, Canada, Europe and Israel. Enrollment is now complete. If successful, GRACE will provide the basis for a new drug application (“NDA”) for relacorilant as a treatment for patients with any etiology of endogenous Cushing’s syndrome.
Our second Phase 3 trial of relacorilant, GRADIENT, is studying patients whose Cushing’s syndrome is caused by a benign adrenal tumor. These patients often exhibit less severe symptoms or have a more gradual course of disease than patients with other etiologies of Cushing’s syndrome, although their health outcomes are ultimately poor. Half of the patients in GRADIENT will receive relacorilant for 22 weeks and half will receive placebo. The trial’s primary endpoints are improvements in glucose metabolism and hypertension. The planned enrollment for this study is 130 patients.
The United States Food and Drug Administration (“FDA”) and the European Commission (“EC”) have designated relacorilant as an orphan drug for the treatment of Cushing’s syndrome. In the United States, relacorilant’s orphan designation confers tax credits, reduced regulatory fees and, provided we obtain approval for the treatment of patients with Cushing’s syndrome, seven years of exclusive marketing rights. Benefits of orphan drug designation by the EC are similar, but also include protocol assistance from the European Medicines Agency (“EMA”), access to the centralized marketing authorization procedure in the European Union (“EU”) and, if we obtain approval, ten years of exclusive marketing rights in the EU for the treatment of patients with Cushing’s syndrome.
Oncology
There is substantial evidence that cortisol activity at the GR reduces the efficacy of certain anti-cancer therapies and that modulating cortisol’s activity may help anti-cancer treatments achieve their intended effect. In some cancers, cortisol retards cellular apoptosis – the tumor-killing effect many treatments are meant to stimulate. In other cancers, cortisol activity promotes tumor growth. Cortisol also suppresses the body’s immune response; activating – not suppressing – the immune system is beneficial in fighting certain cancers. Many types of solid tumors express the GR and are potential targets for cortisol modulation therapy, among them ovarian, adrenal and prostate cancer.
Relacorilant in Patients with Advanced Ovarian Cancer. In May 2021, we announced preliminary results from our 178-patient, controlled, multi-center, Phase 2 trial of relacorilant combined with nab-paclitaxel in patients with platinum-resistant ovarian cancer. Study participants were randomized to one of three treatment arms: 60 women received 150 mg of relacorilant intermittently (the day before, the day of and the day after their weekly nab-paclitaxel infusion) and 58 women received a daily relacorilant dose of 100 mg per day in addition to nab-paclitaxel. Sixty women received nab-paclitaxel alone. The trial’s primary endpoint was progression-free survival (i.e., the time from random assignment in a clinical trial to disease progression or death from any cause or “PFS”).
Patients in both of the relacorilant plus nab-paclitaxel treatment arms experienced longer PFS than did the patients who received nab-paclitaxel alone. Patients who received a higher dose of relacorilant intermittently exhibited a statistically significant improvement in median PFS (5.6 months versus 3.8 months, hazard ratio: 0.66; p-value: 0.038). Patients who received a lower dose of relacorilant daily exhibited a median PFS that was 1.5 months longer than did the patients who received nab-paclitaxel alone (5.3 months versus 3.8 months, hazard ratio: 0.83; p-value: not significant). Patients who received relacorilant intermittently also had a longer median duration of response (“DoR”) (5.6 months versus 3.7 months, hazard ratio: 0.36; p-value: 0.006) compared to those who received nab-paclitaxel alone. Patients who received relacorilant intermittently
3

also lived longer (median OS: 13.9 months versus 12.2 months, hazard ratio: 0.67; p-value: 0.066) compared to those who received nab-paclitaxel alone.
Safety and tolerability of relacorilant plus nab-paclitaxel were comparable to nab-paclitaxel monotherapy.
The final analysis from our Phase 2 trial was published in the Journal of Clinical Oncology (Colombo et al., 2023), the premiere journal of the American Society of Clinical Oncology (ASCO).
In June 2022, we initiated a pivotal Phase 3 trial (“ROSELLA”) that seeks to replicate the positive results observed in our Phase 2 study. ROSELLA has a planned enrollment of 360 women with recurrent, platinum-resistant ovarian cancer, half of whom will receive 150 mg of relacorilant intermittently in addition to nab-paclitaxel, with the other half receiving nab-paclitaxel monotherapy. The primary endpoint is PFS; overall survival is a key secondary endpoint. Patients in ROSELLA will have received prior bevacizumab therapy, which is the standard of care for patients with platinum-resistant ovarian cancer. Women with a history of tumors that do not respond to initial platinum-based treatments (i.e., women with “primary platinum-refractory” disease) and those who have received more than three prior lines of therapy will be excluded.
Relacorilant in Patients with Adrenal Cancer with Cortisol Excess. We are conducting an open-label, Phase 1b trial of relacorilant plus the PD-1 checkpoint inhibitor pembrolizumab in patients with metastatic or unresectable adrenal cancer whose tumors produce cortisol. The trial is examining whether adding relacorilant to pembrolizumab therapy reduces cortisol-activated immune suppression sufficiently to help pembrolizumab achieve its intended tumor-killing effect. Relacorilant is also expected to treat the patients’ Cushing’s syndrome generated by their tumors’ excess production of cortisol.
Relacorilant in Patients with Prostate Cancer. Androgen deprivation is the standard treatment for prostate cancer because androgens stimulate prostate tumor growth. Tumors often escape androgen deprivation therapy when cortisol’s activity at the GR stimulates tumor growth. Combining a cortisol modulator with an androgen modulator may block this escape route. Our collaborators at the University of Chicago have initiated a randomized, placebo-controlled Phase 2 trial of relacorilant plus enzalutamide in patients with prostate cancer, pre-prostatectomy. We are providing relacorilant and placebo for the study and have licensed patents covering the use of relacorilant combined with anticancer agents such as enzalutamide in the treatment of patients with this indication.
ALS
ALS, also known as Lou Gehrig’s disease, is a devastating neuromuscular illness. Our selective cortisol modulator dazucorilant improved motor performance and reduced neuroinflammation and muscular atrophy in animal models of ALS. Following these compelling results, we initiated a Phase 2 trial (“DAZALS”) of dazucorilant in patients with ALS in October 2022. DAZALS has a planned enrollment of 198 patients, randomized 1:1:1 to receive either 150 mg or 300 mg of dazucorilant or placebo daily for 24 weeks. The primary endpoint is the difference between dazucorilant and placebo demonstrated by patients on the ALS Functional Rating Scale-Revised (ALSFRS-R).
Metabolic Diseases
Liver Disease. Nonalcoholic steatohepatitis (“NASH”) is an advanced form of nonalcoholic fatty liver disease that afflicts millions of patients and is a leading cause of liver-related mortality. In April 2021, we suspended our Phase 2a trial of our selective cortisol modulator miricorilant as a potential treatment for NASH after four of the five patients who received miricorilant exhibited both elevated liver enzymes and large rapid reductions in liver fat. Liver enzyme levels in all affected patients returned to baseline or below baseline (i.e. to healthier levels) after miricorilant was withdrawn. Our Phase 1b study has identified a dosing regimen that effectively reduced liver fat, improved liver health and key metabolic and lipid measures and was well-tolerated. Following these compelling results, we initiated a Phase 2b trial (“MONARCH”) of miricorilant in patients with NASH in October 2023. MONARCH has a planned enrollment of 150 patients, randomized 2:1 to receive either 100 mg of miricorilant twice weekly or placebo for 48 weeks. The primary endpoint is reduction in liver fat, with NASH resolution and fibrosis improvement as key secondary endpoints.
AIWG. In the United States, six million people take antipsychotic medications such as olanzapine and risperidone to treat illnesses such as schizophrenia, bipolar disorder and depression. While these drugs are very effective, they often cause rapid and sustained weight gain, other metabolic disturbances and, ultimately, cardiovascular disease. Patients taking these medications experience a 10 to 25-year reduction in life expectancy, due largely to increased cardiovascular events, such as heart attacks and strokes. Patients in our two double-blind, placebo-controlled, Phase 2 trials (“GRATITUDE” and “GRATITUDE II”) of miricorilant with already existing weight gain stimulated by anti-psychotic medication did not exhibit weight loss. However, numerous replicated pre-clinical study results as well as the results of our double-blind, placebo-controlled trial in healthy subjects (published in the Journal of Clinical Psychopharmacology (Hunt et al., 2021)) suggest that
4

miricorilant may significantly prevent weight gain caused by the administration of olanzapine. In October 2023, we initiated a double-blind, placebo-controlled, Phase 1 trial to further study miricorilant’s potential to prevent AIWG.
Development of our Other Selective Cortisol Modulators
Our portfolio of proprietary selective cortisol modulators consists of four structurally distinct series. More than 1,000 of these compounds, including relacorilant, exicorilant, miricorilant and dazucorilant, potently bind to the GR but not the progesterone, estrogen or androgen receptors. We hold U.S. and foreign patents covering these compounds and their methods of use in a wide range of indications. We have applied, and will continue to apply, for patents covering the composition and method of use of our products and product candidates. See “Business – Intellectual Property” for additional information.
We continue to identify selective cortisol modulators and plan to advance the most promising of them towards the clinic.
Studies by Independent Investigators
For many years we have advanced our understanding of cortisol modulation by supporting the work of independent academic investigators. These researchers have studied the potential utility of mifepristone and our proprietary selective cortisol modulators in a wide range of disorders, including central serous retinopathy, post-traumatic stress disorder, anxiety, alcoholism, cocaine addiction, Alzheimer’s disease, ALS, Cushing’s syndrome, metabolic syndrome, atherosclerosis, fatty liver disease, sarcoma, melanoma and solid tumors, including triple-negative breast, prostate, ovarian and non-small cell lung cancers.
Clinical Trial Agreements
We typically conduct our clinical trials with the assistance of clinical research organizations (“CROs”). ICON plc is helping us conduct our GRACE and GRADIENT trials. Syneos Health is helping us conduct our ROSELLA trial. Julius Clinical is helping us conduct our DAZALS trial. Medpace Research is helping us conduct our MONARCH trial. We may terminate our agreements with ICON, Syneos Health and Julius Clinical on 60 days’ written notice. Our agreement with Medpace may be terminated by us without cause at any time.
Research and Development Spending
We incurred $184.4 million, $131.0 million and $113.9 million of research and development expense in the years ended December 31, 2023, 2022 and 2021, respectively, which accounted for 49 percent, 45 percent and 47 percent, respectively, of our total operating expenses in those years.
Manufacturing Korlym
We rely on contract manufacturers to produce Korlym and our product candidates.
Because we have an agreement with one third-party manufacturer to supply mifepristone, the active pharmaceutical ingredient (“API”) in Korlym, we have purchased and hold significant quantities of API. We have two third-party manufacturers to produce and bottle Korlym tablets.
Competition for Korlym
Korlym competes with established treatments, including surgery, radiation and other medications, including “off-label” uses of drugs such as ketoconazole, an anti-fungal medication, and metyrapone, which is approved for testing hypothalamic-pituitary function. Korlym also competes with Signifor® (pasireotide) Injection and Isturisa® (osilodrostat). Both of these drugs are approved by the FDA for the treatment of adult patients with Cushing’s disease who are not candidates for pituitary surgery or for whom surgery did not work, and both are sold by the Italian pharmaceutical company Recordati S.p.A (“Recordati”). Cushing’s disease is a subset of Cushing’s syndrome. In the EU, osilodrostat is also approved as a treatment for Cushing’s syndrome. Korlym also competes with Recorlev® (levoketoconazole), a chiral form of the commonly-prescribed cortisol synthesis inhibitor ketoconazole, that is sold by Xeris Biopharma Holdings, Inc. (“Xeris”), as a treatment for patients with Cushing’s syndrome.
The orphan drug marketing exclusivity period for Korlym ended in February 2019, which means a competitor that receives FDA approval for a generic equivalent of Korlym may market its drug to patients with Cushing’s syndrome, provided doing so would not infringe any of our patents. We sued Teva Pharmaceuticals USA, Inc. (“Teva”) in federal district court to prevent them from marketing generic versions of Korlym in violation of our patents. In response, Teva separately challenged the validity of one of our patents in a post grant review (“PGR”) proceeding before the Patent Trial and Appeal Board (“PTAB”). In November 2020, the PTAB rejected Teva’s claims, affirming the validity of our patent in its entirety. Teva
5

appealed to the Federal Circuit Court of Appeals, which affirmed the PTAB’s decision. On December 29, 2023, the federal district in which we had sued Teva issued a ruling finding that Teva’s proposed product would not infringe the two patents we had asserted against it. We have appealed that decision to the Federal Circuit of Appeals. See “Part I, Item 3, Legal Proceedings” for additional information.
Intellectual Property
Overview. Patents and other proprietary rights are important to our business. We own U.S. composition of matter patents related to our next-generation cortisol modulators. Foreign counterparts of some of these patents have been issued in Europe, Japan, China, Canada, Australia and other countries. The expiration dates of these patents and their foreign counterparts range from 2025 to 2041.
We also own U.S. and foreign patents directed to the use of our selective cortisol modulators in the treatment of a variety of serious disorders, including Cushing’s syndrome, various cancers, fatty liver disease, AIWG, and other disorders.
We continue to file patent applications in the United States and abroad. There can be no guarantee that any of these applications will result in the issuance of patents, that any issued patent will include claims of the breadth we are seeking or that competitors or other third parties will not successfully challenge or circumvent our patents if they are issued.
We believe our patents are valid and that the production and use of our patented compounds and methods do not infringe the proprietary rights of others. Accordingly, we believe we are not obligated to pay royalties relating to the use of intellectual property to any third parties except the University of Chicago, from which we have licensed certain patents, as described below.
Cushing’s Syndrome. The composition of matter patent covering Korlym’s active ingredient, mifepristone, has expired. We own U.S. method of use patents directed to the use of Korlym in the treatment of patients with Cushing’s syndrome, with expiration dates ranging from 2028 to 2038. Furthermore, we own U.S. compound and method of use patents using our proprietary selective cortisol modulators directed to the treatment of patients with Cushing’s syndrome, with expiration dates ranging from 2033 to 2041. We have asserted two patents directed to patients with Cushing’s syndrome in a lawsuit against Teva Pharmaceuticals USA, Inc. (“Teva”) in a lawsuit filed in Federal District Court. On December 29, 2023, the Court found that Teva’s proposed generic version of Korlym would not infringe either patent. We are appealing that decision. See “Part I, Item 3, Legal Proceedings” for additional details.
Oncology. We own U.S. patents covering methods of treating cancer using our proprietary selective cortisol modulators with expiration dates ranging from 2033 to 2041. In addition, we have exclusively licensed from the University of Chicago U.S. patents for (a) the use of cortisol modulators in the treatment of triple-negative breast cancer, and (b) the use of cortisol modulators to treat castration resistant prostate cancer (“CRPC”). We are required to pay the University of Chicago customary milestone fees and royalties on revenue from products commercialized under the issued patents or patents that may issue pursuant to the pending applications. Our license will end upon expiration of the licensed patents in 2031 and 2033 or upon notification by us to the University of Chicago. See “Business – License Agreements” for additional information.
We hold U.S. and international patents covering relacorilant’s composition of matter, as well as U.S. patents covering its use to treat patients with ovarian and pancreatic cancer. We also own or have exclusively licensed U.S. and European patents covering the use of GR modulators, including relacorilant, miricorilant, exicorilant, dazucorilant, and other of our proprietary compounds to treat a variety of disorders, including CRPC and other solid tumors. Relacorilant has been designated an orphan drug in both the United States and the EU for the treatment of pancreatic cancer.
Other Indications. In addition to the United States and foreign patents we own or have licensed relating to Cushing’s syndrome and various cancers, we also own U.S. and foreign patents for the use of cortisol modulators to treat ALS, AIWG, fatty liver disease, delirium, catatonia, psychosis induced by interferon-alpha therapy, migraine headaches, gastroesophageal reflux disease, neurological damage in premature infants, for the improvement of therapeutic response to electroconvulsive therapy, and in the treatment of diseases using combined steroid and GR modulator therapy. The expiration dates of these patents and their foreign counterparts range from 2025 to 2039.
Government Regulation
Prescription pharmaceutical products are subject to extensive pre- and post-approval regulation governing the research, development, testing, manufacturing, safety, efficacy, labeling, storage, record keeping, and advertising and promotion of the products under the Federal Food, Drug and Cosmetic Act. All of our product candidates require regulatory approval by government agencies prior to commercialization and are subject to continued regulatory oversight thereafter. Before a new drug may be marketed in the United States, the FDA generally requires completion of preclinical laboratory and animal testing, performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed drug’s
6

intended use and approval by the FDA. Complying with these and other federal and state statutes and regulations involves significant time and expense.
Prior to beginning the first clinical trial with a product candidate in the United States, a sponsor must submit an investigational new drug application (“IND”) to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. The IND also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamics characteristics of the drug, chemistry, manufacturing, and controls information, and any available human data or literature to support the use of the investigational drug. An IND must become effective before human clinical trials may begin.
Clinical trials involve the administration of the investigational drug to human subjects under the supervision of qualified investigators in accordance with Good Clinical Practice regulations, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. Typically, human clinical trials are conducted in three sequential phases that may overlap.
•Phase 1. The product candidate is administered to a small number of healthy subjects or patients with the target disease or condition to provide preliminary information as to its safety, tolerability and pharmacokinetics and sometimes to provide preliminary information as to its activity and/or efficacy.
•Phase 2. The product candidate is administered to a limited patient population with a specified disease or condition to evaluate its preliminary efficacy, optimal dosages and to identify possible adverse events and safety risks.
•Phase 3. The product candidate is administered to a larger group of patients with the target disease or condition to further evaluate dosage, establish its risk/benefit ratio and to provide an adequate basis for product approval.
The FDA and the institutional review boards associated with clinical trial sites closely monitor the progress of clinical trials conducted in the United States and may reevaluate, alter, suspend or terminate a trial at any time for various reasons, including a belief that the subjects are being exposed to unacceptable risks. The FDA may also require that additional trials be conducted to address and evaluate any potential safety risks.
Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, drug developers will submit the results of preclinical studies, clinical trials, formulation studies and data supporting manufacturing to the FDA in the form of an NDA requesting approval to market the drug for one or more indications. The submission of an NDA requires payment of a substantial application user fee to the FDA, unless a waiver or exemption applies. Within 60 days following submission of the application, the FDA reviews an NDA submitted to determine if it is substantially complete before the FDA accepts it for filing. Once filed, the FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is sufficient to assure and preserve the drug’s identity, strength, quality and purity. Under the Prescription Drug User Fee Act, the FDA has a goal of responding to NDAs within ten months of the filing date for standard review, and six months for priority review, which the FDA may undertake, in its sole discretion, if a sponsor shows that its drug candidate is designed to treat a serious condition, and if approved, would provide a significant improvement in safety or effectiveness compared to marketed drugs. FDA approvals may not be granted on a timely basis or at all.
In addition, under the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 individuals in the United States and when there is no reasonable expectation that the cost of developing and making available the drug in the United States will be recovered from sales in the United States for that drug. If a product that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full NDA, to market the same drug for the same indication for seven years, except in limited circumstances. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the NDA application user fee.
If the FDA approves the marketing of a new drug, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. The FDA may withdraw its approval at any time if compliance with regulatory standards is not maintained. The holder of an approved NDA must submit periodic reports to the FDA, including reports of adverse patient experiences, which could cause the FDA to impose marketing restrictions through labeling changes or remove the drug from the market. The FDA may also require post-approval studies, referred to as “Phase 4
7

studies,” to monitor or further explore the effect of approved products, and may limit marketing of the drug based on the results of such studies.
In addition, most changes to an approved drug, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. The FDA imposes complex regulations regarding the promotion and sale of pharmaceuticals, including standards for direct-to-consumer advertising, off-label promotion, and industry-sponsored scientific and educational activities. In addition, facilities involved in the manufacture of drugs must comply with FDA-mandated current Good Manufacturing Practices regulations (“cGMP”) and are subject to periodic inspection by the FDA and other regulatory authorities. Failure to abide by these regulations can result in penalties including the issuance of a warning letter or untitled letter directing a company to correct deviations from FDA regulations, mandated modification of promotional materials and labeling, the issuance of corrective information, clinical holds, restrictions on manufacturing, product recalls, product detentions or seizures, refusal to approve pending applications or supplements and injunctions, in addition to state and federal civil and criminal penalties.
Marketing Approvals Outside the United States
If we choose to distribute our product candidates outside the United States, we will have to complete an approval process similar to the one imposed by the FDA. The approval procedure and the time required for approval vary from country to country and may involve additional preclinical and clinical trials. Foreign approvals may not be granted on a timely basis, or at all. Regulatory approval of pricing is required in most countries other than the United States, which pricing may be too low to generate an acceptable return. We are not seeking regulatory approval to market Korlym outside the United States.
Coverage and Reimbursement
Sales of our products will depend, in part, on the extent to which they will be covered by government health care programs and commercial insurance and managed healthcare organizations. Third-party payers are increasingly limiting coverage and reducing reimbursements for medical products and services, although this trend has not to-date had a material impact on the amount or timing of our revenues. In addition, the United States government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures and adoption of more restrictive policies in jurisdictions with existing controls and measures could limit our revenue. Decreases in third-party reimbursement for our products or a decision by a third-party payer to not cover our products could reduce our sales and have a material adverse effect on our results of operations and financial condition.
Examples of legislation in this area include the Patient Protection and Affordable Care Act (“ACA”) which was passed in 2010, and the Inflation Reduction Act of 2022 (the “IRA”). The ACA substantially changed the way health care is financed by both governmental and private insurers. The ACA, among other things, expanded Medicaid program eligibility and access to commercial health insurance coverage, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs, and promoted a new Medicare Part D coverage gap discount program. More recently, the Inflation Reduction Act of 2022 (the “IRA”) was signed into law on August 16, 2022, which, among other things, requires the Secretary of the U.S. Department of Health and Human Services (“HHS”) to negotiate the price of a set number of high Medicare spend drugs starting in 2026, requires rebates from manufacturers who increase their drug prices above inflation, and makes several changes to the Medicare Part D benefit that will increase manufacturer liability for drug costs previously borne by the government and beneficiaries under the program. We also expect there to be other healthcare reform measures that could impact coverage, reimbursement, and drug prices.
Other Healthcare Laws
In addition to the laws and regulations outlined in the “Government Regulations” section, we are subject to healthcare regulation and enforcement by the federal government and the states where we conduct business. These laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, and physicians’ sunshine (e.g. transparency) laws and regulations. Foreign governments have comparable regulations, and violating these laws and regulations in any jurisdiction could result in significant criminal, civil, and administrative sanctions.
The federal Anti-Kickback Statute prohibits, among other things, any person from knowingly and willfully offering, soliciting, receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual, for an item or service or the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs. In the past, the government has enforced the Anti-Kickback Statute to reach large settlements with healthcare companies based on sham consulting and other financial arrangements with physicians and other third parties. The Anti-Kickback Statute is subject to evolving interpretations, and in the absence of substantive
8

guidance, it is possible for future initiatives or engagements with healthcare professionals to be challenged under this Statute, which could adversely impact our operations. While this Statute has a number of exceptions and regulatory safe harbors that safeguard certain common, industry practices from prosecution, these exceptions and safe harbors are narrowly defined, and parties must satisfy all elements of an available exception or safe harbor to avoid scrutiny. Further, a person or entity does not need to have actual knowledge of these statutes or specific intent to violate them to have committed a violation. For example, through legislative action, the government may assert that an Anti-Kickback Statute violation could implicate the federal civil False Claims Act. The majority of states also have anti-kickback laws, which establish similar prohibitions and in some cases may apply to items or services reimbursed by any third-party payor, including commercial insurers.
The civil False Claims Act prohibits knowingly presenting or causing the presentation of a false, fictitious or fraudulent claim for payment to federal programs (including Medicare and Medicaid). Actions under the False Claims Act may be brought directly by the government or as a qui tam action by a private individual (acting as a “whistleblower”) in the name of the government. In addition, as noted directly above, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act. Violations of the False Claims Act can result in significant monetary penalties including treble damages, and carry the potential for exclusion from participation in federal healthcare programs. The federal government has and continues to use the False Claims Act, and the accompanying threat of significant liability, in its investigation and prosecution of pharmaceutical and biotechnology companies in connection with the potential or actual false claims resulting from promotion of products for unapproved uses or other sales and marketing practices. The government has obtained multi-billion dollar settlements under the False Claims Act and individual criminal convictions under applicable criminal statutes. We expect that the government will continue to devote substantial resources to investigating potential or actual violations of the False Claims Act.
The federal criminal statute on false statements makes it a crime to knowingly and willfully (in connection with the delivery of or payment for health care benefits, items, or services): (i) falsify, conceal, or cover up any material fact, (ii) make any materially false, fictitious, or fraudulent statements or representations, or (iii) make or use any materially false writing or document while knowing such writings or documents contain materially false, fictitious, or fraudulent statements.
The Civil Monetary Penalties Law provides the government the ability to impose civil monetary penalties against any party or entity who offers or transfers anything of value to a federal health care program beneficiary when a party or entity knows or should know that providing a transfer of value is likely to influence the beneficiary’s selection of a particular provider, practitioner, or supplier for the order or receipt of any item or service reimbursable by a federal health care program. Notably, while pharmaceutical and biotech companies are generally not considered “providers, practitioners, or suppliers,” offering anything of value to a beneficiary that is likely to influence the beneficiary to select a particular provider, practitioner, or supplier (e.g., a physician or pharmacy) could implicate the Civil Monetary Penalties Law.
The federal Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) prohibits, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of these statutes or specific intent to violate them to have committed a violation.
The federal physician Payments Sunshine Act (generally referred to as the Open Payments™ Program) is a provision under the Patent Protection and Affordable Care Act (“ACA”). The Open Payments Program imposes reporting requirements on covered entities (e.g., drug manufacturers) for payments made or transfers of value provided by them to certain healthcare organizations (e.g., teaching hospitals) and physicians, which is broadly defined to include doctors, dentists, optometrists, podiatrists and chiropractors, and certain non-physician practitioners (e.g., physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists, anesthesiology assistants and certified nurse midwives). Covered entities are also required to report ownership and investment interests held by physicians and their immediate family members (as it relates to the Covered entities). This information is then analyzed and made public, available via searchable databases. Failure to submit required information may result in significant civil monetary penalties for any payments, transfers of value, or ownership or investment interests that are not timely, accurately and completely reported in an annual submission. Similarly, certain states also mandate the tracking and reporting of gifts, compensation and other remuneration to physicians. Some of these states also require the implementation of commercial compliance programs and impose restrictions on drug manufacturer marketing practices.
Federal and state agencies continue to spend time, energy and resources combating healthcare fraud and abuse. This regulatory environment, taken together with the evolving commercial compliance environment and the need to build, enhance and maintain robust and expandable systems and controls to comply with different compliance and/or reporting requirements in multiple jurisdictions increase the possibility that a healthcare company may violate one or more of the requirements. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to penalties, including, without limitation, civil and criminal penalties, damages, fines, the curtailment or restructuring
9

of our operations, exclusion from participation in federal and state healthcare programs and imprisonment, any of which could adversely affect our ability to operate our business and our financial results.
In addition to the above “fraud and abuse” laws and regulations, we must also account for other applicable state and foreign laws and regulations that could impact our business activities. For example, some states require pharmaceutical companies to certify that they are in compliance with the pharmaceutical industry’s voluntary compliance guidelines and certain federal government compliance guidance, while other states (and some local governments) require the public registration of pharmaceutical sales representatives.
Data Privacy and Security
Numerous state, federal and foreign laws and regulations govern the collection of, disclosure of, use of, access to, transfer of, and confidentiality and security of health-related and other personal information and could apply now or in the future to our operations or the operations of our partners. For example, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (“HITECH”), and their implementing regulations, imposes requirements relating to the privacy, security and transmission of protected health information on HIPAA covered entities, which include certain healthcare providers, health plans and healthcare clearinghouses, and their business associates who conduct certain activities for or on their behalf involving protected health information on their behalf. Entities that are found to be in violation of HIPAA as the result of a breach of unsecured protected health information, a complaint about privacy practices or an audit by the United States Department of Health and Human Services (“HHS”) may be subject to significant civil, criminal and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA non-compliance. Further, entities that knowingly receive individually identifiable health information from a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA may be subject to criminal penalties.
Even when HIPAA does not apply, according to the Federal Trade Commission or the FTC, failing to take appropriate steps to keep consumers’ personal information secure constitutes unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act. The FTC expects a company’s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. In 2022, the FTC also began a rulemaking proceeding to develop additional data privacy rules and requirements, which may add additional complexity to compliance obligations going forward.
In addition, certain state laws govern the privacy and security of health information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. For example, the California Confidentiality of Medical Information Act imposes restrictive requirements regulating the use and disclosure of health information and other personally identifiable information. Further, the California Consumer Privacy Act (“CCPA”) which took effect on January 1, 2020, created individual privacy rights for California consumers and increased the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability. Further, the California Privacy Rights Act (“CPRA”) revised and expanded the CCPA, adding additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It also created a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The CPRA is in full effect as of January 1, 2023, and similar laws passed in Virginia, Colorado, Connecticut, and Utah took effect in 2023. Additionally, Delaware, Indiana, Iowa, Montana, Oregon, Tennessee and Texas have adopted privacy laws, which take effect from July 1, 2024 through 2026. Further, Washington's My Health My Data Act, taking effect July 1, 2024, imposes similar requirements specific to consumer health data. As a result, additional compliance investment and potential business process changes may be required. In the event that we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition. Additional legislation proposed at the federal level and in other states, along with increased regulatory action, reflect a trend toward more stringent privacy legislation in the United States.
In Europe, the General Data Protection Regulation (“GDPR”) went into effect in May 2018 and imposes stringent data protection requirements for controllers and processors of personal data of persons within the EU. The GDPR applies to any company established in the EU or the European Economic Area (“EEA”) as well as to those outside the EU or the EEA if they collect and use personal data in connection with the offering of goods or services to individuals in the EU or the monitoring of their behavior. Companies that must comply with the GDPR face increased compliance obligations and risk, including more
10

robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to €20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. In addition, the GDPR increases the scrutiny of transfers of personal data from clinical trial sites located in the EEA to the United States and other jurisdictions that the EC does not recognize as having “adequate” data protection laws. Transfers of personal information out of the European Union face a constantly shifting set of requirements, as courts in Europe have invalidated intergovernmental agreements and European regulators have required changes to standard contracting terms, which themselves do not fit all situations. As a result, significant uncertainty exists with respect to GDPR compliance and the attendant obligations going forward as the regulatory environment is rapidly developing. In addition, from January 1, 2021, companies have had to comply with both the GDPR and the GDPR as incorporated into United Kingdom national law, the latter regime having the ability to separately fine up to the greater of £17.5 million or 4% of global turnover. The EC has adopted an adequacy decision in favor of the United Kingdom, enabling data transfers from EU member states to the United Kingdom without additional safeguards. However, the UK adequacy decision will automatically expire in June 2025 unless the EC re-assesses and renews/extends that decision. Outside Europe, significant data privacy regulatory regimes exist in major markets including Brazil, India, China, and elsewhere. The ever-shifting landscape of global data privacy regulation requires significant investment and attention to avoid significant noncompliance liabilities.
Employees
We are managed by experienced pharmaceutical executives and also enlist the expertise of independent advisors with extensive pharmaceutical experience. As of December 31, 2023, we had 352 employees. We consider our employee relations to be good. Our employees are not covered by a collective bargaining agreement.
We seek to hire, retain and motivate smart, ethical, hard-working employees, officers and directors. To achieve this goal, we offer a collegial work environment where creativity, collaboration and initiative are encouraged. We offer competitive salaries, performance bonuses and equity grants, as well as industry-leading health, retirement and childcare benefits. To align our people’s goals with Corcept’s goals, we offer annual performance-based cash bonuses and stock-based compensation.
About Corcept
We were incorporated in the State of Delaware on May 13, 1998. Our registered trademarks include Corcept® and Korlym®. Other service marks, trademarks and trade names referred to in this document are the property of their respective owners.
Available Information
We are subject to the information requirements of the Securities Exchange Act of 1934, as amended, and we therefore file periodic reports, proxy statements and other information with the SEC relating to our business, consolidated financial statements and other matters. The SEC maintains an Internet site, www.sec.gov, that contains reports, proxy statements and other information regarding issuers such as Corcept.
For more information about Corcept, including free access to our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports, visit our website at www.corcept.com or the SEC’s website, www.sec.gov. The information found on or accessible through our website is not incorporated into, and does not form a part of, this Form 10-K.
ITEM 1A. RISK FACTORS
Investing in our common stock involves significant risks. Before investing, carefully consider the risks described below and the other information in this Annual Report on Form 10-K, including our consolidated financial statements and related notes. The risks and uncertainties described below are the ones we believe may materially affect us. There may be others of which we are unaware that could materially harm our business or financial condition and cause the price of our stock to decline, in which case you could lose all or part of your investment.
Summary of Principal Risks
The following bullet points summarize the principal risks we face, each of which could adversely affect our business, operations and financial results. Below, we have arranged these risks by the part of our business they most directly affect.
Risks Related to our Commercial Activities
•Failure to generate sufficient revenue from the sale of Korlym would harm our financial results and would likely cause our stock price to decline.
11

•If a generic version of Korlym is successfully commercialized, our business, results of operations and financial position would be adversely affected.
•New laws, government regulations, or changes to existing laws and regulations could make it difficult or impossible for us to obtain acceptable prices or adequate insurance coverage and reimbursement for Korlym, which would adversely affect our results of operations and financial position.
Risks Related to our Research and Development Activities
•Our efforts to discover, develop and commercialize our product candidates may not succeed. Clinical drug development is lengthy, expensive and often unsuccessful. Results of early studies and trials are often not predictive of later trial results. Failure can occur at any time. Even if we deem that our product candidates’ clinical trial results demonstrate safety and efficacy, regulatory authorities may not agree. Failure to obtain or maintain regulatory approvals for our product candidates would prevent us from commercializing them.
•Vendors perform many of the activities necessary to carry out our clinical trials, including drug product distribution, trial management and oversight and data collection and analysis. Failure of these vendors to perform their duties or meet expected timelines may prevent or delay approval of our product candidates.
Risks Relating to our Intellectual Property
•To succeed, we must secure, maintain and effectively assert adequate patent protection for the composition and methods of use of our proprietary, selective cortisol modulators and for the use of Korlym to treat Cushing’s syndrome.
Risks Related to our Stock
•The price of our common stock fluctuates widely and is likely to continue to do so. Opportunities for investors to sell shares may be limited.
•Our stock price may decline if our financial performance does not meet the guidance we have provided to the public, estimates published by research analysts or other investor expectations.
General Risks
•We rely on information technology to conduct our business. A breakdown or breach of our information technology systems or our failure to protect confidential information concerning our business, patients or employees could interrupt the operation of our business and subject us to liability.
Risk Factors – Discussion
The following section discusses the principal risks listed above, as well as other risks we believe to be material.
Risks Related to our Commercial Activities
Failure to generate sufficient revenue from the sale of Korlym would harm our financial results and would likely cause our stock price to decline.
Our ability to generate revenue and to fund our commercial operations and development programs is dependent on the sale of Korlym to treat patients with Cushing’s syndrome. Physicians will prescribe Korlym only if they determine that it is preferable to other treatments, even if those treatments are not approved for Cushing’s syndrome. Most physicians are inexperienced diagnosing or caring for patients with Cushing’s syndrome and it can be hard to persuade them to identify appropriate patients and treat them with Korlym.
Many factors could limit our Korlym revenue, including:
•the preference of some physicians for competing treatments for Cushing’s syndrome, including off-label treatments and generic versions of Korlym; and
•lack of availability of government or private insurance, the shift of a significant number of patients to Medicaid, which reimburses Korlym at a significantly lower price, or the introduction of government price controls or other price-reducing regulations, such as the Inflation Reduction Act of 2022, that may significantly limit Medicare reimbursement rates.
Failure to generate sufficient Korlym revenue could prevent us from fully funding our planned commercial and clinical activities and would likely cause our stock price to decline.
12

If a generic version of Korlym is successfully commercialized, our business, results of operations and financial position would be adversely affected.
The marketing exclusivity provided by Korlym’s orphan drug designation expired in February 2019, which means other companies may now seek to introduce generic equivalents of Korlym for Korlym’s approved indication, provided such parties receive FDA approval and can show that they would not infringe our applicable patents or that those patents are invalid or unenforceable. If our patents are successfully challenged and a generic version of Korlym becomes available, our sales of Korlym tablets and their price could decline rapidly and significantly, which would reduce our revenue and materially harm our results of operations and financial position. Competition from a generic version of Korlym may also cause our revenue to be materially less than the public guidance we have provided, which would likely cause the price of our common stock to decline.
Legal action to enforce or defend intellectual property rights is complex, costly and involves significant commitments of management time. There can be no assurance of a successful outcome. We have sued Teva in Federal District Court with respect to its proposed generic versions of Korlym. On December 29, 2023, the Court issued a ruling in that case finding that Teva’s generic product would not infringe the patents we have asserted against Teva. We have appealed that decision to the Federal Circuit Court of Appeals, but there can be no assurance our appeal will be successful. Because Teva has received FDA approval, it has been able, since August 2020, to market its generic product, notwithstanding our ongoing litigation. Teva has announced the launch of its generic product. If its launch is successful, it may materially harm our results of operations and financial condition, even if our on-going appeal is successful and Teva were required to withdraw its product and pay us damages.
We had also sued Sun and Hikma with respect to their proposed generic versions of Korlym, although we settled those lawsuits in June 2021 and December 2022, respectively. The terms of these settlements permit entry by Sun and Hikma, with customary restrictions, following the start of sales of Teva’s generic product. Market entry by Sun or Hikma could materially harm our results of operations and financial condition, even if our on-going appeal is successful and they were required to withdraw its product and pay us damages. Please see “Part I, Item 3, Legal Proceedings” for additional details.
It is likely that other companies will seek FDA approval to market a generic version of Korlym. While we will vigorously protect our intellectual property, there can be no assurance our efforts will be successful.
Other companies offer different medications to treat patients with Cushing’s syndrome. The availability of competing treatments could limit our revenue from Korlym.
Since 2012, a medication owned by the Italian pharmaceutical company Recordati-S.p.A., the somatostatin analogue Signifor® (pasireotide) Injection, has been marketed in both the United States and the EU for adult patients with Cushing’s disease (a subset of Cushing’s syndrome). On March 6, 2020, the FDA granted Recordati approval to market another cortisol synthesis inhibitor, Isturisa® (osilodrostat) tablets, to treat patients with Cushing’s disease. Osilodrostat is approved in the EU for the treatment of patients with Cushing’s syndrome.
On December 30, 2021, Xeris received FDA approval to market the cortisol synthesis inhibitor Recorlev® (levoketoconazole) to treat patients with Cushing’s syndrome in the United States. Levoketoconazole is an enantiomer of the generic anti-fungal medication, ketoconazole, that is prescribed off-label to treat patients with Cushing’s syndrome.
Osilodrostat and levoketoconazole have been designated orphan drugs in both the EU and the United States.
Physician preference for any of these medications, or for the off-label use of generic medications such as ketoconazole, to treat patients with Cushing’s syndrome could reduce our revenue materially and harm our results of operations, which would cause our stock price to decline.
New laws, government regulations, or changes to existing laws and regulations could make it difficult or impossible for us to obtain acceptable prices or adequate insurance coverage and reimbursement for Korlym, which would adversely affect our results of operations and financial position.
The commercial success of Korlym depends on the availability of acceptable pricing and adequate insurance coverage and reimbursement. Government payers, including Medicare, Medicaid and the Veterans Administration, as well as private insurers and health maintenance organizations, are increasingly attempting to contain healthcare costs by limiting reimbursement for medicines. In many foreign markets, drug prices and the profitability of prescription medications are subject to government control. In the United States, we expect that there will continue to be federal and state proposals for similar controls. Also, the trends toward managed health care in the United States and recent laws and legislation intended to increase the public visibility of drug prices and reduce the cost of government and private insurance programs could significantly influence the purchase of health care services and products and may result in lower prices for Korlym. If government or private
13

payers cease to provide adequate and timely coverage, pricing and reimbursement for Korlym, physicians may not prescribe the medication and patients may not purchase it, even if it is prescribed, or the price we receive may be reduced, which would reduce our revenue.
In the United States, there have been and continue to be legislative initiatives to contain healthcare costs. The Patient Protection and Affordable Care Act (“ACA”) which was passed in 2010, substantially changed the way health care is financed by both governmental and private insurers. The IRA introduced some of the most significant changes to Medicare payment for prescription drugs since the ACA. Among its many provisions, the IRA requires the Secretary of the U.S. Department of Health and Human Services (“HHS”) to negotiate Medicare prices for selected drugs and biologicals, including both physician-administered products covered under Medicare’s Part B benefit and self-administered drugs covered under the Part D benefit. Each year, the Secretary will select for price negotiation a specified number of negotiation-eligible drugs with the highest total Part B or D expenditures over a preceding 12-month period. To be eligible for price negotiation a drug must have been on the market for at least seven years without generic competition. Orphan drugs indicated for only one rare disease or condition and drugs with less than $200 million in annual Medicare expenditures are exempt from the negotiation program. For the first two years of the program, 2026 and 2027, only Part D drugs are eligible. The Secretary will publish the negotiated price, known as the “Maximum Fair Price” (“MFP”), for each of the selected products. Manufacturers of selected drugs would be required to offer the drug for Medicare recipients at the MFP. Manufacturers who fail to negotiate or offer the MFP can face significant civil money penalties or excise tax liability on sales of that drug. Depending on the share of Medicare spending each year that is attributed to Korlym or any other drug candidate that we develop and whether or not those drugs become eligible for Medicare negotiation, those drugs and our revenue may be adversely impacted by this provision.
The IRA also establishes an inflation rebate program that requires manufacturers to pay rebates to the Medicare program if any of the medications they provide Medicare recipients increase in price faster than the rate of inflation. The Part D inflation rebate provision went into effect on October 1, 2022. Although manufacturers are generally familiar with inflation rebates under the Medicaid program, where they have existed for decades, the IRA represents the first time that inflation rebates have been extended to the Medicare program.
Beginning in 2025, the IRA will also shift a significant portion of the Medicare beneficiary costs from the government and beneficiaries to manufacturers. We anticipate that this provision will significantly limit the revenue we receive and may materially reduce our revenue and profits.
We make grants to independent charitable foundations that help financially needy patients with their premium, co-pay, and co-insurance obligations with respect to their Cushing's syndrome treatment, whether that treatment includes Korlym or not. There has been enhanced scrutiny of company-sponsored patient assistance programs, including insurance premium and co-pay assistance programs and donations to third-party charities that provide such assistance. As a result of this scrutiny, these assistance programs and charities may decide to reduce or eliminate entirely the assistance they provide to patients, which could result in fewer patients receiving the financial support they need to cover the cost of their Cushing’s syndrome care, including the cost of medication, which may include Korlym.
There continues to be federal and state initiatives to contain healthcare costs, in part informed by the current atmosphere of mounting criticism of prescription drug costs in the United States. We expect governmental oversight and scrutiny of pharmaceutical companies will continue to increase and there will continue to be proposals to change the healthcare system in ways that could harm our ability to sell Korlym profitably. We anticipate that the United States Congress, state legislatures, and regulators may implement healthcare policies intended to curb healthcare costs, such as federal and state controls on reimbursement for drugs (including under Medicare and commercial health plans), new or increased requirements to pay prescription drug rebates and penalties to government health care programs and policies that require drug companies to disclose and justify the prices they charge.
We depend on vendors to manufacture Korlym’s active ingredient, form it into tablets, package it and dispense it to patients. We also depend on vendors to manufacture the active pharmaceutical ingredient (“API”) and capsules or tablets for our product candidates. If our suppliers become unable or unwilling to perform these functions and we cannot transfer these activities to replacement vendors in a timely manner, our business will be harmed.
In the event any of our vendors fails to perform its contractual obligations to us or is materially impaired in its performance, we may experience disruptions and delays in our supply chain and our ability to deliver Korlym to patients, which would adversely affect our business, results of operations and financial position.
Our single specialty pharmacy, Optime, dispenses Korlym and performs related pharmacy and patient support services, including the collection of payments from insurers representing approximately 99 percent of our revenue. If Optime does not adhere to its agreements with payers or does not continue to meet regulatory requirements concerning pharmacy operations, it may not be able to collect some or all of the payments due to us. In addition, if Optime becomes unable or unwilling to perform
14

its obligations under our agreement, we may not be able to dispense Korlym in a timely manner to some or all of our patients. Our agreement with Optime extends to March 31, 2024, subject to customary termination provisions, including the right of Optime to terminate in the event of a material breach by us that we do not cure in a reasonable period of time after receiving written notice. In addition, we may terminate the agreement for convenience.
The facilities used by our vendors to manufacture and package the API and drug product for Korlym and our product candidates and distribute them to hospitals, clinics and patients, must be approved by government regulators in the United States, Europe, and elsewhere. We do not control the activities of these vendors, including whether they maintain adequate quality control and hire qualified personnel. We are dependent on them for compliance with the regulatory requirements known as current good manufacturing practices (“cGMPs”). If our vendors cannot manufacture material that conforms to our specifications and the strict requirements of the FDA or others, they will not be able to maintain regulatory authorizations for their facilities and we could be prohibited from using the API or drug product they have provided. If the FDA, European Medicines Agency (“EMA”), the Medicines and Healthcare products Regulatory Agency (“MHRA”) or other regulatory authorities withdraw regulatory authorizations of these facilities, we may need to find alternative vendors or facilities, which would be time-consuming, complex and expensive and could significantly hamper our ability to develop, obtain regulatory approval for and market our products. Sanctions could be imposed on us, including fines, injunctions, civil penalties, refusal of regulators to approve our product candidates, delays, suspensions or withdrawals of approvals, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could harm our business.
The unfavorable public perception of mifepristone may limit our ability to sell Korlym.
The active ingredient in Korlym, mifepristone, is approved by the FDA in another drug for the termination of early pregnancy. On June 24, 2022, the United States Supreme Court published its decision in the case of Dobbs v. Jackson Women’s Health Organization (“Dobbs”), which overturned Roe v. Wade, the 1973 Supreme Court decision establishing a woman’s right to terminate her pregnancy, subject to certain limitations. Dobbs has stimulated many states to enact laws making abortion illegal in virtually every circumstance, including during early pregnancy. More laws banning or heavily restricting termination of pregnancy may be adopted and existing laws may be made more restrictive. Two highly publicized cases regarding mifepristone have been filed in the U.S. since the Dobbs decision, one of which seeks to invalidate the FDA’s approval of mifepristone and the other of which seeks to uphold the FDA’s approval in certain jurisdictions. On April 7, 2023, the United States District Court for the Northern District of Texas, Amarillo Division, issued a preliminary injunction blocking the FDA’s approval of mifepristone. This ruling has been stayed and will have no effect until the U.S. Supreme Court hears the case, which it is expected to do in 2024. The ultimate outcome is uncertain. Heightened public perception of mifepristone as an abortifacient may draw the attention of hostile state government officials or political activists to Korlym – even though Korlym is not approved for the termination of pregnancy, we do not promote it for that use and we have taken measures to minimize the chance that it will accidentally be prescribed to a pregnant woman. In addition, physicians and patients may choose not to use Korlym as a treatment for Cushing’s syndrome simply to avoid the risk of terminating a pregnancy.
Natural disasters, such as earthquakes, fires, extreme weather events or widespread outbreaks of a deadly disease such as COVID-19, could disrupt our commercial and clinical activities or damage or destroy clinical trial sites, our office spaces, the residences of our employees or the facilities or residences of our vendors, contractors or consultants, which could significantly harm our operations.
A resurgence of COVID-19 or the widespread occurrence of another deadly illness could adversely affect our business, operations and financial results. The COVID-19 pandemic made it difficult to grow our commercial business and slowed the pace of some of our clinical trials.
We are also vulnerable to natural disasters, including earthquakes, fires, hurricanes, floods, blizzards and the extended periods of extreme heat, cold and precipitation made more frequent and severe by global warming. For example, our headquarters are in the San Francisco Bay Area, which experiences earthquakes, wildfires and flooding. Our specialty pharmacy, tablet manufacturers and warehouses are in areas subject to hurricanes and tornadoes. All our activities, as well as the activities of our vendors, consultants, clinical investigators, patients, physicians and regulators, are subject to the risks posed by global warming.
The loss of life, property damage and disruptions to electrical power distribution, communications, travel and shipping caused by natural disasters could make it difficult or impossible to conduct our commercial activities or complete our drug discovery activities or clinical trials. Patients may be unwilling or unable to travel to clinical trial sites, for example, or clinical materials or data may be lost.
Our insurance, if available at all, would likely be insufficient to cover losses resulting from disasters or other business interruptions.
15

We may not have adequate insurance to cover our exposure to product liability claims.
We may be subject to product liability or other claims based on allegations that Korlym or one of our product candidates has harmed a patient. Such a claim may damage our reputation by raising questions about Korlym or our product candidates’ safety and could prevent or interfere with product development or commercialization. Less common adverse effects of a pharmaceutical product are sometimes not known until long after the product is approved for marketing. Because the active ingredient in Korlym is used to terminate pregnancy, clinicians using Korlym in clinical trials and physicians prescribing the medicine to women must take strict precautions to ensure that it is not administered to pregnant women. Failure to observe these precautions could result in significant product liability claims.
Our insurance may not fully cover our potential product liabilities. Inability to obtain adequate insurance coverage could delay development of our product candidates or result in significant uninsured liability. Defending a lawsuit could be costly and divert management from productive activities.
If we are unable to maintain regulatory approval of Korlym or if we fail to comply with other requirements, we will be unable to generate revenue and may be subject to penalties.
We are subject to oversight by the FDA and other regulatory authorities in the United States and elsewhere with respect to our research, testing, manufacturing, labeling, distribution, adverse event reporting, storage, advertising, promotion, recordkeeping and sales and marketing activities. These requirements include submissions of safety information, annual updates on manufacturing activities and continued compliance with FDA regulations, including cGMPs, good laboratory practices and good clinical practices (“GCPs”). The FDA enforces these regulations through inspections of us and the laboratories, manufacturers and clinical sites we use. Foreign regulatory authorities have comparable requirements and enforcement mechanisms. Discovery of previously unknown problems with a product or product candidate, such as adverse events of unanticipated severity or frequency or deficiencies in manufacturing processes or management, as well as failure to comply with FDA or other U.S. or foreign regulatory requirements, may subject us to substantial civil and criminal penalties, injunctions, holds on clinical trials, product seizure, refusal to permit the import or export of products, restrictions on product marketing, withdrawal of the product from the market, product recalls, total or partial suspension of production, refusal to approve pending new drug applications (“NDAs”) or supplemental NDAs, and suspension or revocation of product approvals.
We may be subject to civil or criminal penalties if our marketing of Korlym violates FDA regulations or health care fraud and abuse laws.
We are subject to FDA regulations governing the promotion and sale of medications. Although physicians are permitted to prescribe drugs for any indication they choose, manufacturers may only promote products for their FDA-approved use. All other uses are referred to as “off-label,” manufacturers are prohibited from engaging in any “off-label” promotion. In the United States, we market Korlym to treat hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and for whom surgery has failed or is not an option. Among other activities, we provide promotional materials and training programs to physicians covering the use of Korlym for this indication. The FDA may change its policies or enact new regulations at any time that may restrict our ability to promote our products, which could adversely impact our business.
If the FDA were to determine that we engaged in off-label promotion, the FDA could require us to change our practices and subject us to regulatory enforcement actions, including issuance of a public “warning letter,” untitled letter, injunction, seizure, civil fine or criminal penalties. Other federal or state enforcement authorities might act if they believe that the alleged improper promotion led to the submission and payment of claims for an unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement. Even if it is determined that we are not in violation of these laws, we may receive negative publicity, incur significant expenses and be forced to devote management time to defending our position.
In addition to laws prohibiting off-label promotion, we are also subject to federal and state healthcare fraud and abuse laws and regulations designed to prevent fraud, kickbacks, self-dealing and other abusive practices. The United States healthcare laws and regulations that may affect our ability to operate include, but are not limited to:
•the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal health care programs such as Medicare and Medicaid. And, although we structure our applicable business arrangements in accordance with the safe harbors, it is difficult to determine exactly how the law will be applied in specific circumstances. Accordingly, it is possible that certain practices of ours may be challenged under the federal
16

Anti-Kickback Statute. From a liability perspective, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;
•federal false claims laws, including, without limitation, the False Claims Act, which prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to get a false claim paid. The federal False Claims Act is unique in that it allows private individuals (whistleblowers) to bring actions on behalf of the federal government via qui tam actions. Importantly, under the False Claims Act the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;
•the federal Civil Monetary Penalties law, which prohibits, among other things, offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary’s decision to order or receive items or services reimbursable by the government from a particular provider or supplier;
•HIPAA, which created federal criminal laws that prohibit executing a scheme to defraud any health care benefit program or making false statements relating to health care matters; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;
•federal “sunshine” laws, including the federal Physician Payment Sunshine Act (or sometimes referred to as the Open PaymentsTM Program), that require transparency regarding financial arrangements with health care providers, such as the reporting and disclosure requirements imposed by the ACA on drug manufacturers regarding any “transfer of value” made or distributed to physicians, certain non-physician practitioners, teaching hospitals, and ownership or investment interests held by physicians and their immediate family members;
•federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;
•state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payer, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; and
•state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and pricing information.
The risk of being found in violation of these laws and regulations is increased by the fact that many of them have not been definitively interpreted by regulatory authorities or the courts and their provisions are open to a variety of interpretations. Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available under them, it is possible that some of our business activities, including our relationships with physicians and other healthcare providers (some of whom recommend, purchase and/or prescribe our products) and the manner in which we promote our products, could be subject to challenge and scrutiny. We are also exposed to the risk that our employees, independent contractors, principal investigators, consultants, vendors, distributors and contract research organizations (“CROs”) may engage in fraudulent or other illegal activity. Although we have policies and procedures prohibiting such activity, it is not always possible to identify and deter misconduct and the precautions we take may not be effective in controlling unknown risks or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with applicable laws and regulations.
In November 2021, we received a records subpoena from the United States Attorney’s Office for the District of New Jersey (the “NJ USAO”) seeking information relating to the sale and promotion of Korlym, our relationships with and payments to health care professionals who can prescribe or recommend Korlym and prior authorizations and reimbursement for Korlym. The NJ USAO has informed us that it is investigating whether any criminal or civil violations by us occurred in connection with the matters referenced in the subpoena. It has also informed us that it does not currently consider us a defendant but rather an entity whose conduct is within the scope of the government’s investigation. We are cooperating with the investigation. Please see “Part I, Item 3, Legal Proceedings” for additional details.
If we are found in violation of any of the laws described above or any other government regulations, we may be subject to civil and criminal penalties, damages, fines, exclusion from governmental health care programs, a corporate integrity
17

agreement or other agreement to resolve allegations of non-compliance, individual imprisonment, and the curtailment or restructuring of our operations, any of which could adversely affect our financial results and ability to operate.
Risks Related to our Research and Development Activities
Our efforts to discover, develop and commercialize our product candidates may not succeed. Clinical drug development is lengthy, expensive and often unsuccessful. Results of early studies and trials are often not predictive of later trial results. Failure can occur at any time. Even if we deem that our product candidates' clinical trial results demonstrate safety and efficacy, regulatory authorities may not agree. Failure to obtain or maintain regulatory approvals for our product candidates would prevent us from commercializing them.
Clinical development is costly, time-consuming and unpredictable. Positive data from clinical trials are susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The results from early clinical trials are often not predictive of results in later clinical trials. Product candidates may fail to show the desired safety and efficacy traits despite having produced positive results in preclinical studies and initial clinical trials. Many companies have suffered significant setbacks in late-stage clinical trials due to lack of efficacy or unanticipated or unexpectedly severe adverse events.
Our current clinical trials may prove inadequate to support marketing approvals. Even trials that generate positive results may have to be confirmed in much larger, more expensive and lengthier trials before we could seek regulatory approval.
Clinical trials may take longer to complete, cost more than expected and fail for many reasons, including:
•failure to show efficacy or acceptable safety;
•slow patient enrollment or delayed activation of clinical trial sites;
•delays obtaining regulatory permission to start a trial, changes to the size or design of a trial or changes in regulatory requirements for a trial already underway;
•inability to secure acceptable terms with vendors and an appropriate number of clinical trial sites;
•delays or inability to obtain institutional review board (“IRB”) approval at prospective trial sites;
•failure of patients or investigators to comply with the clinical trial protocol;
•unforeseen safety issues; and
•negative findings of inspections of clinical sites or manufacturing operations by us, the FDA or other authorities.
A trial may also be suspended or terminated by us, the trial’s data safety monitoring board, the IRBs governing the sites where the trial is being conducted or the FDA for many reasons, including failure to comply with regulatory requirements or clinical protocols, negative findings in an inspection of our clinical trial operations or trial sites by the FDA or other authorities, unforeseen safety issues, failure to demonstrate a benefit or changes in government regulations.
During the development of a product candidate, we may decide, or the FDA or other regulatory authorities may require us, to conduct more pre-clinical or clinical studies or to change the size or design of a trial already underway, thereby delaying or preventing the completion of development and increase its cost. Even if we conduct the clinical trials and supportive studies that we consider appropriate and the results are positive, we may not receive regulatory approval. Following regulatory approval, there are significant risks to its commercial success, such as development of competing products by other companies or the reluctance of physicians to prescribe it.
Vendors perform many of the activities necessary to carry out our clinical trials, including drug product distribution, trial management and oversight and data collection and analysis. Failure of these vendors to perform their duties or meet expected timelines may prevent or delay approval of our product candidates.
Third-party clinical investigators and clinical sites enroll patients and CROs manage many of our trials and perform data collection and analysis. Although we control only certain aspects of these third parties’ activities, we are responsible for ensuring that every study adheres to its protocol and meets regulatory and scientific standards. If any of our vendors does not perform its duties or meet expected deadlines or fails to adhere to applicable GCPs, or if the quality or accuracy of the data it produces is compromised, affected clinical trials may be extended, delayed or terminated and we may be unable to obtain approval for our product candidates. Outside parties may have staffing difficulties, may undergo changes in priorities or may become financially distressed, adversely affecting their willingness or ability to conduct our clinical trials. Problems with the timeliness or quality of the work of a CRO may lead us to seek to terminate the relationship and use an alternative service
18

provider. However, making this change may be costly and may delay our trials, and it may be challenging to find a replacement organization that can conduct our trials in an acceptable manner and at an acceptable cost. Failure of our manufacturing vendors to perform their duties or comply with cGMPs may require us to recall drug product or repeat clinical trials, which would delay regulatory approval. If our agreements with any of these vendors terminate, we may not be able to enter into alternative arrangements in a timely manner or on reasonable terms.
Our ability to physically inspect our vendors and clinical sites was limited by COVID-19 pandemic-related and associated public health restrictions, which increased the risk that failures to meet applicable requirements went undetected.
We may be unable to obtain or maintain regulatory approvals for our product or product candidates, which would prevent us from commercializing our product candidates.
We cannot sell a product without the approval of the FDA or comparable foreign regulatory authority. Obtaining such approval is difficult, uncertain, lengthy and expensive. Failure can occur at any stage. In order to receive FDA approval for a new drug, we must demonstrate to the FDA’s satisfaction that the new drug is safe and effective for its intended use and that our manufacturing processes comply with cGMPs. Our inability or the inability of our vendors to comply with applicable FDA and other regulatory requirements can result in delays in or denials of new product approvals, warning letters, untitled letters, fines, consent decrees restricting or suspending manufacturing operations, injunctions, civil penalties, recall or seizure of products, total or partial suspension of product sales and criminal prosecution. We may seek to commercialize our products in international markets, which would require us to receive a marketing authorization and, in many cases, pricing approval, from the appropriate regulatory authorities. Approval procedures vary between countries and can require additional pre-clinical or clinical studies. Obtaining approval may take longer than it does in the United States. Although approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one foreign regulatory authority does not ensure approval by others, failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. Any of these or other regulatory actions could materially harm our business and financial condition.
If we receive regulatory approval for a product candidate, we will be subject to ongoing requirements and oversight by the FDA and other regulatory authorities, such as continued safety and other reporting requirements and possibly post-approval marketing restrictions and additional costly clinical trials. If we are not able to maintain regulatory compliance, we may be required to stop development of a product candidate or to stop selling a product that has already been approved. We may also be subject to product recalls or seizures. Future governmental action or changes in regulatory authority policy or personnel may also result in delays or rejection of pending or anticipated product approvals.
Our products and product candidates may cause undesirable side effects that halt their clinical development, prevent their regulatory approval, limit their commercial potential or cause us significant liability.
Patients in clinical trials report changes in their health, including new illnesses, injuries and discomforts, to their study doctor. Often, it is not possible to determine whether or not these conditions were caused by the drug candidate being studied or something else. As we test our product candidates in larger, longer and more extensive clinical trials, or as use of them becomes more widespread if we receive regulatory approval, patients may report serious adverse events that did not occur or went undetected in previous trials. Many times, serious side effects are only detected in large-scale, Phase 3 clinical trials or following commercial approval.
Adverse events reported in clinical trials can slow or stop patient recruitment, prevent enrolled patients from completing a trial and could give rise to liability claims. Regulatory authorities could respond to reported adverse events by interrupting or halting our clinical trials or limiting the scope of, delaying or denying marketing approval. If we elect, or are required by authorities, to delay, suspend or terminate a clinical trial or commercialization efforts, the commercial prospects of the affected product candidates or products may be harmed and our ability to generate product revenues from them may be delayed or eliminated.
If one of our product candidates receives marketing approval, and we or others later identify undesirable side effects or adverse events, potentially significant negative consequences could result, including but not limited to:
•regulatory authorities may suspend, limit or withdraw approvals of such product;
•regulatory authorities may require additional warnings on the label, including “boxed” warnings, or issue safety alerts and other safety information about the product;
•we may be required to change the way the product is administered or conduct additional studies or clinical trials;
19

•we may be required to create a Risk Evaluation and Mitigation Strategy, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers and/or other elements to assure safe use;
•the product may become less competitive;
•we may be subject to fines, injunctions or the imposition of criminal penalties; and
•we could be sued and held liable for harm caused to patients.
Any of these events could seriously harm our business.
Risks Related to our Capital Needs and Financial Results
We may need additional capital to fund our operations or for strategic reasons. Such capital may not be available on acceptable terms or at all.
We are dependent on revenue from the sale of Korlym and our cash reserves to fund our commercial operations and development programs. If Korlym revenue declines significantly, we may need to curtail our operations or raise funds to support our plans. We may also choose to raise funds for strategic reasons. We cannot be certain funding will be available on acceptable terms or at all. Equity financing would cause dilution, debt financing may involve restrictive covenants. Neither type of financing may be available to us on attractive terms or at all. If we obtain funds through collaborations with other companies, we may have to relinquish rights to one or more of our product candidates. If our revenue declines and our cash reserves are depleted, and if adequate funds are not available from other sources, we may have to delay, reduce the scope of, or eliminate one or more of our development programs.
Risks Relating to our Intellectual Property
To succeed, we must secure, maintain and effectively assert adequate patent protection for the composition and methods of use of our proprietary, selective cortisol modulators and for the use of Korlym to treat Cushing’s syndrome.
Patents are uncertain, involve complex legal and factual questions and are frequently the subject of litigation. The patents issued or licensed to us may be challenged at any time. Competitors may take actions we believe infringe our intellectual property, causing us to take legal action to defend our rights. Intellectual property litigation is lengthy, expensive and requires significant management attention. Outcomes are uncertain. If we do not protect our intellectual property, competitors may erode our competitive advantage. Please see “Part I, Item 3, Legal Proceedings” for additional information.
Our patent applications may not result in issued patents and patents issued to us may be challenged, invalidated, held unenforceable or circumvented. Our patents may not prevent third parties from producing competing products. The foreign countries where we may someday operate may not protect our intellectual property to the extent the laws of the United States do. If we fail to obtain adequate patent protection in other countries, others may produce products in those countries based on our technology.
Risks Related to our Stock
The price of our common stock fluctuates widely and is likely to continue to do so. Opportunities for investors to sell shares may be limited.
We cannot assure investors that a liquid trading market for our common stock will exist at any particular time. As a result, holders of our common stock may not be able to sell shares quickly or at the current market price. During the 52-week period ended February 6, 2024, our average daily trading volume was approximately 902,095 shares and the intra-day sales prices per share of our common stock on The Nasdaq Stock Market ranged from $17.86 to $34.28. As of February 6, 2024, our officers, directors and principal stockholders beneficially owned approximately 20 percent of our common stock.
Our stock price can experience extreme price and volume fluctuations that are unrelated or disproportionate to our operating performance or prospects. Securities class action lawsuits are often instituted against companies following periods of stock market volatility. Such litigation is costly and diverts management’s attention from productive efforts.
Factors that may cause the price of our common stock to fluctuate rapidly and widely include:
•actual or anticipated variations in our operating results or changes to any public guidance we have provided;
•actual or anticipated timing and results of our clinical trials;
20

•actual or anticipated regulatory approvals of our product candidates;
•disputes or other developments relating to our intellectual property, including developments in Abbreviated New Drug Application litigation;
•changes in laws or regulations applicable to the pricing, availability of insurance reimbursement, or approved uses of Korlym, our product candidates or our competitors’ products;
•short-selling of our common stock, the publication of speculative opinions about our business or other market manipulation activities that are intended to lower our stock price or increase its volatility;
•changes in estimates or recommendations by securities analysts or the failure of our performance to meet the published expectations of those analysts or public guidance we have provided;
•purchases of our common stock pursuant to our Stock Repurchase Program or changes to that program;
•general market and economic conditions, including the effects of the COVID-19 pandemic;
•changes in the expected or actual timing of our competitors’ development programs and the approval of competing products;
•purchases or sales of our common stock by our officers, directors or stockholders;
•technological innovations by us, our collaborators or our competitors;
•conditions in the pharmaceutical industry, including the market valuations of companies similar to ours;
•additions or departures of key personnel;
•announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments; and
•additional financing activities.
Our stock price may decline if our financial performance does not meet the guidance we have provided to the public, estimates published by research analysts or other investor expectations.
The guidance we provide as to our expected revenue is only an estimate of what we believe is realizable at the time we give such guidance. It is difficult to predict our revenue and our actual results may vary materially from our guidance. In addition, the rate of physician adoption of Korlym and the actions of government and private payers is uncertain. We may experience competition from generic versions of Korlym, which our public revenue guidance does not anticipate. We may not meet our financial guidance or other investor expectations for other reasons, including those arising from the risks and uncertainties described in this report and in our other public filings and public statements. Research analysts publish estimates of our future revenue and earnings based on their own analysis. The revenue guidance we provide may be one factor they consider when determining their estimates.
General Risk Factors
We need to increase the size of our organization and may experience difficulties in managing growth.
Our commercial and research and development efforts are constrained by our limited administrative, operational and management resources. To date, we have relied on a small management team. Growth will impose significant added responsibilities on members of management, including the need to recruit and retain additional employees. Our financial performance and ability to compete will depend on our ability to manage growth effectively. To that end, we must:
•manage our sales and marketing efforts, clinical trials, research and manufacturing activities effectively;
•hire more management, clinical development, administrative and sales and marketing personnel; and
•continue to develop our administrative systems and controls.
Failure to accomplish any of these tasks could harm our business.
21

If we lose key personnel or are unable to attract more skilled personnel, we may be unable to pursue our product development and commercialization goals.
Our ability to operate successfully and manage growth depends upon hiring and retaining skilled managerial, scientific, sales, marketing and financial personnel. The job market for qualified personnel is intensely competitive and turnover rates have reached record highs within our industry and the geographical areas from which we recruit. We depend on the principal members of our management and scientific staff. Any officer or employee may terminate his or her relationship with us at any time and work for a competitor. We do not have employment insurance covering any of our personnel. The loss of key individuals could delay our research, development and commercialization efforts.
We are subject to government regulation and other legal obligations relating to privacy and data protection. Compliance with these requirements is complex and costly. Failure to comply could materially harm our business.
We and our partners are subject to federal, state and foreign laws and regulations concerning data privacy and security, including HIPAA and the EU General Data Protection Regulation (the “GDPR”). These and other regulatory frameworks are evolving rapidly as new rules are enacted and existing ones updated and made more stringent.
In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy, laws, and federal and state consumer protection laws and regulations (e.g., Section 5 of the Federal Trade Commission Act), that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA. Depending on the facts and circumstances, we could be subject to criminal penalties if we knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.
Even when HIPAA does not apply, according to the Federal Trade Commission (the “FTC”), violating consumers’ privacy or failing to take appropriate steps to keep consumers’ personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act. The FTC expects a company’s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. In 2022, the FTC also began a rulemaking proceeding to develop additional data privacy rules and requirements, which may add additional complexity to compliance obligations going forward.
In addition, certain state laws govern the privacy and security of health information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. For example, the California Confidentiality of Medical Information Act imposes restrictive requirements regulating the use and disclosure of health information and other personally identifiable information. Further, the California Consumer Privacy Act, or the CCPA, which took effect on January 1, 2020, created individual privacy rights for California consumers and increased the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability. Further, the California Privacy Rights Act, or CPRA, revised and expanded the CCPA, adding additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It also created a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The CPRA is in full effect as of January 1, 2023, and similar laws passed in Virginia, Colorado, Connecticut and Utah have taken effect and other states have passed similar laws that will take effect in or after 2024. As a result, additional compliance investment and potential business process changes may be required. In the event that we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition. Additional legislation proposed at the federal level and in other states, along with increased regulatory action, reflect a trend toward more stringent privacy legislation in the United States.
Outside the United States, many jurisdictions have or are in the process of enacting sweeping data privacy regulatory regimes. In Europe, the GDPR took effect in 2018, and is imposing stringent requirements for controllers and processors of personal data of individuals within the EEA, particularly with respect to clinical trials. The GDPR provides that EEA member states may make their own further laws and regulations limiting the processing of health data, which could limit our ability to
22

use and share personal data or could cause our costs to increase and harm our business and financial condition. In addition, the GDPR increases the scrutiny that clinical trial sites located in the EEA should apply to transfers of personal data from such sites to countries that are considered to lack an adequate level of data protection, such as the United States. Recent legal developments have added complexity and compliance uncertainty regarding certain transfers of information from the EEA to the United States. Following EU court decisions, updated standard contractual clauses (“SCCs”) were adopted to account for these judicial decisions, imposing new requirements on data transfers. The revised SCCs must be used for relevant new data transfers from September 27, 2021, and existing SCC arrangements were required to be migrated by December 27, 2022. There is some uncertainty around whether the revised clauses can be used for all types of data transfers, particularly whether they can be relied on for data transfers to non-EEA entities subject to the GDPR. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the SCCs cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results. The GDPR imposes substantial fines for breaches of data protection requirements, which can be up to four percent of global revenue for the preceding financial year or €20 million, whichever is greater, and it also confers a private right of action on data subjects for breaches of data protection requirements. Compliance with European data protection laws is a rigorous and time intensive process that may increase our cost of doing business, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation and reputational harm in connection with our European activities. From January 1, 2021, we have had to comply with the GDPR and separately the United Kingdom GDPR, which, together with the amended United Kingdom Data Protection Act 2018, retains the GDPR in United Kingdom national law, each regime having the ability to fine up to the greater of €20 million/ £17.5 million or 4 percent of global turnover. It is unclear how United Kingdom data protection laws and regulations will develop in the medium to longer term and these changes may lead to additional costs and increase our overall risk exposure. On June 28, 2021, the EC adopted an adequacy decision in favor of the United Kingdom, enabling data transfers from EU member states to the United Kingdom without additional safeguards. However, the United Kingdom adequacy decision will automatically expire in June 2025 unless the EC renews or extends that decision and remains under review by the Commission during this period.
Complying with U.S. and foreign privacy and security laws and regulations is complex and costly. Failure to comply by us or our vendors could subject us to litigation, government enforcement actions and substantial penalties and fines, which could harm our business.
We rely on information technology to conduct our business. A breakdown or breach of our information technology systems or our failure to protect confidential information concerning our business, patients or employees could interrupt the operation of our business and subject us to liability.
We store valuable confidential information relating to our business, patients and employees on our computer networks and on the networks of our vendors. In addition, we rely heavily on internet technology, including video conference, teleconference and file-sharing services, to conduct business. Despite our security measures, our networks and the networks of our vendors are at risk of break-ins, installation of malware or ransomware, denial-of-service attacks, data theft and other forms of malfeasance by persons seeking to commit fraud or theft, which could result in unauthorized access to, and/or misuse of, our clinical data or other confidential information, including confidential information relating to our patients or employees. We may continue to increase our cybersecurity risks, due to our reliance on internet technology and the number of our employees that are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities.
We and our vendors have experienced data breaches, theft, “phishing” attacks and other unauthorized access to confidential data and information. There can be no assurance that our cybersecurity systems and processes will prevent unauthorized access in the future that causes serious harm to us, our patients or employees. We may also experience security breaches that remain undetected for an extended period.
Disruptions or security breaches that result in the disclosure of confidential or proprietary information could cause us to incur liability and delay or otherwise harm our research, development and commercialization efforts. We may be liable for losses suffered by patients or employees or other individuals whose confidential information is stolen as a result of a breach of the security of the systems that we or third parties and our vendors store this information on, and any such liability could be material. Even if we are not liable for such losses, any breach of these systems could expose us to material costs in notifying affected individuals, as well as regulatory fines or penalties. In addition, any breach of these systems could disrupt our normal business operations and expose us to reputational damage and harm our business, operating results and financial condition. Any insurance we maintain against the risk of this type of loss may not be sufficient to cover actual losses or may not apply to the circumstances relating to any particular loss.
23

Changes in federal, state and local tax laws may reduce our net earnings.
Our earnings are subject to federal, state and local taxes. We offset a portion of our earnings using net operating losses and our taxes using research and development tax credits, which reduces the amount of tax we pay. Some jurisdictions require that we pay taxes or fees calculated as a percentage of sales, payroll expense, or other indicia of our activities. Please see “Part IV, Item 15, Notes to Consolidated Financial Statements – Income Taxes.” Changes to existing tax laws could materially increase the amounts we pay, which would reduce our after tax net income.
Research analysts may not continue to provide or initiate coverage of our common stock or may issue negative reports.
The market for our common stock may be affected by the reports financial analysts publish about us. If any of the analysts covering us downgrades or discontinues coverage of our stock, the price of our common stock could decline rapidly and significantly. Paucity of research coverage may also adversely affect our stock price.
Acquisition of Corcept shares through our stock repurchase program will reduce our cash reserves.
In January 2024, our Board of Directors authorized the repurchase of up to $200 million of our common stock pursuant to the Stock Repurchase Program. The Stock Repurchase Program does not require us to acquire any specific number of shares and it may be modified, suspended or discontinued at any time without notice. It is possible that other uses of our capital would have been more advantageous or that our future capital requirements increase unexpectedly. By reducing our cash balance, our repurchases of common stock could hamper our ability to execute our plans, meet financial obligations or access financing.
Sale of a substantial number of shares of our common stock may cause its price to decline.
Sales of a substantial number of shares of our stock in the public market could reduce its price. As additional shares of our stock become available for public resale, whether by the exercise of stock options by employees or directors or because of an equity financing by us, the supply of our stock will increase, which could cause its price to fall. Substantially all of our outstanding shares are eligible for sale, subject to applicable volume and certain other resale restrictions.
Changes in laws and regulations may significantly increase our costs or reduce our revenue, which could harm our financial results.
New laws and regulations, as well as changes to existing laws and regulations, including statutes and regulations concerning taxes and the development, approval, marketing and pricing of medications, the provisions of the ACA requiring the reporting of aggregate spending related to health care professionals, the provisions of the Sarbanes-Oxley Act of 2002, the Dodd Frank Act of 2010 and rules adopted by the SEC and by The Nasdaq Stock Market have and will likely continue to increase our cost of doing business and divert management’s attention from revenue-generating activities.
Anti-takeover provisions in our charter and bylaws and under Delaware law may make an acquisition of us or a change in our management more expensive or difficult, even if an acquisition or a management change would be beneficial to our stockholders.
Provisions in our charter and bylaws may delay or prevent an acquisition of us or a change in our management. Some of these provisions allow us to issue preferred stock without any vote or further action by the stockholders, require advance notification of stockholder proposals and nominations of candidates for election as directors and prohibit stockholders from acting by written consent. In addition, a supermajority vote of stockholders is required to amend our bylaws. Our bylaws provide that special meetings of the stockholders may be called only by our Chairman, President or the Board of Directors and that the authorized number of directors may be changed only by resolution of the Board of Directors. These provisions may prevent or delay a change in our Board of Directors or our management, which our Board of Directors appoints. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law. Section 203 may prohibit large stockholders, in particular those owning 15 percent or more of our outstanding voting stock, from merging or combining with us. These provisions in our charter and bylaws and under Delaware law could reduce the price that investors would be willing to pay for shares of our common stock.
Our officers, directors and principal stockholders, acting as a group, could significantly influence corporate actions.
As of February 6, 2024, our officers and directors beneficially owned approximately 20 percent of our common stock. Acting together, these stockholders could significantly influence any matter requiring approval by our stockholders, including the election of directors and the approval of mergers or other business combinations. The interests of this group may not always coincide with our interests or the interests of other stockholders and may prevent or delay a change in control. This significant concentration of share ownership may adversely affect the trading price of our common stock because many investors perceive disadvantages to owning stock in companies with controlling stockholders.
24

We have in the past and may in the future be subject to short selling strategies that may drive down the market price of our common stock.
Short sellers have in the past and may attempt in the future to drive down the market price of our common stock. Short selling is the practice of selling securities that the seller does not own but may have borrowed with the intention of buying identical securities back at a later date. The short seller hopes to profit from a decline in the value of the securities between the time the securities are borrowed and the time they are replaced. As it is in the short seller’s best interests for the price of the stock to decline, many short sellers (sometime known as “disclosed shorts”) publish, or arrange for the publication of, negative opinions regarding the relevant issuer and its business prospects to create negative market momentum. Although traditionally these disclosed shorts were limited in their ability to access mainstream business media or to otherwise create negative market rumors, the rise of the Internet and technological advancements regarding document creation, videotaping and publication by weblog (“blogging”) have allowed many disclosed shorts to publicly attack a company’s credibility, strategy and veracity by means of so-called “research reports” that mimic the type of investment analysis performed by large Wall Street firms and independent research analysts. These short attacks have, in the past, led to selling of shares in the market. Further, these short seller publications are not regulated by any governmental, self-regulatory organization or other official authority in the U.S. and they are not subject to certification requirements imposed by the SEC. Accordingly, the opinions they express may be based on distortions, omissions or fabrications. Companies that are subject to unfavorable allegations, even if untrue, may have to expend a significant amount of resources to investigate such allegations and/or defend themselves, including shareholder suits against the company that may be prompted by such allegations. We may in the future be the subject of shareholder suits that we believe were prompted by allegations made by short sellers.
ITEM 1B. UNRESOLVED STAFF COMMENTS
None.
ITEM 1C. CYBERSECURITY
In the normal course of business, we collect and store personal information and other sensitive information, including proprietary and confidential business information, intellectual property, information regarding patients and clinical trial participants, sensitive third-party information and employee information. To protect this information, we use managed detection and response services to monitor our network infrastructure and associated endpoints for possible cybersecurity threats. In addition, we use multi-factor authentication, perform penetration testing and engage third parties to assess the effectiveness of our cybersecurity practices. We conduct a thorough risk assessment by identifying critical assets, recognizing potential threats and vulnerabilities, and implement strategies to mitigate these risks and their possible impacts. We establish incidence response plans and provide cybersecurity training to our employees and monitor their activity to ensure adherence to our security protocols.
No risks from cybersecurity threats have occurred that have affected our business strategy, results of operations, or financial condition.
The Corporate Governance and Nominating Committee of our Board of Directors oversees management of risks associated with corporate governance, including cybersecurity. This committee meets regularly with Corcept management and reports to the full Board of Directors.
See “Risk Factors – General Risk Factors” for additional information about the risks to our business associated with a breach or compromise to our information security systems.
ITEM 2. PROPERTIES
We lease 50,777 square feet of office space in Menlo Park, California for our corporate facilities. Our current lease expires in June 2024.
ITEM 3. LEGAL PROCEEDINGS
Teva Litigation
In February 2018, we received a Paragraph IV Notice Letter advising that Teva Pharmaceuticals USA, Inc. (“Teva”) had submitted an Abbreviated New Drug Application (“ANDA”) to the FDA seeking authorization to manufacture and sell a generic version of Korlym prior to the expiration of patents related to Korlym that are listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”). In March 2018, we filed a lawsuit in the United States District Court for the District of New Jersey (“D.N.J.”) against Teva for infringement of our patents. In August 2020, Teva received final approval from the FDA for its ANDA in accordance with the Hatch-Waxman Act. In May 2019, Teva
25

submitted to the Patent Trial and Appeal Board (“PTAB”) a petition for post-grant review (“PGR”) of U.S. Patent No. 10,195,214 (the “’214 patent”). The PTAB agreed to initiate the PGR, and in November 2020, issued a decision upholding the validity of the ’214 patent in its entirety, which decision the Federal Circuit Court of Appeals upheld. This matter is closed. In D.N.J., the parties completed briefing on cross-motions for summary judgment regarding infringement of the ’214 patent in July 2021. On February 27, 2023, the Court denied both motions without prejudice.
The patents currently at issue are the ʼ214 patent and U.S. Patent No. 10,842,800 (the “’800 patent”). Trial was held from September 26, 2023 through September 28, 2023 before Judge Renee Marie Bumb. On December 29, 2023, Judge Bumb issued a ruling finding that Teva’s proposed generic product would not infringe either the ‘214 or ‘800 patent. We have appealed that decision to the Federal Circuit Court of Appeals. Teva has announced the launch of its generic product.
We will vigorously enforce our intellectual property rights relating to Korlym but cannot predict the outcome of these matters.
Hikma ANDA Litigation and Settlement
In February 2021, we received a Paragraph IV Notice Letter advising that Hikma Pharmaceuticals USA Inc. (“Hikma”) had submitted an ANDA to the FDA seeking authorization to manufacture, use or sell a generic version of Korlym in the United States. In March 2021, we filed a lawsuit in the United States District Court for the District of New Jersey against Hikma for infringement of the ’214 patent, U.S. Patent No. 10,500,216, the ’800 patent and U.S. Patent Nos. 10,842,801.
On December 7, 2022, we entered into an agreement with Hikma resolving this litigation. Pursuant to the agreement, we have granted Hikma the right to sell a generic version of Korlym in the United States beginning October 1, 2034 or earlier under circumstances customary for settlement agreements of this type, including following the start of Teva's sales of a generic product. As required by law, we submitted the settlement agreement to the United States Federal Trade Commission and the United States Department of Justice for review.
Other Matters
In March 2019, a purported securities class action complaint was filed in the United States District Court for the Northern District of California by Nicholas Melucci (Melucci v. Corcept Therapeutics Incorporated, et al., Case No. 5:19-cv-01372-LHK) (the “Melucci litigation”). The complaint named us and certain of our executive officers as defendants asserting violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder and alleges that the defendants made false and materially misleading statements and failed to disclose adverse facts about our business, operations and prospects. The complaint asserts a putative class period extending from August 2, 2017 to February 5, 2019 and seeks unspecified monetary relief, interest and attorneys’ fees. In October 2019, the Court appointed a lead plaintiff and lead counsel. The lead plaintiff’s consolidated complaint was filed in December 2019. With respect to these allegations, we have stated, from the beginning, that we have done nothing wrong.
On February 8, 2023, we reached an agreement in principle (the “Proposed Settlement”) to resolve all claims in the Melucci litigation. Under the Proposed Settlement, we have agreed to make a one-time payment of $14.0 million, which will be covered in full by our insurers. The Court granted preliminary approval of the Proposed Settlement on January 4, 2024, following which we paid $14.0 million into escrow. Our insurers reimbursed us in full. The Proposed Settlement does not include admission of liability on our part. The Proposed Settlement is subject to the final approval of the Court. The Court has issued its preliminary approval and has scheduled a hearing with respect to final approval on June 6, 2024.
In September 2019, a purported shareholder derivative complaint was filed in the United States District Court for the District of Delaware by Lauren Williams, captioned Lauren Williams v. G. Leonard Baker, et al., Civil Action No. 1:19-cv-01830. The complaint named our board of directors, Chief Executive Officer and current Chief Business Officer as defendants, and us as nominal defendant. The complaint alleges breach of fiduciary duty, violation of Section 14(a) of the Exchange Act, insider selling, misappropriation of insider information and waste of corporate assets and seeks damages in an amount to be proved at trial. In October 2019, this action was stayed pending a resolution of our motions to dismiss the Melucci litigation. In December 2020, the case was further stayed pending a resolution of our motion to dismiss the third amended complaint in the Melucci litigation. In September 2021, the case was further stayed pending a resolution of the Melucci litigation.
In December 2019, a second purported shareholder derivative complaint was filed in the United States District Court for the District of Delaware by Jeweltex Pension Plan, captioned Jeweltex Pension Plan v. James N. Wilson, et al., Civil Action No. 1:19-cv-02308. The complaint named our board of directors, Chief Executive Officer and current Chief Business Officer as defendants, and us as nominal defendant. The complaint alleges causes of action for breach of fiduciary duty, violation of Section 14(a) of the Exchange Act, waste of corporate assets, contribution and indemnification, aiding and abetting, and gross
26

mismanagement. The complaint seeks damages in an amount to be proved at trial. In April 2020, this action was stayed pending a resolution of our motions to dismiss the Melucci litigation. In December 2020, the case was further stayed pending a resolution of our motion to dismiss the third amended complaint in the Melucci litigation. In September 2021, the case was further stayed pending a resolution of the Melucci litigation.
In January 2022, a purported shareholder derivative complaint was filed in the Delaware Court of Chancery by Joel B. Ritchie, captioned Joel B. Ritchie v. G. Leonard Baker, et al., Case No. 2022-0102-SG. The complaint named our Board of Directors, Chief Executive Officer, current Chief Business Officer and President of Corcept Endocrinology as defendants, and us as nominal defendant. The complaint alleges a single cause of action for breach of fiduciary duty. The complaint seeks damages in an amount to be proved at trial. In April 2022, the case was further stayed pending a resolution of the Melucci litigation.
As settlement of the Melucci litigation advances, we expect all stays of the above-described derivative actions to be lifted and for litigation to commence.
We will respond vigorously to the above allegations but cannot predict the outcome of these matters.
In November 2021, we received a records subpoena from the United States Attorney’s Office for the District of New Jersey (the “NJ USAO”) pursuant to Section 248 of the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) seeking information relating to the sale and promotion of Korlym, our relationships with and payments to health care professionals who can prescribe or recommend Korlym and prior authorizations and reimbursement for Korlym. The NJ USAO has informed us that it is investigating whether any criminal or civil violations by us occurred in connection with the matters referenced in the subpoena. It has also informed us that it does not currently consider us a defendant but rather an entity whose conduct is within the scope of the government’s investigation.
In addition to the above-described matters, we are involved from time-to-time in other legal proceedings arising in the ordinary course of our business. Although the outcome of any such matters and the amount, if any, of our liability with respect to them cannot be predicted with certainty, we do not believe that they will have a material adverse effect on our business, results of operations or financial position.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
27

PART II
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
Market Information
Our common stock is traded on The Nasdaq Capital Market under the symbol “CORT.”
Stockholders of Record and Dividends
As of February 6, 2024, we had 103,517,388 shares of common stock outstanding held by 379 stockholders of record. Because almost all of our common stock is held by brokers, nominees and other institutions on behalf of stockholders, we are unable to estimate the actual number of our stockholders. We have never declared or paid cash dividends. We do not anticipate paying cash dividends in the foreseeable future.
Sale of Unregistered Securities
None.
Repurchases of Securities
The following table contains information relating to the purchases of our common stock in the three months ended December 31, 2023 as part of the cashless net exercises of stock options (in thousands, except average price per share):
Fiscal Period
Total Number of Shares Purchased(1)
Average Price Per Share
Total Purchase Price of Shares(2)
October 1, 2023 to October 31, 20231 $28.34 $22 
November 1, 2023 to November 30, 202343 25.65 1,114 
December 1, 2023 to December 31, 202376 29.50 2,240 
Total120 $28.10 $3,376 
(1) In October 2023, we issued 1,250 shares of common stock as part of net-share settlement of cashless option exercises, of which 783 shares were surrendered to us in satisfaction of related exercise cost and tax obligations. In November 2023, we issued 62,115 shares of common stock as part of net-share settlement of cashless option exercises, of which 43,435 shares were surrendered to us. In December 2023, we issued 161,773 shares of common stock as part of net-share settlement of cashless option exercises, of which 75,914 shares were surrendered to us.
(2) We paid $0.5 million to satisfy the tax withholding obligations associated with the net-share settlement of these cashless option exercises.
Market Performance Graph
The graph and the accompanying text below is not “soliciting material,” is not deemed filed with the SEC and is not to be incorporated by reference in any filings by us under the Securities Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in such filing.
We have elected to use the Nasdaq US Benchmark TR Index and Nasdaq Biotechnology Index (consisting of a group of 120 companies in the biotechnology sector, including us) for purposes of the performance comparison that appears below.
The graph shows the cumulative total stockholder return assuming the investment of $100 and the reinvestment of any dividends and is based on the returns of the component companies weighted according to their market capitalizations as of the end of the period for which returns are indicated. We have never paid dividends on our common stock.
The return shown in the graph below for our common stock is not necessarily indicative of future performance. We do not make or endorse any predictions as to future stockholder returns.
28

Five-Year Cumulative Total Returns of our Common Stock (CORT),
the Nasdaq US Benchmark TR Index (NQUSBT) and
the Nasdaq Biotechnology Index (NBI)
2421
ITEM 6. [RESERVED]
29

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is intended to help the reader understand our results of operations and financial condition and is provided as a supplement to, and should be read in conjunction with our audited consolidated financial statements and the accompanying notes to financial statements, risk factors and other disclosures included in this Form 10-K. Our consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”).
We make statements in this section that are “forward-looking” within the meaning of the federal securities laws. For a complete discussion of such statements and the potential risks and uncertainties that may affect their accuracy, see the “Risk Factors” section of this Form 10-K and the “Overview” and “Liquidity and Capital Resources” sections of this MD&A. Discussions of 2021 items and year-to-year comparisons between 2022 and 2021 are not included, and can be found in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7 of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022.
Overview
We are a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. Since 2012, we have marketed Korlym® for the treatment of patients suffering from Cushing’s syndrome. Our portfolio of proprietary selective cortisol modulators consists of four structurally distinct series totaling more than 1,000 compounds.
Cushing’s Syndrome
Korlym. We sell Korlym in the United States, using experienced sales representatives to call on physicians caring for patients with hypercortisolism (“Cushing’s syndrome”). We also have a field-based force of medical science liaisons. We use one specialty pharmacy and one specialty distributor to distribute Korlym and provide logistical support to physicians and patients. Our policy is that no patient with Cushing’s syndrome will be denied access to Korlym for financial reasons. To help us achieve that goal, we fund our own patient support programs and donate money to independent charitable foundations that help patients pay for all aspects of their Cushing’s syndrome care, whether or not that care includes taking Korlym.
Because many people who suffer from Cushing’s syndrome are undiagnosed or inadequately treated, we have developed and continue to refine and expand programs to educate physicians and patients about screening for hypercortisolism and the role Korlym can play in treating patients with the disorder. We have initiated a Phase 4 study (“CATALYST”), to determine the prevalence of Cushing’s syndrome in patients with difficult-to-control diabetes (HbA1c of 7.5 percent or higher) despite receiving standard treatment. In CATALYST’s first phase, 1,000 patients will be evaluated. Those found to have Cushing’s syndrome may elect to enter the second phase of the study, in which patients will be randomized to receive either Korlym or placebo for 24 weeks. We expect that data from CATALYST will help physicians better identify patients with Cushing’s syndrome and determine their optimal treatment.
Relacorilant. We are conducting two Phase 3 trials (“GRACE” and “GRADIENT”) of our proprietary, selective cortisol modulator, relacorilant, as a treatment for patients with Cushing’s syndrome. Relacorilant was well-tolerated in its Phase 1 and Phase 2 trials. Patients in the Phase 2 trial exhibited meaningful improvements in glucose control, hypertension, weight, liver function, coagulopathy, cognition, mood, insulin resistance and quality of life measures. Relacorilant shares Korlym’s affinity for the glucocorticoid receptor (“GR”), but, unlike Korlym, has no affinity for the progesterone receptor (“PR”), and so is not the “abortion pill.” It does not cause other effects associated with PR affinity, including endometrial thickening and vaginal bleeding. There is no evidence that relacorilant causes hypokalemia (low potassium), a potentially serious condition that is a leading cause of patients stopping treatment with Korlym. Forty-four percent of patients in Korlym’s pivotal trial experienced hypokalemia. Unlike all other medications used to treat Cushing’s syndrome, relacorilant does not prolong the heart’s QT interval, a potentially deadly off-target effect.
In the GRACE trial, each patient receives relacorilant for 22 weeks. Patients who exhibit pre-specified improvements in hypertension and/or glucose metabolism enter a 12-week, double-blind, “randomized withdrawal” phase, in which half of the patients continue receiving relacorilant and half receive placebo. The trial’s primary endpoint is the rate and degree of relapse of hypertension in patients receiving placebo measured against the rate and degree of relapse of hypertension in those continuing relacorilant. GRACE has enrolled 152 patients at sites in the United States, Canada, Europe and Israel. Enrollment is now complete. If successful, GRACE will provide the basis for a new drug application (“NDA”) for relacorilant as a treatment for patients with any etiology of endogenous Cushing’s syndrome.
30

Our second Phase 3 trial of relacorilant, GRADIENT, is studying patients whose Cushing’s syndrome is caused by a benign adrenal tumor. These patients often exhibit less severe symptoms or have a more gradual course of disease than patients with other etiologies of Cushing’s syndrome, although their health outcomes are ultimately poor. Half of the patients in GRADIENT will receive relacorilant for 22 weeks and half will receive placebo. The trial’s primary endpoints are improvements in glucose metabolism and hypertension.
The United States Food and Drug Administration (“FDA”) and the European Commission (“EC”) have designated relacorilant as an orphan drug for the treatment of Cushing’s syndrome. In the United States, relacorilant’s orphan designation confers tax credits, reduced regulatory fees and, provided we obtain approval for the treatment of patients with Cushing’s syndrome, seven years of exclusive marketing rights. Benefits of orphan drug designation by the EC are similar, but also include protocol assistance from the European Medicines Agency (“EMA”), access to the centralized marketing authorization procedure in the European Union (“EU”) and, if we obtain approval, ten years of exclusive marketing rights in the EU for the treatment of patients with Cushing’s syndrome.
Oncology
There is substantial evidence that cortisol activity at the GR reduces the efficacy of certain anti-cancer therapies and that modulating cortisol’s activity may help anti-cancer treatments achieve their intended effect. In some cancers, cortisol retards cellular apoptosis – the tumor-killing effect many treatments are meant to stimulate. In other cancers, cortisol activity promotes tumor growth. Cortisol also suppresses the body’s immune response; activating – not suppressing – the immune system is beneficial in fighting certain cancers. Many types of solid tumors express the GR and are potential targets for cortisol modulation therapy, among them ovarian, adrenal and prostate cancer.
Relacorilant in Patients with Advanced Ovarian Cancer. In May 2021, we announced preliminary results from our 178-patient, controlled, multi-center, Phase 2 trial of relacorilant combined with nab-paclitaxel in patients with platinum-resistant ovarian cancer. Study participants were randomized to one of three treatment arms: 60 women received 150 mg of relacorilant intermittently (the day before, the day of and the day after their weekly nab-paclitaxel infusion) and 58 women received a daily relacorilant dose of 100 mg per day in addition to nab-paclitaxel. Sixty women received nab-paclitaxel alone. The trial’s primary endpoint was progression-free survival (i.e., the time from random assignment in a clinical trial to disease progression or death from any cause or “PFS”).
Patients in both of the relacorilant plus nab-paclitaxel treatment arms experienced longer PFS than did the patients who received nab-paclitaxel alone. Patients who received a higher dose of relacorilant intermittently exhibited a statistically significant improvement in median PFS (5.6 months versus 3.8 months, hazard ratio: 0.66; p-value: 0.038). Patients who received a lower dose of relacorilant daily exhibited a median PFS that was 1.5 months longer than did the patients who received nab-paclitaxel alone (5.3 months versus 3.8 months, hazard ratio: 0.83; p-value: not significant). Patients who received relacorilant intermittently also had a longer median duration of response (“DoR”) (5.6 months versus 3.7 months, hazard ratio: 0.36; p-value: 0.006) compared to those who received nab-paclitaxel alone. Patients who received relacorilant intermittently also lived longer (median OS: 13.9 months versus 12.2 months, hazard ratio: 0.67; p-value: 0.066) compared to those who received nab-paclitaxel alone.
Safety and tolerability of relacorilant plus nab-paclitaxel were comparable to nab-paclitaxel monotherapy.
The final analysis from our Phase 2 trial was published in the Journal of Clinical Oncology (Colombo et al., 2023), the premiere journal of the American Society of Clinical Oncology (ASCO).
In June 2022, we initiated a pivotal Phase 3 trial (“ROSELLA”) that seeks to replicate the positive results observed in our Phase 2 study. ROSELLA has a planned enrollment of 360 women with recurrent, platinum-resistant ovarian cancer, half of whom will receive 150 mg of relacorilant intermittently in addition to nab-paclitaxel, with the other half receiving nab-paclitaxel monotherapy. The primary endpoint is PFS; overall survival is a key secondary endpoint. Patients in ROSELLA will have received prior bevacizumab therapy, which is the standard of care for patients with platinum-resistant ovarian cancer. Women with a history of tumors that do not respond to initial platinum-based treatments (i.e., women with “primary platinum-refractory” disease) and those who have received more than three prior lines of therapy will be excluded.
Relacorilant in Patients with Adrenal Cancer with Cortisol Excess. We are conducting an open-label, Phase 1b trial of relacorilant plus the PD-1 checkpoint inhibitor pembrolizumab in patients with metastatic or unresectable adrenal cancer whose tumors produce cortisol. The trial is examining whether adding relacorilant to pembrolizumab therapy reduces cortisol-activated immune suppression sufficiently to help pembrolizumab achieve its intended tumor-killing effect. Relacorilant is also expected to treat the patients’ Cushing’s syndrome generated by their tumors’ excess production of cortisol.
31

Relacorilant in Patients with Prostate Cancer. Androgen deprivation is the standard treatment for prostate cancer because androgens stimulate prostate tumor growth. Tumors often escape androgen deprivation therapy when cortisol’s activity at the GR stimulates tumor growth. Combining a cortisol modulator with an androgen modulator may block this escape route. Our collaborators at the University of Chicago have initiated a randomized, placebo-controlled Phase 2 trial of relacorilant plus enzalutamide in patients with prostate cancer, pre-prostatectomy. We are providing relacorilant and placebo for the study and have licensed patents covering the use of relacorilant combined with anticancer agents such as enzalutamide in the treatment of patients with this indication.
Amyotrophic Lateral Sclerosis (“ALS”)
ALS, also known as Lou Gehrig’s disease, is a devastating neuromuscular illness. Our selective cortisol modulator dazucorilant improved motor performance and reduced neuroinflammation and muscular atrophy in animal models of ALS. Following these compelling results, we initiated a Phase 2 trial (“DAZALS”) of dazucorilant in patients with ALS in October 2022. DAZALS has a planned enrollment of 198 patients, randomized 1:1:1 to receive either 150 mg or 300 mg of dazucorilant or placebo daily for 24 weeks. The primary endpoint is the difference between dazucorilant and placebo demonstrated by patients on the ALS Functional Rating Scale-Revised (ALSFRS-R).
Metabolic Diseases
Liver Disease. Nonalcoholic steatohepatitis (“NASH”) is an advanced form of nonalcoholic fatty liver disease that afflicts millions of patients and is a leading cause of liver-related mortality. In April 2021, we suspended our Phase 2a trial of our selective cortisol modulator miricorilant as a potential treatment for NASH after four of the five patients who received miricorilant exhibited both elevated liver enzymes and large rapid reductions in liver fat. Liver enzyme levels in all affected patients returned to baseline or below baseline (i.e., to healthier levels) after miricorilant was withdrawn. Our Phase 1b study has identified a dosing regimen that effectively reduced liver fat, improved liver health and key metabolic and lipid measures and was well-tolerated. Following these compelling results, we initiated a Phase 2b trial (“MONARCH”) of miricorilant in patients with NASH in October 2023. MONARCH has a planned enrollment of 150 patients, randomized 2:1 to receive either 100 mg of miricorilant twice weekly or placebo for 48 weeks. The primary endpoint is reduction in liver fat, with NASH resolution and fibrosis improvement as key secondary endpoints.
Antipsychotic-Induced Weight Gain (“AIWG”). In the United States, six million people take antipsychotic medications such as olanzapine and risperidone to treat illnesses such as schizophrenia, bipolar disorder and depression. While these drugs are very effective, they often cause rapid and sustained weight gain, other metabolic disturbances and, ultimately, cardiovascular disease. Patients taking these medications experience a 10 to 25-year reduction in life expectancy, due largely to increased cardiovascular events, such as heart attacks and strokes. Patients in our two double-blind, placebo-controlled, Phase 2 trials (“GRATITUDE” and “GRATITUDE II”) of miricorilant with already existing weight gain stimulated by anti-psychotic medication did not exhibit weight loss. However, numerous replicated pre-clinical study results as well as the results of our double-blind, placebo-controlled trial in healthy subjects (published in the Journal of Clinical Psychopharmacology (Hunt et al., 2021)) suggest that miricorilant may significantly prevent weight gain caused by the administration of olanzapine. In October 2023, we initiated a double-blind, placebo-controlled, Phase 1 trial to further study miricorilant’s potential to prevent AIWG.
COVID-19 Pandemic
Public health restrictions and measures voluntarily undertaken by patients, physicians, hospitals and health clinics to reduce the impact of COVID-19 reduced our revenue growth and made it difficult to grow our Korlym business.
The pandemic’s impact on our clinical development programs was variable. Some of our trials of indications not considered immediately life-threatening, such as Cushing’s syndrome, experienced slower enrollment and difficulty retaining patients. In addition, some clinical sites reduced the frequency with which physicians were able to examine study participants. Trials in patients with immediately life-threatening diseases, such as our Phase 2 trial in women with platinum-resistant ovarian cancer, did not encounter delays.
Although the impact of COVID-19 on our business is now significantly reduced, some physicians and hospitals continue to limit interactions with sales representatives and medical science liaisons, which makes growing our business more difficult.
Inflation Reduction Act of 2022
The Inflation Reduction Act of 2022 (“IRA”) was enacted on August 16, 2022. The IRA includes provisions requiring manufacturers to pay a rebate to the Centers for Medicare & Medicaid Services (“CMS”) if the price of a Medicare Part B or Part D drug increases faster than the rate of inflation. In addition, beginning in 2025, the IRA will also shift a significant portion
32

of the Medicare beneficiary costs currently borne by the government and beneficiaries to manufacturers. We anticipate this provision will significantly limit the revenue we receive from Medicare patients and may materially reduce our profits. The IRA also permits CMS to negotiate prices for certain high-expenditure Medicare Part B or Part D drugs, imposes a one percent excise tax on certain share repurchases and introduces a 15 percent corporate alternative minimum tax on adjusted financial statement income. The corporate alternative minimum tax became effective for us on January 1, 2024. We do not expect it to significantly affect our consolidated financial statements.
Please see the risk factor under Item 1A of this Annual Report on Form 10-K, “New laws, government regulations, or changes to existing laws and regulations could make it difficult or impossible for us to obtain acceptable prices or adequate insurance coverage and reimbursement for Korlym, which would adversely affect our results of operations and financial position.”
Results of Operations
Net Product Revenue – Net product revenue is gross product revenue from sales to our customers less deductions for estimated government rebates and chargebacks, patient co-pay assistance program, discounts provided to our specialty distributor for prompt payment and reserves for expected returns.
Net product revenue was $482.4 million for the year ended December 31, 2023, compared to $401.9 million and $366.0 million for the years ended December 31, 2022 and 2021, respectively. Higher sales volume accounted for 57.4 percent of the increase for the year ended December 31, 2023, with the remaining growth due to a price increase effective January 1, 2023.
Cost of sales – Cost of sales includes the cost of API, tableting, packaging, personnel, overhead, stability testing and distribution.
Cost of sales was $6.5 million for the year ended December 31, 2023, compared to $5.4 million and $5.3 million for the years ended December 31, 2022 and 2021, respectively. Cost of sales as a percentage of revenue was 1.3 percent for each of the years ended December 31, 2023 and 2022.
Research and development expense – Research and development expense includes the cost of (1) clinical trials, (2) recruiting and compensating development personnel, (3) manufacturing investigational drug product (4) preclinical studies, (5) drug discovery research and (6) the development of new drug formulations and manufacturing processes.
Research and development expense was $184.4 million for the year ended December 31, 2023, compared to $131.0 million and $113.9 million for the years ended December 31, 2022 and 2021, respectively. The increase for the year ended December 31, 2023 compared to 2022 was primarily due to increased spending on our development programs and employee compensation expenses.
 Year Ended December 31,
 202320222021
(in thousands)
Development programs:   
Oncology$41,433 $20,987 $17,984 
Cushing’s syndrome41,196 30,031 28,639 
Metabolic diseases36,104 24,270 20,594 
Pre-clinical and early-stage selective cortisol modulators and ALS30,852 26,084 21,924 
Unallocated activities, including manufacturing and regulatory activities19,366 16,819 10,617 
Stock-based compensation15,402 12,800 14,106 
Total research and development expense$184,353 $130,991 $113,864 
It is difficult to predict the timing and cost of development activities, which are subject to many uncertainties and risks, including inconclusive or negative results, slow patient enrollment, adverse side effects and difficulties in the formulation or manufacture of study drugs and lack of drug-candidate efficacy. In addition, clinical development is subject to government oversight and regulations that may change without notice. We expect our research and development expense to be higher in 2024 than in 2023 as we add new clinical trials and our existing trials enroll more patients. Research and development spending in future years will depend on the outcome of our pre-clinical and clinical trials and our development plans.
33

Selling, general and administrative expense – Selling, general and administrative expense includes (1) compensation of employees, consultants and contractors engaged in commercial and administrative activities, (2) the cost of vendors supporting commercial activities and (3) legal and accounting fees.
Selling, general and administrative expense for the years ended December 31, 2023, 2022 and 2021 was $184.3 million, $152.8 million and $122.4 million, respectively. The increase for the year ended December 31, 2023 compared to 2022 was primarily due to increased employee compensation expenses and legal fees.
We expect our selling, general and administrative expense to be higher in 2024 than in 2023 due to increased commercial and administrative activities, including litigation and administrative support for increased research and development and marketing efforts.
Interest and other income – Interest and other income for the years ended December 31, 2023, 2022 and 2021 was $17.3 million, $3.6 million and $0.5 million, respectively, and consisted primarily of interest income from marketable securities. The increase for the year ended December 31, 2023 compared to 2022 was due to market-wide increase in interest rates.
Income tax expense – Income tax expense for the years ended December 31, 2023, 2022, and 2021 was $18.4 million, $14.8 million, and $12.5 million, respectively. The increase for the year ended December 31, 2023 compared to 2022 was due to decreased excess tax benefits for stock option exercises.
Liquidity and Capital Resources
Since 2015, we have relied on revenues from the sale of Korlym to fund our operations.
Based on our current plans and expectations, we expect to fund our operations and planned research and development activities over the next 12 months and beyond without needing to raise additional funds, although we may choose to raise additional funds for other reasons. If we were to raise funds, equity financing would be dilutive, debt financing could involve restrictive covenants and funds raised through collaborations with other companies may require us to relinquish certain rights in our product candidates.
As of December 31, 2023, we had cash, cash equivalents and marketable securities of $425.4 million, consisting of cash and cash equivalents of $135.6 million and marketable securities of $289.8 million, compared to cash, cash equivalents and marketable securities of $436.6 million, consisting of cash and cash equivalents of $66.3 million and marketable securities of $370.3 million as of December 31, 2022.
The cash in our bank accounts and our marketable securities could be reduced or our access to them restricted if the financial institutions holding them were to fail or severely adverse conditions were to arise in the markets for public or private debt securities. We have never experienced a material lack of access to cash or material realized losses.
Net cash provided by operating activities for the years ended December 31, 2023, 2022 and 2021 was $127.0 million, $120.3 million and $167.9 million, respectively. The increase for the year ended December 31, 2023 compared to 2022 was primarily due to higher revenue.
Net cash provided by (used in) investing activities for the years ended December 31, 2023, 2022 and 2021 was $90.9 million, $(114.3) million and $136.1 million, respectively. The change for the year ended December 31, 2023 compared to 2022 was primarily due to allocation of cash proceeds from maturities of marketable securities towards cash equivalents in anticipation of the closing of our tender offer in April 2023 and in anticipation of our share buyback program announced in January 2024.
Net cash used in financing activities was $148.7 million, $17.3 million and $302.6 million for the years ended December 31, 2023, 2022 and 2021, respectively. In the year ended December 31, 2023, we spent $154.5 million acquiring shares of our common stock, comprised of $145.4 million pursuant to our tender offer, $7.4 million acquiring shares of our common stock in connection with the net exercise of employee and director stock options and $1.7 million to satisfy tax withholding requirements from vesting of restricted stock grants, offset by $3.8 million received in connection with our ESPP and $2.0 million net cash received from the exercise of stock options, resulting in net cash used in financing activities of $148.7 million. For the year ended December 31, 2022, we spent $21.7 million acquiring shares of our common stock, offset by $4.4 million received from the exercise of stock options, resulting in net cash used in financing activities of $17.3 million.
As of December 31, 2023, we had retained earnings of $402.5 million.
34

Net Operating Loss Carryforwards
See Note 9, Income Taxes in our audited consolidated financial statements.
Critical Accounting Policies and Estimates
Our consolidated financial statements have been prepared in accordance with U.S. GAAP, which requires us to make estimates and judgments that affect the amount of assets, liabilities and expenses we report. We base our estimates on historical experience and on other assumptions we believe to be reasonable. Actual results may differ from our estimates. Our significant accounting policies are described in Note 1, Basis of Presentation and Summary of Significant Accounting Policies, of the Notes to Consolidated Financial Statements included in Part IV of this Annual Report on Form 10-K. We believe the following accounting estimates and policies to be critical:
Net Product Revenue
To determine net product revenue, we deduct from sales the cost of our patient co-pay assistance program and our estimates of (i) government chargebacks and rebates, (ii) discounts provided to our specialty distributor (“SD”) for prompt payment and (iii) reserves for expected returns. We record these estimates at the time we recognize revenue and update them as new information becomes available. Our estimates take into account our understanding of the range of possible outcomes. If results differ from our estimates, we adjust our estimates, which changes our net product revenue and earnings. We report any changes in the period they become known, even if they concern transactions occurring in prior periods.
Government Rebates
Korlym is eligible for purchase by, or qualifies for reimbursement from, Medicaid, Medicare and other government programs that are eligible for rebates on the price they pay for Korlym. To determine the appropriate amount to reserve against these rebates, we identify Korlym sold to patients covered by government-funded programs, apply the applicable government discount to these sales, then estimate utilization of such programs by government payors. We (i) deduct this reserve from revenue in the period to which the rebates relate and (ii) include in accrued expenses on our consolidated balance sheet a current liability of equal amount.
Chargebacks
Although we sell Korlym to the SD at full price, some of the government entities to which the SD sells receive a discount. The SD recovers the full amount of any related discounts by reducing its payment to us (this reduction is called a “chargeback”). Chargebacks sometimes relate to Korlym sold to the SD in prior periods. We deduct from our revenue in each period chargebacks claimed by the SD for Korlym we sold to the SD that period. We also create a reserve for chargebacks we estimate the SD will claim in future periods against Korlym it purchased in the current period but has not yet resold. We determine the amount of this reserve based on our experience with SD chargebacks and our understanding of the SD’s customer base and business practices. We deduct this reserve from revenue and include in accrued expenses on our consolidated balance sheet a current liability of equal amount.
Patient Assistance Program and Charitable Support
It is our policy that no patient be denied Korlym due to inability to pay. We provide financial assistance to eligible patients whose insurance policies have high deductibles or co-payments and deduct the amount of such assistance from gross revenue. We determine the assistance we provide each patient by applying our program guidelines to that patient’s financial position and their insurance policy’s co-payment and deductible requirements. We also donate cash to charities that help patients with financial need pay for the treatment of Cushing’s syndrome (which treatment may not include Korlym). We do not include in our revenue payments these charities make on behalf of patients receiving Korlym. We provide Korlym at no cost to uninsured patients who do not qualify for charitable support.
Inventory and Cost of Sales
We value inventory at the lower of cost or net realizable value and determine the cost of inventory we sell using the specific identification method, which approximates a first-in, first-out basis. We assess our inventory levels at each reporting period and write down inventory that is either expected to be at risk of expiration prior to sale, has a cost basis in excess of its expected net realizable value, or for which there are inventory quantities in excess of expected requirements. We destroy expired inventory and recognize the related costs as cost of sales in that period’s statement of income.
35

Cost of sales includes the cost of manufacturing Korlym, including materials, third-party manufacturing costs and indirect personnel and other overhead costs, based on the number of Korlym tablets for which we recognize revenue, as well as costs of stability testing, logistics and distribution.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The primary objective of our investment activities is to preserve capital. As of December 31, 2023, the fair value of our cash and cash equivalents and marketable securities was $425.4 million. Our marketable securities consisted of corporate notes, commercial paper, asset-backed securities, U.S. Treasury and government agency securities and a money market fund invested in short-term U.S. Treasury securities maintained at a major U.S. financial institution. To minimize our exposure to interest rate and other market risks, we have limited the maturities of our investments to less than three years, with the duration of our portfolio not to exceed two years. Additionally, except for securities issued by the United States government or its agencies, securities of any one issuer may not make up more than ten percent of our portfolio’s market value. Due to the short-term nature and high liquidity of these instruments, an increase or decrease in market interest rates by 25 basis points would not have a material impact on the total value of our portfolio as of December 31, 2023.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
The consolidated financial statements required by this item are set forth beginning at page F-1 and are incorporated herein by reference.
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
None.
ITEM 9A. CONTROLS AND PROCEDURES
(a) Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports we file with the SEC is recorded, processed, summarized and filed within the time periods specified in the SEC’s rules and forms and that such information is accumulated and discussed with our management, including our Chief Executive Officer and Chief Financial Officer, so as to allow timely decisions regarding disclosure.
As of December 31, 2023, our Chief Executive Officer and Chief Financial Officer evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act). Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.
There were no changes in our internal controls over financial reporting during the quarter ended December 31, 2023 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
(b) Management’s Report on Internal Control Over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). Our internal control system is designed to provide reasonable assurance regarding the preparation and fair presentation of externally-reported consolidated financial statements in accordance with U.S. GAAP. As discussed in Item 9A(a) above, internal control systems, no matter how well designed, have inherent limitations and can provide only reasonable assurance that their objectives have been met.
As of December 31, 2023, our management conducted an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our internal control over financial reporting based upon the framework in “Internal Control-Integrated Framework (2013)” issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our internal control over financial reporting was effective as of December 31, 2023.
Our independent registered public accounting firm has issued an attestation report on our internal control over financial reporting. It is set forth below.
36

(c) Inherent Limitations on Effectiveness of Controls
Management recognizes that controls and procedures, no matter how well designed and operated, can only provide reasonable, not absolute, assurance the desired control objectives will be met. In reaching a reasonable level of assurance, management has weighed the cost of contemplated controls against their intended benefits. The design of any system of controls is based on management’s assumptions about the likelihood of future events. We cannot assure you that our controls will achieve their stated goals under all possible conditions. Changes in future conditions may render our controls inadequate or may cause our degree of compliance with them to deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.
(d) Report of Independent Registered Public Accounting Firm
To the Stockholders and Board of Directors of Corcept Therapeutics Incorporated
Opinion on Internal Control over Financial Reporting
We have audited Corcept Therapeutics Incorporated’s internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Corcept Therapeutics Incorporated (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023, based on the COSO criteria.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets as of December 31, 2023 and 2022, the related consolidated statements of income, comprehensive income, cash flows and stockholders’ equity for each of the three years in the period ended December 31, 2023, and the related notes and our report dated February 15, 2024 expressed an unqualified opinion thereon.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.
Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control Over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
37

/s/ Ernst & Young LLP
San Mateo, California
February 15, 2024
ITEM 9B. OTHER INFORMATION
Insider Trading Arrangements
During the three months ended December 31, 2023, no directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted, terminated or modified any contract, instruction or written plan for the purchase or sales of our securities intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange or any “non-Rule 10b5-1 trading arrangement,” as defined in Item 408(a) of Regulation S-K.
ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS
Not applicable.
38

PART III
Certain information required by Part III is omitted from this Form 10-K because we expect to file with the United States Securities and Exchange Commission, not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, a definitive proxy statement (“Proxy Statement”), pursuant to Regulation 14A in connection with the solicitation of proxies for our 2024 Annual Meeting of Stockholders, and certain information included therein is incorporated herein by reference.
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
The information required by this Item will be included in the Proxy Statement and is incorporated herein by reference.
ITEM 11. EXECUTIVE COMPENSATION
Compensation Discussion and Analysis
The information required by this Item will be included in the Proxy Statement and is incorporated herein by reference.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
The information required by this Item will be included in the Proxy Statement and is incorporated herein by reference.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
The information required by this Item will be included in the Proxy Statement and is incorporated herein by reference.
ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES
The information required by this Item will be included in the Proxy Statement and is incorporated herein by reference.
39

PART IV
ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
The following documents are filed as part of this Form 10-K
(1) Financial Statements:
(2) Financial Statement Schedules:
All schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto.
(3) Exhibits:
Item 601 of Regulation S-K requires the exhibits listed below. Each management contract or compensatory plan or arrangement required to be filed as an exhibit to this Form 10-K has been identified.
(A)    EXHIBITS
Exhibit NumberDescription of Document
3.1
3.2
  
4.1
  
4.2
10.1† 
  
10.2†
  
10.3†
  
10.4†
  
10.5†
  
40

Exhibit NumberDescription of Document
10.6†
10.7†
10.8†
10.9†
  
10.10
  
10.11
  
10.12
  
10.13
  
10.14#
  
10.15#
  
10.16##
10.17##
10.18#
10.19#
10.20
10.21
10.22
10.23
41

Exhibit NumberDescription of Document
10.24
10.25†
10.26†
10.27†
10.28
10.29
10.30†
10.31†
10.32†
10.33†
10.34
10.35
10.36
97
23.1
  
24.1
  
31.1
  
31.2
  
32.1
  
32.2
  
101.INSXBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
42

Exhibit NumberDescription of Document
101.SCHXBRL Schema Document
101.CALXBRL Calculation Linkbase Document
101.DEFXBRL Definition Linkbase Document
101.LABXBRL Labels Linkbase Document
101.PREXBRL Presentation Linkbase Document
104Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL Document
#Confidential treatment granted
##Certain identified information has been omitted pursuant to Item 601(b)(10) of Regulation S-K because such information is both (i) not material and (ii) information that the registrant treats as private or confidential. The Registrant hereby undertakes to furnish supplemental copies of the unredacted exhibit upon request by the SEC.
†Management contract or compensatory plan or arrangement
ITEM 16. FORM 10-K SUMMARY
None.
43

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 CORCEPT THERAPEUTICS INCORPORATED
  
 By:/s/ JOSEPH K. BELANOFF
  Joseph K. Belanoff, M.D.,
  Chief Executive Officer and President
 Date:February 15, 2024
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Joseph K. Belanoff and Atabak Mokari, and each of them acting individually, as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, with full power of each to act alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Exchange Act, this Annual Report on Form 10-K has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated:
44

Signature Title Date
/s/ JOSEPH K. BELANOFF Chief Executive Officer, President and Director February 15, 2024
Joseph K. Belanoff, M.D. (Principal Executive Officer)  
     
/s/ ATABAK MOKARI Chief Financial Officer February 15, 2024
Atabak Mokari (Principal Financial Officer)  
     
/s/ JOSEPH DOUGLAS LYONChief Accounting OfficerFebruary 15, 2024
Joseph Douglas Lyon(Principal Accounting Officer)
/s/ JAMES N. WILSON Director and Chairman of the Board of Directors February 15, 2024
James N. Wilson    
     
/s/ GREGG ALTONDirectorFebruary 15, 2024
Gregg Alton
/s/ G. LEONARD BAKER, JR. Director February 15, 2024
G. Leonard Baker, Jr.    
/s/ GILLIAN CANNONDirectorFebruary 15, 2024
Gillian Cannon
/s/ DAVID L. MAHONEY Director February 15, 2024
David L. Mahoney    
/s/ JOSHUA MURRAYDirectorFebruary 15, 2024
Joshua Murray
/s/ KIMBERLY PARK Director February 15, 2024
Kimberly Park    
/s/ DANIEL N. SWISHER, JR Director February 15, 2024
Daniel N. Swisher, Jr.    
45

CORCEPT THERAPEUTICS INCORPORATED
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
F-1

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Stockholders and Board of Directors of Corcept Therapeutics Incorporated
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Corcept Therapeutics Incorporated (the Company) as of December 31, 2023 and 2022, the related consolidated statements of income, comprehensive income, cash flows and stockholders’ equity for each of the three years in the period ended December 31, 2023, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 15, 2024 expressed an unqualified opinion thereon.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matter
The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the account or disclosure to which it relates.
F-2

Net Product Revenue - Accounting for Government Rebates
Description of the matter
As of December 31, 2023, accrued government rebates were $18.5 million, and the Company recognized $52.3 million in revenue reductions associated with rebates during the year-ended December 31, 2023. As discussed in Note 1 to the consolidated financial statements, the Company recognizes revenues net of government rebates and accrues for rebates in the same period the product is sold. However, third-party reporting and payment of the rebate amount occur on a time lag. Allowances for rebates include mandated discounts due to the Company’s participation in various government health care programs. The Company estimates accrued rebates, considering actual revenue, formulaic rebate rates, historical payment experience and expected utilization under each program, and changes in product pricing and information regarding changes in program regulations and guidelines.

Auditing government rebates was complex due to the time lag associated with third-party reporting of rebate amounts, complexity in the calculations of government pricing used to determine the rebate price and the judgmental nature of the utilization assumptions. The complexities associated with government pricing calculations required the involvement of specialists.
How we addressed the matter in our audit
We obtained an understanding, evaluated the design and tested the operating effectiveness of controls that address the risks of material misstatement relating to the measurement and valuation of government rebates. For example, we tested controls over management’s review of the government rebate accrual, including the significant assumptions and data inputs provided by third parties.

To test government rebates, our audit procedures included, among others, evaluating the methodologies, key assumptions, and testing the underlying data used by the Company. We performed analytics on the Company’s net product revenue. We evaluated the reasonableness of management’s assumptions by comparing against historical trends, evaluated the change in estimated accruals from the prior periods, and assessed the historical accuracy of the Company’s estimates against actual results. We utilized government pricing specialists in evaluating the Company’s application of government rebate program regulations and calculations of government prices used to estimate rebates during the year ended December 31, 2023.
/s/ Ernst & Young LLP
We have served as the Company’s auditor since 2001.
San Mateo, California
February 15, 2024
F-3

CORCEPT THERAPEUTICS INCORPORATED
CONSOLIDATED BALANCE SHEETS
(In thousands, except per share data)
 December 31,
 20232022
ASSETS  
Current assets:  
Cash and cash equivalents$135,551 $66,329 
Short-term marketable securities232,670 365,343 
Trade receivables, net of allowances41,123 31,057 
Insurance recovery receivable related to Melucci litigation (Note 10)14,000 14,000 
Inventory7,730 6,100 
Prepaid expenses and other current assets27,562 16,424 
Total current assets458,636 499,253 
Strategic inventory8,244 10,931 
Operating lease right-of-use asset120 1,143 
Property and equipment, net of accumulated depreciation and amortization195 633 
Long-term marketable securities57,176 4,947 
Other assets6,541 5,058 
Deferred tax assets, net90,605 61,465 
Total assets$621,517 $583,430 
LIABILITIES AND STOCKHOLDERS' EQUITY  
Current liabilities:  
Accounts payable$17,396 $11,976 
Accrued research and development expenses21,330 14,573 
Accrued and other liabilities51,628 30,799 
Accrued settlement related to Melucci litigation (Note 10)14,000 14,000 
Short-term operating lease liability151 1,143 
Total current liabilities104,505 72,491 
Long-term accrued income taxes payable10,307 9,097 
Total liabilities114,812 81,588 
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred stock, par value $0.001 per share, 10,000 shares authorized and no shares outstanding as of December 31, 2023 and December 31, 2022
— — 
Common stock, par value $0.001 per share, 280,000 shares authorized and 134,344 issued and 103,405 outstanding as of December 31, 2023 and 130,959 shares issued and 107,835 outstanding as of December 31, 2022
133 131 
Treasury stock; at cost; 30,938 shares of common stock as of December 31, 2023 and 23,124 shares of common stock as of December 31, 2022
(635,078)(456,148)
Additional paid-in capital738,515 662,342 
Accumulated other comprehensive income (loss)609 (869)
Retained earnings402,526 296,386 
Total stockholders’ equity506,705 501,842 
Total liabilities and stockholders’ equity$621,517 $583,430 
The accompanying notes are an integral part of these consolidated financial statements.
F-4

CORCEPT THERAPEUTICS INCORPORATED
CONSOLIDATED STATEMENTS OF INCOME
(In thousands, except per share data)
Year Ended December 31,
202320222021
Product revenue, net$482,375 $401,858 $365,978 
Operating expenses:
Cost of sales6,481 5,385 5,281 
Research and development184,353 130,991 113,864 
Selling, general and administrative184,259 152,848 122,356 
Settlement expense related to Melucci litigation— 14,000 — 
Insurance recovery related to Melucci litigation— (14,000)— 
Total operating expenses375,093 289,224 241,501 
Income from operations107,282 112,634 124,477 
Interest and other income17,275 3,557 529 
Income before income taxes124,557 116,191 125,006 
Income tax expense(18,417)(14,773)(12,494)
Net income$106,140 $101,418 $112,512 
Net income attributable to common stockholders$105,496 $101,288 $112,512 
Basic net income per common share$1.02 $0.95 $0.97 
Diluted net income per common share$0.94 $0.87 $0.89 
Weighted-average shares outstanding used in computing net income per common share
Basic103,560 106,787 115,653 
Diluted111,742 115,966 125,963 
The accompanying notes are an integral part of these consolidated financial statements.
F-5

CORCEPT THERAPEUTICS INCORPORATED
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In thousands, except per share data)
Year Ended December 31,
202320222021
Net income$106,140 $101,418 $112,512 
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities, net of tax impact of $(353), $105, and $198
1,120 (331)(621)
Foreign currency translation gain (loss), net of tax358 (311)(21)
Total comprehensive income107,618 100,776 111,870 
The accompanying notes are an integral part of these consolidated financial statements.
F-6

CORCEPT THERAPEUTICS INCORPORATED
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
 Year Ended December 31,
 202320222021
Cash flows from operating activities:   
Net income$106,140 $101,418 $112,512 
Adjustments to reconcile net income to net cash provided by operations:   
Stock-based compensation48,940 42,442 42,931 
(Accretion) of discount and Amortization of premium on marketable securities, net(9,128)1,383 5,083 
Amortization of cloud computing arrangements465 477 409 
Depreciation and amortization of property and equipment577 782 1,072 
Deferred income taxes(29,493)(33,905)4,346 
Non-cash amortization of right-of-use asset1,320 2,187 1,995 
Other— — 10 
Changes in operating assets and liabilities:   
Trade receivables(10,066)(3,432)(1,427)
Insurance recovery receivable related to Melucci litigation— (14,000)— 
Inventory1,265 1,199 3,444 
Prepaid expenses and other current assets(11,603)(6,557)(4,006)
Other assets(1,483)(1,975)1,917 
Accounts payable5,778 4,757 (3,597)
Accrued research and development expenses6,757 2,131 (1,262)
Accrued and other liabilities17,649 2,927 6,479 
Accrued settlement related to Melucci litigation— 14,000 — 
Long-term accrued income taxes1,210 8,688 11 
Operating lease liability(1,289)(2,199)(2,025)
Net cash provided by operating activities127,039 120,323 167,892 
Cash flows from investing activities:   
Purchases of property and equipment(139)(413)(469)
Proceeds from maturities of marketable securities419,793 241,152 398,937 
Proceeds from sales of marketable securities— — 50,463 
Purchases of marketable securities(328,748)(355,066)(312,805)
Net cash provided (used in) by investing activities90,906 (114,327)136,126 
Cash flows from financing activities:   
Proceeds from issuance of common stock under our incentive award plan, net of issuance costs5,811 4,381 16,229 
Repurchase of common stock in connection with Tender Offer(145,428)— (207,500)
Repurchases of common stock in connection with Stock Repurchase Program— — (88,485)
Cash paid to satisfy statutory withholding requirement for net settlement of cashless option exercises and vesting of restricted stock grants(9,106)(21,665)(22,835)
Net cash used in financing activities(148,723)(17,284)(302,591)
Net increase (decrease) in cash and cash equivalents69,222 (11,288)1,427 
Cash and cash equivalents, at beginning of period66,329 77,617 76,190 
Cash and cash equivalents, at end of period$135,551 $66,329 $77,617 
F-7

Supplemental disclosure:
Income taxes paid$47,602 $39,747 $9,104
Exercise cost of shares repurchased for net settlement of cashless option exercises$25,032 $24,388 $15,796
Recognition of right-of-use asset in exchange for lease liability$297 $2,816 $—
The accompanying notes are an integral part of these consolidated financial statements
F-8

CORCEPT THERAPEUTICS INCORPORATED
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(In thousands)
Common StockAdditional
Paid-in
Capital		Treasury StockAccumulated
Other
Comprehensive
Income (Loss)		Retained EarningsTotal
Stockholders'
Equity
SharesAmount
Balance at December 31, 2020116,735 $122 $516,140 $(75,795)$415 $82,456 $523,338 
Issuance of common stock upon exercise of options4,632 5 32,041 — — — 32,046 
Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises(1,560)— — (38,631)— — (38,631)
Stock-based compensation— — 43,168 — — — 43,168 
Other comprehensive loss, net of tax— — — — (642)— (642)
Purchase of treasury stock in connection with Stock Repurchase Program(3,867)— — (88,485)— — (88,485)
Purchase of treasury stock in connection with Tender Offer(10,000)— — (207,500)— — (207,500)
Net income— — — — — 112,512 112,512 
Balance at December 31, 2021105,940 127 591,349 (410,411)(227)194,968 375,806 
Issuance of common stock under our incentive award plan3,741 4 28,478 — — — 28,482 
Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises(1,846)— — (45,737)— — (45,737)
Stock-based compensation— — 42,515 — — — 42,515 
Other comprehensive loss, net of tax— — — — (642)— (642)
Net income— — — — — 101,418 101,418 
Balance at December 31, 2022107,835 131 662,342 (456,148)(869)296,386 501,842 
Issuance of common stock under incentive award plan3,383 2 29,126 — — — 29,128 
Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises(1,203)— (32,424)— — (32,424)
Repurchase of common stock in connection with Tender Offer(6,610)— — (145,428)— — (145,428)
Excise tax related to net share repurchases— — — (1,078)— — (1,078)
Stock-based compensation— — 45,977 — — — 45,977 
Vesting of RSAs in connection with ESPP— — 1,070 — — — 1,070 
Other comprehensive gain, net of tax— — — — 1,478 — 1,478 
Net income— — — — — 106,140 106,140 
Balance at December 31, 2023103,405 $133 $738,515 $(635,078)$609 $402,526 $506,705 
The accompanying notes are an integral part of these consolidated financial statements
F-9

CORCEPT THERAPEUTICS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. Basis of Presentation and Summary of Significant Accounting Policies
Description of Business and Basis of Presentation
Corcept Therapeutics Incorporated (collectively, “Corcept,” the “Company,” “we,” “us” and “our”) is a commercial-stage pharmaceutical company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. In 2012, the United States Food and Drug Administration (“FDA”) approved Korlym (“mifepristone”) 300 mg tablets, as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. We have discovered and patented four structurally distinct series of selective cortisol modulators, consisting of more than 1,000 compounds. We are developing compounds from these series as potential treatments for a broad range of serious disorders.
We were incorporated in the State of Delaware in May 1998. Our headquarters are located in Menlo Park, California.
Basis of Presentation
The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”).
Principles of Consolidation
Our consolidated financial statements include the financial position and results of operations of Corcept Therapeutics UK Limited, our wholly owned subsidiary, which we incorporated in the United Kingdom in March 2017. All material intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates
The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates.
We reevaluate our estimates and assumptions each quarter, including those related to revenue recognition, recognition and measurement of income tax assets and liabilities, inventory, allowances for doubtful accounts and other accrued liabilities, including our bonus accrual, clinical trial accruals and stock-based compensation.
Fair Value Measurements
We value financial instruments using assumptions we believe third-party market participants would use. When choosing which assumptions to make when determining the value of a financial instrument, we look first for quoted prices in active markets for identical instruments (“Level 1 inputs”). If no Level 1 inputs are available, we consider (i) quoted prices in non-active markets for identical instruments; (ii) active markets for similar instruments; (iii) inputs other than quoted prices for the instrument; and (iv) inputs that are not directly observable, but that can be corroborated by observable data (“Level 2 inputs”). In the absence of Level 2 inputs, we rely on unobservable inputs, such as our estimates of the assumptions market participants would use in pricing the instrument (“Level 3 inputs”).
Cash and Cash Equivalents and Marketable Securities
We consider highly liquid investments that will mature in three months or less from the time we purchase them to be cash equivalents. Cash equivalents are valued using Level 1 inputs, which approximate our cost.
We invest the majority of our funds in marketable securities, primarily corporate notes, U.S. Treasury and government agency securities, asset-backed securities and commercial paper. We classify our marketable securities as available-for-sale securities and report them at fair value as “cash equivalents” or “marketable securities” on our consolidated balance sheet, with related unrealized gains and losses included in stockholders' equity. Realized gains and losses and permanent declines in value are included in “interest and other income (expense)” on our consolidated statements of income.
F-10
CORCEPT THERAPEUTICS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Continued

Credit and Concentration Risks
Our cash, cash equivalents and marketable securities are held in four financial institutions. We are subject to credit risk from our cash equivalents and marketable securities. We limit our investments to U.S. Treasury obligations and high-grade corporate debt and asset-backed securities with less than a 36-month maturity at the time of purchase. These investments are diversified and do not expose us to concentrations of credit risk. We have never experienced a loss in, or lack of access to, our operating or investment accounts.
We have an agreement with one third-party manufacturer to supply mifepristone, the active pharmaceutical ingredient (“API”), in Korlym.
We have a concentration of risk in regard to the distribution of our product. A single specialty pharmacy, Optime Care, Inc. (“Optime”), dispenses Korlym to patients for us. Optime is an independent third party. Its unwillingness or inability to dispense Korlym to patients in a timely manner would harm our business.
We sell Korlym that Optime dispenses directly to patients, with title to the medicine passing directly from us to the patient upon the patient’s receipt of the drug. Our receivables risk is spread among various third-party payers – pharmacy benefit managers, insurance companies, government programs and private charities. We monitor our exposure and record an allowance against uncollectible trade receivables as necessary. To date, we have not recorded an allowance for credit losses.
Inventory and Cost of Sales
Regulatory approval of product candidates is uncertain. Because product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained, we record the cost of manufacturing our product candidates as research and development expense at the time such costs are incurred. Once a product candidate is approved by the FDA, we begin capitalizing manufacturing costs. We capitalize to inventory manufacturing costs related to Korlym.
We value inventory at the lower of cost or net realizable value and determine the cost of inventory we sell using the specific identification method, which approximates a first-in, first-out basis. We assess our inventory levels at each reporting period and write down inventory that is either expected to be at risk of expiration prior to sale, has a cost basis in excess of its expected net realizable value, or for which there are inventory quantities in excess of expected requirements. We destroy expired inventory and recognize the related costs as cost of sales in that period’s statement of income.
Cost of sales also includes the cost of manufacturing Korlym, including materials, third-party manufacturing costs and indirect personnel and other overhead costs, based on the number of Korlym tablets for which we recognize revenue, as well as costs of stability testing, logistics and distribution.
We classify inventory we do not expect to sell within 12 months of the balance sheet date as strategic inventory, a non-current asset.
Net Product Revenue
We sell Korlym directly to patients through a single specialty pharmacy. We also sell Korlym to a specialty distributor (“SD”), for which we recognize revenue at the time the SD receives Korlym. SD sales were less than one percent of our net revenue in each of the years ended December 31, 2023, 2022 and 2021.
To determine our revenue from the sale of Korlym, we (i) identify our contract with each customer; (ii) identify the obligations of Corcept and the customer under the contract; (iii) determine the contracted transaction price; (iv) allocate the transaction price to the contract’s performance obligations, which in our case consists of delivering Korlym to the customer; and (v) recognize revenue once Korlym has been delivered, provided we deem it probable that we will collect the payment due to us.
Confirmation of coverage by private or government insurance or by a third-party charity is a prerequisite for selling Korlym to a patient.
To determine net product revenue, we deduct from sales the cost of our patient co-pay assistance program and our estimates of (a) government chargebacks and rebates, (b) discounts provided to our SD for prompt payment and (c) reserves for expected returns. We record these estimates at the time we recognize revenue and update them as new information becomes available. Our estimates take into account our understanding of the range of possible outcomes. If results differ from our estimates, we adjust our estimates, which changes our net product revenue and earnings. We report any changes in the period they become known, even if they concern transactions occurring in prior periods.
F-11
CORCEPT THERAPEUTICS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Continued

Government Rebates: Korlym is eligible for purchase by, or qualifies for reimbursement from, Medicaid, Medicare and other government programs that are eligible for rebates on the price they pay for Korlym. To determine the appropriate amount to reserve against these rebates, we identify Korlym sold to patients covered by government-funded programs, apply the applicable government discount to these sales, then estimate utilization of such programs by government payors. We (i) deduct this reserve from revenue in the period to which the rebates relate and (ii) include in accrued expenses on our consolidated balance sheet a current liability of an equal amount.
Chargebacks: Although we sell Korlym to the SD at full price, some of the government entities to which the SD sells receive a discount. The SD recovers the full amount of any related discounts by reducing its payment to us (this reduction is called a “chargeback”). Chargebacks sometimes relate to Korlym purchased by the SD in prior periods. We deduct from our revenue in each period chargebacks claimed by the SD for Korlym it purchased in that period. We also create a reserve for chargebacks we estimate the SD will claim in future periods against Korlym it purchased in the current period but has not yet resold. We determine the amount of this reserve based on our experience with SD chargebacks and our understanding of the SD’s customer base and business practices. We deduct this reserve from revenue and include in accrued expenses on our consolidated balance sheet a current liability of equal amount.
Patient Assistance Program and Charitable Support: It is our policy that no patient be denied Korlym due to inability to pay. We provide financial assistance to eligible patients whose insurance policies have high deductibles or co-payments and deduct the amount of such assistance from gross revenue. We determine the assistance we provide each patient by applying our program guidelines to that patient’s financial position and their insurance policy’s co-payment and deductible requirements for the purchase of Korlym. We donate cash to charities that help patients with financial need pay for the treatment of Cushing’s syndrome. We do not include payments from these charities in revenue, but as a deduction to selling, general and administrative expenses. We provide Korlym at no cost to uninsured patients who do not qualify for charitable support.
Sales Returns: Federal law prohibits the return of Korlym sold to patients. Sales to our SD are subject to return. We deduct the amount of Korlym we estimate the SD will return from each period’s gross revenue. We base our estimates on quantitative and qualitative information including, but not limited to, historical return rates, the amount of Korlym held by the SD and projected demand. If we cannot reasonably estimate returns with respect to a particular sale, we defer recognition of revenue until we can make a reasonable estimate. To date, returns have not been significant.
The following table summarizes activity in each of the product revenue allowance and reserve categories for the years ended December 31, 2023, 2022 and 2021:
ChargebacksGovernment RebatesTotal
(in thousands)
Balance at December 31, 2020$163 $9,412 $9,575 
Provision related to current period sales394 33,709 34,103 
Provision related to prior period sales(29)(1,047)(1,076)
Credit or payments made during the period(478)(30,900)(31,378)
Balance at December 31, 202150 11,174 11,224 
Provision related to current period sales557 38,745 39,302 
Provision related to prior period sales78 (68)10 
Credit or payments made during the period(455)(38,753)(39,208)
Balance at December 31, 2022230 11,098 11,328 
Provision related to current period sales346 52,825 53,171 
Provision related to prior period sales(88)(555)(643)
Credit or payments made during the period(266)(44,900)(45,166)
Balance at December 31, 2023$222 $18,468 $18,690 
Research and Development
Research and development expense includes the direct cost of discovering and screening new compounds, pre-clinical studies, clinical trials, manufacturing development, submissions to regulatory agencies and related overhead costs. We expense nonrefundable payments and the cost of technologies and materials used in research and development as we incur them.
F-12
CORCEPT THERAPEUTICS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Continued

We base our accruals for discovery research, preclinical studies and clinical trials on our estimates of work completed, milestones achieved, patient enrollment and past experience with similar activities. Our estimates include assessments of information from contract research organizations and the status of our own research, development and administrative activities.
Segment Reporting
We determine our operating segments based on the way we organize our business, make decisions and assess performance. We have one operating segment, which is the discovery, development and commercialization of pharmaceutical products.
Stock-Based Compensation
We recognize stock-based compensation expense for stock options, restricted stock awards (“RSAs”) and restricted stock units (“RSUs”), net of estimated forfeitures, on a straight-line basis over the period during which an employee is required to provide services in exchange for the award (the vesting period of the award). We estimate future forfeitures during the first quarter of each fiscal year, and revise the estimates, if necessary, in subsequent periods if actual forfeitures differ significantly from those estimates.
We determine the fair value of stock options based on the value of the award at the grant date, using the Black-Scholes model. We recognize stock-based compensation expense over the applicable vesting period, net of estimated forfeitures. If actual forfeitures differ from our estimates, we adjust stock-based compensation expense accordingly.
In addition, we have issued RSAs in connection with our Employee Stock Purchase Plan (“ESPP”) that vest on the condition that the participating employee hold the corresponding shares purchased under the ESPP for one year from the purchase date. The participating employee is granted one RSA for each share purchased in the ESPP. We initially measure the fair value of these RSAs based on the grant date fair value determined using the closing price of our common stock on the date the purchase of the corresponding ESPP shares is made. This fair value of the RSA is amortized over the one-year holding period. As a result of the RSA’s being reported as liability-classified awards, they must be remeasured at each reporting date until settlement. Ultimately, the compensation cost recognized for the RSA award will equal the fair value of the Company’s common stock on the date the RSA is fully vested and settled. See Note 7, Preferred Stock and Stockholders’ Equity regarding our ESPP.
Income Taxes
We account for income taxes in accordance with ASC 740, Income Taxes (“ASC 740”), which requires recognition of deferred tax assets and liabilities for the expected tax consequences of our future financial and operating activities. Under ASC 740, we determine deferred tax assets and liabilities based on the temporary difference between the financial statement and tax bases of assets and liabilities using the tax rates in effect for the year in which we expect such differences to reverse. If we determine that it is more likely than not that we will not generate sufficient taxable income to realize the value of some or all of our deferred tax assets (net of our deferred tax liabilities), we establish a valuation allowance offsetting the amount we do not expect to realize. We perform this analysis each reporting period and reduce our measurement of deferred taxes if the likelihood we will realize them becomes uncertain.
The deferred tax assets that we record each period depend primarily on our ability to generate future taxable income in the United States. Each period, we evaluate the need for a valuation allowance against our deferred tax assets and, if necessary, adjust the valuation allowance so that net deferred tax assets are recorded only to the extent we conclude it is more likely than not that these deferred tax assets will be realized. If our outlook for future taxable income changes significantly, our assessment of the need for, and the amount of, a valuation allowance may also change.
We are also required to evaluate and quantify other sources of taxable income, such as the possible reversal of future deferred tax liabilities, should any arise, and the implementation of tax planning strategies. Evaluating and quantifying these amounts is difficult and involves significant judgment, based on all of the available evidence and assumptions about our future activities.
We account for uncertain tax positions in accordance with ASC 740, which requires us to adjust our consolidated financial statements to reflect only those tax positions that are more-likely-than-not to be sustained upon review by federal or state examiners. We recognize in the consolidated financial statements the largest expected tax benefit that has a greater than 50 percent likelihood of being sustained on examination by the taxing authorities. We report interest and penalties related to unrecognized tax benefits as income tax expense.
F-13
CORCEPT THERAPEUTICS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Continued

Recently Issued Accounting Pronouncements Not Yet Adopted
In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-09, which requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. This ASU is effective for public companies with annual periods beginning after December 15, 2024, with early adoption permitted. We plan to adopt this guidance for the fiscal year ending December 31, 2025. We are currently evaluating the effects adoption of this guidance will have on the consolidated financial statements.
In November 2023, the FASB issued ASU No. 2023-07, to improve the disclosures about a public entity’s reportable segments and address requests from investors for additional, more detailed information about a reportable segment’s expenses. The standard is effective for public companies with annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 with early adoption permitted. We plan to adopt this guidance for the fiscal year ending December 31, 2024. We are currently evaluating the effects adoption of this guidance will have on the consolidated financial statements.
2. Significant Agreements
Commercial Agreement
In August 2017, we entered into a distribution services agreement with an independent third party, Optime, to provide exclusive specialty pharmacy and patient services programs for Korlym beginning August 10, 2017. Under the terms of this agreement, Optime acts as the exclusive specialty pharmacy distributor of Korlym in the United States, subject to certain exceptions. Optime provides services related to pharmacy operations; patient intake, access and reimbursement; patient support; claims management and accounts receivable; and data and reporting. We provide Korlym to Optime, which it dispenses to patients. Optime does not purchase Korlym from us and it does not take title to the product. Title passes directly from us to the patient at the time the patient receives the medicine.
The initial term of our agreement with Optime was five years. In August 2022, we amended our agreement to extend its term to September 30, 2022. In September 2022, we amended our agreement to further extend its term to March 31, 2024, unless terminated earlier by us upon 90 days’ notice. The agreement contains additional customary termination provisions, representations, warranties and covenants. Subject to certain limitations, we have agreed to indemnify Optime for certain third-party claims related to the product, and we have each agreed to indemnify the other for certain breaches of representations, warranties, covenants and other specified matters.
3. Available for Sale Marketable Securities and Fair Value Measurements
The available-for-sale securities in our Consolidated Balance Sheets are as follows:
December 31,
20232022
(in thousands)
Cash equivalents$97,170 $36,380 
Short-term marketable securities232,670 365,343 
Long-term marketable securities57,176 4,947 
Total marketable securities$387,016 $406,670 
F-14
CORCEPT THERAPEUTICS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Continued

The following table presents our available-for-sale securities grouped by asset type:
 Fair Value
Hierarchy
Level		December 31, 2023December 31, 2022
Amortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair ValueAmortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
  (in thousands)
Corporate bondsLevel 2$120,508 $307 $— $120,815 $151,069 $— $(625)$150,444 
Commercial paperLevel 275,308 20 (9)75,319 136,132 — — 136,132 
U.S. government agency securitiesLevel 2— — — — 25,113 23 — 25,136 
Asset-backed securitiesLevel 2— — — — 185 — — 185 
U.S. Treasury securitiesLevel 193,655 61 (4)93,712 58,536 — (142)58,394 
Money market fundsLevel 197,170 — — 97,170 36,379 — — 36,379 
Total marketable securities$386,641 $388 $(13)$387,016 $407,414 $23 $(767)$406,670 
We estimate the fair value of marketable securities classified as Level 1 using quoted market prices obtained from a commercial pricing service for these or identical investments. We estimate the fair value of marketable securities classified as Level 2 using inputs that may include benchmark yields, reported trades, broker/dealer quotes and issuer spreads.
We periodically review our debt securities to determine if any of our investments is impaired due to the issuer’s poor credit or other reasons. If the fair value of our investment is less than our amortized cost, we evaluate quantitative and subjective factors – including, but not limited to, the nature of security, changes in credit ratings and analyst reports concerning the security’s issuer and industry, and interest rate fluctuations and general market conditions – to determine whether an allowance for credit losses is appropriate.
None of our investments, including those with unrealized losses, are impaired. Unrealized losses on our investments are due to interest rate fluctuations. We do not intend to sell investments that currently have unrealized losses and it is highly unlikely that we will sell any investment before recovery of its amortized cost basis, which may be at maturity. Accordingly, we have not recorded an allowance for credit losses for these investments.
We classified accrued interest on our marketable securities of $1.7 million and $1.8 million as of December 31, 2023 and 2022, respectively, as prepaid and other current assets on our consolidated balance sheets.
As of December 31, 2023, all our marketable securities had original maturities of no more than 27 months and all our marketable securities classified as short-term have maturities of less than one year. The weighted-average maturity of our holdings was seven months. As of December 31, 2023, our long-term marketable securities had remaining maturities between 13 months and 22 months. None of our marketable securities changed from one fair value hierarchy to another during the year ended December 31, 2023.
4. Composition of Certain Balance Sheet Items
Inventory
Year Ended December 31,
20232022
(in thousands)
Work in progress$8,233 $7,827 
Finished goods7,741 9,204 
Total inventory15,974 17,031 
Less strategic inventory classified as non-current(8,244)(10,931)
Total inventory classified as current$7,730 $6,100 
Because we rely on one manufacturer to produce Korlym’s API, we have purchased and hold significant quantities of API, included in work in progress inventory. We classify inventory we do not expect to sell within 12 months of the balance sheet date as “Strategic inventory,” a non-current asset.
F-15
CORCEPT THERAPEUTICS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Continued

Accrued and other liabilities
Year Ended December 31,
20232022
(in thousands)
Accrued compensation$25,457 $15,511 
Government rebates18,468 11,098 
Income taxes payable1,814 89 
Accrued selling and marketing costs1,771 434 
Accrued Manufacturing Costs1,455 20 
Excise tax payable1,078 — 
Legal fees542 2,673 
Professional fees389 211 
Other654 763 
Total accrued and other liabilities$51,628 $30,799 
Other assets
As of December 31, 2023 and 2022, other assets included $6.4 million and $4.9 million of deposits for clinical trials, respectively.
5. Leases
We lease our office facilities in Menlo Park, California. On April 1, 2023, we signed an amendment to extend our lease through June 30, 2024. As a result of this amendment, we recognized an additional right-of-use asset and corresponding lease liability of $0.3 million in the year ended December 31, 2023. The right-of-use asset and lease liability recognized equals the present value of the remaining payments due under our amended lease.
As the operating lease for our facilities does not expressly state an interest rate, we calculated the present value of remaining lease payments using a discount rate equal to the interest rate we would pay on a collateralized loan with monthly payments and a term equal to the monthly payments and remaining term of our lease. We recognize operating lease payments as expenses using the straight-line method over the term of the lease.
Operating lease expense for the years ended December 31, 2023, 2022 and 2021 was $2.4 million, $2.3 million and $2.1 million, respectively.
Our right-of-use assets and related lease liabilities were as follows (in thousands, except weighted average amounts):
Year Ended December 31,
20232022
Cash paid for operating lease liabilities$2,391 $2,265 
Recognition of right-of-use asset in exchange for lease liability$297 $2,816 
Weighted-average remaining lease term6 months6 months
Weighted-average discount rate8.0 %4.0 %
As of December 31, 2023, future minimum lease payments under non-cancelable operating leases were as follows (in thousands):
2024$155 
Total operating lease payments155 
Less imputed interest(4)
Present value of operating lease liabilities$151 
F-16
CORCEPT THERAPEUTICS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Continued

As of December 31, 2023, future minimum lease payments under non-cancellable short-term leases were $1.1 million for 2024. We do not recognize right-of-use assets or lease liabilities for leases with a term of twelve months or less, rather, we recognize the associated lease payments in the condensed consolidated statements of income on a straight-line basis over the lease term.
6. Related Party Transactions
There were no related party transactions during the years ended December 31, 2023, 2022, and 2021.
7. Preferred Stock and Stockholders’ Equity
Preferred Stock
Our Board of Directors is authorized, subject to any limitations prescribed by law, without stockholder approval, to issue up to an aggregate of 10.0 million shares of preferred stock at $0.001 par value in one or more series and to fix the rights, preferences, privileges and restrictions granted to or imposed upon the preferred stock, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences. The rights of the holders of common stock will be subject to the rights of holders of any preferred stock that may be issued in the future. As of December 31, 2023 and 2022, we had no outstanding shares of preferred stock.
Treasury Stock
In March 2023, we announced that our Board of Directors approved a tender offer to purchase up to 7.5 million shares of our common stock. The tender offer commenced on March 6, 2023 and expired on March 31, 2023. On April 5, 2023, we purchased 6.6 million shares through the tender offer at a price of $22.00 per share for an aggregate purchase price of $145.4 million, excluding related fees and expenses. We recorded purchased shares as treasury stock on our condensed consolidated balance sheet at cost.
In November 2021, we announced that our Board of Directors approved a tender offer to purchase up to 10 million shares of our common stock. The tender offer commenced on November 8, 2021 and expired on December 15, 2021. We repurchased 10 million shares through the tender offer at a price of $20.75 per share for an aggregate purchase price of $207.5 million, excluding fees and expenses relating to the tender offer.
In November 2020, we announced that our Board of Directors approved a program to repurchase up to $200 million of our common stock (the “Stock Repurchase Program”). The terms of this program did not require us to acquire any shares and allowed for repurchases by a variety of methods, including open market purchases, privately negotiated transactions, block trades, accelerated share repurchase transactions or any combination of such methods. The Stock Repurchase Program expired by its terms on September 30, 2021. During the year ended December 31, 2021, we purchased 3.9 million shares of common stock under the Stock Repurchase Program in open market transactions at an average price of $22.88 per share, for aggregate purchase price of $88.5 million.
During the years ended December 31, 2023, 2022 and 2021, we issued 2.4 million, 3.7 million and 4.6 million shares, respectively, of our common stock upon the exercise of stock options. Some option holders exercised their options on a “net exercise” basis, pursuant to which they surrendered to us, and we purchased from them, at the then current market price, shares equal in value to the associated exercise price and tax withholding obligations. During the years ended December 31, 2023, 2022 and 2021, we purchased 1.2 million, 1.8 million and 1.6 million shares, respectively, in connection with such option net exercises and paid $7.4 million, $21.3 million and $22.8 million, respectively, to satisfy associated tax withholding obligations.
We recorded purchased shares as treasury stock on our consolidated balance sheets, at cost. It has not been determined whether purchased shares will be retired or sold.
We have never declared or paid any dividends.
Incentive Award Plan
We have one stock option plan – the Corcept Therapeutics Incorporated 2012 Incentive Award Plan (the “2012 Plan”).
In 2012, our Board of Directors and stockholders approved the 2012 Plan. Under the 2012 Plan, we can issue options, stock purchase and stock appreciation rights, and restricted stock awards to our employees, officers, directors and consultants. The 2012 Plan provides that the exercise price for incentive stock options will be no less than 100 percent of the fair value of our common stock as of the date of grant. Options granted under the 2012 Plan carry a contractual term of ten years and are
F-17
CORCEPT THERAPEUTICS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Continued

expected to vest over periods ranging from one year to four years. We assume the vesting period of the options that we grant under the 2012 Plan to be equal to the option grantee’s period of service.
As of December 31, 2023, we had 7.7 million shares available for future issuance under the 2012 plan.
Stock Option activity during 2023
The following table summarizes option activity under the 2012 Plan:
Outstanding Options
Number of OptionsWeighted-Average Exercise PriceWeighted-Average Remaining Contractual LifeAggregate Intrinsic Value
(in thousands)(in years)(in thousands)
Balance at December 31, 202223,198 $15.13 
Options granted3,178 $23.49 
Options exercised(2,355)$11.47 
Options cancelled and forfeited(651)$21.16 
Balance at December 31, 202323,370 $16.47 5.79$374,129 
Options exercisable at December 31, 202317,924 $14.41 5.00$323,814 
Options fully vested and expected to vest at
December 31, 2023		23,149 $16.40 5.76$372,158 
The total intrinsic value of options exercised during the years ended December 31, 2023, 2022 and 2021 was $36.0 million, $63.4 million and $78.9 million, respectively, based on the difference between the closing price of our common stock on the date of exercise and the exercise price.
The total fair value of options that vested during the years ended December 31, 2023, 2022 and 2021 was $42.4 million, $43.2 million and $40.4 million, respectively.
As of December 31, 2023, we had $67.3 million of unrecognized compensation expense for options outstanding, which had a weighted-average remaining vesting period of 2.35 years.
RSA and RSU (collectively, “restricted stock”) activity during 2023
The following table summarizes restricted stock activity under the 2012 Plan:
Outstanding Restricted Stock
Number of Restricted StockWeighted-Average Grant Date Fair ValueWeighted-Average Remaining Vesting LifeAggregate Intrinsic Value
(in thousands)(in years)(in thousands)
Balance at December 31, 2022455 $23.91 
Restricted stock granted659 $24.04 
Restricted stock vested(184)$23.87 
Restricted stock cancelled and forfeited(103)$23.26 
Balance at December 31, 2023827 $24.10 2.73$4,910 
As of December 31, 2023, we had $14.9 million of unrecognized compensation expense for restricted stock outstanding, which had a weighted-average remaining vesting period of 2.66 years.
F-18
CORCEPT THERAPEUTICS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Continued

ESPP
In February 2022, we adopted an ESPP that allows employees to set aside, by means of payroll deductions, up to ten percent of their annual compensation for the purchase of our common stock. Shares are issued to participating employees from the 2012 Plan on March 1st and September 1st of each year (or, if those dates fall on holidays or weekends, on the first business day thereafter) at the then-current fair market value of our stock, as determined at the close of trading on those days. Payroll deductions for participating employees began April 1, 2022, and the first purchase under the plan took place on September 1, 2022.
In January 2023, we increased the number of ESPP purchase dates to occur quarterly on March 1st, June 1st, September 1st and December 1st (or, if those dates fall on holidays or weekends, on the first business day thereafter).
For each purchased share, the participating employee will receive one matching share, also issued from the 2012 Plan, if certain conditions are met. There is no vesting requirement for shares issued pursuant to the ESPP purchase. The matching share will be granted in the form of a RSA that will vest on the one-year anniversary of the respective ESPP purchase date, net of applicable tax withholding. The vesting condition on the RSA is that the participating employee hold the corresponding share purchased under the ESPP for one year from the purchase date. Shares purchased pursuant to the ESPP and any matching shares issued upon satisfaction of the one-year holding requirement may be held, sold or transferred at the employee’s sole discretion.
As of December 31, 2023 and 2022, we recorded $3.2 million and $0.2 million, respectively, of stock-based compensation related to RSAs granted in connection with our ESPP in “Accrued and other liabilities” on our consolidated balance sheet.
Option Valuation Assumptions
The following table summarizes the weighted-average assumptions and resultant fair value-based measurements for options granted.
Year Ended December 31,
202320222021
Weighted-average assumptions for options granted:
Risk-free interest rate3.87%1.97%0.76%
Expected term6.7 years6.4 years6.3 years
Expected volatility of stock price53.0%56.5%60.7%
Dividend rate0%0%0%
Weighted-average grant date fair value-based measurement$13.65$11.27$15.06
The expected term of options reflected in the table above is based on a formula that considers the expected service period and expected post-vesting termination behavior depending on whether the option holder is an employee, officer or director.
The expected volatility of our stock used in determining the fair value-based measurement of option grants to employees, officers and directors is based on the volatility of our stock price. The volatility is based on historical data of the price for our common stock for periods of time equal to the expected term of these grants.
We calculate employee stock-based compensation expense using the number of options we expect to vest, based on our estimate of the option grantees’ average length of employment, and reduced by our estimate of option forfeitures. We estimate forfeitures at the time of option grant and revise this estimate in subsequent periods if actual forfeitures differ from our estimates.
F-19
CORCEPT THERAPEUTICS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Continued

Stock-based Compensation
The following table summarizes our stock-based compensation by financial statement classification.
 Year Ended December 31,
 202320222021
 (in thousands)
Stock-based compensation capitalized in inventory$208 $280 $237 
Cost of sales52 70 59 
Research and development15,402 12,800 14,106 
Selling, general and administrative33,486 29,572 28,766 
Total stock-based compensation$49,148 $42,722 $43,168 
8. Net Income Per Share
We compute our basic and diluted net income per share in conformity with the two-class method required for companies with participating shares. Under the two-class method, net income is determined by allocating net income between common stock and unvested RSAs. We compute basic net income per share by dividing our net income attributable to common stockholders by the weighted-average number of common shares outstanding during the period. We compute diluted net income per share by dividing our net income attributable to common stockholders by the weighted-average number of common shares outstanding during the period, including potentially dilutive stock options and unvested RSUs, less unvested RSAs. We use the treasury stock method to determine the number of dilutive shares of common stock resulting from stock options and unvested RSUs.
The following table shows the computation of net income per share for each period:
Year Ended December 31,
202320222021
(in thousands, except per share data)
Numerator:
Net income attributable to common stockholders$105,496 $101,288 $112,512 
Denominator:
Weighted-average shares used to compute basic net income per common share103,560 106,787 115,653 
Dilutive effect of employee stock options and unvested RSUs8,182 9,179 10,310 
Weighted-average shares used to compute diluted net income per common share111,742 115,966 125,963 
Net income per share attributable to common stockholders
Basic$1.02 $0.95 $0.97 
Diluted$0.94 $0.87 $0.89 
We excluded from the computation of diluted net income per share, on a weighted-average basis, 9.1 million stock options and unvested RSUs outstanding during the year ended December 31, 2023, and 7.3 million and 4.5 million stock options outstanding during the years ended December 31, 2022 and 2021, respectively, because including them would have reduced dilution.
F-20
CORCEPT THERAPEUTICS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Continued

9. Income Taxes
The domestic and foreign components of income before income taxes were as follows:
Year Ended December 31,
202320222021
(in thousands)
Domestic $125,691 $116,871 $126,308 
Foreign (1,134)(680)(1,302)
Income before income taxes $124,557 $116,191 $125,006 
The income tax expense for the years ended December 31, 2023, 2022, and 2021 consisted of the following:
Year Ended December 31,
202320222021
(in thousands)
U.S. federal taxes:
Current$40,265 $39,132 $4,675 
Deferred(25,613)(28,122)5,066 
Total U.S. federal taxes14,652 11,010 9,741 
State taxes:
Current7,590 9,515 3,432 
Deferred(2,645)(5,313)(274)
Total state taxes4,945 4,202 3,158 
Foreign taxes:
Current56 30 41 
Deferred(1,236)(469)(446)
Total foreign taxes(1,180)(439)(405)
Total provision for income taxes$18,417 $14,773 $12,494 
Beginning in 2022, the Tax Cuts and Jobs Act of 2017 eliminates the right to deduct research and development expenditures for tax purposes in the period the expenses were incurred and instead requires all U.S. and foreign research and development expenditures to be amortized over five and fifteen tax years, respectively. Congress has considered legislation that would defer the amortization requirement to later years, but as of December 31, 2023, the requirement has not been modified. Accordingly, we have capitalized our research and development expenses for tax purposes, resulting in higher cash paid for taxes as compared to prior years.
F-21
CORCEPT THERAPEUTICS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Continued

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets are as follows:
Year Ended December 31,
20232022
Deferred tax assets:(in thousands)
Federal and state net operating losses$3,942 $4,882 
Capitalized research and patent costs908 1,911 
Capitalized research expenditures61,760 36,465 
Research credits11,682 9,963 
Stock-based compensation costs21,676 17,956 
Operating lease liability37 280 
Other6,577 5,127 
Total deferred tax assets106,582 76,584 
Valuation allowance(15,947)(14,839)
Deferred tax liabilities
Operating lease right-of-use asset(30)(280)
Total deferred tax liabilities(30)(280)
Net deferred tax assets$90,605 $61,465 
Each quarter, we assess the likelihood that we will generate sufficient taxable income to use our federal and state deferred tax assets. Except for the valuation allowances that offset our California net deferred tax assets, we have determined that it is more likely than not we will realize the benefit related to all other deferred tax assets. To the extent we increase a valuation allowance, we will include an expense in the Consolidated Statement of Income in the period in which such determination is made.
The valuation allowance increased by $1.1 million, $1.9 million and $1.4 million for the years ended December 31, 2023, 2022 and 2021, respectively.
As of December 31, 2023, we had California net operating loss carryforwards of $55.6 million, which will begin to expire in the year 2032, and net operating loss carryforwards from other states of $0.7 million, which will begin to expire in the year 2035 if not utilized.
As of December 31, 2023, we also had California research and development credits of $16.8 million, which have no expiration date.
The following table presents a reconciliation from the statutory federal income tax rate to the effective rate.
 Year Ended December 31,
 202320222021
 (in thousands)
U.S. federal taxes at statutory rate$26,157 $24,400 $26,251 
R&D and other credits(11,508)(9,114)(7,579)
State income taxes, net of federal benefit3,897 3,320 2,495 
Non-deductible compensation3,295 4,354 990 
Stock-based compensation(2,951)(7,980)(9,568)
Other(473)(207)(95)
Total$18,417 $14,773 $12,494 
F-22
CORCEPT THERAPEUTICS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Continued

We maintain liabilities for uncertain tax positions. The measurement of these liabilities involves considerable judgment and estimation and are continuously monitored by management based on the best information available, including changes in tax regulations, the outcome of relevant court cases, and other pertinent information.
The aggregate annual changes in the balance of gross unrecognized tax benefits are as follows:
Year Ended December 31,
202320222021
(in thousands)
Beginning balance$11,425 $9,237 $7,471 
Increase in tax positions for prior years112 53 103 
Decreases in tax positions for prior years(205)— — 
Decrease in tax positions for expirations of statute of limitations(750)— — 
Increase in tax positions for current year2,440 2,135 1,663 
Decrease in tax positions for current year— — — 
Ending balance$13,022 $11,425 $9,237 
As of December 31, 2023, the amount of unrecognized tax benefits that would favorably impact the effective tax rate were approximately $10.2 million, and approximately $2.8 million of unrecognized tax benefits would be offset by a change in the valuation allowance. A valuation allowance is maintained on the remaining tax benefits related to California deferred tax assets and would not impact the effective tax rate. We had no or insignificant amounts of accrued interest and no accrued penalties related to unrecognized tax benefits as of December 31, 2023, 2022 and 2021. We do not expect our unrecognized tax benefits to change materially over the next 12 months.
While we believe we have adequately provided for all tax positions, amounts asserted by tax authorities could be greater or less than the recorded position. Accordingly, our provisions on federal and state tax-related matters to be recorded in the future may change as revised estimates are made or the underlying matters are settled or otherwise resolved.
The Company’s primary tax jurisdiction is the United States. For federal tax purposes, the years 2022 through 2023 remain open and subject to tax examination. For US state tax purposes, the years 2004 through 2023 generally remain open and subject to tax examination by the appropriate state taxing authorities.
10. Commitments and Contingencies
Manufacturing Agreements
We have an agreement with one third-party manufacturer to supply mifepristone, the active pharmaceutical ingredient (“API”) in Korlym, and two additional third-party manufacturers to produce and bottle Korlym tablets.
As of December 31, 2023, we had a $0.7 million remaining obligation in connection with commitments to purchase API from these third-party manufacturers. In January 2024, to ensure we have sufficient API to meet future demand of Korlym tablets, we committed to purchase an additional $3.0 million of API.
Taxes
As of December 31, 2023, we have recorded non-current taxes payable of $10.3 million related to uncertain tax positions.
Legal Proceedings
In the ordinary course of business, we may be subject to legal claims and regulatory actions that could have a material adverse effect on our business or financial position. We assess our potential liability in such situations by analyzing the possible outcomes of various litigation, regulatory and settlement strategies. If we determine a loss is probable and its amount can be reasonably estimated, we accrue an amount equal to the estimated loss.
F-23
CORCEPT THERAPEUTICS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Continued

Melucci Litigation and Settlement
On March 14, 2019, a purported securities class action complaint was filed in the United States District Court for the Northern District of California by Nicholas Melucci (Melucci v. Corcept Therapeutics Incorporated, et al., Case No. 5:19-cv-01372-LHK) (the “Melucci litigation”). The complaint named us and certain of our executive officers as defendants asserting violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder and alleges that the defendants made false and materially misleading statements and failed to disclose adverse facts about our business, operations and prospects. The complaint asserts a putative class period extending from August 2, 2017 to February 5, 2019 and seeks unspecified monetary relief, interest and attorneys’ fees. On October 7, 2019, the Court appointed a lead plaintiff and lead counsel. The lead plaintiff’s consolidated complaint was filed on December 6, 2019.
On February 8, 2023, we reached an agreement in principle (the “Proposed Settlement”) to resolve all claims in the Melucci litigation. Under the Proposed Settlement, we have agreed to make a one-time payment of $14.0 million, which will be covered in full by our insurers. In connection with the Proposed Settlement, we recorded a settlement expense of $14.0 million and corresponding insurance recovery of $14.0 million in Operating Expenses on our Consolidated Statement of Income in the fourth quarter of 2022. Accordingly, we recorded an accrued liability of $14.0 million for this settlement and a corresponding insurance recovery receivable of $14.0 million on our Consolidated Balance Sheet. The Court granted preliminary approval of the Proposed Settlement on January 4, 2024, following which we paid $14.0 million into escrow. Our insurers reimbursed us in full. Payment of any funds out of the designated escrow is pending the Court’s final approval of the Proposed Settlement, a hearing for which is scheduled for June 6, 2024.
No other losses and no other provisions for a loss contingency have been recorded to date.
F-24
CORCEPT THERAPEUTICS INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Continued

11. Subsequent Events
On January 8, 2024, our Board of Directors approved a program authorizing the repurchase of up to $200 million of our common stock. Purchases under this program may be made in the open market, in privately negotiated transactions or otherwise. The timing and amount of any repurchases will be determined based on market conditions, our stock price and other factors. The program does not require us to repurchase any specific number of shares of its common stock and may be modified, suspended or discontinued at any time without notice.
F-25
 EX-10.36 2 cort202310-kex1036.htm EX-10.36 Document

CORCEPT THERAPEUTICS INCORPORATED
INSIDER TRADING POLICY
and Guidelines with Respect to Certain Transactions in Company Securities
Purpose
This Policy provides guidelines with respect to transactions in the securities of Corcept Therapeutics Incorporated (the “Company”). For purposes of this Policy, the Company’s Compliance Officer is the Chief Business Officer (or the Chief Accounting Officer, if there is no Chief Business Officer or if a transaction or matter under this Policy relates to the Chief Business Officer) or such other executive officer as may be designated by the Compliance Officer to fulfill the duties of this position during the absence of the Compliance Officer.
Applicability of Policy
This Policy applies to all transactions in the Company’s securities, including common stock, options for common stock, restricted stock units, restricted stock awards and any other securities the Company may issue from time to time, such as preferred stock, warrants and convertible debentures, as well as to derivative securities relating to the Company’s stock, whether or not issued by the Company, such as exchange-traded options.
This Policy applies to all employees, officers and directors of the Company. For purposes of this Policy, “officer” means an “officer” as defined under Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). This Policy also applies to (a) family members of these persons sharing the households of these persons, (b) other members of the households of these persons, and (c) investment funds and other entities (such as trusts and corporations) over which these persons have or share voting or investment control. In the discretion of the Compliance Officer, it may also apply to consultants and contractors to the Company who receive or have access to Material Nonpublic Information. The group of people to whom this Policy applies is sometimes referred to in this Policy as “Insiders.” This Policy also applies to any person who receives Material Nonpublic Information from any Insider. Bases for determining what constitutes Material Nonpublic Information are discussed under “Definition of Material Nonpublic Information” below.
Statement of Policy
General Policy
It is the policy of the Company to prohibit the unauthorized disclosure of any nonpublic information and the misuse of Material Nonpublic Information in trading in the Company’s securities.


1


Specific Policies Applicable
to All Employees and Other Insiders
1.No Trading on Material Nonpublic Information. Except pursuant to a trading plan described under “Rule 10b5-1 Trading Plans” below, no Insider, and no entity over which any Insider has or shares voting or investment control, shall engage in any transaction involving a purchase or sale of the Company’s securities, including any offer to purchase or offer to sell, during any period commencing with the date that such individual or party possesses Material Nonpublic Information and ending at the close of business on the second Trading Day following the date of public disclosure of that information by the Company, or at such time as such nonpublic information is no longer material. The term “Trading Day” shall mean a day on which the Nasdaq Stock Market LLC (“Nasdaq”) is open for trading.
It does not matter whether there is an independent justifiable reason for a transaction – if an Insider has Material Nonpublic Information, this prohibition still applies. Accordingly, an Insider who possesses Material Nonpublic Information must forego a proposed transaction in the Company’s securities even though the Insider planned to make the transaction before learning of the Material Nonpublic Information and even though the failure to execute such transaction may result in an economic loss or the non-realization of anticipated profit.
2.No Tipping. No Insider shall (a) disclose (“tip”) Material Nonpublic Information to any other person (including family members, friends and acquaintances) where such information may be used by such person to profit by trading in the securities of companies to which such information relates or (b) make recommendations or express opinions on the basis of Material Nonpublic Information as to trading in the Company’s securities or the securities of any other company which is the subject of Material Nonpublic Information. Communications deemed to constitute tipping include not only directly providing Material Nonpublic Material to a specific person, but also indirectly providing Material Nonpublic Information through channels of mass media, such as the Internet.
Insiders should not give trading advice concerning the Company or its securities to third parties even when the Insider does not possess Material Nonpublic Information.
3.Confidentiality of Nonpublic Information. Nonpublic information relating to the Company is the property of the Company and the unauthorized disclosure of such information is forbidden. No Insider may disclose Material Nonpublic Information to any outside person (including family members, analysts, individual investors and members of the investment community and news media), unless required as part of the regular duties of such Insider for the Company or expressly authorized by the Compliance Officer. All inquiries from outsiders regarding Material Nonpublic Information must be forwarded to the Compliance Officer.
4.No Disclosure in Internet “Chat Rooms”. The Company will regard it as a violation of this Policy for any Insider to disclose, or participate in the disclosure of, any information related to the Company’s business, prospects, financial condition or employees by means of an Internet “chat room,” blog or other similar space on the Internet in which either the Company’s business or the value of its securities is discussed or posted. Any employee violator of this provision will be subject to the possible disciplinary actions described below.
2


5.No Short Sales. No Insider may directly or indirectly sell any equity security of the Company if the person selling the security: (1) does not own the security sold, or (2) if owning the security, does not deliver it against such sale within 20 days thereafter, or does not within five days after such sale deposit it in the mails or other usual channels of transportation.
6.No Prohibited Hedging. Certain hedging or monetization transactions can be accomplished through a number of possible mechanisms, including through the use of financial instruments such as prepaid variable forwards, equity swaps, zero-cost and other collars and exchange funds. Such transactions may permit a director, officer, or employee to continue to own Company securities obtained through employee benefit plans or otherwise, but without the full risks and rewards of ownership. When that occurs, the director, officer or employee may no longer have the same objectives as the Company’s other shareholders. Therefore, directors, officers and employees are prohibited from engaging in transactions, including those involving derivative securities, to hedge or offset any decrease in the market value of Company securities held by the individual.
7.Margin Accounts and Pledges. Securities held in margin accounts or pledged as collateral may be sold by a broker or lender without an account holder or debtor’s consent if such holder or debtor fails to meet a margin call or defaults on the loan. Because a margin or foreclosure sale could occur at a time when such a holder or debtor is aware of Material Nonpublic Information or otherwise is not permitted to trade in Company securities, directors and officers of the Company are prohibited from pledging Company securities as collateral for a loan.
8.Bona Fide Gifts. Bona fide gifts of securities are not transactions subject to this Policy unless the person making the gift has reason to believe that the recipient intends to sell the Company securities while the officer, director or employee is aware of Material Nonpublic Information, or the proposed gift would occur during a closed trading window. Gifts of securities may include gifts to trusts for estate planning purposes, as well as donations to a charitable organization. Whether a gift is “bona fide” may depend on various circumstances surrounding the gift. Accordingly, this Policy treats gifts of the Company’s securities as transactions subject to the same notification requirements applicable to any other transaction in the Company’s securities such that notice of such gifts must be submitted to the Compliance Officer.
9.Restricted Companies. “Restricted Companies” include all significant collaborators, customers, partners, suppliers, competitors and other companies about which the Company’s directors, officers and employees have learned material non-public information during the course of performing their duties for the Company. Persons subject to this Policy who learn material non-public information about any Restricted Company shall keep all such information confidential until it is disclosed publicly and may not provide “investment tips” about such company or engage in any other action to take advantage of such confidential information.
10.401(k) Plan. This Policy does not apply to purchases of Company securities in the Company’s 401(k) plan resulting from an Insider’s periodic contribution of money to the 401(k) plan pursuant to a payroll deduction election. This Policy does apply, however, to certain elections the Insider may make under the 401(k) plan, including: (i) an election to
3


increase or decrease the percentage of the Insider’s periodic contributions that will be allocated to any Company stock fund; (ii) an election to make an intra-plan transfer of an existing account balance into or out of any Company stock fund; (iii) an election to borrow money against the Insider’s 401(k) plan account if the loan will result in a liquidation of some or all of any Company stock fund balance; and (iv) an election to pre-pay a plan loan if the pre-payment will result in allocation of loan proceeds to any Company stock fund.
Trading Windows and Notification Policy
1.Trading Windows. From time to time, the Company may require that directors, officers, selected employees and others suspend trading because of developments known to the Company and not yet disclosed to the public. Those developments include, for example, the events and circumstances listed below under “Definition of Material Nonpublic Information.” In such event, the Compliance Officer will “close the trading window” and notify Insiders of such closure. Insiders should not engage in any transaction involving the purchase or sale of the Company’s securities during a closed trading window, and should not disclose to others the fact of such closed trading window. The Compliance Officer is not obligated to provide any explanation to an Insider as to why the trading window is open or closed.

The trading window will remain closed until it has been reopened by the Compliance Officer. Reopening will generally occur at the end of the second Trading Day for the Company’s stock on the Nasdaq following the release of the material information to the investing public through the issuance of a press release to the major wire services, Form 8-K and/or Securities and Exchange Commission periodic report. There may be instances where the trading window will remain closed even after the release of information to the public in instances where there may be additional material information that has not yet been made public. Reopening may also occur at the point that the information is no longer considered material. The Compliance Officer will issue a notification to the Insiders of the timing for re-opening of the trading window.

It should be noted, however, that even during an open trading window, any person possessing Material Nonpublic Information should not engage in any transactions in the Company’s securities until such information has been known publicly for at least two Trading Days, whether or not the Company has recommended a suspension of trading to that person. Trading in the Company’s securities during an open trading window should not be considered a “safe harbor,” and all directors, officers and other persons are responsible for their compliance with rules governing insider trading and should use good judgment at all times.

2.Notification of Transactions. The Company has determined that an Insider must refrain from trading in the Company’s securities without first complying with the Company’s notification process. Any Insider who proposes to engage in a transaction in the Company’s securities must submit to the Compliance Officer a notification describing the proposed transaction prior to commencing such transaction. It is Company policy to have the Compliance Officer, or duly authorized delegate, available to receive such notifications during business hours. The Compliance Officer, or duly authorized delegate, will provide the Company’s view on the status of the trading window as it applies to the proposed transaction.

4


3.Not a Safe Harbor. Notification of the Compliance Officer is not a “safe harbor,” and persons possessing Material Nonpublic Information may not trade regardless of whether trading window information has been provided.

Certain Exceptions for Transactions with the Company
And Transactions under10b5-1 Trading Plans
1.Transactions with the Company. The trading prohibitions and restrictions of this Policy do not apply to (i) the exercise (without a sale) of stock options or stock purchase rights under the Company’s equity incentive or employee stock purchase plans, (ii) the receipt or vesting of stock pursuant to the Company’s equity incentive plan, employee stock purchase or similar plan, (iii) any withholding of stock by the Company to satisfy tax withholding or exercise or purchase price requirements, or (iv) any other transaction solely with the Company approved by the Company’s Board of Directors or any standing or ad hoc committee thereof that has been authorized to approve such transactions. The trading prohibitions and restrictions of this Policy apply to all sales of securities acquired through the exercise of stock options or stock purchase rights or the vesting of equity awards.
2.Rule 10b5-1 Trading Plans. The trading prohibitions described in this Policy do not apply to transactions in the Company’s securities made by an Insider under a blind trust or other arrangement or plan to trade securities under Rule 10b5-1 of the Exchange Act (a “Plan”) that complies with the 10b5-1 Trading Plan Guidelines attached hereto (as may be amended or restated from time to time, the “Guidelines”) and has been submitted to the Company’s Compliance Officer and acknowledged in writing by the Company. In the case of any Plan entered into by the CEO, any such Plan must be submitted to and acknowledged by a member of the Company’s Compensation Committee of the Board of Directors. Insiders who are interested in adopting such a Plan should refer to the Guidelines.
Definition of Material Nonpublic Information
It is not possible to define all categories of material information. However, information should be regarded as material if there is a reasonable likelihood that it would be considered important to an investor in making an investment decision regarding the purchase or sale of stock or other securities of the Company. Either positive or negative information may be material. Nonpublic information is information that has not been previously disclosed to the general public and is otherwise not available to the general public. Please also see “Restricted Companies” above.
While it may be difficult under this standard to determine whether particular information is material, there are various categories of information that are particularly sensitive and, as a general rule, should always be considered for their potential materiality. Examples of such information may include:
•Major discoveries or significant changes or developments in products or research;
•Product development milestones, including clinical trial results, regulatory approvals and announcements by the Company;
•New strategic relationships and collaborations;
•Significant litigation exposure due to actual or threatened litigation or the resolution of litigation;
•News of a pending or proposed acquisition or merger, tender offer or joint venture;
5


•Potential corporate collaborations, research contracts or strategic alliances;
•News of the acquisition or disposition of assets;
•Projections of future earnings or losses, or other earnings guidance;
•Impending bankruptcy or financial liquidity problems;
•Gain or loss of major contracts, licenses, orders or suppliers;
•Stock splits;
•Establishment of a stock repurchase program;
•New equity or debt offerings;
•A significant cybersecurity incident; and
•Major changes in senior management.

Potential Criminal and Civil Liability and/or Disciplinary Action
1.Liability for Insider Trading. The purchase or sale of securities while aware of material nonpublic information, or the disclosure of material nonpublic information to others who then engage in transactions in the Company’s securities, is prohibited by the federal and state laws. Insider trading violations are pursued vigorously by the SEC, U.S. Attorneys and state enforcement authorities, as well as enforcement authorities in foreign jurisdictions. Punishment for insider trading violations is severe and could include significant fines and imprisonment.
2.Liability for Tipping. Insiders may also be liable for improper transactions by any person (commonly referred to as a “tippee”) to whom they have disclosed nonpublic information regarding the Company or to whom they have made recommendations or expressed opinions on the basis of such information as to trading in the Company’s securities. The SEC has imposed large penalties even when the disclosing person did not profit from the trading. The SEC, the stock exchanges and the Financial Industry Regulatory Authority use sophisticated electronic surveillance techniques to uncover insider trading.
3.Possible Disciplinary Actions. Employees of the Company who violate this Policy shall also be subject to disciplinary action by the Company, which may include ineligibility for future participation in the Company’s equity incentive plans or termination of employment for cause. A violation of this Policy is not necessarily the same as a violation of law. In fact, the restriction imposed under this Policy are intended to be broader than those imposed under the law.
4.Reporting of Violations. Any Insider who violates this Policy or any federal or state laws governing insider trading or tipping, or knows of any such violation by any other Insider, must report the violation immediately to the Compliance Officer.
Individual Responsibility to Comply with Policy
Every Insider has the individual responsibility to comply with this Policy regardless of whether any acknowledgment is made pursuant to this Policy with respect to a proposed transaction. The guidelines set forth in this Policy are guidelines only, and appropriate judgment should be exercised in connection with any transaction in the Company’s securities.
An Insider may, from time to time, have to forego a proposed transaction in the Company’s securities even if the Insider planned to make the transaction before learning of the
6


Material Nonpublic Information and even though the Insider may suffer an economic loss or forego anticipated profit by waiting.
Insiders are responsible for ensuring compliance by their families and other household members and other entities over which they exercise voting or investment control.
Additional Information - Directors and Officers
1.Section 16 Obligations. Company directors and officers and holders of more than 10% of the Company’s stock must also comply with the reporting obligations and limitations on short-swing transactions set forth in Section 16 of the Exchange Act. The practical effect of these provisions is that officers, directors and 10%+ stockholders who purchase and sell the Company’s securities in non-exempt transactions within a six-month period must disgorge all profits to the Company whether or not they had knowledge of any Material Nonpublic Information.
2.Securities Filings. A Company director or officer engaging in a transaction in Company securities may have filing obligations under Section 13 of the Exchange Act, Section 16 of the Exchange Act and/or Rule 144 of the Securities Act of 1933, as amended. Although the Company may assist directors and officers with these filings, the filings are the responsibility of the directors and officers.
Application of Policy after Termination
If your employment, directorship, advisory or consulting relationship with the Company terminates at a time when you have or think you may have Material Nonpublic Information, the prohibition on trading on that information continues through the first full trading day after its public announcement by the Company, or until the information is no longer material. If you have questions as to whether you possess Material Nonpublic Information after you have left your position with the Company, you should contact the Compliance Officer.
Exceptions for Emergency, Hardship or Other Special Circumstances
In order to respond to emergency, hardship or other special circumstances, exceptions to the prohibition against trading during black-out periods will require the approval of the Compliance Officer, the Chief Executive Officer and at least one member of the Compensation Committee.
Inquiries
Please direct your questions as to any of the matters discussed in this Policy to the Compliance Officer.
7


10B5-1 TRADING PLAN GUIDELINES
CORCEPT THERAPEUTICS INCORPORATED
These 10b5-1 Trading Plan Guidelines (these “Guidelines”) have been adopted by the Board of Directors of Corcept Therapeutics Incorporated (the “Company”) pursuant to the Company’s insider trading policy (the “Insider Trading Policy”). All transactions in the Company’s securities must be compliant with the Insider Trading Policy. As noted in the Insider Trading Policy, the trading prohibitions described in the Insider Trading Policy do not apply to transactions in the Company’s securities made by an employee, officer or director of the Company under a plan (a “Plan”) to trade securities under, and in compliance with, Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that has been submitted to the Company’s Compliance Officer (as defined in the Insider Trading Policy) and acknowledged by the Company in accordance with the Insider Trading Policy. For purposes of these Guidelines, “officer” means an “officer” as defined under Rule 16a-1(f) of the Exchange Act. These Guidelines may be amended or restated from time to time by the Board, a committee thereof, or by Company management; provided that, any amendment made to these Guidelines must comply with the Insider Trading Policy.
No Plan may become effective (that is, no transaction may occur) until the Plan participant has (i) delivered a complete copy of such Plan to the Compliance Officer, which must be delivered to the Compliance Officer at least five days prior to the Plan’s effective date, and (ii) received written acknowledgement of the Plan in accordance with the Insider Trading Policy. The terms and amendments of any Plan adopted by an officer or director of the Company must be publicly disclosed by the Company in accordance with Item 408 of Regulation S-K promulgated by the Securities and Exchange Commission.
While it is always the responsibility of the Plan holder to ensure compliance with applicable laws regarding the use of such Plans and the Company’s Insider Trading Policy, the following sets forth the Company’s guidance with respect to the terms, adoption and disclosure of any Plan; provided that such Plan must meet Rule 10b5-1 and other applicable laws and regulations:
1.The Plan is a written plan or binding agreement entered into with a national brokerage firm or other financial professional reasonably acceptable to the Company.
2.The Plan should clearly state that both the Plan participant and the brokerage firm intend that all transactions will comply with Rule 10b5-1 under the Exchange Act of 1934.
3.The Plan must include a representation by the participant to the Company at the time of adoption or modification of the Plan that (i) the participant is not aware of material nonpublic information about the Company or Company securities, and (ii) the participant is adopting the Plan in good faith and not as part of a plan or scheme to evade the prohibitions of Rule 10b-5.
4.The participant is solely responsible for determining Plan compliance with Rule 10b5-1 and other applicable laws and regulations. Acknowledgement of the Plan by the Company should not be characterized or understood to signify consent, approval or a legal opinion as to the Plan’s effectiveness or the participant’s compliance with Rule 10b5-1.
5.The Plan is adopted during an open trading window described under the “Trading Window” section of the Insider Trading Policy.
6.For Plan participants who are officers and directors, no transaction may take place under the Plan until the later of (a) 90 days after adoption or modification (as specified in Rule 10b5-1) of the Plan, and (b) two business days following the disclosure of the Company’s financial results in a Form 10-Q or Form 10-K for the fiscal quarter (the Company’s fourth fiscal quarter in the case of a Form 10-K) in which the Plan was adopted or modified (as specified in Rule 10b5-1), in all cases not to exceed 120 days after adoption or modification of the Plan.
10B5-1 Trading Plan Guidelines
Page 1 of 2

7.For Plan participants other than officers and directors, no transaction may take place under the Plan until 30 days following the adoption or modification (as specified in Rule 10b5-1) of the Plan.
8.Each Plan must (a) specify the amount of securities to be purchased or sold and the price at which and the date on which the securities are to be purchased or sold, or (b) include a written formula or algorithm, or computer program, for determining the amount of securities to be purchased or sold and the price at which and the date on which the securities were to be purchased or sold. In any case, such Plan must prohibit the participant and any other person who possesses material nonpublic information from exercising any subsequent influence over how, when, or whether to effect purchases or sales.
9.Subject to certain limited exceptions specified in Rule 10b5-1, Plan participants may not have more than one Plan outstanding at the same time.
10.The Plan participant is not at the time of entering into the Plan, and will not during the term of the Plan become, a party to a corresponding or hedging transaction involving Company securities.
11.The Plan participant will cooperate with the Company’s decisions regarding public disclosure of the Plan. If the Plan participant is a director or officer, the Plan participant (i) acknowledges that the Company and such director or officer must make certain disclosures in SEC filings concerning the Plan, and (ii) must promptly provide any information requested by the Company regarding the Plan for the purpose of providing the required disclosures or any other disclosures that the Company deems to be required or appropriate under the circumstances.
12.Although modifications to the Plan are not prohibited, the Plan should be adopted with the intention that it will not be amended, modified or terminated prior to its expiration.
13.The Plan provides for multiple transactions (as opposed to a single transaction); provided that Plan participants may also, subject to certain limited exceptions specified in Rule 10b5-1, adopt one Plan that provides for a single transaction in any consecutive 12-month period.
14.The Plan provides for same-day confirmation (by e-mail) by the financial institution to one or more individuals specified by the Company of each transaction made under the Plan, and of any proposed modification, amendment or termination of the Plan.
15.Subject to Rule 10b5-1, the Company may determine, in its sole discretion, that any suspension, modification or amendment of the Plan has terminated the Plan.
10B5-1 Trading Plan Guidelines
Page 2 of 2
 EX-23.1 3 cort202310-kex231.htm EX-23.1 Document

Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements (Form S-8 Nos. 333-183284, 333-187316, 333-194663, 333-202753, 333-210076, 333-216658, 333-223318, 333-229857, 333-236601, 333-253413 and 333-262752) pertaining to the 2012 Incentive Award Plan of Corcept Therapeutics Incorporated of our reports dated February 15, 2024, with respect to the consolidated financial statements of Corcept Therapeutics Incorporated and the effectiveness of internal control over financial reporting of Corcept Therapeutics Incorporated included in this Annual Report (Form 10-K) of Corcept Therapeutics Incorporated for the year ended December 31, 2023.
/s/ Ernst & Young LLP
San Mateo, California
February 15, 2024

 EX-31.1 4 cort202310-kex311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION
I, Joseph K. Belanoff, M.D., certify that:
1.I have reviewed this Annual Report on Form 10-K for the period ended December 31, 2023 of Corcept Therapeutics Incorporated;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
/s/ Joseph K. Belanoff
Joseph K. Belanoff, M.D.
Chief Executive Officer and President
(Principal Executive Officer)
February 15, 2024


 EX-31.2 5 cort202310-kex312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION
I, Atabak Mokari, certify that:
1.I have reviewed this Annual Report on Form 10-K for the period ended December 31, 2023 of Corcept Therapeutics Incorporated;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
/s/ Atabak Mokari
Atabak Mokari
Chief Financial Officer
(Principal Financial Officer)
February 15, 2024


 EX-32.1 6 cort202310-kex321.htm EX-32.1 Document

Exhibit 32.1
Corcept Therapeutics Incorporated
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Corcept Therapeutics Incorporated (the “Company”) on Form 10-K for the period ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Joseph K. Belanoff, M.D., Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ Joseph K. Belanoff
Joseph K. Belanoff, M.D.
Chief Executive Officer and President
(Principal Executive Officer)
February 15, 2024
 
This certification is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Corcept Therapeutics Incorporated under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, irrespective of any general incorporation language contained in such filing.

 EX-32.2 7 cort202310-kex322.htm EX-32.2 Document

Exhibit 32.2
Corcept Therapeutics Incorporated
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Corcept Therapeutics Incorporated (the “Company”) on Form 10-K for the period ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Atabak Mokari, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ Atabak Mokari
Atabak Mokari
Chief Financial Officer
(Principal Financial Officer)
February 15, 2024
 
This certification is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Corcept Therapeutics Incorporated under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, irrespective of any general incorporation language contained in such filing.

 EX-97 8 cort202310-kex97.htm EX-97 Document

CORCEPT THERAPEUTICS INCORPORATED
COMPENSATION CLAWBACK POLICY
Corcept Therapeutics Incorporated (the “Company”) believes that it is in the best interests of the Company and its stockholders to adopt this Compensation Clawback Policy (this “Policy”), which provides for the recovery of certain Incentive-Based Compensation in the event of an Accounting Restatement (each as defined below). This Policy is designed to comply with, and shall be interpreted to be consistent with, Section 10D of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Rule 10D-1 promulgated under the Exchange Act (“Rule 10D-1”) and Nasdaq Listing Rule 5608.
1.Administration
This Policy is applicable to all current and former executive officers (as defined in Rule 10D-1 under the Exchange Act) of the Company. This Policy will also apply to such other employees, or classes of employees, of the Company as may be determined from time to time by the Company’s Board of Directors or the Compensation Committee of the Board (collectively, the “Board”). Each person to whom this Policy applies is referred to herein as a “Covered Person.” Unless otherwise determined by the Board, the Compensation Committee shall administer this Policy (the Board, the Compensation Committee, or such other committee charged with administration of this Policy, the “Administrator”). The interpretation and construction by the Administrator of any provision of this Policy and all determinations made by the Administrator under this Policy shall be final, binding and conclusive.
2.Definitions
In addition to the definitions provided contextually herein, as used in this Policy, the following definitions shall apply:
•“Accounting Restatement” means an accounting restatement of the Company’s financial statements due to the Company’s material noncompliance with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.
•“Applicable Period” means the three completed fiscal years immediately preceding the date on which the Company is required to prepare an Accounting Restatement, as well as any transition period (that results from a change in the Company’s fiscal year) within or immediately following those three completed fiscal years (except that a transition period that comprises a period of at least nine months shall count as a completed fiscal year). The “date on which the Company is required to prepare an Accounting Restatement” is the earlier to occur of (a) the date the Board, a committee of the Board or the officer or officers of the Company authorized to take such action if Board action is not required, concludes or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement or (b) the date a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement, in each case regardless of if or when the restated financial statements are filed.
•“Applicable Rules” means any rules or regulations adopted by The Nasdaq Stock Market LLC (the “Nasdaq”) pursuant to Rule 10D-1 under the Exchange Act and any applicable rules or regulations adopted by the SEC pursuant to Section 10D of the Exchange Act.
•“Erroneously Awarded Compensation” is the amount of Incentive-Based Compensation received by a Covered Person that exceeds the amount of Incentive-Based Compensation that
1


otherwise would have been received by the Covered Person had it been determined based on the restated amounts resulting from an Accounting Restatement, which shall be computed by the Administrator without regard to any taxes paid by the Covered Person in respect of the Erroneously Awarded Compensation.
•A “Financial Reporting Measure” is any measure that is determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, and any measure that is derived wholly or in part from such measure. A Financial Reporting Measure need not be presented within the Company’s financial statements or included in a filing with the Securities and Exchange Commission.
•“Incentive-Based Compensation” means any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure. Incentive-Based Compensation is “received” for purposes of this Policy in the Company’s fiscal period during which the Financial Reporting Measure specified in the Incentive-Based Compensation award is attained, even if the payment or grant of such Incentive-Based Compensation occurs after the end of that period.
3.Applicable Incentive-Based Compensation
This Policy applies to Incentive-Based Compensation received on or after the Effective Date of this Policy by a Covered Person (a) after beginning services as a Covered Person; (b) if that person served as a Covered Person at any time during the performance period for such Incentive-Based Compensation; and (c) while the Company had a listed class of securities on a national securities exchange.
4.Recovery of Erroneously Awarded Compensation Following an Accounting Restatement
In the event the Company is required to prepare an Accounting Restatement, the Company shall reasonably promptly recover from any Covered Person the amount of any Erroneously Awarded Compensation received by such Covered Person during the Applicable Period. The recovered amount shall in no event be greater than the difference between the amount that was received and the amount that would have been received based on the restated data. Recovery under this Section 4 shall not require a finding of any misconduct by the Covered Person. For Incentive-Based Compensation based on stock price or total shareholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement, the amount shall be based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation was received. The Administrator shall determine the amount of any Erroneously Awarded Compensation and the repayment schedule for each Covered Person in compliance with this Section 4. The Administrator shall also maintain documentation of such determination and provide such documentation to the Nasdaq to the extent required by the Applicable Rules.
5.Method of Compensation Recovery
The Administrator shall determine, in its sole discretion, the method for recovering Incentive-Based Compensation hereunder, which may include, without limitation, any one or more of the following:
a.requiring reimbursement of cash Incentive-Based Compensation previously paid;
b.seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer or other disposition of any equity-based awards;
c.cancelling or rescinding some or all outstanding vested or unvested equity-based awards;
2


d.adjusting or withholding from unpaid compensation or other set-off;
e.cancelling or setting-off against planned future grants of equity-based awards; and/or
f.any other method permitted by applicable law or contract.
Notwithstanding the foregoing, a Covered Person will be deemed to have satisfied such person’s obligation to return Incentive-Based Compensation to the Company if such Incentive-Based Compensation is returned in the exact same form in which it was received; provided that equity withheld to satisfy tax obligations will be deemed to have been received in cash in an amount equal to the tax withholding payment made.
6.Exception to Compensation Recovery Requirement
The Company may elect not to recover Incentive-Based Compensation pursuant to this Policy if the Administrator determines that recovery would be impracticable under certain conditions as provided for under the Applicable Rules. These conditions may include, but shall not be limited to circumstances in which (i) the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount to be recovered, and the Company has made a reasonable attempt to recover such Incentive-Based Compensation; or (ii) recovery would likely cause an otherwise tax-qualified retirement plan to fail to be so qualified under applicable regulations.
7.No Indemnification of Covered Persons
Notwithstanding the terms of any indemnification or insurance policy or any contractual arrangement with any Covered Person that may be interpreted to the contrary, the Company shall not indemnify any Covered Persons against (a) the loss of any Incentive-Based Compensation, including any payment or reimbursement for the cost of third-party insurance purchased by any Covered Persons to fund potential clawback obligations under this Policy, or (b) any claims relating to the Company’s enforcement of its rights under this Policy.
8.Administrator Indemnification
Any member of the Board, or Company officer or officers authorized to take such action, who assist in the administration of this Policy shall not be personally liable for any action, determination or interpretation made with respect to this Policy and shall be fully indemnified by the Company to the fullest extent under applicable law and Company policy with respect to any such action, determination or interpretation. The foregoing sentence shall not limit any other rights to indemnification of the members of the Board under applicable law or Company policy.
9.Effective Date
This Policy shall be effective as of October 2, 2023 (the “Effective Date”).
10.Amendment; Termination
Unless otherwise determined by the Board, Company management or the Compensation Committee may amend, modify, supplement, rescind or replace all or any portion of this Policy at any time and from time to time in its discretion; provided that any such amendment, modification, supplement, rescission or replacement complies with Applicable Rules. To the extent this Policy is in any manner deemed inconsistent with the Applicable Rules, this Policy shall be treated as automatically and retroactively amended to be compliant with such Applicable Rules.
11.Policy Interpretation
This Policy shall be interpreted in a manner that is consistent with the Applicable Rules and any other applicable law and shall otherwise be interpreted (including in the determination of
3


amounts recoverable) in the business judgment of the Compensation Committee. Nothing contained in this Policy, and no recovery as contemplated by this Policy, shall limit any other claims, damages or other legal remedies the Company or any of its affiliates may have against a Covered Person (including reimbursement of legal fees incurred by or on behalf of the Company or any of its affiliates) arising out of or resulting from any actions or omissions by the Covered Person.
12.Successors
This Policy shall be binding and enforceable against all Covered Persons and their beneficiaries, heirs, executors, administrators or other legal representatives.
13.Governing Law; Venue
This Policy and all rights and obligations hereunder are governed by and construed in accordance with the internal laws of the State of California, excluding any choice of law rules or principles that may direct the application of the laws of another jurisdiction. All actions arising out of or relating to this Policy shall be heard and determined exclusively in a court of competent jurisdiction located in the State of California or, if such court declines to exercise jurisdiction or if subject matter jurisdiction over the matter that is the subject of any such legal action or proceeding is vested exclusively in the U.S. federal courts, the U.S. District Court for the Northern District of California.
Adopted November 2, 2023
4


[TO BE SIGNED BY THE COMPANY’S EXECUTIVE OFFICERS:]
Compensation Clawback Policy Acknowledgment
I, the undersigned, agree and acknowledge that I am fully bound by, and subject to, all of the terms and conditions of Corcept Therapeutics Incorporated’s Compensation Clawback Policy (as may be amended, restated, supplemented or otherwise modified from time to time, the “Policy”). In the event of any inconsistency between the Policy and the terms of any agreement to which I am a party, or the terms of any compensation plan, program or agreement under which any compensation has been granted, awarded, earned or paid, the terms of the Policy shall govern. The Policy will apply both during and after the undersigned’s employment with the Company. In the event it is determined by the Administrator that any amounts granted, awarded, earned or paid to me must be forfeited or reimbursed to the Company, I will promptly take any action necessary to effectuate such forfeiture and/or reimbursement. Any capitalized terms used in this Acknowledgment without definition shall have the meaning set forth in the Policy.
By:
[Name]Date
[Title]

5

 EX-101.SCH 9 cort-20231231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONSOLIDATED STATEMENTS OF INCOME link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000009 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Significant Agreements link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Available for Sale Marketable Securities and Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Composition of Certain Balance Sheet Items link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Preferred Stock and Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Net Income Per Share link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Available for Sale Marketable Securities and Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Composition of Certain Balance Sheet Items (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Preferred Stock and Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Net Income Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Summary of Allowance Activity Included in Trade Receivables Includes Allowance for Doubtful Accounts, Prompt Pay Cash Discounts and Chargebacks) (Details) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Significant Agreements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Available for Sale Marketable Securities and Fair Value Measurements - Summary of the classification of available-for-sale securities in condensed consolidated balance sheets (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Available for Sale Marketable Securities and Fair Value Measurements - Schedule of Available-for-Sale Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Available for Sale Marketable Securities and Fair Value Measurements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Composition of Certain Balance Sheet Items - Composition of Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Composition of Certain Balance Sheet Items - Composition of Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Composition of Certain Balance Sheet Items - Other Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Composition of Certain Balance Sheet Items - Other Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Leases - Right-of-use Assets and Related Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Leases - Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Leases - Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Preferred Stock and Stockholders' Equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Preferred Stock and Stockholders' Equity - Summary of Stock Plan Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Preferred Stock and Stockholders' Equity - Summary of Restricted Stock Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Preferred Stock and Stockholders' Equity - Summary of Weighted-Average Assumptions and Resultant Fair Value-Based Measurements for Options Granted to Employees and Directors (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Preferred Stock and Stockholders' Equity - Summary of Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Net Income Per Share - Schedule of Computation of Net Income (Loss) Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Net Income Per Share - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Income Taxes - Schedule of Components of income Tax (Benefit) (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Income Taxes - Components of Income Tax (Benefit) (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Income Taxes - Reconciliation of Statutory Federal Income Tax Rate to Effective Rate (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Income Taxes - Changes in Balance of Gross Unrecognized Tax Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Commitments and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 cort-20231231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 11 cort-20231231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 12 cort-20231231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Accrued research and development expenses Increase (Decrease) In Accrued Research and Development Expenses Increase (Decrease) In Accrued Research and Development Expenses Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Credit or payments made during the period Accounts Receivable, Allowance for Credit Loss, Recovery Pay vs Performance Disclosure [Line Items] Proceeds from sales of marketable securities Proceeds from Sale of Debt Securities, Available-for-Sale Entity Voluntary Filers Entity Voluntary Filers Schedule of Other Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Accrued and other liabilities Total accrued and other liabilities Accrued Liabilities, Current Statistical Measurement [Domain] Statistical Measurement [Domain] Research and development Research and Development Expense Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Accounting Standards Update 2016-02 Accounting Standards Update 2016-02 [Member] Expiration period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Equity Award Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Research and Development Research and Development Expense, Policy [Policy Text Block] Number of stock option plans Number Of Stock Option Plans Number of stock option plans. Schedule of Available-for-Sale Securities Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Accounts payable Accounts Payable, Current Weighted average remaining contractual life, Options exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Government rebates Accrued Government Rebate Current Accrued government rebate current. Long-term accrued income taxes Increase (Decrease) in Accrued Taxes Payable Restatement Determination Date: Restatement Determination Date [Axis] Interest and other income Nonoperating Income (Expense) Summary of Allowance Activity Included in Trade Receivables Includes Allowance for Doubtful Accounts, Prompt Pay Cash Discounts and Chargebacks Financing Receivable, Current, Allowance for Credit Loss [Table Text Block] Commitments and contingencies (Note 10) Commitments and Contingencies Insider Trading Policies and Procedures [Line Items] Options exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Recognition of right-of-use asset in exchange for lease liability Non Cash Transaction, Recognition Of Right Of Use Asset And Lease Liability Non Cash Transaction, Recognition Of Right Of Use Asset And Lease Liability Proceeds from issuance of common stock under our incentive award plan, net of issuance costs Proceeds from Issuance or Sale of Equity Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Preferred Stock and Stockholders' Equity Equity [Text Block] Options fully vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Capitalized research expenditures Deferred Tax Assets, Capitalized Research Expenditures Deferred Tax Assets, Capitalized Research Expenditures Type of Arrangement and Non-arrangement Transactions Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Income Taxes Income Tax Disclosure [Text Block] Dividend rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Net income per share attributable to common stockholders Earnings Per Share, Basic and Diluted EPS [Abstract] Earnings Per Share, Basic and Diluted EPS Customer [Axis] Customer [Axis] Current liabilities: Liabilities, Current [Abstract] Deferred Deferred Federal Income Tax Expense (Benefit) Specialty Distributor Specialty Distributor [Member] Specialty Distributor Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Subsequent Event Type [Domain] Subsequent Event Type [Domain] Weighted-Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Diluted net income per share (in dollars per share) Diluted (in dollars per share) Earnings Per Share, Diluted Stock Repurchase Program Stock Repurchase Program [Member] Stock repurchase program. PEO Total Compensation Amount PEO Total Compensation Amount Available For Sale Securities And Fair Value Measurements [Abstract] Available For Sale Securities And Fair Value Measurements [Abstract] Available for sale securities and fair value measurements. Trade receivables, net of allowances Accounts Receivable, after Allowance for Credit Loss, Current Unrecognized tax benefits that would be offset by a change in valuation allowance Unrecognized Tax Benefits That Would Be Offset By A Change In Valuation Allowance Unrecognized Tax Benefits That Would Be Offset By A Change In Valuation Allowance Aggregate Intrinsic Value Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract] Receivable [Domain] Receivable [Domain] Total foreign taxes Foreign Income Tax Expense (Benefit), Continuing Operations Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Treasury stock (in shares) Treasury Stock, Common, Shares Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Litigation Case [Axis] Litigation Case [Axis] Issuance of common stock upon exercise of options Stock Issued During Period, Value, Stock Options Exercised Trading Symbol Trading Symbol U.S. government agency securities US Government Agencies Debt Securities [Member] Number of compounds (more than) Number Of Compounds Number Of Compounds Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Options granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted-average grant date fair value-based measurement (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Net income Net income Net Income (Loss) Total current liabilities Liabilities, Current Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Leases Lessee, Operating Leases [Text Block] Corporate bonds Corporate Bond Securities [Member] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Employee Stock Purchase Plan Employee Stock [Member] Stockholders’ equity: Equity, Attributable to Parent [Abstract] Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Concentration Risk Benchmark Concentration Risk Benchmark [Domain] Issuance of common stock upon exercise of options (in shares) Options exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Domestic Income (Loss) from Continuing Operations before Income Taxes, Domestic Schedule of Computation of Net Income Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Cost of sales Cost of Goods and Services Sold Stock options, vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Litigation Status [Domain] Litigation Status [Domain] Executive Category: Executive Category [Axis] Total inventory Inventory Current Noncurrent Total inventory. Number of Restricted Stock Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Stock-based compensation Income Tax Reconciliation Nondeductible Expense Benefit Share Based Compensation Income tax reconciliation nondeductible expense benefit share based compensation. Options exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Level 1 Fair Value, Inputs, Level 1 [Member] Name Measure Name Net deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Short-term marketable securities Marketable Securities, Current Name Forgone Recovery, Individual Name Increase in tax positions for prior years Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Equity Components [Axis] Equity Components [Axis] Financial Instruments Financial Instruments [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Measurement Basis [Axis] Measurement Basis [Axis] Options granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Local Phone Number Local Phone Number Trade receivables Increase (Decrease) in Accounts Receivable Fair Value Measurement [Domain] Fair Value Measurement [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Selling, general and administrative Selling, General and Administrative Expenses [Member] Income Taxes [Line Items] Income Taxes [Line Items] Income taxes. Summary of Restricted Stock Activity Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Portion at fair value measurement Portion at Fair Value Measurement [Member] Income Statement Location Income Statement Location [Axis] Arrangements and Non-arrangement Transactions Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Leases Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Restricted Stock Awards (RSAs) Restricted Stock Awards (RSAs) [Member] Restricted Stock Awards (RSAs) Income taxes payable Accrued Income Taxes, Current Other Performance Measure, Amount Other Performance Measure, Amount Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Schedule of Information of Leases Asset and Liabilities Lease, Cost [Table Text Block] Inventory Increase (Decrease) in Inventories Total U.S. federal taxes Federal Income Tax Expense (Benefit), Continuing Operations Research and development Research and Development Expense [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Litigation Status [Axis] Litigation Status [Axis] Insurance recovery receivable related to Melucci litigation Increase (Decrease) in Insurance Recovery Receivable Increase (Decrease) in Insurance Recovery Receivable Fair value of options vested Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value Weighted average options excluded from the computation of diluted net income per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type Award Type [Axis] Restricted stock granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Work in progress Inventory Work In Process Current And Noncurrent Inventory, work in process. current and noncurrent. Plan Name Plan Name [Domain] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag State taxes: State and Local Income Tax Expense (Benefit), Continuing Operations [Abstract] Weighted average remaining contractual life Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Recognition of right-of-use asset in exchange for lease liability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Allowance for Doubtful Accounts Receivable [Roll Forward} Accounts Receivable, Allowance for Credit Loss [Roll Forward] Trading Arrangement: Trading Arrangement [Axis] Related Party Transactions Related Party Transactions Disclosure [Text Block] Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Weighted-Average Remaining Contractual Life Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract] Use of Estimates Use of Estimates, Policy [Policy Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Schedule of Components of Income Tax (Benefit) Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Debt And Credit Agreements [Line Items] Debt And Credit Agreements [Line Items] Debt and credit agreements. Entity File Number Entity File Number Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Short-term operating lease liability Operating Lease, Liability, Current Capitalized research and patent costs Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs Deferred tax assets deferred expense capitalized research and development costs. Finished goods Inventory Finished Goods Current And Noncurrent Inventory, finished goods, current and noncurrent. Decreases in tax positions for prior years Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Auditor Firm ID Auditor Firm ID Amortization of cloud computing arrangements Amortization of Intangible Assets Preferred stock, par value $0.001 per share, 10,000 shares authorized and no shares outstanding as of December 31, 2023 and December 31, 2022 Preferred Stock, Value, Outstanding Entity Shell Company Entity Shell Company Recently Issued Accounting Pronouncements Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Cost per share (in dollars per share) Shares Acquired, Average Cost Per Share Increase in tax positions for current year Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Excise tax related to net share repurchases Treasury Stock, Value, Acquired, Excise Tax Treasury Stock, Value, Acquired, Excise Tax Cash and cash equivalents, at beginning of period Cash and cash equivalents, at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Long term marketable securities, remaining maturity Long Term Marketable Securities, Remaining Maturity Long Term Marketable Securities, Remaining Maturity Schedule of Income before Income Tax, Domestic and Foreign Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Commitment And Contingencies [Table] Commitment And Contingencies [Table] Commitment and contingencies. Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign Weighted-average shares outstanding used in computing net income per common share Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Common stock, shares, issued Common Stock, Shares, Issued Restricted stock vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Summary of Weighted-Average Assumptions and Resultant Fair Value-Based Measurements for Options Granted to Employees and Directors Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Treasury stock; at cost; 30,938 shares of common stock as of December 31, 2023 and 23,124 shares of common stock as of December 31, 2022 Treasury Stock, Common, Value Accounting Policies [Line Items] Accounting Policies [Line Items] Accounting Policies [Line Items] Security Exchange Name Security Exchange Name R&D and other credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Stock-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Selling, general and administrative Selling, General and Administrative Expense Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Stock Options Outstanding Stock Options to Purchase Common Stock Employee Stock Option [Member] Interest receivable, current Interest Receivable, Current Provision related to current period sales Provision For Doubtful Accounts, Current Period Sales Provision For Doubtful Accounts, Current Period Sales Unrecognized compensation expense, weighted-average vesting period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Total operating expenses Costs and Expenses Maximum Maximum Maximum [Member] Total comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Unrecognized compensation expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Document Type Document Type Tabular List, Table Tabular List [Table Text Block] Type of Adoption [Domain] Accounting Standards Update [Domain] Maximum maturity period, short-term securities Short Term Marketable Securities Maximum Maturity Period Short Term Marketable Securities Maximum Maturity Period Government Rebates Government Rebates [Member] Government rebates. Entity Address, Address Line One Entity Address, Address Line One Purchase of treasury stock Aggregate purchase price Treasury Stock, Value, Acquired, Cost Method Long-term marketable securities Marketable Securities, Noncurrent Deposits for clinical trials Deposits For Clinical Trials Deposits For Clinical Trials Inventory and Cost of Sales Inventory, Policy [Policy Text Block] Receivable Type [Axis] Receivable Type [Axis] Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Subsequent Event [Table] Subsequent Event [Table] Current Current Federal Tax Expense (Benefit) Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Other Other Noncash Income (Expense) Short-term marketable securities Short Term Marketable Securities [Member] Short Term Marketable Securities [Member] Outstanding Options, Weighted- Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Subsequent Event Subsequent Event [Member] Net operating loss carryforwards Operating Loss Carryforwards Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate Customer Concentration Risk Customer Concentration Risk [Member] Deferred Deferred State and Local Income Tax Expense (Benefit) Income Statement [Abstract] Operating expenses: Costs and Expenses [Abstract] Options canceled and forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Title of 12(b) Security Title of 12(b) Security Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Numerator: Net Income (Loss) Attributable to Parent [Abstract] Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Operating lease liability Deferred Tax Assets, Operating Lease Liability Deferred Tax Assets, Operating Lease Liability Shareholders Equity [Line Items] Class of Stock [Line Items] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] U.S. federal taxes at statutory rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Unrealized gain (loss) on marketable securities, tax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax Entity Tax Identification Number Entity Tax Identification Number Inventory Total inventory classified as current Inventory, Net Purchases of marketable securities Payments to Acquire Marketable Securities Stock-based compensation capitalized in inventory Share-Based Payment Arrangement, Amount Capitalized Statistical Measurement [Axis] Statistical Measurement [Axis] Insurance recovery related to Melucci litigation Insurance recoveries Insurance Recoveries Strategic inventory Less strategic inventory classified as non-current Inventory, Noncurrent Financial Instrument [Axis] Financial Instrument [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Entity Interactive Data Current Entity Interactive Data Current Debt Securities, Available-for-Sale [Table] Debt Securities, Available-for-Sale [Table] Chargebacks Chargebacks [Member] Chargebacks. Total Shareholder Return Amount Total Shareholder Return Amount Repurchase of common stock Payments for Repurchase of Common Stock Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Deferred Deferred Foreign Income Tax Expense (Benefit) Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Retained earnings Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Net Product Revenue Revenue from Contract with Customer [Policy Text Block] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets: Assets, Current [Abstract] Leases [Abstract] Leases [Abstract] Schedule of Significant Components of Deferred Tax Assets Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Other losses for contingent liability Loss Contingency Accrual, Other Loss Contingency Accrual, Other Cash paid for operating lease liabilities Operating Lease, Payments Unrealized gain (loss) on marketable securities, net of tax impact of $(353), $105, and $198 OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Common stock, shares, outstanding Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Proceeds from maturities of marketable securities Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale PEO PEO [Member] Credit and Concentration Risks Concentration Risk, Credit Risk, Policy [Policy Text Block] Auditor Location Auditor Location Cash equivalents Cash Equivalents [Member] Available for Sale Marketable Securities and Fair Value Measurements Available For Sale Securities And Fair Value Measurements Disclosure [Text Block] Available for sale securities and fair value measurements disclosure. State income taxes, net of federal benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Class of Stock [Domain] Class of Stock [Domain] Net cash provided (used in) by investing activities Net Cash Provided by (Used in) Investing Activities Taxes payable Taxes Payable Customer [Domain] Customer [Domain] Schedule of Composition of Inventory Schedule of Inventory, Current [Table Text Block] Net income attributable to common stockholders, basic Net income attributable to common stockholders Net Income (Loss) Available to Common Stockholders, Basic Number of Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Settlement expense related to Melucci litigation Litigation settlement, expense Litigation Settlement, Expense Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Deferred tax liabilities Deferred Tax Liabilities, Gross [Abstract] Present value of operating lease liabilities Operating Lease, Liability Total liabilities Liabilities Expected volatility of stock price Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Options fully vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Balance Sheet Related Disclosures [Abstract] Balance Sheet Related Disclosures [Abstract] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Shares available for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance All Executive Categories All Executive Categories [Member] Settled Litigation Settled Litigation [Member] Title of Individual [Axis] Title of Individual [Axis] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Plan Name Plan Name [Axis] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Subsequent Event [Line Items] Subsequent Event [Line Items] 2012 Equity Incentive Award Plan Stock Options Fiscal Twenty Twelve Plan [Member] Stock options fiscal 2012 plan. Professional fees Accrued Professional Fees, Current Non-cash amortization of right-of-use asset Operating Lease, Right-of-Use Asset, Periodic Reduction Accrued settlement related to Melucci litigation (Note 10) Accrued liability, litigation Loss Contingency, Accrual, Current Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Current Current State and Local Tax Expense (Benefit) Segment Reporting Segment Reporting, Policy [Policy Text Block] Total current assets Assets, Current All Individuals All Individuals [Member] Supplemental disclosure: Supplemental Cash Flow Information [Abstract] Unrecognized tax benefits, accrued penalties Unrecognized Tax Benefits, Income Tax Penalties Accrued Adjustments for New Accounting Pronouncements [Axis] Accounting Standards Update [Axis] Litigation Case [Domain] Litigation Case [Domain] Entity Filer Category Entity Filer Category Purchase obligation Purchase Obligation Weighted average maturity period Marketable Securities Weighted Average Maturity Period Marketable securities weighted-average maturity period. Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Authorized amount Stock Repurchase Program, Authorized Amount Excise tax payable Sales and Excise Tax Payable, Current Schedule of Reconciliation of Statutory Federal Income Tax Rate to Effective Rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Beginning balance Ending balance Unrecognized Tax Benefits Income Tax Authority Income Tax Authority [Axis] PEO Name PEO Name Percentage of sales to one specialty distributor, less than Concentration Risk, Percentage Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Foreign taxes: Foreign Income Tax Expense (Benefit), Continuing Operations [Abstract] Restricted stock granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Income Taxes [Table] Income Taxes [Table] Income taxes. Initial agreement period Long-Term Purchase Commitment, Period Asset-backed securities Asset-Backed Securities [Member] Stock-based compensation costs Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Schedule Of Debt And Credit Agreements [Table] Schedule Of Debt And Credit Agreements [Table] Schedule Of Debt And Credit Agreements [Table] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Options exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Class of Stock [Axis] Class of Stock [Axis] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Other Other Accrued Liabilities, Current Depreciation and amortization of property and equipment Depreciation, Depletion and Amortization Payment awarded to other party Litigation Settlement, Amount Awarded to Other Party Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Auditor Information [Abstract] Auditor Information Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Total stockholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Cash and Cash Equivalents and Marketable Securities Cash And Cash Equivalents And Marketable Securities Policy [Policy Text Block] Disclosure of accounting policy for cash and cash equivalents and marketable securities, including the policy for determining which items are treated as cash equivalents and available-for-sale securities. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. Commercial paper Commercial Paper [Member] Unrecognized tax benefits that would impact effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Total state taxes State and Local Income Tax Expense (Benefit), Continuing Operations Valuation allowance Deferred Tax Assets, Valuation Allowance Restricted Stock Restricted Stock [Member] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Foreign currency translation gain (loss), net of tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Concentration Risk Type Concentration Risk Type [Axis] Expected term Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Subsequent Events [Abstract] Income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Vesting of RSAs in connection with ESPP APIC, Share-Based Payment Arrangement, ESPP, Increase for Cost Recognition Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Number of series of selective cortisol modulators Number Of Series Of Selective Cortisol Modulators Number Of Series Of Selective Cortisol Modulators U.S. federal taxes: Federal Income Tax Expense (Benefit), Continuing Operations [Abstract] Level 2 Fair Value, Inputs, Level 2 [Member] Weighted-average assumptions for options granted: Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract] Long-term marketable securities Long Term Marketable Securities [Member] Long Term Marketable Securities [Member] Entity Emerging Growth Company Entity Emerging Growth Company Total deferred tax assets Deferred Tax Assets, Gross Accrued settlement related to Melucci litigation Increase (Decrease) in Accrued Settlement Litigation Liabilities Increase (Decrease) in Accrued Settlement Litigation Liabilities Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus 2024 Lessee, Operating Lease, Liability, to be Paid, Year One Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Antidilutive Securities Antidilutive Securities [Axis] Number of RSAs granted for each share purchased (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted Title Trading Arrangement, Individual Title Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Operating lease expense Operating Lease, Expense Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Common Stock Common Stock [Member] Long-term accrued income taxes payable Accrued Income Taxes, Noncurrent Individual: Individual [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Net Income Per Share Earnings Per Share [Text Block] Decrease in tax positions for expirations of statute of limitations Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Income Statement Location Income Statement Location [Domain] Accounting Policies [Table] Accounting Policies [Table] Accounting Policies [Table] Document Fiscal Year Focus Document Fiscal Year Focus Additional Disclosures Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Accrued selling and marketing costs Accrued Marketing Costs, Current Employee and Director Stock Option Employee And Director Stock Option [Member] Employee and director stock option. Minimum Minimum Minimum [Member] Denominator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Property and equipment, net of accumulated depreciation and amortization Property, Plant and Equipment, Net Share Repurchase Program [Domain] Share Repurchase Program [Domain] Summary of Stock Plan Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Exercise Price Award Exercise Price Other comprehensive loss, net of tax Other Comprehensive Income (Loss), Net of Tax Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] ASSETS Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Operating lease liability Increase (Decrease) in Operating Lease Liability Decrease in tax positions for current year Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions Cash paid to satisfy statutory withholding requirement for net settlement of cashless option exercises and vesting of restricted stock grants Payment, Tax Withholding, Share-Based Payment Arrangement Deferred tax assets: Deferred Tax Assets, Net [Abstract] Other Deferred Tax Assets, Other U.S. Treasury securities US Treasury Securities [Member] Income taxes paid Income Taxes Paid, Net Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Deferred tax assets, net Deferred Income Tax Assets, Net Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Retained Earnings Retained Earnings [Member] Summary of Stock-Based Compensation Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] (Accretion) of discount and Amortization of premium on marketable securities, net Accretion (Amortization) of Discounts and Premiums, Investments Total liabilities and stockholders’ equity Liabilities and Equity Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Other assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Basic net income per share (in dollars per share) Basic (in dollars per share) Earnings Per Share, Basic Operating lease right-of-use asset Operating lease right-of-use asset Operating Lease, Right-of-Use Asset Accounting Policies [Abstract] Accounting Policies [Abstract] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Current Current Foreign Tax Expense (Benefit) Total intrinsic value of options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Net income attributable to common stockholders, diluted Net Income (Loss) Available to Common Stockholders, Diluted Arrangement Duration Trading Arrangement Duration Other Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Future minimum short-term lease payments, 2024 Lessee, Short-Term Lease, Liability, to be Paid, Year One Lessee, Short-Term Lease, Liability, to be Paid, Year One Principles of Consolidation Consolidation, Policy [Policy Text Block] Composition of Certain Balance Sheet Items Supplemental Balance Sheet Disclosures [Text Block] Accrued and other liabilities Increase (Decrease) in Other Accrued Liabilities Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Termination Date Trading Arrangement Termination Date Accounts payable Increase (Decrease) in Accounts Payable Common stock, shares authorized Common Stock, Shares Authorized Estimated Fair Value Debt Securities, Available-for-Sale Schedule of Changes in Balance of Gross Unrecognized Tax Benefits Summary of Income Tax Contingencies [Table Text Block] Entity Public Float Entity Public Float Legal fees Accrued Legal Fees Current Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to legal services. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Increase in valuation allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Adjustments to reconcile net income to net cash provided by operations: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Related Party Transactions [Abstract] Related Party Transactions [Abstract] All Trading Arrangements All Trading Arrangements [Member] ESPP ESPP [Member] ESPP All Adjustments to Compensation All Adjustments to Compensation [Member] Common stock, par value $0.001 per share, 280,000 shares authorized and 134,344 issued and 103,405 outstanding as of December 31, 2023 and 130,959 shares issued and 107,835 outstanding as of December 31, 2022 Common Stock, Value, Outstanding Award Timing Disclosures [Line Items] Other States Other States [Member] Other States [Member] Title of Individual [Domain] Title of Individual [Domain] Compensation Amount Outstanding Recovery Compensation Amount Melucci Melucci [Member] Melucci Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Additional paid-in capital Additional Paid in Capital Provision related to prior period sales Provision For Doubtful Accounts, Prior Period Sales Provision For Doubtful Accounts, Prior Period Sales Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Restricted stock cancelled and forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Operating lease right-of-use asset Deferred Tax Liabilities, Leasing Arrangements Deferred income taxes Deferred Income Tax Expense (Benefit) Subsequent Event Type [Axis] Subsequent Event Type [Axis] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Options canceled and forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Income Taxes Income Tax, Policy [Policy Text Block] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Document Financial Statement Error Correction [Flag] Document Financial Statement Error Correction [Flag] Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Restricted stock cancelled and forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Insider Trading Arrangements [Line Items] Balance at beginning of period Balance at end of period Accounts Receivable, Allowance for Credit Loss Aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Dilutive effect of employee stock options and unvested RSUs (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Other assets Increase (Decrease) in Other Operating Assets Adjustment to Compensation, Amount Adjustment to Compensation Amount Cost of sales Cost of Sales [Member] Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Auditor Name Auditor Name Exercise cost of shares repurchased for net settlement of cashless option exercises Shares Repurchased In Net Settlement Of Cashless Option Exercise Shares Repurchased In Net Settlement Of Cashless Option Exercise Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Adoption Date Trading Arrangement Adoption Date Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Options exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Treasury Stock Treasury Stock, Common [Member] Entity Central Index Key Entity Central Index Key Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Non-cash stock-based compensation expense Total stock-based compensation Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Income tax expense Total provision for income taxes Income Tax Expense (Benefit) Weighted-average remaining vesting period Weighted-Average Remaining Vesting Life Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Income Tax Authority Income Tax Authority [Domain] Accrued Manufacturing Costs Accrued Manufacturing Costs, Current Accrued Manufacturing Costs, Current Accrued compensation Employee-related Liabilities, Current Number of operating segments Number of Operating Segments Sales Revenue, Net Revenue Benchmark [Member] Name Trading Arrangement, Individual Name Payments for legal settlements Payments for Legal Settlements Equity [Abstract] Equity [Abstract] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Weighted-average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Product revenue, net Revenue from Contract with Customer, Excluding Assessed Tax Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Amendment Flag Amendment Flag Money market funds Money Market Funds [Member] Research and development tax credits Tax Credit Carryforward, Amount Insurance recovery receivable related to Melucci litigation (Note 10) Insurance recovery receivable Loss Contingency, Receivable, Current Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Tender Offer Tender Offer [Member] Tender Offer Purchase of treasury stock (in shares) Shares repurchased (in shares) Treasury Stock, Shares, Acquired Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Diluted (in shares) Weighted average shares used to compute diluted net income per common share (in shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Additional Paid-in Capital Additional Paid-in Capital [Member] Document Annual Report Document Annual Report Balance Sheet Location [Axis] Balance Sheet Location [Axis] Significant Agreements Commitments Disclosure [Text Block] Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Share Repurchase Program [Axis] Share Repurchase Program [Axis] Cover [Abstract] Cover [Abstract] Weighted average remaining contractual life, Options fully vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Subsequent Events Subsequent Events [Text Block] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Restricted stock vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Non-NEOs Non-NEOs [Member] Total operating lease payments Lessee, Operating Lease, Liability, to be Paid Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Other provisions for a loss contingency Loss Contingency Accrual, Provision, Other Loss Contingency Accrual, Provision, Other Non-PEO NEO Non-PEO NEO [Member] Equity Component [Domain] Equity Component [Domain] Accrued research and development expenses Accrued Research And Development Expenses, Current Accrued Research And Development Expenses, Current Adjustment to Compensation: Adjustment to Compensation [Axis] Exercise price as percentage of fair value of common stock, no less than Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent California State State and Local Jurisdiction [Member] Research credits Deferred Tax Assets, Tax Credit Carryforwards, Research Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Federal and state net operating losses Deferred Tax Assets, Operating Loss Carryforwards Basic (in shares) Weighted-average shares used to compute basic net income per common share (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Concentration Risk Type Concentration Risk Type [Domain] Income from operations Operating Income (Loss) Optime Care, Inc. Optime Care Inc [Member] Optime Care, Inc. Commitment And Contingencies [Line Items] Commitment And Contingencies [Line Items] Commitment and contingencies. Concentration Risk Benchmark Concentration Risk Benchmark [Axis] Total deferred tax liabilities Deferred Tax Liabilities, Gross Non-deductible compensation Income Tax Reconciliation Nondeductible Expense Compensation Cost Income tax reconciliation nondeductible expense compensation cost. Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Statement [Line Items] Statement [Line Items] Estimate of fair value measurement Estimate of Fair Value Measurement [Member] Unrecognized tax benefits, accrued interest Unrecognized Tax Benefits, Interest on Income Taxes Accrued Total stock-based compensation Share-Based Payment Arrangement, Expensed and Capitalized, Amount Options fully vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Maximum maturity period Marketable Securities Maximum Maturity Period Marketable securities maximum original maturity period. Summary of the Classification of Available-for-Sale Securities in Condensed Consolidated Balance Sheets Debt Securities, Available-for-Sale [Table Text Block] EX-101.PRE 13 cort-20231231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 14 cort-20231231_g1.jpg begin 644 cort-20231231_g1.jpg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end XML 15 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover Page - USD ($)
 12 Months Ended
Dec. 31, 2023
Feb. 06, 2024
Jun. 30, 2023
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2023    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 000-50679    
Entity Registrant Name CORCEPT THERAPEUTICS INC    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 77-0487658    
Entity Address, Address Line One 149 Commonwealth Drive    
Entity Address, City or Town Menlo Park    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 94025    
City Area Code 650    
Local Phone Number 327-3270    
Title of 12(b) Security Common Stock, $0.001 par value    
Trading Symbol CORT    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Public Float     $ 1,827,006,147
Entity Common Stock, Shares Outstanding   103,517,388  
Documents Incorporated by Reference
Portions of the Registrant’s definitive proxy statement for its 2024 Annual Meeting of Stockholders are incorporated by reference in Items 10, 11, 12, 13 and 14 of Part III.
    
Amendment Flag false    
Document Fiscal Year Focus 2023    
Document Fiscal Period Focus FY    
Entity Central Index Key 0001088856    

XML 16 R2.htm IDEA: XBRL DOCUMENT v3.24.0.1
Audit Information
 12 Months Ended
Dec. 31, 2023
Auditor Information [Abstract]  
Auditor Firm ID 42
Auditor Name Ernst & Young LLP
Auditor Location San Mateo, California
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 135,551 $ 66,329
Short-term marketable securities 232,670 365,343
Trade receivables, net of allowances 41,123 31,057
Insurance recovery receivable related to Melucci litigation (Note 10) 14,000 14,000
Inventory 7,730 6,100
Prepaid expenses and other current assets 27,562 16,424
Total current assets 458,636 499,253
Strategic inventory 8,244 10,931
Operating lease right-of-use asset 120 1,143
Property and equipment, net of accumulated depreciation and amortization 195 633
Long-term marketable securities 57,176 4,947
Other assets 6,541 5,058
Deferred tax assets, net 90,605 61,465
Total assets 621,517 583,430
Current liabilities:    
Accounts payable 17,396 11,976
Accrued research and development expenses 21,330 14,573
Accrued and other liabilities 51,628 30,799
Accrued settlement related to Melucci litigation (Note 10) 14,000 14,000
Short-term operating lease liability 151 1,143
Total current liabilities 104,505 72,491
Long-term accrued income taxes payable 10,307 9,097
Total liabilities 114,812 81,588
Commitments and contingencies (Note 10)
Stockholders’ equity:    
Preferred stock, par value $0.001 per share, 10,000 shares authorized and no shares outstanding as of December 31, 2023 and December 31, 2022 0 0
Common stock, par value $0.001 per share, 280,000 shares authorized and 134,344 issued and 103,405 outstanding as of December 31, 2023 and 130,959 shares issued and 107,835 outstanding as of December 31, 2022 133 131
Treasury stock; at cost; 30,938 shares of common stock as of December 31, 2023 and 23,124 shares of common stock as of December 31, 2022 (635,078) (456,148)
Additional paid-in capital 738,515 662,342
Accumulated other comprehensive income (loss) 609 (869)
Retained earnings 402,526 296,386
Total stockholders’ equity 506,705 501,842
Total liabilities and stockholders’ equity $ 621,517 $ 583,430
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Dec. 31, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized (in shares) 10,000,000 10,000,000
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized 280,000,000 280,000,000
Common stock, shares, issued 134,344,000 130,959,000
Common stock, shares, outstanding 103,405,000 107,835,000
Treasury stock (in shares) 30,938,000 23,124,000
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]      
Product revenue, net $ 482,375 $ 401,858 $ 365,978
Operating expenses:      
Cost of sales 6,481 5,385 5,281
Research and development 184,353 130,991 113,864
Selling, general and administrative 184,259 152,848 122,356
Settlement expense related to Melucci litigation 0 14,000 0
Insurance recovery related to Melucci litigation 0 (14,000) 0
Total operating expenses 375,093 289,224 241,501
Income from operations 107,282 112,634 124,477
Interest and other income 17,275 3,557 529
Income before income taxes 124,557 116,191 125,006
Income tax expense (18,417) (14,773) (12,494)
Net income 106,140 101,418 112,512
Net income attributable to common stockholders, basic 105,496 101,288 112,512
Net income attributable to common stockholders, diluted $ 105,496 $ 101,288 $ 112,512
Basic net income per share (in dollars per share) $ 1.02 $ 0.95 $ 0.97
Diluted net income per share (in dollars per share) $ 0.94 $ 0.87 $ 0.89
Weighted-average shares outstanding used in computing net income per common share      
Basic (in shares) 103,560 106,787 115,653
Diluted (in shares) 111,742 115,966 125,963
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Statement of Comprehensive Income [Abstract]      
Net income $ 106,140 $ 101,418 $ 112,512
Other comprehensive income (loss):      
Unrealized gain (loss) on marketable securities, net of tax impact of $(353), $105, and $198 1,120 (331) (621)
Foreign currency translation gain (loss), net of tax 358 (311) (21)
Total comprehensive income $ 107,618 $ 100,776 $ 111,870
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Statement of Comprehensive Income [Abstract]      
Unrealized gain (loss) on marketable securities, tax $ (353) $ 105 $ 198
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Cash flows from operating activities:      
Net income $ 106,140 $ 101,418 $ 112,512
Adjustments to reconcile net income to net cash provided by operations:      
Stock-based compensation 48,940 42,442 42,931
(Accretion) of discount and Amortization of premium on marketable securities, net (9,128) 1,383 5,083
Amortization of cloud computing arrangements 465 477 409
Depreciation and amortization of property and equipment 577 782 1,072
Deferred income taxes (29,493) (33,905) 4,346
Non-cash amortization of right-of-use asset 1,320 2,187 1,995
Other 0 0 10
Changes in operating assets and liabilities:      
Trade receivables (10,066) (3,432) (1,427)
Insurance recovery receivable related to Melucci litigation 0 (14,000) 0
Inventory 1,265 1,199 3,444
Prepaid expenses and other current assets (11,603) (6,557) (4,006)
Other assets (1,483) (1,975) 1,917
Accounts payable 5,778 4,757 (3,597)
Accrued research and development expenses 6,757 2,131 (1,262)
Accrued and other liabilities 17,649 2,927 6,479
Accrued settlement related to Melucci litigation 0 14,000 0
Long-term accrued income taxes 1,210 8,688 11
Operating lease liability (1,289) (2,199) (2,025)
Net cash provided by operating activities 127,039 120,323 167,892
Cash flows from investing activities:      
Purchases of property and equipment (139) (413) (469)
Proceeds from maturities of marketable securities 419,793 241,152 398,937
Proceeds from sales of marketable securities 0 0 50,463
Purchases of marketable securities (328,748) (355,066) (312,805)
Net cash provided (used in) by investing activities 90,906 (114,327) 136,126
Cash flows from financing activities:      
Proceeds from issuance of common stock under our incentive award plan, net of issuance costs 5,811 4,381 16,229
Cash paid to satisfy statutory withholding requirement for net settlement of cashless option exercises and vesting of restricted stock grants (9,106) (21,665) (22,835)
Net cash used in financing activities (148,723) (17,284) (302,591)
Net increase (decrease) in cash and cash equivalents 69,222 (11,288) 1,427
Cash and cash equivalents, at beginning of period 66,329 77,617 76,190
Cash and cash equivalents, at end of period 135,551 66,329 77,617
Supplemental disclosure:      
Income taxes paid 47,602 39,747 9,104
Exercise cost of shares repurchased for net settlement of cashless option exercises 25,032 24,388 15,796
Recognition of right-of-use asset in exchange for lease liability 297 2,816 0
Tender Offer      
Cash flows from financing activities:      
Repurchase of common stock (145,428) 0 (207,500)
Stock Repurchase Program      
Cash flows from financing activities:      
Repurchase of common stock $ 0 $ 0 $ (88,485)
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
shares in Thousands, $ in Thousands
Total
Stock Repurchase Program
Tender Offer
Common Stock
Common Stock
Stock Repurchase Program
Common Stock
Tender Offer
Additional Paid-in Capital
Treasury Stock
Treasury Stock
Stock Repurchase Program
Treasury Stock
Tender Offer
Accumulated Other Comprehensive Income (Loss)
Retained Earnings
Beginning balance (in shares) at Dec. 31, 2020       116,735                
Beginning balance at Dec. 31, 2020 $ 523,338     $ 122     $ 516,140 $ (75,795)     $ 415 $ 82,456
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Issuance of common stock upon exercise of options (in shares)       4,632                
Issuance of common stock upon exercise of options 32,046     $ 5     32,041          
Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises (in shares)       (1,560)                
Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises (38,631)             (38,631)        
Stock-based compensation 43,168           43,168          
Other comprehensive loss, net of tax (642)                   (642)  
Purchase of treasury stock (in shares)         (3,867) (10,000)            
Purchase of treasury stock   $ (88,485) $ (207,500)           $ (88,485) $ (207,500)    
Net income 112,512                     112,512
Ending balance (in shares) at Dec. 31, 2021       105,940                
Ending balance at Dec. 31, 2021 375,806     $ 127     591,349 (410,411)     (227) 194,968
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Issuance of common stock upon exercise of options (in shares)       3,741                
Issuance of common stock upon exercise of options 28,482     $ 4     28,478          
Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises (in shares)       (1,846)                
Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises (45,737)             (45,737)        
Stock-based compensation 42,515           42,515          
Other comprehensive loss, net of tax (642)                   (642)  
Net income $ 101,418                     101,418
Ending balance (in shares) at Dec. 31, 2022 107,835     107,835                
Ending balance at Dec. 31, 2022 $ 501,842     $ 131     662,342 (456,148)     (869) 296,386
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Issuance of common stock upon exercise of options (in shares) 2,355     3,383                
Issuance of common stock upon exercise of options $ 29,128     $ 2     29,126          
Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises (in shares)       (1,203)                
Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises (32,424)             (32,424)        
Stock-based compensation 45,977           45,977          
Other comprehensive loss, net of tax 1,478                   1,478  
Purchase of treasury stock (in shares)           (6,610)            
Purchase of treasury stock     $ (145,428)             $ (145,428)    
Excise tax related to net share repurchases (1,078)             (1,078)        
Vesting of RSAs in connection with ESPP 1,070           1,070          
Net income $ 106,140                     106,140
Ending balance (in shares) at Dec. 31, 2023 103,405     103,405                
Ending balance at Dec. 31, 2023 $ 506,705     $ 133     $ 738,515 $ (635,078)     $ 609 $ 402,526
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.24.0.1
Basis of Presentation and Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation and Summary of Significant Accounting Policies
Description of Business and Basis of Presentation
Corcept Therapeutics Incorporated (collectively, “Corcept,” the “Company,” “we,” “us” and “our”) is a commercial-stage pharmaceutical company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. In 2012, the United States Food and Drug Administration (“FDA”) approved Korlym (“mifepristone”) 300 mg tablets, as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. We have discovered and patented four structurally distinct series of selective cortisol modulators, consisting of more than 1,000 compounds. We are developing compounds from these series as potential treatments for a broad range of serious disorders.
We were incorporated in the State of Delaware in May 1998. Our headquarters are located in Menlo Park, California.
Basis of Presentation
The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”).
Principles of Consolidation
Our consolidated financial statements include the financial position and results of operations of Corcept Therapeutics UK Limited, our wholly owned subsidiary, which we incorporated in the United Kingdom in March 2017. All material intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates
The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates.
We reevaluate our estimates and assumptions each quarter, including those related to revenue recognition, recognition and measurement of income tax assets and liabilities, inventory, allowances for doubtful accounts and other accrued liabilities, including our bonus accrual, clinical trial accruals and stock-based compensation.
Fair Value Measurements
We value financial instruments using assumptions we believe third-party market participants would use. When choosing which assumptions to make when determining the value of a financial instrument, we look first for quoted prices in active markets for identical instruments (“Level 1 inputs”). If no Level 1 inputs are available, we consider (i) quoted prices in non-active markets for identical instruments; (ii) active markets for similar instruments; (iii) inputs other than quoted prices for the instrument; and (iv) inputs that are not directly observable, but that can be corroborated by observable data (“Level 2 inputs”). In the absence of Level 2 inputs, we rely on unobservable inputs, such as our estimates of the assumptions market participants would use in pricing the instrument (“Level 3 inputs”).
Cash and Cash Equivalents and Marketable Securities
We consider highly liquid investments that will mature in three months or less from the time we purchase them to be cash equivalents. Cash equivalents are valued using Level 1 inputs, which approximate our cost.
We invest the majority of our funds in marketable securities, primarily corporate notes, U.S. Treasury and government agency securities, asset-backed securities and commercial paper. We classify our marketable securities as available-for-sale securities and report them at fair value as “cash equivalents” or “marketable securities” on our consolidated balance sheet, with related unrealized gains and losses included in stockholders' equity. Realized gains and losses and permanent declines in value are included in “interest and other income (expense)” on our consolidated statements of income.
Credit and Concentration Risks
Our cash, cash equivalents and marketable securities are held in four financial institutions. We are subject to credit risk from our cash equivalents and marketable securities. We limit our investments to U.S. Treasury obligations and high-grade corporate debt and asset-backed securities with less than a 36-month maturity at the time of purchase. These investments are diversified and do not expose us to concentrations of credit risk. We have never experienced a loss in, or lack of access to, our operating or investment accounts.
We have an agreement with one third-party manufacturer to supply mifepristone, the active pharmaceutical ingredient (“API”), in Korlym.
We have a concentration of risk in regard to the distribution of our product. A single specialty pharmacy, Optime Care, Inc. (“Optime”), dispenses Korlym to patients for us. Optime is an independent third party. Its unwillingness or inability to dispense Korlym to patients in a timely manner would harm our business.
We sell Korlym that Optime dispenses directly to patients, with title to the medicine passing directly from us to the patient upon the patient’s receipt of the drug. Our receivables risk is spread among various third-party payers – pharmacy benefit managers, insurance companies, government programs and private charities. We monitor our exposure and record an allowance against uncollectible trade receivables as necessary. To date, we have not recorded an allowance for credit losses.
Inventory and Cost of Sales
Regulatory approval of product candidates is uncertain. Because product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained, we record the cost of manufacturing our product candidates as research and development expense at the time such costs are incurred. Once a product candidate is approved by the FDA, we begin capitalizing manufacturing costs. We capitalize to inventory manufacturing costs related to Korlym.
We value inventory at the lower of cost or net realizable value and determine the cost of inventory we sell using the specific identification method, which approximates a first-in, first-out basis. We assess our inventory levels at each reporting period and write down inventory that is either expected to be at risk of expiration prior to sale, has a cost basis in excess of its expected net realizable value, or for which there are inventory quantities in excess of expected requirements. We destroy expired inventory and recognize the related costs as cost of sales in that period’s statement of income.
Cost of sales also includes the cost of manufacturing Korlym, including materials, third-party manufacturing costs and indirect personnel and other overhead costs, based on the number of Korlym tablets for which we recognize revenue, as well as costs of stability testing, logistics and distribution.
We classify inventory we do not expect to sell within 12 months of the balance sheet date as strategic inventory, a non-current asset.
Net Product Revenue
We sell Korlym directly to patients through a single specialty pharmacy. We also sell Korlym to a specialty distributor (“SD”), for which we recognize revenue at the time the SD receives Korlym. SD sales were less than one percent of our net revenue in each of the years ended December 31, 2023, 2022 and 2021.
To determine our revenue from the sale of Korlym, we (i) identify our contract with each customer; (ii) identify the obligations of Corcept and the customer under the contract; (iii) determine the contracted transaction price; (iv) allocate the transaction price to the contract’s performance obligations, which in our case consists of delivering Korlym to the customer; and (v) recognize revenue once Korlym has been delivered, provided we deem it probable that we will collect the payment due to us.
Confirmation of coverage by private or government insurance or by a third-party charity is a prerequisite for selling Korlym to a patient.
To determine net product revenue, we deduct from sales the cost of our patient co-pay assistance program and our estimates of (a) government chargebacks and rebates, (b) discounts provided to our SD for prompt payment and (c) reserves for expected returns. We record these estimates at the time we recognize revenue and update them as new information becomes available. Our estimates take into account our understanding of the range of possible outcomes. If results differ from our estimates, we adjust our estimates, which changes our net product revenue and earnings. We report any changes in the period they become known, even if they concern transactions occurring in prior periods.
Government Rebates: Korlym is eligible for purchase by, or qualifies for reimbursement from, Medicaid, Medicare and other government programs that are eligible for rebates on the price they pay for Korlym. To determine the appropriate amount to reserve against these rebates, we identify Korlym sold to patients covered by government-funded programs, apply the applicable government discount to these sales, then estimate utilization of such programs by government payors. We (i) deduct this reserve from revenue in the period to which the rebates relate and (ii) include in accrued expenses on our consolidated balance sheet a current liability of an equal amount.
Chargebacks: Although we sell Korlym to the SD at full price, some of the government entities to which the SD sells receive a discount. The SD recovers the full amount of any related discounts by reducing its payment to us (this reduction is called a “chargeback”). Chargebacks sometimes relate to Korlym purchased by the SD in prior periods. We deduct from our revenue in each period chargebacks claimed by the SD for Korlym it purchased in that period. We also create a reserve for chargebacks we estimate the SD will claim in future periods against Korlym it purchased in the current period but has not yet resold. We determine the amount of this reserve based on our experience with SD chargebacks and our understanding of the SD’s customer base and business practices. We deduct this reserve from revenue and include in accrued expenses on our consolidated balance sheet a current liability of equal amount.
Patient Assistance Program and Charitable Support: It is our policy that no patient be denied Korlym due to inability to pay. We provide financial assistance to eligible patients whose insurance policies have high deductibles or co-payments and deduct the amount of such assistance from gross revenue. We determine the assistance we provide each patient by applying our program guidelines to that patient’s financial position and their insurance policy’s co-payment and deductible requirements for the purchase of Korlym. We donate cash to charities that help patients with financial need pay for the treatment of Cushing’s syndrome. We do not include payments from these charities in revenue, but as a deduction to selling, general and administrative expenses. We provide Korlym at no cost to uninsured patients who do not qualify for charitable support.
Sales Returns: Federal law prohibits the return of Korlym sold to patients. Sales to our SD are subject to return. We deduct the amount of Korlym we estimate the SD will return from each period’s gross revenue. We base our estimates on quantitative and qualitative information including, but not limited to, historical return rates, the amount of Korlym held by the SD and projected demand. If we cannot reasonably estimate returns with respect to a particular sale, we defer recognition of revenue until we can make a reasonable estimate. To date, returns have not been significant.
The following table summarizes activity in each of the product revenue allowance and reserve categories for the years ended December 31, 2023, 2022 and 2021:
ChargebacksGovernment RebatesTotal
(in thousands)
Balance at December 31, 2020$163 $9,412 $9,575 
Provision related to current period sales394 33,709 34,103 
Provision related to prior period sales(29)(1,047)(1,076)
Credit or payments made during the period(478)(30,900)(31,378)
Balance at December 31, 202150 11,174 11,224 
Provision related to current period sales557 38,745 39,302 
Provision related to prior period sales78 (68)10 
Credit or payments made during the period(455)(38,753)(39,208)
Balance at December 31, 2022230 11,098 11,328 
Provision related to current period sales346 52,825 53,171 
Provision related to prior period sales(88)(555)(643)
Credit or payments made during the period(266)(44,900)(45,166)
Balance at December 31, 2023$222 $18,468 $18,690 
Research and Development
Research and development expense includes the direct cost of discovering and screening new compounds, pre-clinical studies, clinical trials, manufacturing development, submissions to regulatory agencies and related overhead costs. We expense nonrefundable payments and the cost of technologies and materials used in research and development as we incur them.
We base our accruals for discovery research, preclinical studies and clinical trials on our estimates of work completed, milestones achieved, patient enrollment and past experience with similar activities. Our estimates include assessments of information from contract research organizations and the status of our own research, development and administrative activities.
Segment Reporting
We determine our operating segments based on the way we organize our business, make decisions and assess performance. We have one operating segment, which is the discovery, development and commercialization of pharmaceutical products.
Stock-Based Compensation
We recognize stock-based compensation expense for stock options, restricted stock awards (“RSAs”) and restricted stock units (“RSUs”), net of estimated forfeitures, on a straight-line basis over the period during which an employee is required to provide services in exchange for the award (the vesting period of the award). We estimate future forfeitures during the first quarter of each fiscal year, and revise the estimates, if necessary, in subsequent periods if actual forfeitures differ significantly from those estimates.
We determine the fair value of stock options based on the value of the award at the grant date, using the Black-Scholes model. We recognize stock-based compensation expense over the applicable vesting period, net of estimated forfeitures. If actual forfeitures differ from our estimates, we adjust stock-based compensation expense accordingly.
In addition, we have issued RSAs in connection with our Employee Stock Purchase Plan (“ESPP”) that vest on the condition that the participating employee hold the corresponding shares purchased under the ESPP for one year from the purchase date. The participating employee is granted one RSA for each share purchased in the ESPP. We initially measure the fair value of these RSAs based on the grant date fair value determined using the closing price of our common stock on the date the purchase of the corresponding ESPP shares is made. This fair value of the RSA is amortized over the one-year holding period. As a result of the RSA’s being reported as liability-classified awards, they must be remeasured at each reporting date until settlement. Ultimately, the compensation cost recognized for the RSA award will equal the fair value of the Company’s common stock on the date the RSA is fully vested and settled. See Note 7, Preferred Stock and Stockholders’ Equity regarding our ESPP.
Income Taxes
We account for income taxes in accordance with ASC 740, Income Taxes (“ASC 740”), which requires recognition of deferred tax assets and liabilities for the expected tax consequences of our future financial and operating activities. Under ASC 740, we determine deferred tax assets and liabilities based on the temporary difference between the financial statement and tax bases of assets and liabilities using the tax rates in effect for the year in which we expect such differences to reverse. If we determine that it is more likely than not that we will not generate sufficient taxable income to realize the value of some or all of our deferred tax assets (net of our deferred tax liabilities), we establish a valuation allowance offsetting the amount we do not expect to realize. We perform this analysis each reporting period and reduce our measurement of deferred taxes if the likelihood we will realize them becomes uncertain.
The deferred tax assets that we record each period depend primarily on our ability to generate future taxable income in the United States. Each period, we evaluate the need for a valuation allowance against our deferred tax assets and, if necessary, adjust the valuation allowance so that net deferred tax assets are recorded only to the extent we conclude it is more likely than not that these deferred tax assets will be realized. If our outlook for future taxable income changes significantly, our assessment of the need for, and the amount of, a valuation allowance may also change.
We are also required to evaluate and quantify other sources of taxable income, such as the possible reversal of future deferred tax liabilities, should any arise, and the implementation of tax planning strategies. Evaluating and quantifying these amounts is difficult and involves significant judgment, based on all of the available evidence and assumptions about our future activities.
We account for uncertain tax positions in accordance with ASC 740, which requires us to adjust our consolidated financial statements to reflect only those tax positions that are more-likely-than-not to be sustained upon review by federal or state examiners. We recognize in the consolidated financial statements the largest expected tax benefit that has a greater than 50 percent likelihood of being sustained on examination by the taxing authorities. We report interest and penalties related to unrecognized tax benefits as income tax expense.
Recently Issued Accounting Pronouncements Not Yet Adopted
In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-09, which requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. This ASU is effective for public companies with annual periods beginning after December 15, 2024, with early adoption permitted. We plan to adopt this guidance for the fiscal year ending December 31, 2025. We are currently evaluating the effects adoption of this guidance will have on the consolidated financial statements.
In November 2023, the FASB issued ASU No. 2023-07, to improve the disclosures about a public entity’s reportable segments and address requests from investors for additional, more detailed information about a reportable segment’s expenses. The standard is effective for public companies with annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 with early adoption permitted. We plan to adopt this guidance for the fiscal year ending December 31, 2024. We are currently evaluating the effects adoption of this guidance will have on the consolidated financial statements.
XML 25 R11.htm IDEA: XBRL DOCUMENT v3.24.0.1
Significant Agreements
 12 Months Ended
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Significant Agreements Significant Agreements
Commercial Agreement
In August 2017, we entered into a distribution services agreement with an independent third party, Optime, to provide exclusive specialty pharmacy and patient services programs for Korlym beginning August 10, 2017. Under the terms of this agreement, Optime acts as the exclusive specialty pharmacy distributor of Korlym in the United States, subject to certain exceptions. Optime provides services related to pharmacy operations; patient intake, access and reimbursement; patient support; claims management and accounts receivable; and data and reporting. We provide Korlym to Optime, which it dispenses to patients. Optime does not purchase Korlym from us and it does not take title to the product. Title passes directly from us to the patient at the time the patient receives the medicine.
The initial term of our agreement with Optime was five years. In August 2022, we amended our agreement to extend its term to September 30, 2022. In September 2022, we amended our agreement to further extend its term to March 31, 2024, unless terminated earlier by us upon 90 days’ notice. The agreement contains additional customary termination provisions, representations, warranties and covenants. Subject to certain limitations, we have agreed to indemnify Optime for certain third-party claims related to the product, and we have each agreed to indemnify the other for certain breaches of representations, warranties, covenants and other specified matters.
XML 26 R12.htm IDEA: XBRL DOCUMENT v3.24.0.1
Available for Sale Marketable Securities and Fair Value Measurements
 12 Months Ended
Dec. 31, 2023
Available For Sale Securities And Fair Value Measurements [Abstract]  
Available for Sale Marketable Securities and Fair Value Measurements Available for Sale Marketable Securities and Fair Value Measurements
The available-for-sale securities in our Consolidated Balance Sheets are as follows:
December 31,
20232022
(in thousands)
Cash equivalents$97,170 $36,380 
Short-term marketable securities232,670 365,343 
Long-term marketable securities57,176 4,947 
Total marketable securities$387,016 $406,670 
The following table presents our available-for-sale securities grouped by asset type:
 Fair Value
Hierarchy
Level		December 31, 2023December 31, 2022
Amortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair ValueAmortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
  (in thousands)
Corporate bondsLevel 2$120,508 $307 $— $120,815 $151,069 $— $(625)$150,444 
Commercial paperLevel 275,308 20 (9)75,319 136,132 — — 136,132 
U.S. government agency securitiesLevel 2— — — — 25,113 23 — 25,136 
Asset-backed securitiesLevel 2— — — — 185 — — 185 
U.S. Treasury securitiesLevel 193,655 61 (4)93,712 58,536 — (142)58,394 
Money market fundsLevel 197,170 — — 97,170 36,379 — — 36,379 
Total marketable securities$386,641 $388 $(13)$387,016 $407,414 $23 $(767)$406,670 
We estimate the fair value of marketable securities classified as Level 1 using quoted market prices obtained from a commercial pricing service for these or identical investments. We estimate the fair value of marketable securities classified as Level 2 using inputs that may include benchmark yields, reported trades, broker/dealer quotes and issuer spreads.
We periodically review our debt securities to determine if any of our investments is impaired due to the issuer’s poor credit or other reasons. If the fair value of our investment is less than our amortized cost, we evaluate quantitative and subjective factors – including, but not limited to, the nature of security, changes in credit ratings and analyst reports concerning the security’s issuer and industry, and interest rate fluctuations and general market conditions – to determine whether an allowance for credit losses is appropriate.
None of our investments, including those with unrealized losses, are impaired. Unrealized losses on our investments are due to interest rate fluctuations. We do not intend to sell investments that currently have unrealized losses and it is highly unlikely that we will sell any investment before recovery of its amortized cost basis, which may be at maturity. Accordingly, we have not recorded an allowance for credit losses for these investments.
We classified accrued interest on our marketable securities of $1.7 million and $1.8 million as of December 31, 2023 and 2022, respectively, as prepaid and other current assets on our consolidated balance sheets.
As of December 31, 2023, all our marketable securities had original maturities of no more than 27 months and all our marketable securities classified as short-term have maturities of less than one year. The weighted-average maturity of our holdings was seven months. As of December 31, 2023, our long-term marketable securities had remaining maturities between 13 months and 22 months. None of our marketable securities changed from one fair value hierarchy to another during the year ended December 31, 2023.
XML 27 R13.htm IDEA: XBRL DOCUMENT v3.24.0.1
Composition of Certain Balance Sheet Items
 12 Months Ended
Dec. 31, 2023
Balance Sheet Related Disclosures [Abstract]  
Composition of Certain Balance Sheet Items Composition of Certain Balance Sheet Items
Inventory
Year Ended December 31,
20232022
(in thousands)
Work in progress$8,233 $7,827 
Finished goods7,741 9,204 
Total inventory15,974 17,031 
Less strategic inventory classified as non-current(8,244)(10,931)
Total inventory classified as current$7,730 $6,100 
Because we rely on one manufacturer to produce Korlym’s API, we have purchased and hold significant quantities of API, included in work in progress inventory. We classify inventory we do not expect to sell within 12 months of the balance sheet date as “Strategic inventory,” a non-current asset.
Accrued and other liabilities
Year Ended December 31,
20232022
(in thousands)
Accrued compensation$25,457 $15,511 
Government rebates18,468 11,098 
Income taxes payable1,814 89 
Accrued selling and marketing costs1,771 434 
Accrued Manufacturing Costs1,455 20 
Excise tax payable1,078 — 
Legal fees542 2,673 
Professional fees389 211 
Other654 763 
Total accrued and other liabilities$51,628 $30,799 
Other assets
As of December 31, 2023 and 2022, other assets included $6.4 million and $4.9 million of deposits for clinical trials, respectively.
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.24.0.1
Leases
 12 Months Ended
Dec. 31, 2023
Leases [Abstract]  
Leases Leases
We lease our office facilities in Menlo Park, California. On April 1, 2023, we signed an amendment to extend our lease through June 30, 2024. As a result of this amendment, we recognized an additional right-of-use asset and corresponding lease liability of $0.3 million in the year ended December 31, 2023. The right-of-use asset and lease liability recognized equals the present value of the remaining payments due under our amended lease.
As the operating lease for our facilities does not expressly state an interest rate, we calculated the present value of remaining lease payments using a discount rate equal to the interest rate we would pay on a collateralized loan with monthly payments and a term equal to the monthly payments and remaining term of our lease. We recognize operating lease payments as expenses using the straight-line method over the term of the lease.
Operating lease expense for the years ended December 31, 2023, 2022 and 2021 was $2.4 million, $2.3 million and $2.1 million, respectively.
Our right-of-use assets and related lease liabilities were as follows (in thousands, except weighted average amounts):
Year Ended December 31,
20232022
Cash paid for operating lease liabilities$2,391 $2,265 
Recognition of right-of-use asset in exchange for lease liability$297 $2,816 
Weighted-average remaining lease term6 months6 months
Weighted-average discount rate8.0 %4.0 %
As of December 31, 2023, future minimum lease payments under non-cancelable operating leases were as follows (in thousands):
2024$155 
Total operating lease payments155 
Less imputed interest(4)
Present value of operating lease liabilities$151 
As of December 31, 2023, future minimum lease payments under non-cancellable short-term leases were $1.1 million for 2024. We do not recognize right-of-use assets or lease liabilities for leases with a term of twelve months or less, rather, we recognize the associated lease payments in the condensed consolidated statements of income on a straight-line basis over the lease term.
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.24.0.1
Related Party Transactions
 12 Months Ended
Dec. 31, 2023
Related Party Transactions [Abstract]  
Related Party Transactions Related Party Transactions
There were no related party transactions during the years ended December 31, 2023, 2022, and 2021.
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.24.0.1
Preferred Stock and Stockholders' Equity
 12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
Preferred Stock and Stockholders' Equity Preferred Stock and Stockholders’ Equity
Preferred Stock
Our Board of Directors is authorized, subject to any limitations prescribed by law, without stockholder approval, to issue up to an aggregate of 10.0 million shares of preferred stock at $0.001 par value in one or more series and to fix the rights, preferences, privileges and restrictions granted to or imposed upon the preferred stock, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences. The rights of the holders of common stock will be subject to the rights of holders of any preferred stock that may be issued in the future. As of December 31, 2023 and 2022, we had no outstanding shares of preferred stock.
Treasury Stock
In March 2023, we announced that our Board of Directors approved a tender offer to purchase up to 7.5 million shares of our common stock. The tender offer commenced on March 6, 2023 and expired on March 31, 2023. On April 5, 2023, we purchased 6.6 million shares through the tender offer at a price of $22.00 per share for an aggregate purchase price of $145.4 million, excluding related fees and expenses. We recorded purchased shares as treasury stock on our condensed consolidated balance sheet at cost.
In November 2021, we announced that our Board of Directors approved a tender offer to purchase up to 10 million shares of our common stock. The tender offer commenced on November 8, 2021 and expired on December 15, 2021. We repurchased 10 million shares through the tender offer at a price of $20.75 per share for an aggregate purchase price of $207.5 million, excluding fees and expenses relating to the tender offer.
In November 2020, we announced that our Board of Directors approved a program to repurchase up to $200 million of our common stock (the “Stock Repurchase Program”). The terms of this program did not require us to acquire any shares and allowed for repurchases by a variety of methods, including open market purchases, privately negotiated transactions, block trades, accelerated share repurchase transactions or any combination of such methods. The Stock Repurchase Program expired by its terms on September 30, 2021. During the year ended December 31, 2021, we purchased 3.9 million shares of common stock under the Stock Repurchase Program in open market transactions at an average price of $22.88 per share, for aggregate purchase price of $88.5 million.
During the years ended December 31, 2023, 2022 and 2021, we issued 2.4 million, 3.7 million and 4.6 million shares, respectively, of our common stock upon the exercise of stock options. Some option holders exercised their options on a “net exercise” basis, pursuant to which they surrendered to us, and we purchased from them, at the then current market price, shares equal in value to the associated exercise price and tax withholding obligations. During the years ended December 31, 2023, 2022 and 2021, we purchased 1.2 million, 1.8 million and 1.6 million shares, respectively, in connection with such option net exercises and paid $7.4 million, $21.3 million and $22.8 million, respectively, to satisfy associated tax withholding obligations.
We recorded purchased shares as treasury stock on our consolidated balance sheets, at cost. It has not been determined whether purchased shares will be retired or sold.
We have never declared or paid any dividends.
Incentive Award Plan
We have one stock option plan – the Corcept Therapeutics Incorporated 2012 Incentive Award Plan (the “2012 Plan”).
In 2012, our Board of Directors and stockholders approved the 2012 Plan. Under the 2012 Plan, we can issue options, stock purchase and stock appreciation rights, and restricted stock awards to our employees, officers, directors and consultants. The 2012 Plan provides that the exercise price for incentive stock options will be no less than 100 percent of the fair value of our common stock as of the date of grant. Options granted under the 2012 Plan carry a contractual term of ten years and are
expected to vest over periods ranging from one year to four years. We assume the vesting period of the options that we grant under the 2012 Plan to be equal to the option grantee’s period of service.
As of December 31, 2023, we had 7.7 million shares available for future issuance under the 2012 plan.
Stock Option activity during 2023
The following table summarizes option activity under the 2012 Plan:
Outstanding Options
Number of OptionsWeighted-Average Exercise PriceWeighted-Average Remaining Contractual LifeAggregate Intrinsic Value
(in thousands)(in years)(in thousands)
Balance at December 31, 202223,198 $15.13 
Options granted3,178 $23.49 
Options exercised(2,355)$11.47 
Options cancelled and forfeited(651)$21.16 
Balance at December 31, 202323,370 $16.47 5.79$374,129 
Options exercisable at December 31, 202317,924 $14.41 5.00$323,814 
Options fully vested and expected to vest at
December 31, 2023		23,149 $16.40 5.76$372,158 
The total intrinsic value of options exercised during the years ended December 31, 2023, 2022 and 2021 was $36.0 million, $63.4 million and $78.9 million, respectively, based on the difference between the closing price of our common stock on the date of exercise and the exercise price.
The total fair value of options that vested during the years ended December 31, 2023, 2022 and 2021 was $42.4 million, $43.2 million and $40.4 million, respectively.
As of December 31, 2023, we had $67.3 million of unrecognized compensation expense for options outstanding, which had a weighted-average remaining vesting period of 2.35 years.
RSA and RSU (collectively, “restricted stock”) activity during 2023
The following table summarizes restricted stock activity under the 2012 Plan:
Outstanding Restricted Stock
Number of Restricted StockWeighted-Average Grant Date Fair ValueWeighted-Average Remaining Vesting LifeAggregate Intrinsic Value
(in thousands)(in years)(in thousands)
Balance at December 31, 2022455 $23.91 
Restricted stock granted659 $24.04 
Restricted stock vested(184)$23.87 
Restricted stock cancelled and forfeited(103)$23.26 
Balance at December 31, 2023827 $24.10 2.73$4,910 
As of December 31, 2023, we had $14.9 million of unrecognized compensation expense for restricted stock outstanding, which had a weighted-average remaining vesting period of 2.66 years.
ESPP
In February 2022, we adopted an ESPP that allows employees to set aside, by means of payroll deductions, up to ten percent of their annual compensation for the purchase of our common stock. Shares are issued to participating employees from the 2012 Plan on March 1st and September 1st of each year (or, if those dates fall on holidays or weekends, on the first business day thereafter) at the then-current fair market value of our stock, as determined at the close of trading on those days. Payroll deductions for participating employees began April 1, 2022, and the first purchase under the plan took place on September 1, 2022.
In January 2023, we increased the number of ESPP purchase dates to occur quarterly on March 1st, June 1st, September 1st and December 1st (or, if those dates fall on holidays or weekends, on the first business day thereafter).
For each purchased share, the participating employee will receive one matching share, also issued from the 2012 Plan, if certain conditions are met. There is no vesting requirement for shares issued pursuant to the ESPP purchase. The matching share will be granted in the form of a RSA that will vest on the one-year anniversary of the respective ESPP purchase date, net of applicable tax withholding. The vesting condition on the RSA is that the participating employee hold the corresponding share purchased under the ESPP for one year from the purchase date. Shares purchased pursuant to the ESPP and any matching shares issued upon satisfaction of the one-year holding requirement may be held, sold or transferred at the employee’s sole discretion.
As of December 31, 2023 and 2022, we recorded $3.2 million and $0.2 million, respectively, of stock-based compensation related to RSAs granted in connection with our ESPP in “Accrued and other liabilities” on our consolidated balance sheet.
Option Valuation Assumptions
The following table summarizes the weighted-average assumptions and resultant fair value-based measurements for options granted.
Year Ended December 31,
202320222021
Weighted-average assumptions for options granted:
Risk-free interest rate3.87%1.97%0.76%
Expected term6.7 years6.4 years6.3 years
Expected volatility of stock price53.0%56.5%60.7%
Dividend rate0%0%0%
Weighted-average grant date fair value-based measurement$13.65$11.27$15.06
The expected term of options reflected in the table above is based on a formula that considers the expected service period and expected post-vesting termination behavior depending on whether the option holder is an employee, officer or director.
The expected volatility of our stock used in determining the fair value-based measurement of option grants to employees, officers and directors is based on the volatility of our stock price. The volatility is based on historical data of the price for our common stock for periods of time equal to the expected term of these grants.
We calculate employee stock-based compensation expense using the number of options we expect to vest, based on our estimate of the option grantees’ average length of employment, and reduced by our estimate of option forfeitures. We estimate forfeitures at the time of option grant and revise this estimate in subsequent periods if actual forfeitures differ from our estimates.
Stock-based Compensation
The following table summarizes our stock-based compensation by financial statement classification.
 Year Ended December 31,
 202320222021
 (in thousands)
Stock-based compensation capitalized in inventory$208 $280 $237 
Cost of sales52 70 59 
Research and development15,402 12,800 14,106 
Selling, general and administrative33,486 29,572 28,766 
Total stock-based compensation$49,148 $42,722 $43,168 
XML 31 R17.htm IDEA: XBRL DOCUMENT v3.24.0.1
Net Income Per Share
 12 Months Ended
Dec. 31, 2023
Earnings Per Share [Abstract]  
Net Income Per Share Net Income Per Share
We compute our basic and diluted net income per share in conformity with the two-class method required for companies with participating shares. Under the two-class method, net income is determined by allocating net income between common stock and unvested RSAs. We compute basic net income per share by dividing our net income attributable to common stockholders by the weighted-average number of common shares outstanding during the period. We compute diluted net income per share by dividing our net income attributable to common stockholders by the weighted-average number of common shares outstanding during the period, including potentially dilutive stock options and unvested RSUs, less unvested RSAs. We use the treasury stock method to determine the number of dilutive shares of common stock resulting from stock options and unvested RSUs.
The following table shows the computation of net income per share for each period:
Year Ended December 31,
202320222021
(in thousands, except per share data)
Numerator:
Net income attributable to common stockholders$105,496 $101,288 $112,512 
Denominator:
Weighted-average shares used to compute basic net income per common share103,560 106,787 115,653 
Dilutive effect of employee stock options and unvested RSUs8,182 9,179 10,310 
Weighted-average shares used to compute diluted net income per common share111,742 115,966 125,963 
Net income per share attributable to common stockholders
Basic$1.02 $0.95 $0.97 
Diluted$0.94 $0.87 $0.89 
We excluded from the computation of diluted net income per share, on a weighted-average basis, 9.1 million stock options and unvested RSUs outstanding during the year ended December 31, 2023, and 7.3 million and 4.5 million stock options outstanding during the years ended December 31, 2022 and 2021, respectively, because including them would have reduced dilution.
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes
 12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
The domestic and foreign components of income before income taxes were as follows:
Year Ended December 31,
202320222021
(in thousands)
Domestic $125,691 $116,871 $126,308 
Foreign (1,134)(680)(1,302)
Income before income taxes $124,557 $116,191 $125,006 
The income tax expense for the years ended December 31, 2023, 2022, and 2021 consisted of the following:
Year Ended December 31,
202320222021
(in thousands)
U.S. federal taxes:
Current$40,265 $39,132 $4,675 
Deferred(25,613)(28,122)5,066 
Total U.S. federal taxes14,652 11,010 9,741 
State taxes:
Current7,590 9,515 3,432 
Deferred(2,645)(5,313)(274)
Total state taxes4,945 4,202 3,158 
Foreign taxes:
Current56 30 41 
Deferred(1,236)(469)(446)
Total foreign taxes(1,180)(439)(405)
Total provision for income taxes$18,417 $14,773 $12,494 
Beginning in 2022, the Tax Cuts and Jobs Act of 2017 eliminates the right to deduct research and development expenditures for tax purposes in the period the expenses were incurred and instead requires all U.S. and foreign research and development expenditures to be amortized over five and fifteen tax years, respectively. Congress has considered legislation that would defer the amortization requirement to later years, but as of December 31, 2023, the requirement has not been modified. Accordingly, we have capitalized our research and development expenses for tax purposes, resulting in higher cash paid for taxes as compared to prior years.
Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets are as follows:
Year Ended December 31,
20232022
Deferred tax assets:(in thousands)
Federal and state net operating losses$3,942 $4,882 
Capitalized research and patent costs908 1,911 
Capitalized research expenditures61,760 36,465 
Research credits11,682 9,963 
Stock-based compensation costs21,676 17,956 
Operating lease liability37 280 
Other6,577 5,127 
Total deferred tax assets106,582 76,584 
Valuation allowance(15,947)(14,839)
Deferred tax liabilities
Operating lease right-of-use asset(30)(280)
Total deferred tax liabilities(30)(280)
Net deferred tax assets$90,605 $61,465 
Each quarter, we assess the likelihood that we will generate sufficient taxable income to use our federal and state deferred tax assets. Except for the valuation allowances that offset our California net deferred tax assets, we have determined that it is more likely than not we will realize the benefit related to all other deferred tax assets. To the extent we increase a valuation allowance, we will include an expense in the Consolidated Statement of Income in the period in which such determination is made.
The valuation allowance increased by $1.1 million, $1.9 million and $1.4 million for the years ended December 31, 2023, 2022 and 2021, respectively.
As of December 31, 2023, we had California net operating loss carryforwards of $55.6 million, which will begin to expire in the year 2032, and net operating loss carryforwards from other states of $0.7 million, which will begin to expire in the year 2035 if not utilized.
As of December 31, 2023, we also had California research and development credits of $16.8 million, which have no expiration date.
The following table presents a reconciliation from the statutory federal income tax rate to the effective rate.
 Year Ended December 31,
 202320222021
 (in thousands)
U.S. federal taxes at statutory rate$26,157 $24,400 $26,251 
R&D and other credits(11,508)(9,114)(7,579)
State income taxes, net of federal benefit3,897 3,320 2,495 
Non-deductible compensation3,295 4,354 990 
Stock-based compensation(2,951)(7,980)(9,568)
Other(473)(207)(95)
Total$18,417 $14,773 $12,494 
We maintain liabilities for uncertain tax positions. The measurement of these liabilities involves considerable judgment and estimation and are continuously monitored by management based on the best information available, including changes in tax regulations, the outcome of relevant court cases, and other pertinent information.
The aggregate annual changes in the balance of gross unrecognized tax benefits are as follows:
Year Ended December 31,
202320222021
(in thousands)
Beginning balance$11,425 $9,237 $7,471 
Increase in tax positions for prior years112 53 103 
Decreases in tax positions for prior years(205)— — 
Decrease in tax positions for expirations of statute of limitations(750)— — 
Increase in tax positions for current year2,440 2,135 1,663 
Decrease in tax positions for current year— — — 
Ending balance$13,022 $11,425 $9,237 
As of December 31, 2023, the amount of unrecognized tax benefits that would favorably impact the effective tax rate were approximately $10.2 million, and approximately $2.8 million of unrecognized tax benefits would be offset by a change in the valuation allowance. A valuation allowance is maintained on the remaining tax benefits related to California deferred tax assets and would not impact the effective tax rate. We had no or insignificant amounts of accrued interest and no accrued penalties related to unrecognized tax benefits as of December 31, 2023, 2022 and 2021. We do not expect our unrecognized tax benefits to change materially over the next 12 months.
While we believe we have adequately provided for all tax positions, amounts asserted by tax authorities could be greater or less than the recorded position. Accordingly, our provisions on federal and state tax-related matters to be recorded in the future may change as revised estimates are made or the underlying matters are settled or otherwise resolved.
The Company’s primary tax jurisdiction is the United States. For federal tax purposes, the years 2022 through 2023 remain open and subject to tax examination. For US state tax purposes, the years 2004 through 2023 generally remain open and subject to tax examination by the appropriate state taxing authorities.
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.24.0.1
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Manufacturing Agreements
We have an agreement with one third-party manufacturer to supply mifepristone, the active pharmaceutical ingredient (“API”) in Korlym, and two additional third-party manufacturers to produce and bottle Korlym tablets.
As of December 31, 2023, we had a $0.7 million remaining obligation in connection with commitments to purchase API from these third-party manufacturers. In January 2024, to ensure we have sufficient API to meet future demand of Korlym tablets, we committed to purchase an additional $3.0 million of API.
Taxes
As of December 31, 2023, we have recorded non-current taxes payable of $10.3 million related to uncertain tax positions.
Legal Proceedings
In the ordinary course of business, we may be subject to legal claims and regulatory actions that could have a material adverse effect on our business or financial position. We assess our potential liability in such situations by analyzing the possible outcomes of various litigation, regulatory and settlement strategies. If we determine a loss is probable and its amount can be reasonably estimated, we accrue an amount equal to the estimated loss.
Melucci Litigation and Settlement
On March 14, 2019, a purported securities class action complaint was filed in the United States District Court for the Northern District of California by Nicholas Melucci (Melucci v. Corcept Therapeutics Incorporated, et al., Case No. 5:19-cv-01372-LHK) (the “Melucci litigation”). The complaint named us and certain of our executive officers as defendants asserting violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder and alleges that the defendants made false and materially misleading statements and failed to disclose adverse facts about our business, operations and prospects. The complaint asserts a putative class period extending from August 2, 2017 to February 5, 2019 and seeks unspecified monetary relief, interest and attorneys’ fees. On October 7, 2019, the Court appointed a lead plaintiff and lead counsel. The lead plaintiff’s consolidated complaint was filed on December 6, 2019.
On February 8, 2023, we reached an agreement in principle (the “Proposed Settlement”) to resolve all claims in the Melucci litigation. Under the Proposed Settlement, we have agreed to make a one-time payment of $14.0 million, which will be covered in full by our insurers. In connection with the Proposed Settlement, we recorded a settlement expense of $14.0 million and corresponding insurance recovery of $14.0 million in Operating Expenses on our Consolidated Statement of Income in the fourth quarter of 2022. Accordingly, we recorded an accrued liability of $14.0 million for this settlement and a corresponding insurance recovery receivable of $14.0 million on our Consolidated Balance Sheet. The Court granted preliminary approval of the Proposed Settlement on January 4, 2024, following which we paid $14.0 million into escrow. Our insurers reimbursed us in full. Payment of any funds out of the designated escrow is pending the Court’s final approval of the Proposed Settlement, a hearing for which is scheduled for June 6, 2024.
No other losses and no other provisions for a loss contingency have been recorded to date.
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.24.0.1
Subsequent Events
 12 Months Ended
Dec. 31, 2023
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events
On January 8, 2024, our Board of Directors approved a program authorizing the repurchase of up to $200 million of our common stock. Purchases under this program may be made in the open market, in privately negotiated transactions or otherwise. The timing and amount of any repurchases will be determined based on market conditions, our stock price and other factors. The program does not require us to repurchase any specific number of shares of its common stock and may be modified, suspended or discontinued at any time without notice.
XML 35 R21.htm IDEA: XBRL DOCUMENT v3.24.0.1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Pay vs Performance Disclosure      
Net income $ 106,140 $ 101,418 $ 112,512
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.24.0.1
Insider Trading Arrangements
 12 Months Ended
Dec. 31, 2023
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.24.0.1
Basis of Presentation and Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”).
Principles of Consolidation
Principles of Consolidation
Our consolidated financial statements include the financial position and results of operations of Corcept Therapeutics UK Limited, our wholly owned subsidiary, which we incorporated in the United Kingdom in March 2017. All material intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates
Use of Estimates
The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates.
We reevaluate our estimates and assumptions each quarter, including those related to revenue recognition, recognition and measurement of income tax assets and liabilities, inventory, allowances for doubtful accounts and other accrued liabilities, including our bonus accrual, clinical trial accruals and stock-based compensation.
Fair Value Measurements
Fair Value Measurements
We value financial instruments using assumptions we believe third-party market participants would use. When choosing which assumptions to make when determining the value of a financial instrument, we look first for quoted prices in active markets for identical instruments (“Level 1 inputs”). If no Level 1 inputs are available, we consider (i) quoted prices in non-active markets for identical instruments; (ii) active markets for similar instruments; (iii) inputs other than quoted prices for the instrument; and (iv) inputs that are not directly observable, but that can be corroborated by observable data (“Level 2 inputs”). In the absence of Level 2 inputs, we rely on unobservable inputs, such as our estimates of the assumptions market participants would use in pricing the instrument (“Level 3 inputs”).
Cash and Cash Equivalents and Marketable Securities
Cash and Cash Equivalents and Marketable Securities
We consider highly liquid investments that will mature in three months or less from the time we purchase them to be cash equivalents. Cash equivalents are valued using Level 1 inputs, which approximate our cost.
We invest the majority of our funds in marketable securities, primarily corporate notes, U.S. Treasury and government agency securities, asset-backed securities and commercial paper. We classify our marketable securities as available-for-sale securities and report them at fair value as “cash equivalents” or “marketable securities” on our consolidated balance sheet, with related unrealized gains and losses included in stockholders' equity. Realized gains and losses and permanent declines in value are included in “interest and other income (expense)” on our consolidated statements of income.
Credit and Concentration Risks
Credit and Concentration Risks
Our cash, cash equivalents and marketable securities are held in four financial institutions. We are subject to credit risk from our cash equivalents and marketable securities. We limit our investments to U.S. Treasury obligations and high-grade corporate debt and asset-backed securities with less than a 36-month maturity at the time of purchase. These investments are diversified and do not expose us to concentrations of credit risk. We have never experienced a loss in, or lack of access to, our operating or investment accounts.
We have an agreement with one third-party manufacturer to supply mifepristone, the active pharmaceutical ingredient (“API”), in Korlym.
We have a concentration of risk in regard to the distribution of our product. A single specialty pharmacy, Optime Care, Inc. (“Optime”), dispenses Korlym to patients for us. Optime is an independent third party. Its unwillingness or inability to dispense Korlym to patients in a timely manner would harm our business.
We sell Korlym that Optime dispenses directly to patients, with title to the medicine passing directly from us to the patient upon the patient’s receipt of the drug. Our receivables risk is spread among various third-party payers – pharmacy benefit managers, insurance companies, government programs and private charities. We monitor our exposure and record an allowance against uncollectible trade receivables as necessary. To date, we have not recorded an allowance for credit losses.
Inventory and Cost of Sales
Inventory and Cost of Sales
Regulatory approval of product candidates is uncertain. Because product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained, we record the cost of manufacturing our product candidates as research and development expense at the time such costs are incurred. Once a product candidate is approved by the FDA, we begin capitalizing manufacturing costs. We capitalize to inventory manufacturing costs related to Korlym.
We value inventory at the lower of cost or net realizable value and determine the cost of inventory we sell using the specific identification method, which approximates a first-in, first-out basis. We assess our inventory levels at each reporting period and write down inventory that is either expected to be at risk of expiration prior to sale, has a cost basis in excess of its expected net realizable value, or for which there are inventory quantities in excess of expected requirements. We destroy expired inventory and recognize the related costs as cost of sales in that period’s statement of income.
Cost of sales also includes the cost of manufacturing Korlym, including materials, third-party manufacturing costs and indirect personnel and other overhead costs, based on the number of Korlym tablets for which we recognize revenue, as well as costs of stability testing, logistics and distribution.
We classify inventory we do not expect to sell within 12 months of the balance sheet date as strategic inventory, a non-current asset.
Net Product Revenue
Net Product Revenue
We sell Korlym directly to patients through a single specialty pharmacy. We also sell Korlym to a specialty distributor (“SD”), for which we recognize revenue at the time the SD receives Korlym. SD sales were less than one percent of our net revenue in each of the years ended December 31, 2023, 2022 and 2021.
To determine our revenue from the sale of Korlym, we (i) identify our contract with each customer; (ii) identify the obligations of Corcept and the customer under the contract; (iii) determine the contracted transaction price; (iv) allocate the transaction price to the contract’s performance obligations, which in our case consists of delivering Korlym to the customer; and (v) recognize revenue once Korlym has been delivered, provided we deem it probable that we will collect the payment due to us.
Confirmation of coverage by private or government insurance or by a third-party charity is a prerequisite for selling Korlym to a patient.
To determine net product revenue, we deduct from sales the cost of our patient co-pay assistance program and our estimates of (a) government chargebacks and rebates, (b) discounts provided to our SD for prompt payment and (c) reserves for expected returns. We record these estimates at the time we recognize revenue and update them as new information becomes available. Our estimates take into account our understanding of the range of possible outcomes. If results differ from our estimates, we adjust our estimates, which changes our net product revenue and earnings. We report any changes in the period they become known, even if they concern transactions occurring in prior periods.
Government Rebates: Korlym is eligible for purchase by, or qualifies for reimbursement from, Medicaid, Medicare and other government programs that are eligible for rebates on the price they pay for Korlym. To determine the appropriate amount to reserve against these rebates, we identify Korlym sold to patients covered by government-funded programs, apply the applicable government discount to these sales, then estimate utilization of such programs by government payors. We (i) deduct this reserve from revenue in the period to which the rebates relate and (ii) include in accrued expenses on our consolidated balance sheet a current liability of an equal amount.
Chargebacks: Although we sell Korlym to the SD at full price, some of the government entities to which the SD sells receive a discount. The SD recovers the full amount of any related discounts by reducing its payment to us (this reduction is called a “chargeback”). Chargebacks sometimes relate to Korlym purchased by the SD in prior periods. We deduct from our revenue in each period chargebacks claimed by the SD for Korlym it purchased in that period. We also create a reserve for chargebacks we estimate the SD will claim in future periods against Korlym it purchased in the current period but has not yet resold. We determine the amount of this reserve based on our experience with SD chargebacks and our understanding of the SD’s customer base and business practices. We deduct this reserve from revenue and include in accrued expenses on our consolidated balance sheet a current liability of equal amount.
Patient Assistance Program and Charitable Support: It is our policy that no patient be denied Korlym due to inability to pay. We provide financial assistance to eligible patients whose insurance policies have high deductibles or co-payments and deduct the amount of such assistance from gross revenue. We determine the assistance we provide each patient by applying our program guidelines to that patient’s financial position and their insurance policy’s co-payment and deductible requirements for the purchase of Korlym. We donate cash to charities that help patients with financial need pay for the treatment of Cushing’s syndrome. We do not include payments from these charities in revenue, but as a deduction to selling, general and administrative expenses. We provide Korlym at no cost to uninsured patients who do not qualify for charitable support.
Sales Returns: Federal law prohibits the return of Korlym sold to patients. Sales to our SD are subject to return. We deduct the amount of Korlym we estimate the SD will return from each period’s gross revenue. We base our estimates on quantitative and qualitative information including, but not limited to, historical return rates, the amount of Korlym held by the SD and projected demand. If we cannot reasonably estimate returns with respect to a particular sale, we defer recognition of revenue until we can make a reasonable estimate. To date, returns have not been significant.
Research and Development
Research and Development
Research and development expense includes the direct cost of discovering and screening new compounds, pre-clinical studies, clinical trials, manufacturing development, submissions to regulatory agencies and related overhead costs. We expense nonrefundable payments and the cost of technologies and materials used in research and development as we incur them.
We base our accruals for discovery research, preclinical studies and clinical trials on our estimates of work completed, milestones achieved, patient enrollment and past experience with similar activities. Our estimates include assessments of information from contract research organizations and the status of our own research, development and administrative activities.
Segment Reporting
Segment Reporting
We determine our operating segments based on the way we organize our business, make decisions and assess performance. We have one operating segment, which is the discovery, development and commercialization of pharmaceutical products.
Stock-Based Compensation
Stock-Based Compensation
We recognize stock-based compensation expense for stock options, restricted stock awards (“RSAs”) and restricted stock units (“RSUs”), net of estimated forfeitures, on a straight-line basis over the period during which an employee is required to provide services in exchange for the award (the vesting period of the award). We estimate future forfeitures during the first quarter of each fiscal year, and revise the estimates, if necessary, in subsequent periods if actual forfeitures differ significantly from those estimates.
We determine the fair value of stock options based on the value of the award at the grant date, using the Black-Scholes model. We recognize stock-based compensation expense over the applicable vesting period, net of estimated forfeitures. If actual forfeitures differ from our estimates, we adjust stock-based compensation expense accordingly.
In addition, we have issued RSAs in connection with our Employee Stock Purchase Plan (“ESPP”) that vest on the condition that the participating employee hold the corresponding shares purchased under the ESPP for one year from the purchase date. The participating employee is granted one RSA for each share purchased in the ESPP. We initially measure the fair value of these RSAs based on the grant date fair value determined using the closing price of our common stock on the date the purchase of the corresponding ESPP shares is made. This fair value of the RSA is amortized over the one-year holding period. As a result of the RSA’s being reported as liability-classified awards, they must be remeasured at each reporting date until settlement. Ultimately, the compensation cost recognized for the RSA award will equal the fair value of the Company’s common stock on the date the RSA is fully vested and settled. See Note 7, Preferred Stock and Stockholders’ Equity regarding our ESPP.
Income Taxes
Income Taxes
We account for income taxes in accordance with ASC 740, Income Taxes (“ASC 740”), which requires recognition of deferred tax assets and liabilities for the expected tax consequences of our future financial and operating activities. Under ASC 740, we determine deferred tax assets and liabilities based on the temporary difference between the financial statement and tax bases of assets and liabilities using the tax rates in effect for the year in which we expect such differences to reverse. If we determine that it is more likely than not that we will not generate sufficient taxable income to realize the value of some or all of our deferred tax assets (net of our deferred tax liabilities), we establish a valuation allowance offsetting the amount we do not expect to realize. We perform this analysis each reporting period and reduce our measurement of deferred taxes if the likelihood we will realize them becomes uncertain.
The deferred tax assets that we record each period depend primarily on our ability to generate future taxable income in the United States. Each period, we evaluate the need for a valuation allowance against our deferred tax assets and, if necessary, adjust the valuation allowance so that net deferred tax assets are recorded only to the extent we conclude it is more likely than not that these deferred tax assets will be realized. If our outlook for future taxable income changes significantly, our assessment of the need for, and the amount of, a valuation allowance may also change.
We are also required to evaluate and quantify other sources of taxable income, such as the possible reversal of future deferred tax liabilities, should any arise, and the implementation of tax planning strategies. Evaluating and quantifying these amounts is difficult and involves significant judgment, based on all of the available evidence and assumptions about our future activities.
We account for uncertain tax positions in accordance with ASC 740, which requires us to adjust our consolidated financial statements to reflect only those tax positions that are more-likely-than-not to be sustained upon review by federal or state examiners. We recognize in the consolidated financial statements the largest expected tax benefit that has a greater than 50 percent likelihood of being sustained on examination by the taxing authorities. We report interest and penalties related to unrecognized tax benefits as income tax expense.
Recently Issued Accounting Pronouncements Not Yet Adopted
Recently Issued Accounting Pronouncements Not Yet Adopted
In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-09, which requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. This ASU is effective for public companies with annual periods beginning after December 15, 2024, with early adoption permitted. We plan to adopt this guidance for the fiscal year ending December 31, 2025. We are currently evaluating the effects adoption of this guidance will have on the consolidated financial statements.
In November 2023, the FASB issued ASU No. 2023-07, to improve the disclosures about a public entity’s reportable segments and address requests from investors for additional, more detailed information about a reportable segment’s expenses. The standard is effective for public companies with annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 with early adoption permitted. We plan to adopt this guidance for the fiscal year ending December 31, 2024. We are currently evaluating the effects adoption of this guidance will have on the consolidated financial statements.
XML 38 R24.htm IDEA: XBRL DOCUMENT v3.24.0.1
Basis of Presentation and Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Summary of Allowance Activity Included in Trade Receivables Includes Allowance for Doubtful Accounts, Prompt Pay Cash Discounts and Chargebacks
The following table summarizes activity in each of the product revenue allowance and reserve categories for the years ended December 31, 2023, 2022 and 2021:
ChargebacksGovernment RebatesTotal
(in thousands)
Balance at December 31, 2020$163 $9,412 $9,575 
Provision related to current period sales394 33,709 34,103 
Provision related to prior period sales(29)(1,047)(1,076)
Credit or payments made during the period(478)(30,900)(31,378)
Balance at December 31, 202150 11,174 11,224 
Provision related to current period sales557 38,745 39,302 
Provision related to prior period sales78 (68)10 
Credit or payments made during the period(455)(38,753)(39,208)
Balance at December 31, 2022230 11,098 11,328 
Provision related to current period sales346 52,825 53,171 
Provision related to prior period sales(88)(555)(643)
Credit or payments made during the period(266)(44,900)(45,166)
Balance at December 31, 2023$222 $18,468 $18,690 
XML 39 R25.htm IDEA: XBRL DOCUMENT v3.24.0.1
Available for Sale Marketable Securities and Fair Value Measurements (Tables)
 12 Months Ended
Dec. 31, 2023
Available For Sale Securities And Fair Value Measurements [Abstract]  
Summary of the Classification of Available-for-Sale Securities in Condensed Consolidated Balance Sheets
The available-for-sale securities in our Consolidated Balance Sheets are as follows:
December 31,
20232022
(in thousands)
Cash equivalents$97,170 $36,380 
Short-term marketable securities232,670 365,343 
Long-term marketable securities57,176 4,947 
Total marketable securities$387,016 $406,670 
Schedule of Available-for-Sale Securities
The following table presents our available-for-sale securities grouped by asset type:
 Fair Value
Hierarchy
Level		December 31, 2023December 31, 2022
Amortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair ValueAmortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
  (in thousands)
Corporate bondsLevel 2$120,508 $307 $— $120,815 $151,069 $— $(625)$150,444 
Commercial paperLevel 275,308 20 (9)75,319 136,132 — — 136,132 
U.S. government agency securitiesLevel 2— — — — 25,113 23 — 25,136 
Asset-backed securitiesLevel 2— — — — 185 — — 185 
U.S. Treasury securitiesLevel 193,655 61 (4)93,712 58,536 — (142)58,394 
Money market fundsLevel 197,170 — — 97,170 36,379 — — 36,379 
Total marketable securities$386,641 $388 $(13)$387,016 $407,414 $23 $(767)$406,670 
XML 40 R26.htm IDEA: XBRL DOCUMENT v3.24.0.1
Composition of Certain Balance Sheet Items (Tables)
 12 Months Ended
Dec. 31, 2023
Balance Sheet Related Disclosures [Abstract]  
Schedule of Composition of Inventory
Inventory
Year Ended December 31,
20232022
(in thousands)
Work in progress$8,233 $7,827 
Finished goods7,741 9,204 
Total inventory15,974 17,031 
Less strategic inventory classified as non-current(8,244)(10,931)
Total inventory classified as current$7,730 $6,100 
Schedule of Other Accrued Liabilities
Accrued and other liabilities
Year Ended December 31,
20232022
(in thousands)
Accrued compensation$25,457 $15,511 
Government rebates18,468 11,098 
Income taxes payable1,814 89 
Accrued selling and marketing costs1,771 434 
Accrued Manufacturing Costs1,455 20 
Excise tax payable1,078 — 
Legal fees542 2,673 
Professional fees389 211 
Other654 763 
Total accrued and other liabilities$51,628 $30,799 
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.24.0.1
Leases (Tables)
 12 Months Ended
Dec. 31, 2023
Leases [Abstract]  
Schedule of Information of Leases Asset and Liabilities
Our right-of-use assets and related lease liabilities were as follows (in thousands, except weighted average amounts):
Year Ended December 31,
20232022
Cash paid for operating lease liabilities$2,391 $2,265 
Recognition of right-of-use asset in exchange for lease liability$297 $2,816 
Weighted-average remaining lease term6 months6 months
Weighted-average discount rate8.0 %4.0 %
Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Leases
As of December 31, 2023, future minimum lease payments under non-cancelable operating leases were as follows (in thousands):
2024$155 
Total operating lease payments155 
Less imputed interest(4)
Present value of operating lease liabilities$151 
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.24.0.1
Preferred Stock and Stockholders' Equity (Tables)
 12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
Summary of Stock Plan Activity
The following table summarizes option activity under the 2012 Plan:
Outstanding Options
Number of OptionsWeighted-Average Exercise PriceWeighted-Average Remaining Contractual LifeAggregate Intrinsic Value
(in thousands)(in years)(in thousands)
Balance at December 31, 202223,198 $15.13 
Options granted3,178 $23.49 
Options exercised(2,355)$11.47 
Options cancelled and forfeited(651)$21.16 
Balance at December 31, 202323,370 $16.47 5.79$374,129 
Options exercisable at December 31, 202317,924 $14.41 5.00$323,814 
Options fully vested and expected to vest at
December 31, 2023		23,149 $16.40 5.76$372,158 
Summary of Restricted Stock Activity
The following table summarizes restricted stock activity under the 2012 Plan:
Outstanding Restricted Stock
Number of Restricted StockWeighted-Average Grant Date Fair ValueWeighted-Average Remaining Vesting LifeAggregate Intrinsic Value
(in thousands)(in years)(in thousands)
Balance at December 31, 2022455 $23.91 
Restricted stock granted659 $24.04 
Restricted stock vested(184)$23.87 
Restricted stock cancelled and forfeited(103)$23.26 
Balance at December 31, 2023827 $24.10 2.73$4,910 
Summary of Weighted-Average Assumptions and Resultant Fair Value-Based Measurements for Options Granted to Employees and Directors
The following table summarizes the weighted-average assumptions and resultant fair value-based measurements for options granted.
Year Ended December 31,
202320222021
Weighted-average assumptions for options granted:
Risk-free interest rate3.87%1.97%0.76%
Expected term6.7 years6.4 years6.3 years
Expected volatility of stock price53.0%56.5%60.7%
Dividend rate0%0%0%
Weighted-average grant date fair value-based measurement$13.65$11.27$15.06
Summary of Stock-Based Compensation
The following table summarizes our stock-based compensation by financial statement classification.
 Year Ended December 31,
 202320222021
 (in thousands)
Stock-based compensation capitalized in inventory$208 $280 $237 
Cost of sales52 70 59 
Research and development15,402 12,800 14,106 
Selling, general and administrative33,486 29,572 28,766 
Total stock-based compensation$49,148 $42,722 $43,168 
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.24.0.1
Net Income Per Share (Tables)
 12 Months Ended
Dec. 31, 2023
Earnings Per Share [Abstract]  
Schedule of Computation of Net Income Per Share
The following table shows the computation of net income per share for each period:
Year Ended December 31,
202320222021
(in thousands, except per share data)
Numerator:
Net income attributable to common stockholders$105,496 $101,288 $112,512 
Denominator:
Weighted-average shares used to compute basic net income per common share103,560 106,787 115,653 
Dilutive effect of employee stock options and unvested RSUs8,182 9,179 10,310 
Weighted-average shares used to compute diluted net income per common share111,742 115,966 125,963 
Net income per share attributable to common stockholders
Basic$1.02 $0.95 $0.97 
Diluted$0.94 $0.87 $0.89 
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Schedule of Income before Income Tax, Domestic and Foreign
The domestic and foreign components of income before income taxes were as follows:
Year Ended December 31,
202320222021
(in thousands)
Domestic $125,691 $116,871 $126,308 
Foreign (1,134)(680)(1,302)
Income before income taxes $124,557 $116,191 $125,006 
Schedule of Components of Income Tax (Benefit)
The income tax expense for the years ended December 31, 2023, 2022, and 2021 consisted of the following:
Year Ended December 31,
202320222021
(in thousands)
U.S. federal taxes:
Current$40,265 $39,132 $4,675 
Deferred(25,613)(28,122)5,066 
Total U.S. federal taxes14,652 11,010 9,741 
State taxes:
Current7,590 9,515 3,432 
Deferred(2,645)(5,313)(274)
Total state taxes4,945 4,202 3,158 
Foreign taxes:
Current56 30 41 
Deferred(1,236)(469)(446)
Total foreign taxes(1,180)(439)(405)
Total provision for income taxes$18,417 $14,773 $12,494 
Schedule of Significant Components of Deferred Tax Assets Significant components of our deferred tax assets are as follows:
Year Ended December 31,
20232022
Deferred tax assets:(in thousands)
Federal and state net operating losses$3,942 $4,882 
Capitalized research and patent costs908 1,911 
Capitalized research expenditures61,760 36,465 
Research credits11,682 9,963 
Stock-based compensation costs21,676 17,956 
Operating lease liability37 280 
Other6,577 5,127 
Total deferred tax assets106,582 76,584 
Valuation allowance(15,947)(14,839)
Deferred tax liabilities
Operating lease right-of-use asset(30)(280)
Total deferred tax liabilities(30)(280)
Net deferred tax assets$90,605 $61,465 
Schedule of Reconciliation of Statutory Federal Income Tax Rate to Effective Rate
The following table presents a reconciliation from the statutory federal income tax rate to the effective rate.
 Year Ended December 31,
 202320222021
 (in thousands)
U.S. federal taxes at statutory rate$26,157 $24,400 $26,251 
R&D and other credits(11,508)(9,114)(7,579)
State income taxes, net of federal benefit3,897 3,320 2,495 
Non-deductible compensation3,295 4,354 990 
Stock-based compensation(2,951)(7,980)(9,568)
Other(473)(207)(95)
Total$18,417 $14,773 $12,494 
Schedule of Changes in Balance of Gross Unrecognized Tax Benefits
The aggregate annual changes in the balance of gross unrecognized tax benefits are as follows:
Year Ended December 31,
202320222021
(in thousands)
Beginning balance$11,425 $9,237 $7,471 
Increase in tax positions for prior years112 53 103 
Decreases in tax positions for prior years(205)— — 
Decrease in tax positions for expirations of statute of limitations(750)— — 
Increase in tax positions for current year2,440 2,135 1,663 
Decrease in tax positions for current year— — — 
Ending balance$13,022 $11,425 $9,237 
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.24.0.1
Basis of Presentation and Summary of Significant Accounting Policies (Narrative) (Details)
compound in Thousands
 12 Months Ended
Dec. 31, 2023
segment
series
compound
shares
Dec. 31, 2022
Dec. 31, 2021
Accounting Policies [Line Items]      
Number of series of selective cortisol modulators | series 4    
Number of compounds (more than) | compound 1    
Number of operating segments | segment 1    
Restricted Stock Awards (RSAs) | ESPP      
Accounting Policies [Line Items]      
Stock options, vesting period 1 year    
Number of RSAs granted for each share purchased (in shares) | shares 1    
Sales Revenue, Net | Customer Concentration Risk | Specialty Distributor      
Accounting Policies [Line Items]      
Percentage of sales to one specialty distributor, less than 1.00% 1.00% 1.00%
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.24.0.1
Basis of Presentation and Summary of Significant Accounting Policies (Summary of Allowance Activity Included in Trade Receivables Includes Allowance for Doubtful Accounts, Prompt Pay Cash Discounts and Chargebacks) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Allowance for Doubtful Accounts Receivable [Roll Forward}      
Balance at beginning of period $ 11,328 $ 11,224 $ 9,575
Provision related to current period sales 53,171 39,302 34,103
Provision related to prior period sales (643) 10 (1,076)
Credit or payments made during the period (45,166) (39,208) (31,378)
Balance at end of period 18,690 11,328 11,224
Chargebacks      
Allowance for Doubtful Accounts Receivable [Roll Forward}      
Balance at beginning of period 230 50 163
Provision related to current period sales 346 557 394
Provision related to prior period sales (88) 78 (29)
Credit or payments made during the period (266) (455) (478)
Balance at end of period 222 230 50
Government Rebates      
Allowance for Doubtful Accounts Receivable [Roll Forward}      
Balance at beginning of period 11,098 11,174 9,412
Provision related to current period sales 52,825 38,745 33,709
Provision related to prior period sales (555) (68) (1,047)
Credit or payments made during the period (44,900) (38,753) (30,900)
Balance at end of period $ 18,468 $ 11,098 $ 11,174
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.24.0.1
Significant Agreements - Narrative (Details)
 1 Months Ended
Aug. 31, 2017
Optime Care, Inc.  
Debt And Credit Agreements [Line Items]  
Initial agreement period 5 years
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.24.0.1
Available for Sale Marketable Securities and Fair Value Measurements - Summary of the classification of available-for-sale securities in condensed consolidated balance sheets (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Debt Securities, Available-for-sale [Line Items]    
Estimated Fair Value $ 387,016 $ 406,670
Cash equivalents    
Debt Securities, Available-for-sale [Line Items]    
Estimated Fair Value 97,170 36,380
Short-term marketable securities    
Debt Securities, Available-for-sale [Line Items]    
Estimated Fair Value 232,670 365,343
Long-term marketable securities    
Debt Securities, Available-for-sale [Line Items]    
Estimated Fair Value $ 57,176 $ 4,947
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.24.0.1
Available for Sale Marketable Securities and Fair Value Measurements - Schedule of Available-for-Sale Securities (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Debt Securities, Available-for-sale [Line Items]    
Estimated Fair Value $ 387,016 $ 406,670
Estimate of fair value measurement    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 386,641 407,414
Gross Unrealized Gains 388 23
Gross Unrealized Losses (13) (767)
Estimated Fair Value 387,016 406,670
Estimate of fair value measurement | Corporate bonds | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 120,508 151,069
Gross Unrealized Gains 307 0
Gross Unrealized Losses 0 (625)
Estimated Fair Value 120,815 150,444
Estimate of fair value measurement | Commercial paper | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 75,308 136,132
Gross Unrealized Gains 20 0
Gross Unrealized Losses (9) 0
Estimated Fair Value 75,319 136,132
Estimate of fair value measurement | U.S. government agency securities | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 0 25,113
Gross Unrealized Gains 0 23
Gross Unrealized Losses 0 0
Estimated Fair Value 0 25,136
Estimate of fair value measurement | Asset-backed securities | Level 2    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 0 185
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 0
Estimated Fair Value 0 185
Estimate of fair value measurement | U.S. Treasury securities | Level 1    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 93,655 58,536
Gross Unrealized Gains 61 0
Gross Unrealized Losses (4) (142)
Estimated Fair Value 93,712 58,394
Estimate of fair value measurement | Money market funds | Level 1    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 97,170 36,379
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 0
Estimated Fair Value $ 97,170 $ 36,379
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.24.0.1
Available for Sale Marketable Securities and Fair Value Measurements - Narrative (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Interest receivable, current $ 1.7 $ 1.8
Maximum maturity period 27 months  
Maximum maturity period, short-term securities 1 year  
Weighted average maturity period 7 months  
Minimum    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Long term marketable securities, remaining maturity 13 months  
Maximum    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Long term marketable securities, remaining maturity 22 months  
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.24.0.1
Composition of Certain Balance Sheet Items - Composition of Inventory (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Balance Sheet Related Disclosures [Abstract]    
Work in progress $ 8,233 $ 7,827
Finished goods 7,741 9,204
Total inventory 15,974 17,031
Less strategic inventory classified as non-current (8,244) (10,931)
Total inventory classified as current $ 7,730 $ 6,100
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.24.0.1
Composition of Certain Balance Sheet Items - Other Accrued Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Balance Sheet Related Disclosures [Abstract]    
Accrued compensation $ 25,457 $ 15,511
Government rebates 18,468 11,098
Income taxes payable 1,814 89
Accrued selling and marketing costs 1,771 434
Accrued Manufacturing Costs 1,455 20
Excise tax payable 1,078 0
Legal fees 542 2,673
Professional fees 389 211
Other 654 763
Total accrued and other liabilities $ 51,628 $ 30,799
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.24.0.1
Composition of Certain Balance Sheet Items - Other Assets (Details) - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Balance Sheet Related Disclosures [Abstract]    
Deposits for clinical trials $ 6.4 $ 4.9
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.24.0.1
Leases - Narrative (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Lessee, Lease, Description [Line Items]      
Operating lease right-of-use asset $ 120 $ 1,143  
Operating lease expense 2,400 $ 2,300 $ 2,100
Present value of operating lease liabilities 151    
Future minimum short-term lease payments, 2024 1,100    
Accounting Standards Update 2016-02      
Lessee, Lease, Description [Line Items]      
Operating lease right-of-use asset 300    
Present value of operating lease liabilities $ 300    
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.24.0.1
Leases - Right-of-use Assets and Related Liabilities (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Leases [Abstract]    
Cash paid for operating lease liabilities $ 2,391 $ 2,265
Recognition of right-of-use asset in exchange for lease liability $ 297 $ 2,816
Weighted-average remaining lease term 6 months 6 months
Weighted-average discount rate 8.00% 4.00%
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.24.0.1
Leases - Future Minimum Lease Payments (Details)
$ in Thousands
Dec. 31, 2023
USD ($)
Leases [Abstract]  
2024 $ 155
Total operating lease payments 155
Less imputed interest (4)
Present value of operating lease liabilities $ 151
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.24.0.1
Preferred Stock and Stockholders' Equity - Narrative (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 12 Months Ended
Apr. 05, 2023
USD ($)
$ / shares
shares
Dec. 15, 2021
USD ($)
$ / shares
shares
Dec. 31, 2023
USD ($)
plan
$ / shares
shares
Dec. 31, 2022
USD ($)
$ / shares
shares
Dec. 31, 2021
USD ($)
$ / shares
shares
Mar. 31, 2023
USD ($)
Nov. 30, 2021
USD ($)
Nov. 30, 2020
USD ($)
Shareholders Equity [Line Items]                
Preferred stock, shares authorized (in shares) | shares     10,000,000 10,000,000        
Preferred stock, par value (in dollars per share) | $ / shares     $ 0.001 $ 0.001        
Preferred stock, shares outstanding (in shares) | shares     0 0        
Issuance of common stock upon exercise of options (in shares) | shares     2,355,000          
Cash paid to satisfy statutory withholding requirement for net settlement of cashless option exercises and vesting of restricted stock grants     $ (9,106) $ (21,665) $ (22,835)      
Total intrinsic value of options exercised     36,000 63,400 78,900      
Fair value of options vested     42,400 43,200 $ 40,400      
Restricted Stock                
Shareholders Equity [Line Items]                
Non-cash stock-based compensation expense     $ 14,900          
Weighted-average remaining vesting period     2 years 7 months 28 days          
Employee Stock Purchase Plan                
Shareholders Equity [Line Items]                
Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate     10.00%          
Restricted Stock Awards (RSAs)                
Shareholders Equity [Line Items]                
Non-cash stock-based compensation expense     $ 3,200 $ 200        
Stock Options Outstanding                
Shareholders Equity [Line Items]                
Issuance of common stock upon exercise of options (in shares) | shares     2,400,000 3,700,000 4,600,000      
Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises (in shares) | shares     (1,200,000) (1,800,000) (1,600,000)      
Cash paid to satisfy statutory withholding requirement for net settlement of cashless option exercises and vesting of restricted stock grants     $ (7,400) $ (21,300) $ (22,800)      
Employee and Director Stock Option                
Shareholders Equity [Line Items]                
Unrecognized compensation expense     $ 67,300          
Unrecognized compensation expense, weighted-average vesting period     2 years 4 months 6 days          
2012 Equity Incentive Award Plan                
Shareholders Equity [Line Items]                
Number of stock option plans | plan     1          
Exercise price as percentage of fair value of common stock, no less than     100.00%          
Expiration period     10 years          
Shares available for future issuance (in shares) | shares     7,700,000          
2012 Equity Incentive Award Plan | Restricted Stock                
Shareholders Equity [Line Items]                
Weighted-average remaining vesting period     2 years 8 months 23 days          
2012 Equity Incentive Award Plan | Minimum                
Shareholders Equity [Line Items]                
Stock options, vesting period     1 year          
2012 Equity Incentive Award Plan | Maximum                
Shareholders Equity [Line Items]                
Stock options, vesting period     4 years          
ESPP | Restricted Stock Awards (RSAs)                
Shareholders Equity [Line Items]                
Stock options, vesting period     1 year          
Number of RSAs granted for each share purchased (in shares) | shares     1          
Tender Offer                
Shareholders Equity [Line Items]                
Aggregate purchase price     $ 145,428   207,500      
Stock Repurchase Program                
Shareholders Equity [Line Items]                
Aggregate purchase price         $ 88,485      
Common Stock | Tender Offer                
Shareholders Equity [Line Items]                
Authorized amount           $ 7,500 $ 10,000  
Shares repurchased (in shares) | shares 6,600,000 10,000,000            
Cost per share (in dollars per share) | $ / shares $ 22.00 $ 20.75            
Aggregate purchase price $ 145,400 $ 207,500            
Common Stock | Stock Repurchase Program                
Shareholders Equity [Line Items]                
Authorized amount               $ 200,000
Shares repurchased (in shares) | shares         3,900,000      
Cost per share (in dollars per share) | $ / shares         $ 22.88      
Aggregate purchase price         $ 88,500      
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.24.0.1
Preferred Stock and Stockholders' Equity - Summary of Stock Plan Activity (Details)
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2023
USD ($)
$ / shares
shares
Number of Options  
Beginning balance (in shares) | shares 23,198
Options granted (in shares) | shares 3,178
Options exercised (in shares) | shares (2,355)
Options canceled and forfeited (in shares) | shares (651)
Ending balance (in shares) | shares 23,370
Options exercisable (in shares) | shares 17,924
Options fully vested and expected to vest (in shares) | shares 23,149
Outstanding Options, Weighted- Average Exercise Price  
Beginning balance (in dollars per share) | $ / shares $ 15.13
Options granted (in dollars per share) | $ / shares 23.49
Options exercised (in dollars per share) | $ / shares 11.47
Options canceled and forfeited (in dollars per share) | $ / shares 21.16
Ending balance (in dollars per share) | $ / shares 16.47
Options exercisable (in dollars per share) | $ / shares 14.41
Options fully vested and expected to vest (in dollars per share) | $ / shares $ 16.40
Weighted-Average Remaining Contractual Life  
Weighted average remaining contractual life 5 years 9 months 14 days
Weighted average remaining contractual life, Options exercisable 5 years
Weighted average remaining contractual life, Options fully vested and expected to vest 5 years 9 months 3 days
Aggregate Intrinsic Value  
Aggregate intrinsic value | $ $ 374,129
Options exercisable | $ 323,814
Options fully vested and expected to vest | $ $ 372,158
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.24.0.1
Preferred Stock and Stockholders' Equity - Summary of Restricted Stock Activity (Details) - Restricted Stock
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2023
USD ($)
$ / shares
shares
Additional Disclosures  
Weighted-Average Remaining Vesting Life 2 years 7 months 28 days
2012 Equity Incentive Award Plan  
Number of Restricted Stock  
Beginning balance (in shares) | shares 455
Restricted stock granted (in shares) | shares 659
Restricted stock vested (in shares) | shares (184)
Restricted stock cancelled and forfeited (in shares) | shares (103)
Ending balance (in shares) | shares 827
Weighted-Average Grant Date Fair Value  
Beginning balance (in dollars per share) | $ / shares $ 23.91
Restricted stock granted (in dollars per share) | $ / shares 24.04
Restricted stock vested (in dollars per share) | $ / shares 23.87
Restricted stock cancelled and forfeited (in dollars per share) | $ / shares 23.26
Ending balance (in dollars per share) | $ / shares $ 24.10
Additional Disclosures  
Weighted-Average Remaining Vesting Life 2 years 8 months 23 days
Aggregate Intrinsic Value | $ $ 4,910
XML 60 R46.htm IDEA: XBRL DOCUMENT v3.24.0.1
Preferred Stock and Stockholders' Equity - Summary of Weighted-Average Assumptions and Resultant Fair Value-Based Measurements for Options Granted to Employees and Directors (Details) - $ / shares
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Weighted-average assumptions for options granted:      
Risk-free interest rate 3.87% 1.97% 0.76%
Expected term 6 years 8 months 12 days 6 years 4 months 24 days 6 years 3 months 18 days
Expected volatility of stock price 53.00% 56.50% 60.70%
Dividend rate 0.00% 0.00% 0.00%
Weighted-average grant date fair value-based measurement (in dollars per share) $ 13.65 $ 11.27 $ 15.06
XML 61 R47.htm IDEA: XBRL DOCUMENT v3.24.0.1
Preferred Stock and Stockholders' Equity - Summary of Stock-Based Compensation (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]      
Stock-based compensation capitalized in inventory $ 208 $ 280 $ 237
Total stock-based compensation 49,148 42,722 43,168
Cost of sales      
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]      
Total stock-based compensation 52 70 59
Research and development      
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]      
Total stock-based compensation 15,402 12,800 14,106
Selling, general and administrative      
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]      
Total stock-based compensation $ 33,486 $ 29,572 $ 28,766
XML 62 R48.htm IDEA: XBRL DOCUMENT v3.24.0.1
Net Income Per Share - Schedule of Computation of Net Income (Loss) Per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Numerator:      
Net income attributable to common stockholders $ 105,496 $ 101,288 $ 112,512
Denominator:      
Weighted-average shares used to compute basic net income per common share (in shares) 103,560 106,787 115,653
Dilutive effect of employee stock options and unvested RSUs (in shares) 8,182 9,179 10,310
Weighted average shares used to compute diluted net income per common share (in shares) 111,742 115,966 125,963
Net income per share attributable to common stockholders      
Basic (in dollars per share) $ 1.02 $ 0.95 $ 0.97
Diluted (in dollars per share) $ 0.94 $ 0.87 $ 0.89
XML 63 R49.htm IDEA: XBRL DOCUMENT v3.24.0.1
Net Income Per Share - Narrative (Details) - shares
shares in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Weighted average options excluded from the computation of diluted net income per share (in shares) 9.1    
Stock Options to Purchase Common Stock      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Weighted average options excluded from the computation of diluted net income per share (in shares)   7.3 4.5
XML 64 R50.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes - Schedule of Components of income Tax (Benefit) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]      
Domestic $ 125,691 $ 116,871 $ 126,308
Foreign (1,134) (680) (1,302)
Income before income taxes $ 124,557 $ 116,191 $ 125,006
XML 65 R51.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes - Components of Income Tax (Benefit) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
U.S. federal taxes:      
Current $ 40,265 $ 39,132 $ 4,675
Deferred (25,613) (28,122) 5,066
Total U.S. federal taxes 14,652 11,010 9,741
State taxes:      
Current 7,590 9,515 3,432
Deferred (2,645) (5,313) (274)
Total state taxes 4,945 4,202 3,158
Foreign taxes:      
Current 56 30 41
Deferred (1,236) (469) (446)
Total foreign taxes (1,180) (439) (405)
Total provision for income taxes $ 18,417 $ 14,773 $ 12,494
XML 66 R52.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes - Significant Components of Deferred Tax Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Deferred tax assets:    
Federal and state net operating losses $ 3,942 $ 4,882
Capitalized research and patent costs 908 1,911
Capitalized research expenditures 61,760 36,465
Research credits 11,682 9,963
Stock-based compensation costs 21,676 17,956
Operating lease liability 37 280
Other 6,577 5,127
Total deferred tax assets 106,582 76,584
Valuation allowance (15,947) (14,839)
Deferred tax liabilities    
Operating lease right-of-use asset (30) (280)
Total deferred tax liabilities (30) (280)
Net deferred tax assets $ 90,605 $ 61,465
XML 67 R53.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes - Narrative (Details) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Taxes [Line Items]      
Increase in valuation allowance $ 1,100,000 $ 1,900,000 $ 1,400,000
Unrecognized tax benefits that would impact effective tax rate 10,200,000    
Unrecognized tax benefits that would be offset by a change in valuation allowance 2,800,000    
Unrecognized tax benefits, accrued interest 0 0 0
Unrecognized tax benefits, accrued penalties 0 $ 0 $ 0
California State      
Income Taxes [Line Items]      
Net operating loss carryforwards 55,600,000    
Research and development tax credits 16,800,000    
Other States      
Income Taxes [Line Items]      
Net operating loss carryforwards $ 700,000    
XML 68 R54.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes - Reconciliation of Statutory Federal Income Tax Rate to Effective Rate (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]      
U.S. federal taxes at statutory rate $ 26,157 $ 24,400 $ 26,251
R&D and other credits (11,508) (9,114) (7,579)
State income taxes, net of federal benefit 3,897 3,320 2,495
Non-deductible compensation 3,295 4,354 990
Stock-based compensation (2,951) (7,980) (9,568)
Other (473) (207) (95)
Total provision for income taxes $ 18,417 $ 14,773 $ 12,494
XML 69 R55.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes - Changes in Balance of Gross Unrecognized Tax Benefits (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]      
Beginning balance $ 11,425 $ 9,237 $ 7,471
Increase in tax positions for prior years 112 53 103
Decreases in tax positions for prior years (205) 0 0
Decrease in tax positions for expirations of statute of limitations (750) 0 0
Increase in tax positions for current year 2,440 2,135 1,663
Decrease in tax positions for current year 0 0 0
Ending balance $ 13,022 $ 11,425 $ 9,237
XML 70 R56.htm IDEA: XBRL DOCUMENT v3.24.0.1
Commitments and Contingencies - Narrative (Details) - USD ($)
 3 Months Ended 12 Months Ended
Jan. 04, 2024
Feb. 08, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Jan. 31, 2024
Commitment And Contingencies [Line Items]              
Purchase obligation       $ 700,000      
Taxes payable       10,300,000      
Litigation settlement, expense       0 $ 14,000,000 $ 0  
Insurance recoveries       0 14,000,000 $ 0  
Accrued liability, litigation     $ 14,000,000 14,000,000 14,000,000    
Insurance recovery receivable     14,000,000 14,000,000 $ 14,000,000    
Other losses for contingent liability       0      
Other provisions for a loss contingency       0      
Melucci | Settled Litigation              
Commitment And Contingencies [Line Items]              
Payment awarded to other party   $ 14,000,000          
Litigation settlement, expense     14,000,000        
Insurance recoveries     $ 14,000,000        
Accrued liability, litigation       14,000,000      
Insurance recovery receivable       $ 14,000,000      
Subsequent Event              
Commitment And Contingencies [Line Items]              
Purchase obligation             $ 3,000,000
Subsequent Event | Melucci | Settled Litigation              
Commitment And Contingencies [Line Items]              
Payments for legal settlements $ 14,000,000            
XML 71 R57.htm IDEA: XBRL DOCUMENT v3.24.0.1
Subsequent Events (Details) - Stock Repurchase Program - Common Stock - USD ($)
Jan. 08, 2024
Nov. 30, 2020
Subsequent Event [Line Items]    
Authorized amount   $ 200,000,000
Subsequent Event    
Subsequent Event [Line Items]    
Authorized amount $ 200,000,000  
EXCEL 73 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

(L8YC@+AM.>APS_&SQ'&2EKJ[,6V8_5Z'CS-C.HP9T0TQM[T( M'6Y&KLVLF4W/EAPR?[V=)^]A^Q[+-.6%:N_^AM+6S_#W1W=N]WJ-Z9H5 ;;I9_= M4I[46W@J;X?Q;[LJ-MQ5U>^766!UX/%5A354L,_HU@14YTWZ:PEKO%QO;X=W M2-,V5&RXH=J^1=_C05HI2B=.-R.@.C?PO"X/HH--G=?E&>^==F:B6%:GQ@J6 M;YGK^I1P=W=W,GU5G<=V[E_3B[ ^7V[=U,?=][Q8)KDBJ7@!E];Y!%)R49\@ MUQ=:KJLSU8746F;5UY7@4#", 'Y_D5)O+\P#=N?XL_\ 4$L#!!0 ( #&" M3UAUOR]#<@, +(* 8 >&PO=V]R:W-H965T&ULK591 M;^(X$/XK5K9:M5+;Q D$K@M(+6&U2%>H"MU[.-V#"0.)FMBL;:![O_XF3IH# M:E ?>$EL9[[/\TT\GNELA7Q5"8 F;WG&5==)M%[=N:Z*$\B9NA4KX/AE(63. M-$[ETE4K"6QN0'GF^IX7NCE+N=/KF+4GV>N(M,_G[ 3*Q[3K4 M>5]X3I>)+A;<7F?%EC !_;)ZDCAS:Y9YF@-7J>!$PJ+KW-.[J%W8&X.?*6S5 MSI@42F9"O!:3X;SK>(5#D$&L"P:&KPWT(9)M9>LY)%XK+?(*C![D M*2_?[*V*PPZ AD< ?@7P#P&-(X"@ @2?!30J0,-$II1BXA QS7H=*;9$%M;( M5@Q,, T:Y:>\^.T3+?%KBCC=ZX]'D_&?P^A^.HC(9(JOQ\%H.B'C[Z0_?GQZ M'OP8C";#GP,R'.%\0&[(RR0BEQ=7Y(*DG$P3L5:,SU7'U>A-P>G&UU%MU%%MG&+OC? F M34WX;#$KL4V#+2[,38]Z(6UX'7>S&PV;&6W0]KY99#&C?I/ZM=F>@F:MH'GR M7(QU I+$>P>B5$0N,Z'4U9U-6?.AA>.I3)+_X4Y M66*)K )(L!YA#7P%S689$ 7Q6J8Z!75-.)ATU.R-I#FZ9687ET$SN+HF%]1K M7A.\#7'T1]OV%TIOPOT3<7BZ/AK=! $].%L6H]"G]I/5JJ/1.AD-+*18)CF6 M'2F!Q[\)7BY<9@>9 ;_8\V-P$]%&DQ.J:Q76MLG]0X M%9IEUNRQ*6E;$KT5'B9ZWV;FM5KA@1R+&:7MEG>@R-VIYCG(I>F*%/J\YKHL MAO5JW7C=FW[C8/T!&[*R?_J?INSF'IEHVM?&PO=V]R:W-H965T&ULK55=;]HP%/TK5UDU MM5+;?$'7=1 )"%61QH<:VCU,>S#)A5A-;&8[T.W7STY"1CNH^K 7[.O<DL^7B2::("I[SC,FNE2JUOK%M&:>8$WG)U\CTDR47.5$Z%"M;K@62I 3E MF>TYSI6=$\JLH%.>S430X87**,.9 %GD.1&_^ICQ;==RK=W!/5VERAS806=- M5ABA>EC/A([LAB6A.3)).0.!RZ[5'HR2!>=/)A@E7V=:YC05Q(Q?,:K"O(*:M6\ESW80_@7AT!>#7 M>PUH'0'X-\D(0ELF,K79VYPX[K2OI5)=Z12EP/QEPS M2QBR!).7!+:6U6CS=MKZWIN,(<:7X+OGX#F>?Z"@P?OAW@%X^'ZX^X8:OWE3 M?LGG'^&+%%&H!TX!7\* YWK*4S-^&X01BWF.\+VWD$KH2?IQJ/L5>^LPNW&7 M&[DF,78M32Q1;- */GYPKYPOASKW/\G"_T3VHJNMIJNMM]B#!Z;-,J._,8&5 M-DDXS;B49Z =2;O@$RJRR! DQH6@BJ(\!T6>#W6WNJ5=WF*L=A-<^&W]I]OL M=^W?)-=IO\P)#^1\OFYR*HWVWKSG*%:E;TJ(><%4-1[-:6/-O=*17IWWM657 M#ON7IO+[,1$KRB1DN-24SN4G79&H/+0*%%^7KK+@2GM4N4WU9P>%2=#/EYRK M76 N:#YDP1]02P,$% @ ,8)/6,E=@"#>"0 8S$ !@ !X;"]W;W)K MBG)2?;7'TD[EB6.F!C0?HEE^^&8SW X\W"D7#X(^:M:3=5UO/TRG5;;FF[1Z+[:\5-\LA=RDM7HK5]-J*WFZ,(,VQ91X7C#= MI'DYF5V:SW[(V:5HZB(O^0^)JF:S2>731UZ(AZL)GCQ_\#-?K6O]P71VN4U7 M_);7?VQ_2/5N>K2RR#>\K')1(LF75Y-K_"%AD1Y@$/_-^4-UCD^)MZX.GUL_7/AKPBJ?XN%W?B#D:WN9*"KS%STO/;6_0;RDMTMQ9-E9:+ZG):JSEH2]/L\'L?][]' M!GX/$_1-E/6Z0I_*!5]T#4S5Y(\,R#.#C\1I,>'9>T3Q.T0\0H$)S5\_G ## MD]U-BC0^N15FNT5+NQ0DLI-DAM<)G6>;G:[Y"\SGGU 7+[WBR# MS>KL\:':IAF_FJCT4'&YXY/9O_^% ^\_D,O&-):,9*SC3G9T)W-9GWU7F3,O M,['AD,_V8WTS5B?(W0Q[ 6;>Y71WZ@T(AAF.NK $@&'B8W*$=1CX1P:^,R"N M%_]364!EVKI"M5"I-A-EEA<Z?GH-'E'#(^&.& MS)C&DI&,=1P>'!T>.$/FMA;9KPM=2Q9(>5<5V,KX$/+@WE)PLN0LBJWX 5"$ M,=(+'P@54PQ'3W@D$SK)O+G.,LGU]-\BL42+O,I$4]9()6]TO1&RSO\VY/27 MRI>;O%$IIU0%1O[B=7JOPJSB62--VGFG@PSR0FC-_"+&I+<]YC8*TXCVG&"# M?.\$U/%!=/1!Y/1!GV=6B&:_M,T^L4J9EBMNMAA$+[(7)O![Y !,&/:X 1@O MAJG%1VJQDUK"U:)E^9Z:7M/46E.= ^HG\R7_J\FWFB;$,K8]WV^LAA]>'9P4AB%O<";0[A*(V]WL(F (Y1 M%@SP.5%=V%V71'EATG5_P:36J1=B>=%4'*55!>^X@_7N9B+]O .@"([Z80G9 MBF-_@"%I&1(GPYMZS24X=V+]GC7Q%R$) ,'>P)Q;[85?$%]KG0@J+7%/=)=> MA,ILH")/[_-B6(/A4478J-:2L:QU7=OJ,.P68GCLI,[7JJ9H M-62V.,@/T#98;0JKG "XP/>M7 O U#(.E9-6X6"WQ#')UD7#UAXJ?OKJ:P[" MXM"JB38,QWAH6[5:!KO%C)*J6IM6:)L^Z9T$$@%E2E]J B@6VHMAHRZH'P_P M(*U6(6ZMHB5WHQ* 3J.IS-8FX!9\QPMAU- M(6Z]\DQ*;:&Z,(>!\S,Y>5G: ! HD3LM=1FVZH8X2_SLJRA7%S67&Y0>N+XD MI@\&N]D=6Y1L5!1$_>X(9&O@<$M:54'T^8D3K%RKL0>U5HREK6N3UNA0UX0.HTJ-JE6.&<=_ DD M<>R(@90+MN(%0@5#N;F5-\0M;WY(D7&^.,3*)JT/'2E-%&Q5@3R!_HL2-U9G M , 1AK'?/UT .!I',1W2#ZT.(FX=U&5;I<6Y1&U=8Z7L%R$) /$]%@STXFBK MCJA;'76B]-6<*-2N(5'(^M(/!/J^=89,0* J!]Y !J>M/*(O]':L#/ZFJ4RU M?:MS.93J0,JVSHF]V.N?A0&8.J&HPW!?-P% 3 .E!P?XMLJ)DK-R^3(OU>'X M-;>LG(KL['M68UI+QK+6]>G)74"W5NOF@+RJ&M-OT-UKL=F($E7Z+@5JRH52 MWZ*16LJI_)[O.$H?4KE VR(M3<->CSF.ST0%'Q"IK<[\".-^K-DH1J/^L0- MX8"0@2I 6[%'W6+/Q)DYRBM!KN_)5,LGY0=5#71W CWD]7HMBH4./*DKGMRK M^*60Q@\GPEZ[41E3B55EH:UIO?)'+K/\N3WPO$-U0U9=RCS3YX"]SU!(8E8 MGR* HTI$QP,G ]H*3.KN6AUN_$IS+'BSX/NKMYKMON^N5MEK_*R/,2S4H6Y6(!4 M;?$6!)3TE2 "\, 6^4&@ 4X'CC%TE8+4K<6=%/ENB7A) GTKI0^\*U49^, M9R0 K.N,+LM6 ]+865-OF^UVGZS2PMRU+4352 Z74:>L'_< 3-6 @2XV:T4EB(&D)Q^& \H3M8J M3N;NU?WDF5B5^? ]4YWF^6-F;N<9M[RB/<3LEAN)^XU7"!3A_MD"0 WD/=8J M0N96A'?<:+V;Y1*^K>H>?FX6&-5:,I:UKNM.G@%C_\P!A3D%Z=D^'=-:,I:U MKD];#_T#R6@(T'AZ#/K(2$ V&],0+:(%_K>T!9K-2-[Q9-?Z(29 M.H4IM;\!&8W:AQS56C*6M:X;6S'*PG]HNSE%[MD^'=-:,I:UKD];UXCY\>_U/@VCP? MW_O\(_Z0[)_W;\WL__W@6RK5$:9297RI3'KO0S4IN7^B?_^F%EOSC/N]J&NQ M,9=KGJJ"J0'J^Z40]?,;_0/'_ZN8_1]02P,$% @ ,8)/6-;6N]1E# M59@ !@ !X;"]W;W)K)8/KR_JSV^SZ,MT5ZU7";C,EWVTV M[@:O"<_1-JD"JA+_+QB3_F+UTK5E%_2]%/UQEM<#=2J1FS-YD6%B,L?G]F4 MK=<5J:S'KP?HX)BS"GSY^IENUXTO&_-+G+-INO[W:E$LKP;C@;)@#_%N7=RE M3RX[-,BH>/-TG=?_*T^'LNI F>_R(MT<@LL:;%;)_F?\Y7 @7@00[40 /010 M+H :)P*T0X!V;@;]$*"?&V < @PN0!N?"# / 2;?!O-$P.@0,.(#1B<"QH> M,=^&4T=I<@B8< 'ZR8Y3GWM.Y2MUJMGDV-E\;^NG&DZ>NYOP_4U.9GGN<%+W M^'!_+M8G\BPNXNO++'U2LJI\R:M>U&JHX\OS=Y54PKTOLO*WJS*NN)[>?+B_ M";W9^X_63+G_6/Z(K \?[Y4;NWQW,PW9PL\K?*=ZWWE\.BK&*5:#@_5.?'?77HB>I\3(MX M+0B;RL/NBW3^2;ECVUTV7Y8R5FZS]#&+-P+2[)4*L&3!,N7FX8%E@FA+'CU- M-YLT^?O?B*G^LZZ3 &'W1"@]&N?T9;_27%?.>[]8K*KA-UXKM_%J<5'V_33> MKL1=Z+URX,MI)]]E7Y53Q\WO$]_GH 6]P*\;IARO=AFN=O!/A(CK]C13E7EVPKSI)5\L@I<%@.#L<1 M@AY'"%HS]1/,']GC*JE@Y02YCI-Y6;NRG_?J?Z/$A3)C\W>*1MXJ5*6J2/)2 M?K4R^2'?QG-V-2@/1,ZRSVQPO3]'10,!$C9#PJP]S*QAU7KI\S4AYD@S+H>? M7\H?F=-!PEPDS$/"?"0L0,)")"P"P5HRUXXRUWK*_!QI[YG&BW/>H)JFC=OG M_%2:NJ]HD3"KVP!"*:=89$('"7,%AY^81%?;#?"ZQ2Y&QFC"C4P^LFH!$A9V M&Z 3KO91M\R8ZH9Y+-52A7Y4A5Z':2=44<['U?1?SGFE%.I7;ZH5;KT46*;K MKXJORW[MTO5;*R\FG.%O\3Z06'3D1(F$S),Q"PFPDS$'"7"3, M0\)\)"Q PD(D+ +!6@.#<1P8#.ETZ>7YKIXETP=E7E]6*7E]?;#;EB_9%Y;- M5WG]VW1;72+E+U?-HK%!FJ[OV("$S9 PR^@LDG53XR=<9$8'"7.1, \)\Y&P M D+D; (!&MIWCQJWL1J7J1SLR, C:JZR2V8I17I*V DS#*[2TY.OY\LUR_.#I(\J?W4^E]:Y[WR.A,V0,&O4D=0%,4SN M1&IG20,!<)\Y P M'PD+D+ 0"8M L-;(,3Z.'.,_X<@A&BW&71EI8U/CIJ:IM#E]QP$DS$+";"3, M0<)<),P[K]-]9,X "0N1L @$:PT$D^- ,)$/!-4R_J(R@"RJE?V6)=4XD"8B MJ4ZZ5[ :,?D=;VF^ODI%PBPDS$;"'"3,/:N;/&1*'PD+D+ 0"8M L)90B=KX M552I5/=_-9^W_FJ^3O/\;3T%E_-N$7\1^D[4[FAKZMS.TU2>O*]NH30+2K.A M- =*FOT^VBN7U')P MWVMJ*&T&I5E0FGV@\0O-4?N\<$3%B%K^:Y=SH97SH#0?2@N@M!!*BU"TMHH; M4QB1N\).JUBH7*@%[$!K^1G&8WW,;43/1.6H.C+X,]J"5L^&TAPHS872/"C- M/[-;@W.[-816+T+1VH)K[%E$[L_Z4*YN5[4[5"@PK3-V$T(-TEG?0IU84)H% MI=E0F@.EN5":!Z7Y4%H I8506O2Z9MI2;3QC1.H\N;:2Q9EV:2+4,M0F!J7- MH#3K0&OU@&I,>/^B#4-C+&*N\$D6?NK5^HF>M :[NG1[QXH6XN*,T5=((Q(9H^X;:)!>4N=*+J MA/];#;1Z 906BAI!^>Z*!*7(1)^\V#EO:Z0Q3Y&]">3;6*D)TKXRA=)F4)H% MI=E0F@.EN5":!Z7Y4%H I8506H2BM8>)QLQ%Y&XNN+%:GJ_W2 &U8D%I%NF: ML;01;V^TH3D=*,V%TCPHS8?2 B@MA-(B%*T] C2F+")W94%LUJ1KKJ%C?=S9 M#X,ZJJ TZT!KW?7&:QGJE(+27'$/C'@'!C2I#Z4%4%H(I44H6ENDC6&*O.*8 M^E.:KN65[CW70TU<4)I%NOZF"S+F[R.QH4D=*,V%TCPHS8?2 B@MA-(B%*W] M;)'&SD7E=JX_CP6;"LPSNC'2N V2J;Q!?4<%*,V"TFPHS8'27"C-.[/O?6C6 M $H+H;0(16L/"XU)C,I-8GT,V;3K6]*IP3\?8BK/V%NW4+\7E&9#:0Z4YI[7 M61XTJ0^E!5!:"*5%*%I;MHTKC,I=8;_7G$V[S\X2F+/ER7LK&/OP+ZB%#$IS MH#072O.@-!]*"Z"T\*QS/$+E; NX<9G1/^(RHX*G9:E$)_S-3_(DO84*=9E! M:3:4YD!I+I3F06D^E!9 :2&4%E&!RZRMF;94&Y<91;G,J%#+(N_5:,P_KG(J MKT5O+4/]8V>VP89F=: T%TKSH#0?2@N@M!!*BU"TMI8;_QC](_XQL7Z[WBM# M)>/NHAGJ'X/2+$$;"'_[NPU-Z4!I+NV:I4R3:GPG>()R%[IA$GW,;S!!_6-0 M6BAJQ-B<\ O8;BDZ,;7QB0=QTL8_1K^E?XQ"_6-0V@Q*LZ T&TISH#072O.@ M-!]*"Z"T$$J+4+3V,-'XQ^@W]H_1KJN*:D9GF0SUA4%IEJ %FC;6^'D6Z@N# MTEPHS8/2?"@M@-)"*"U"T=K*;GQA]!OXPFC75$4GA'9VL*"^,"C-$C6!US+4 M%P:EN53@"RM[P.27S%!?&)060&DAE!:A:&V1-KXP^E?TA\SO*@27TH+8#20B@M0M':LFU\8=K_QQ>F M";Y3L7,+T52>O+>"H;XP*,V&TAPHS872/"C-A]("*"T\ZQR/4#G; G[QY9!R M7]CO?VBG'-SWTAM*FT%I%I1F0VF.UG4A79@FX1_M"4WJ06D^E!9 :2&4%J%H M;:TWQC)-;BSK]VA/.:RWOJ%NLP.M]:1(HALZO]UO0=/:4)H#I;E0F@>E^5!: M<&[GA]"T$8K6%F_C)--><9)]J?\(5JZGE8SMOV>^2/=;8-4<77ZX/]#DP906@BE12A:6\F-WTV3?]OD MSRPOJOWL9HD;%YO65<[WHIU?WLK5''WBP[+GE1Y$4--:U": M!:794)H#I;EG]94'S>E#:0&4%D)I$8K6UG!C1M/D9C3Y[52'X/;M5";A'W\[ ME2?I+52HMPQ*LZ$T!TISH30/2O.AM !*"Z&T2.MZ&3G-M*7:N,LTN;OL_-NI M-*&6NZXFHFJZROM$Y;7HK66HL>S,-MC0K Z4YD)I'I3F0VD!E!9":1&*UM9R M8T+3Y"8T^>U48OU..G.QH9JCKGZAWB\HS1*T@6B\\PN:TH'27$$#1MJX^W00 M0;D+4S,$%ZM0NQ:4%@H:8:K\W52"0KI*#3*FCV4@>J[44G(5H_+XYLBW5X-R$#Y)2V*=%._7+)XP;*J0/G[AS0MGM\, M2_Y3FGVJ4R4[DFS'268F54XR MV4WMSJPKGNS6U=5]@$A(XH0B- 1I1?OKKY_N!@C*LI/Y,'=?$ED$@4:C7YY^ M@;[?^?9S6#O7F2^;N@D_/%EWW?;5LV>A6+N-#6=^ZQIZLO3MQG;T9[MZ%K:M MLR6_M*F?S:?3Y\\VMFJ>O/Z>O[MI7W_O^ZZN&G?3FM!O-K;=OW&UW_WP9/8D M?O&Q6JT[?/'L]?=;NW*WKONTO6GIKV=IEK+:N"94OC&M6_[PY'KVZLT%QO. M?U9N%[+/!CM9>/\9?WPH?W@R!4&N=D6'&2S]=^?>NKK&1$3&;SKGD[0D7LP_ MQ]G?\]YI+PL;W%M?_ZLJN_4/3UX\,:5;VK[N/OK=7YWNYQ+S%;X._*_9R=CG M+Y^8H@^=W^C+1,&F:N1_^T7YD+WP8OK "W-]8LW-E3!^*6Y:5UP36>%5TUI;N68\.RV6C75 MLBILTYGKHO!]TU7-RMSXNBHJ%[Y_UA$EF.]9H:N^D57G#ZPZFYN??-.M@_FQ M*5TYGN 9;2'M8Q[W\6;^Z(SO7'%FSF<3,Y_.SQ^9[SSQY9SG.W]@OB/;-/]] MO0A=2W+T/\=V+/-=')\/NO4J;&WA?GBR!:?;._?D]9__-'L^_>X1:B\2M1>/ MS?Z'G>(?OZIYYT+15EM^E8:_Z0.M$@)/N[ZHBF ]- MX=NM;VWG2G-"6L%J?^?J_<3\^4\OYO/I=_K>A/^ZM1L>;;:VV:='^O7. M'7[3A_@%Z-,O?=_JMT\-T6M-X3<;UQ:5K4]#1Z;-;->6+$C!M-H:S[&<<.J+>;\D =F#!QI7T+A@03.=-1Q:X,X'&M([F*3TQ ML?&U7U7%Q'ABAG[LW%]*T^PF&]+UP:SV)N-+_O:\L& $+=<$O>8 M\_AS3>;/-X[(;CMZJSXC;I.>S>83?ORIJ<#T6SH>.L_WWI>\UKNV7YGKDFQ6 M!:WAHSM1CKU_=YTX9K?;EG9=FK_YMMYOTIA-M73;EMZEI=/@\^G4;(A(NZA= M%R;&@MVT77=:VJHF@6N)O0.K#'DMII'9%5FYWF]=NZKWA=M4EGA8^*:$M!); M^5'<9Q4V.!I+O.G,EB:D]P/9YV[-'%^YQO?!O.W#FA@'$F=7WP43]DW9^HTS MNS7-9^]H<9K4S(GC=N' H@WYH*JC5XFX5=T7/CA:I_,UR3-MA;G'+RYI3\28 MT+\,J5-9E;=<.)10'Q+/"=V!7YIQ7+IB:1N;1LSFTSI="#; MI.1E8&) KPHRQJ>'9DDLPLG0UG5A.LJM!YFD-L-YR?ZL6;3>EH;X0]K$)+85 MF)^DF%?;01FJW!*H9K%LXKUWKK8[RZ/,3W9O9B]?OC@S_R"FK G1_-;;MH-* M8$3MBSC%3ZZIO;FQ[>>)>6OKBDAJ*GOV@'TBN\0\(@$J>89EU="Y8EL!=,BV M^)@6SC6&_,'6MK*2)0O9EBP%+&>?SF[/# F:D\.BQV3!<*B#)24=H+UCICL3W\S?Z\VL!UDL8@$TA?LT>\:EOE%J$AC6K+?NW55K.EPCQZM M6I^_$2M*OY%S;6DXV:>K,W-=D^S2\!:TDHY!N<7V+FP--HNC(?O4!%L(OL3/W_JJ MA<6P#3D*ME]DI#;V,]GHM"XV8 .AZJUZAS5Y!LLFG#ED-Q"50+,1ZS+.?9TX MGKE0CD'6R/0X4K5KLAXT,AXWB6)-_JJB)=O$;3I)U7&8MT0MZVGKW)VM>]9) M.OB'M^(LG:1JY40E4)P4)FU)F4$[L:0E&]/T^*KPA#?P]B3_@V?>.$N&TD4W M &DB,]W9+UC3Z7YKLM(5F6U-%XK'EA6_(>O% 6Y-))6C%R*!C0=7O94YR@,7G4T0>)=M/"HA4 M M_;JC7_)$8ZLE!I:P$0R$M1JQ>0=YKRL'7[6NVO*49)BD MD2#<9P?/1TZ ;(=E[\=GW0='![DF%2G6WO-\HJ0C.51)W6%<29ZO!190B"$$ MTBG8HU1.0%--L1P];4/'+/^M]SAMLGGJ?FL8WI]]*T7A@I.! M_(E798IO7=&WK._0P20NZVJUIOW5%;U9LDT)BFV8T;M*G%0OL*1;DWDD6,7A M,1UIC6@HPB5#VP?.,=N>G!S9!'RY@:KAJ$">&\A3REU.<*NJ5ZH9& M]]+6, MR;\PIYGM!%$[MMQ"/%.RL;_Z%DX+WI[&+!G7T08V T-"8L@$S*'3(^ -=\(NZ M6BF.YK"03,GIJK6ER[2H=(LN0J>C>L$"PW:$W88UY\]/V<"(V8$2VVXP+\3Y M:%[.@&J#&Q'),1WYK98TJM( L_3L4>B( $4VE1\S*Y#,& .= MIE]:A,3PK)[.>KLE.Y5G("35H0[[()U#1&!CN2NYOOD0_0>@G^8V,IK&W,'^ M6)PJ9+I7MF50JSDAPH2+/H["ULDVEQ3 $PXWL.$0KJV#Y-)6E#0"K/_8\F&^ MI>.:(#UVEHB3)P-]M 9K9H@I&%H[I3N *GKBIDZ'_%9#9):.7BDY( $CV>F2 M/?D ?-G HQ%AG,?CTQ$M5_8U."FS4]R)P,CAQG MG :>5&D<]I,03K:*VD_2<&*<TB/"G;?B7Y!7[ P";H40< M?>.6I$D2%[8<7I"]8"(!&@5-B_*3 MT9#IW<$"D#NU%^*1 "4U&E-/$)C-MQ;K?'0K25#M-:%(>@D[)JJ2Y\LJ2&CA MVHXV<&;>N,("'<:!F2E@/OE6PLO[LV_LGLDGX$7^"XZ8+>RQH4@2+; >4AT[ M%QDJ0;CL8E@WAHA'2+>8/CC.;QRFB-6[C@PY(V>L$**[[EO:%PDD'^'])5B] M8SZ6P#YF>O_N>B(1X@K)"KNM.F &D#DFFA<2N!4'L8*E(/K8^#R(SXRD8(SA M3=T5"0?9!$ZL@&TMR1;D!TNQDU5HPJR1>-.-N#Q,N%/S(2@88]B&+JM"([9E M3"%O7+?VY1%D'#AVI>CT%)Y*/GF*GA;("@IN@-R&Y.5EY1J'%K CSFX(I.1$ M'G*:XDYWI)9D//RNR5YD$T<'Y"J&53CP0CFWX'-GLT*[I">5^I4DP4"S$](Y M*4\$I1(6UWUAOPKNT'&D68]QEOTQ%%-X 3(B$(Q$_M93V"6H8S1WFE=S6AL7 M?71)GKOU>Z':E?FAJ^U9-2Q)ZR'CHS(=TL$&-@(5($R0YDYS)^:4J,:R0[B+JR2U+\77+)CE/Y$X.R4.#$+.M/ MACO&(=1(AP;J:M,R.L,WXE$ M?$1 D8K$YQTMP9(3J^/\[YQ/F3[,Q"LG<^D9J\BL*>O L7"2/'8'R(&II=S' M.(Z+XUH@ S72O^!:37>EX9@RCVRR"@%GXZ%^^BJYU=*U,5_-"\1\V*&)EZ=N ME,V7W-AWD@,#N$!-1RN"!X,BQ(L3)?-!;.?F%TY?#51'CU U,?YSL33&.RI= MC2!IL!II@<05SLX18?=%!<%!? U&F\L1.B- !%QTA=.%#E)H0[8;WRW85DM6 MR4EB2>&9@M4]F\&RY]T"UE,\39YKDU4L: 64K,G[1YB(,N6 ) >D2=_3*#NR M>P(I]U(')WC+YC[ FW%VTW%@,%(OU=(#,81P1WB2+!EOEK]BR11%R8TUXR:% MZ(4GDO8P'70B3*]B8#&XA\G$$_LTWR7VL7((I6/F9V$Y5W6R>"K554[ZIW.@ MK6!*4E_LD[[>;+O$;S[GXJG1Q@\QV9E')"_1Q,I(1(9A5.+)+,=QTT(K]-M2 MA7LCL'M'9R5M6SC>4%QT:Y,XY]"60ZAHV<(GO,$9?L9X+UZWVDI"86 M8$_9SJ,.JE4-XJ08A:%RJP)E", PD;SQA%18MJ(!+#$:R/!";L7EC@R;B%M MFR4Y\[FY?/D!%2>^"U[5*@R7<*2&+I5^+A)JW!:^GO@%@SZ6J*?VD']Y7_7V-/E(.F",54 M+G)'0AB:%LUG'E20/7A:>QS)#."T0%\,N)PD$FF2;(G=X#;B&@(#L#3GNGLN M-.E.DB(_2(1+0J<;0H$0D 2X?\\0%"JN+!E9D'3*(QU*08WFF33M*["1R#WT MO \Z(4'>#-$26L3D_%9,%-+!P9@7;G1H#RNUQ&A_@):.5?1&0ZNADTYAWBC]2JK$C%#@DE4] M,J!$XY(;&?K>UM*G%M'?-G9PZFM?DT M5JWG5!J?R3'1&L;OAKV(VD5N[,6%9.DT9N^JKX"C&Z:'A]J4]1569VCX*=3R[KT!DJX1J&(',: :!."<@G:N27$J M:P4E@8D:-9)&%5R1:P;U,/D-\YPW-\ABI%FPU#X90E6;(&ISEM+#C+%?F?>N M9(IJN\.JZVI1=4%]-H9D^95#Y!+G&J#^05U09AC;F5S4==Z'3+02P#S//$@Z ML?M*P=;N())I8@I.V S.,XOT[SPB2$DL.4=PLY:&/*ZRK5'Y:KG"I:2U@O*. M[HIKJ8-CDS*#_U5"G-)1^%QR;( ^&MM(WM\&DO8%P;S$#XV%8HD[Q+22U:Z. M'KTQDLOD8!#A1=[FA3J:6G*T1]:ZG#0BV6')X0BRHD1^#+44:1MDAT1G[\W1Q^=3RF?,7DZN+2]KSY'PZ_^:-7KTP)\^)LMGT=VWO\A*[HA4O MS_'AY60^?7Q[F\OYY,7\TER>$XMFWWZ0+W 0 METSO\XOSWW6(\^=TZ"<7%WJ(%Y>3&;YY9)<0UODQX13[+/GCDHT:Q) =]SDB/1+:G='PLZ=IB[/T)'9 MA24=]WW2%^.R048-VN 6FRJ$V%J9UQG1(36T*,EIC&L)["[BAAK?M X!MQ6 MET&T/)G6N6(M5TI<[&;14@?ZZ4K! 0_PCFL.4G#DA-387:7^5NZD3;=>XFS, MK4-F27/7F%\IBL@3>;@%R)RO';>6;RH20[1PP#ROT>2*_*FB1->T9,T3:-O: MT-V+26)+IAIW+I>/,V<1-TF]+VM?&GPM>_64(D]\\^W*-IJ?&$X !:L^Q(0F MJH #:T9\=5_@U'E&++<@;""1V,KLODD)-*(0WB+R+,W=2+HS+Q"Y<#'@J1B9" M.4TT9.3G)E[:NK6UGS<,N+2DTZ=3!.J9*.O(R0A,SG+$U7)H*N'V*MP6H4T- M;BM@C)5K"B,*)".=8;K'[BF,@\ZLVY,KJ)E0C)4FC1EXIPE\BD";3M'FT'GP M!BUNI[?%VL-A;CS%IV>_4TS3\6?)TO%1/2Y9#,T?YM?C&?RO4B>WFE!ZW7-# MN"U+O:(1^X#(L2'- M71*S&-7MN6ACU:^L61E,2T69Q9E;1DS;'?6MK?*0SQDGD*9&V(*T.*;*A.8F56 M&%@Y"/!0/4VA?BGQQL/+5D%$A&7)@1U2*H)N\-KWLW-85UNSJT[NW>@]ER-" M*Z$\\AM01U43#-OHDZH;=98WR;9SKNLY3YIGRM M! J"1?3Q'NG,#Q06-W!G_U:0(]7DQITRTW%P@]"?F>L@R5)RNCR2#,/[UY"T."ZKN;LSYGY5(O^ MX%JR\")3%P9>2>G+9'ZQ;3$CG">03.+1PS5ZD3E+2CUR,,I.I.3WK"?:S"L$ MEP 0SOSL:?35!%<+EG?!/R^O:MN;J83L:3I'Y;>3JX47%\Z0+=08Z@C'MY M^/)7XO[09T5CD?=E1U.XA,^BHQLRJP0,K#0J/T:W"7+T9/DI/X.O4 M]**-0)S4':@*\8I>BXYR20+EOA5];9S=YLO$=?79<>G/-IR%&;4SX O)*G;( MO"R7R$&C-&2_Z*4A$2.OS6MN[)&EN-4B 1./[QC?3]17WGN>L>CI1#-YM&Z% M"T)&[C1RNCCE=_QR"76*S-2TV;'.*:57\J$"GZ5.81M;[X'Q'NX7Y&*8H/.# M2XXY]2YHM5M87*UQ53\R-F/7)O4*9(VR\%K'6!5/1SL7\M*7](AG%W\T7,O* M$>DH58D.CG%\QU=^8>#,_#BL(6<0+Y-RFYQ3RWG\/&*]ZZ&3)VX>XDM%.5&. M#F<,6D6 R!R=L8W,8=65UC0Q+)T364#O@52#) RQ'H[04+WFA=*.&O\MC MD72.FK36WC+N>0A$CMK<,?G#_4#&&K$?1:R--('KMA]29)IAS;<,4(PF00UN MV%R%-,(F7>V7U6+K(DNE[ETS09%^U?PPW,.N!%8CF=UIO?'.UW?C M$S"_]J7&Q\GHJ]%BILKU\O9Z.WY.XTT0L.P<84I+X6*,6I*,4IE.*4E8);GP,M:06F M;CD?>8=?@UI08*?%'H[A(5CNBX7+:<-!?/7--^+9>"+)'KHQ,(@W,J1,QR6Q M%=?J]:KNY32U;V;&ETY3$.BP!0Z;+/_L '=M[:,39L'JB4?9E0WM>AI=NB.; M:VOVX5EB%K<$$Z[,Z.4FZNPBO$9LN!@(6NE0/DADEO]T3^L;#XD1EA! -/]% MMN^Z]/S3%!3?I:RL5"FP@?>)F]E,MZCH<^[DC><,0_QYF.O;-]DOZAP2,+SV M25K>!A3X*;WVLS_CY4^G+^_):ED%NUH!HLK/(0QI.E$:FWE9[GL9 +4 (&3: M(BYB,:*MD461*89VZWQFJ;<-$'=KJU*\:M#M&.['[Z38PY(M(B67V[S\4H_D M:[CQW+--Z^0W8K(S1 JMYML[T3NS=5O@7I[#3Q;P'=W/W)I"D8G;)N?J+26P5 M;O'3)J7D4OC2:=5U3EI*8&K%L-!CP4.HX*%@7N$Q>1\L; M*#H.!IO=L?[H42(D-JZD]=C':B;SV^P%9SM^IBCU4!M(P)-@$X,'8:5("RT; M&[Z#DS*B\3BC>"K_#V13A%9OFZZRG_ HRU:N)E'D$F)9?Q K1DN:DL&O41Q* MUD/JD:\T*$BJZQ_*]A\@0N<3=: H3&S2:WK_().+;Y#&_SMAO/A_$L9C/S3W M+/OIP(TCQ_:6V_G8ULJO"*9O3?P-QFOYZ<%AN/R XT_D%W&)O'9+>G5Z=G7Y MQ+3RHXCR1^>W_$.$"]]U?L,?4:%R+0;0\Z7W7?P#"Z1?IGS]OU!+ P04 M" Q@D]8(,=GU)0$ ","@ &0 'AL+W=OHB]UMXJ)]2:01Y\PY?4$4Q$M5&K](BA#JZ\G$JX(JZ<>V)H,O M:^LJ&?#J-A-?.Y)Y=*K*23J=?IA44IMD.8^V1[>*H?'=XF TJN*S)>6R,SZ[IS/QP._ M:MKYHV?!2C)KG_GE8[Y(IDR(2E*!$23^;>F>RI*!0.//#C,90K+C\7./_F/4 M#BV9]'1ORZ\Z#\4BN4I$3FO9E.&+W?U$G9X+QE.V]/&OV+5G+])$J,8'6W7. M8%!IT_Z7+UT>CARNIF\XI)U#&GFW@2++!QGDO&GYAN=(;H]=:21/$[<81(>'!SRV9WZ4G$!U)C<38;B72:GIW .QN4GD6\LS?P[FU5Z1#E"6ER M<0^ZVFS(*$U>/&BO2NL;1^*WV\P'AW;Y_;4TM$'.7P_"(W3M:ZEHD6!&/+DM M)T+ ]6\=&(VV:#1D0=9IU=&$_$C_7 M 7,^$D"KG=WJ'"%>5-EXS*OP-3&CL!=U(3&&:A^K5\N@&6B(!\^-DY476%3B MDW7EOA(9;;0Q*'(O838=11EC\00>#C1(0 N\[)HY'='N:?'>@-G'LR=I#7D M ZRAKGH[K#2=_4M74PJ%)J)**2!LLX M%HZ] & ;;@Y'BO169B7=Q \YMDV'R_Y(\EA\'2CWZL&SK^ZNT*H0.G">T 8> M:EA%2^.@.;?X8&P0=>-4@7W;0ZV=K433:F&4_AP+%4&'DAB/:/"6/P2 MK;7T'"S7D!#*_0#4G^X2(4/;#DSBV-X*I[8!*LJUPC0!&V\:1>5IX1;BDMO& M?=OWG:H=&FC-?;,GZ2#V>*K2-$Z5K'@V\F] 0))> D7-O@T$TPJ=0E6&#CZ+ M'9VF$?)@_G?4=>,@R+V&_EDB\_WJ/1^)QI3<1/Q9F]A^$%%J.&=[3F138_"_ MGZ(E]O[]NZMT=GG#E4'#MFDZQ%78N>AU%#'/-;=P^[BOY 7<;;;R\)@':Y:M^T-XW"\ MO:>A.S9A?.,!P M 5W^!5!+ P04 " Q@D]83-0=\2H' !H$@ &0 'AL+W=O;*9$([]G:O"WO8R MY\KKP< FFM2%'BSTB;G#DNS'MC2")YZIEP-HN%P,LBY+'IW-W[O@[F[ MT953LA ?#+-5GG.SNQ=*;V][86^_\:M<9XXV!G++5^HL5/Z6UO2 8))1)'$CC^-N)! M*$6"8,;G1F:O54F,W>>]]+?>=_BRY%8\:/6[3%UVVYOU6"I6O%+N5[W]433^ MC$E>HI7UOVQ;TT[F/994UNF\888%N2SJ?_YW@T.'839\A2%J&")O=ZW(6_D] M=_SNQN@M,T0-:?3@7?7<,$X6%)1'9_!6@L_=+39<*KY4@B' [)'CX6=NGH3S M>X\BJ8QT4EC&BY2]Y=*PW[BJ0"2XK8Q >)R]&3A80O(&2:/UOM8:O:(UC-C/ MNG"993\4J4B/!0S@0NM'M/?C/CHK\7N1]-DH#%@TC$9GY(U:7$9>WNB+N+S= MX](!8_$Z&.R/Q=(Z@VS[\Q0NM=;XM%:JP&M;\D3<]E!B5IB-Z-U]]TTX&;XY MXU/<^A2?D_[58OWUM;*/F6!\+^@*@JXL";(';EDP71GVH NKE4RY$RF[YXH7 M"910>4"!@1 +,Q1:D;UFR!F1+X5I\X9^(G8!42[3E85!]I(]<)LQ\;F2&V@D M6[YE\VD03H=X&$V"T6P(^=JX*R=,CM)L7>L8%XVB8 *.T60Z^+]3GZ M,2F8L#B8QU/V43NN7B&$";-I, PG>(J'$Z^$L*I]E,6:U2P^F\AXPN@\D&NC MJQ+@+7< RV(LN%TIKKN1>8G;\YV(+7) (O^!G =M'7MGM+7L4X&YH?SN.\P+ M^W+[/=:PX0?K9.Y#V%'[%40^#[4VI38@8DN-#?9>;(1B$; -HV$P'LX([^$4 MO]]],XO"Z$WS9A:.Z6DQ53 M) ;D1T-V,;_TJW#.0N17.(I:>?O__?ZG_F.?K?5&F(+*A&&*%LFN&\R]^.<2 MGO]'XR ,D?^CHYW1A"TH!:Z6/'D"7SXIR&L1AC"=@B_?3R?2R4ZN_"R::Q$0BHFXI M-S<^-_7J%:V)0EW*E41 ^,''RE*U?ZXTI7B#0FED @:]="@-;*^,SAEG22<) M04%\-&I ZULT[+!0;YA,D50R 9DL-C#3M^+^_V9SU-@LB[)"9W(9=^#>89VH M*D4-(IDS$L=V4JC4!C@$HCS)/\S75&!C:?23,(,4M8Y:\L[78P&14@\\N8 GL6-?SMO$+#1-2:MQYP=4.S;F.%.*N,7]- MX0=1UF;$KL6GB9,/69'BN&N@HEXA!,)ZZ;!=58F#ASC'UWK0Z(1IZY+4P!+_ M=N_>41BWF?#( T).@]&?"E:'T*AZ1@!K7I9&HRJ@M<]^04LY$?O@@!U-#Q3+ M5KJ,58>94\L+_(ECGR7][E!J%.KB15X12Y-/KV/@$SK5/FA$55#,@*XZ*M6Z MI("XP0I)GW&DP0LK:[A]HF6XPH"NPAGN2>#!\V_)/0CVTJD8.LFY% !1(-H) M#2%?)Y)\.$I1NC5)@+'-9)+Y"E\B.:G6G4^&/ELDB38$I]KY?/:&DF\DV*34 M-,X'[M"VGG>J;N-)$E.)3FHUZ)_N6'#EV[ _Q9U+*7]]!$K8F!TV/,W+LQ 1 MTA&(VI4MZ^(COT"/;H1<2#U)W0J:X-0GK38?DNXA=MD<8OT=#TXM3NL-"* S M_F0<.HUOX66B64QA]BXG@'4[ /X+&23A-#4>T$ M-WU_4MWZ>[-(K\!B<(!ITV)?>)E6J>\O6]*!R5$T!IZ!@OC4%\[8! BN%YB, M5,<=8Y?";06TX#S400)GVKW:;EMX!1C?))N!2]2=%I])^&F2;$N?N@4..K=_S/6U_\9!K;&PO=V]R:W-H965T M2K3K=)$#1OHBWF3-G+N1HMM'FT5:(#IYKJ>P\J)QK M3D=DJU',51-!G57*A@,>OV;LUBIELG MA<); [:M:VZV%RCU9AZP8+]Q)]:5\QNCQ:SA:[Q']VMS:V@U&E!*4:.R0BLP MN)H'Y^ST(O7RGDZ76CWYQ7% M32^;C@,H6NMTO5,F!K50_X-=2RON..+F=$;,%Z: MT/RD<[73)G)"^:3<.T.G@O3P24:1YF$"RZY*A#NN\*X=EC; MVL[V(WT6\PN($$A9" M',7).WC)X'W2X25OX+UT\PXE=UC"E;"%U+8U:.&/\Z5UAFKGS]?\[]'3U]'] M?3JU#2]P'M"%L6B>,%A\_, FT=D[W-.!>_H>^G_,W/^%#=?J"9739@N_(S=] MIH'RA/42S9 K_XGAF#!1AG"0T9F$>9_!% M*$&E7<):Z]+29I8RF(9QE,(OVG%)RGOC;!Q.LQ18%D8)@Y\\FL^;P[4H#L0* MR:T5*T&8W(+2ZKNB-88.X9A,I^DG.&91.$W8IV\LO%3=JWFJ61+1. E9%,$% M%KRU"!ND)TMNP0=0(=U8U:ZHBJBF##CM72Y;BN2/VLAM_?%#'K/LS,+Y[77H M52O^A-"TIJCHP2%[JH1*RQ*L6"NB4'"R_+6E+Z6(BI12U&D*53<^3GD__(KF*D.@ZU_UU)GNN0GH-^W+H MNT=)P?:1\<[$T=G]M]$/NR-V!OQ%Y(D(NA,X+PK3[IS5!&] "KX4LG?Q7Q?7 M'JZ@4J8>PKM:/H)X'*;CC"94,&/&X'O]A$;5GH?!)3&VP/(PG>3 6!A-$R>P.?G0MC.X(&Y*,N[P++XC(I[386Y0N(S3F.(PTF6P*W1*\HR M.;D_2XA>3![^W,5R,DXAFR2[JN;OQOH(QBR /#_\WB+U!+ P04 " Q@D]8\78J M)_4$ !G# &0 'AL+W=O+*$6Z)!4E^_6[(V7);_'V M81\BD]+=Q75R!Z>"J5=M->X?WJ:C!P68&E<'VS0DU?%L:6PM/6 M+@=N95'D0:E4@W0XO!B40NK>;!+>W=O9Q%1>28WW%EQ5EL(^WZ R];27]-8O M'N2R\/QB,)NLQ!(_H?]M=6]I-VA1!WR76;F,- M',G:^F/8N>Y#C0E3*/YCZ9VSB.6>\S"@7GE!'V82$L\IY4S;*Y$$I=?P5 M3TT>-A0NAR\HI(U"&OR.AH*7[X07LXDU-5B6)C1>A%"#-CDG-1?ED[?T59*> MGWU "LE-!IZP^,T@:_1NHE[Z@EZ2PIW1OG#P7N>8;P,,R(G6DW3MR4UZ%/$= M9GT8):>0#M/1$;Q1&]DHX(V.1@9_7L^=MU3\OPX%&2'&AR&X(:[<2F0X[1'C M'=I'[,U^^"ZY&/YXQ,%QZ^#X&/J1U/\7/?B"H'@%IK)@%@N9(2Q$)I7TDCY+ M#7>HE8%[8;^>PJU0DEI82]&'CQJN5U8J:))]"C6"DTN-.0AJ%.JYG/X\> /X MY&D7;$1KOK"F6A;P:Z411L. ,.[#M0-!3>JH&<@9DI*N PH&+&9FJ>7?C9$\ ME]R60H'EQCDSB[.*X(5S-(D$F$S2;Q@;1=_PUO\5@GE GQ@ 27F4:@*8YP< M& \_=G(EGCE.8%2>Z1W'@@$0X(SH;)*T2X_[&OG9S38>ELY?BD@ERXSE8Z0,6RF M (-M66-CM:E4SA# HY6*I=BR)99QRI0A#VOI"RAY2)#?K3%.M@ 2+;)VQR(!M/C.9:BH@9V-!I3*U@U>A94SE2,V=4D 9KCQ),3#W*"6# M3F4B+U/"O;Z"/[BWWA^., 9X*UQ!F9=Y)/-.RC:=.8'T=/0V";_IQ3D\Q$*& M@YJINM^DY"VY6 B]C$G?;5A">OLFX%TF%\2-&,;9.HQ=\H<27T36N6ZQI[?= M$Y?](7P/X_"D-B9/#]1Z4?F*4DV'M2RK_%]QQ\!= M8:P_"\78C/PDZ=@?JAT/&>KXW(2!V#7^H4;8HP=[WY+&Q1 .LSL*DE6I,U-B M')_;XXANF71ZMM.H(VS_T*UCL''Y*]$NPQ7706!MO >V;]M;]'6\/';B\0I^ M)^Q2:D<6%Z0Z[+\Y[\7\KC?>K,)5&ULG51-;]LP#/TK@@;L5,1?:5=DMH&DW; ="@1IMQV&'12; ML87JPY.8NOWWDV3'RX T0'>12.GQZ5$4E??:/-H6 ,FS%,H6M$7L%E%DJQ8D MLS/=@7([.VTD0^>:)K*= 5:'("FB-(ZO(LFXHF4>UM:FS/4>!5>P-L3NI63F M905"]P5-Z&%APYL6_4)4YAUKX![P6[H(;$,(3.1F_1TXZ'>D#C^T#^^>0 MN\MERRS<:/&#U]@6])J2&G9L+W"C^R\PYG/I^2HM;!A)/V S!Z[V%K4<@YT" MR=4PL^?Q'HX"KN-7 M(Q( VZAX."REN&K,R-[HGQ:,?FC9!JB';BN/)%N4?C M=KF+PW(#@B'49,T,OI 'PY1EX;YL'J'C]ZBH&KE6 U?Z"E>2DCNML+7DDZJA M_I<@E!W2H]RW@+U8QDR05)XS0[PY=-V6:!+WMSMN3G0):OG^77,4?SXB>3Z+GY]C?6*+_Y2(/+1@@O1^4 M=OTV +L Q&-@O3=<-01;("_ C"7@JTUA M$;8:75L%LW7_&!@/Z4:L7GLJCLJ[-=VS8O+BYLME.EM*.Z416>;&I3RA:7 M9GMA&Z-DSIO*XF(R'B\N2JFKL]?VR[MI"5^K:"-N5I33W;U11W[TZ M2\_"C8]ZNVOIQL7KEXW.='+ZL+R7W'GULYP M8M;9MB[]9ER7NG+_R\]>#X,-J_$#&R9^PX3Y=@ MM#B-]EQDGO(;1WGR .5T(KZMJW9GQ?LJ5_D^@0NP&7F=!%[?3!ZE^$YE(S%- M$S$93Z:/T)M&V:=,;_H /2>9^.?5VK8&[O&O4T(Z$K/3)"AD7MA&9NK5&6+" M*G.KSE[_\0_I8OS5(PS.(H.SQZC_+N,\2ODTWU\Z[H]_6$W2Y5?^4'&X_+O. MB#>U-+FH-^*=-HB[VEBAK9!=NZN-_EGE":)__6\\$6T-^O>BT*5N)06H%<1) M9O0:%-=X(N\2! -V=JVP/1M"-HVI;V61$ UM;:=$USAZ0FZW1FUEJXB'=#P: M(V:*@L+?[B3(T^TF\FV=F*TXQ\IQ*AII! B#H*Y$78&($65ME(""-#:30G#. M1G\6[4X)0Q%O$T]059GB"WVK"[7URW%F:W3F!-P:6;6*:8"R+IO:XJIKP![1 M.V L 1=9T>6ZVHK;NJ7_PHDYSL@5D?1]Y'X>Q2*]$0L>F1=78'K8JU&EJSW=L\V$AF/M1YNX/62WE/ M--B$.:F<2&RZMC-J)*YX+T)>E6L8/80]"X ?$_@&V).YJ*#,KK4M'I"*'K0S MQ$/6LIVY]_[Z=26^E2;;,5TF)ZNJ[J"*W/%7GW9HYW]8)$4+&X"Y>H.#2 =- M!WK($=XAEZ/Y"?\CLD-E.KWOD:+'BAFI Y.+@?SJ8@ 8DN4[&P70^F2!&1(,'O%&@(-B/N"A\ MOR>=S4>S<& "OH,_&U5(BH2-\CX)D9#IR0E_A!NIK#;(&0/&/;,2_ 8K.D^" M($ZAX+RBE?AEZX+\FW!$%A)Z%*[ @419;=L1F?YO,"%[%K24_D^LGYX"GU]K M_,CFBNV9'MH_!DCJ#)YZ!?::.V;C%UM\/%K.?Z7%)^.!TP\M?F1IYP/TR(/' MD)4C$XU_FXGP Z!;TA&]3KQ]P&NOFA.F$4^)*TIZD_%7#C(^]C2N'65^G'[U M+-C1E!X[M8V'YYI0J@4'P%WHL;."HK75Y*Q+I@ M4#8RIPTRRU U&U[G+#_0W7"C8(>X)ZVM=>42"EBS'2#)\^?T\I#VHB=#.HW$ MX?57B1O5M![XQ\&OWW6&O07T[A4R-;E+?I0AT@/$FXXN3X3AGIT[]KOV,3ZI M'AAH=T\)%#6("N1?=#'[@+E:]>&3N/AY+'A6JSYVCN2U#P@\Y;^3D!B=_#ZG M3H;H.QTMHR9H\>PH%U#18!O%C5)QGYP,BEBMJ,_*9-HRYQZ*N=J R6_J4OFK M6 B$Y12Z2INPF(PM0Y!54&U8YP.+6BY-3MP9VZ%ZHLBYV^F,T0N!TR'!D_E< M5=61]T*T/0_8F+JDU65"IF*DV<&4&6]M8\"0%9+@(HA469#573GH$4I:6VZ6BU9\_TB_:$/,B.E6^( MB5<7J]Y40_4[,&HDH.M\.?2BH15S=4TS%U(MW4T>S*=5/FS M!@F6Z$:"(_%]!-)XDQTX P^N4?-1GWAA(P;&(YBV(C<9]C+#3JKOVTA 3J7$ M-WJ=HKY7Y/2H(!"3AONDH0SD(EV!1J'U:2ER2:F:#&5=7;$';R[ ";MUU.T> MWD4'02=2*,LT*I1=7"S3CM!,;:0._>4I9)6QZ\I] \O](FKZ9K]][([5#!4; M0Q4"9.19!L$7N3:3A*,[T.$"PRBNP3+?B=Y"KZ(F#P:[&BE;X)@MEVP$G.29 MG&ZI\26>F1([/P*Z*QE-F0AM<22"'$%!K%3X 0MPDGT0AP(=ZGJP]8'@A%9^ M]F ')]#4 J9YL%6,'>)RD/@"C-Q*7DYV48:- PX;=FX_Y&CZ82(- M07*'Z]R:D4MM:JK?&.J9O!MVZI^I[#C8>D(/+\1W@U8VV/UO'!^\]9J]]>CY1T4#6B+Z=N @?]4;X$2L2+[&$UU9G8D?V$F? M=Q;\V&=\R<9_=OCDC8=;6/G0"A,!0Z27*W&.#F643H^<&4^7]!3-Z^PR/NVK MA:>39#J?/Z/]Z6BVC"LR.K$HJ,JON%K>*$WTGB[F*:U&FDH7CW$V))9/HI!$"==S2X]1V/B:,$<39)TOG(=1MUR81(LU;RWU9RB#L T?ET MT<_.D/07T[X&<$E_N>H+Z\.DO^;TZ>O$7&_\A DAWMY1UJ7;65%;1HQ0_1[A M8=COP3 ",M=:1P@]&JCG &B'*.0-\+MT,]LKJ\]GT[XJ<[J9C8<+AKKY,EB= M+Y:#^@I+NXJJH6U%XU-2$'7/+COZ3IHA+);3/7XDOE FJA+D/22$1L5$2#@& M[\EH.@] __'FBJ7Z>/.]>)H!WGH[^Y+B,#.'RN(WH>1QFO_%>/FQW^K N@?. MHT='"/EGSDWOR-D^D/LX"'P$2'_P6ON_@.AL/G<8>9D.97$:"E"ZF!-T3&:C M\>QXD7?\I^EJ]LR16BV/5SV(JNEXZK=-OH"JJ\G2<9&.X4?+*2YFR24NONCY MP,_+7^_Y1P[SWPJ!Q2*$P/N;ZVNJDC^HM>DDZJPX@)8Y H^UY18QQO (Q_85 M*3=!-'ZT*#$3FG642E9N1BWO#6(!S4/>A6&,FTY1T;9?/VH:ME24M_=T03K@ MMP>AECXY9;SQ=8^)LP$:6$J#-D(W;@S7\QLZYD&!%D?-*64J>C$4)S1TA_!9 MXBE7BD]K@UZ3>*ZMPV^0A%*$&P>@1[OGT1%RP2?JC9( ]1MM0&O=(3%0'8UU M=!OMW@:E[+-A]_X\=.\,];Z%WRNM_2L4X/6@Q_,4*/?P0IIX_K M(ZNPEA]2UQJ1'\;N/F"3F*6<3/WH,8)8X^K>^A/]HA0XG'IY,MR;?2.KX'0N M6-"'4 OL^Z\J@AQ[8#S)Z9VZHPS*$BBM#?2 &F1HRD1\TZ' YU_[%B7^^^$R M;OR/K#H2'[")G>>@\TZE??=3:S_(0'Z5JN9C@4*&F+H"#G]^6['>U";V$/V0XH:*S]JSAJI-]'F/? M&/ [O &K7=LF.?6ZWHE6ND;-K8'$SSG6@ B:WOR1@_BNJZ\W3GA$PE,>HMXT MABHG' T,:4'C?(#!B)B+MAJ0QS5@]=S TOW\<"\Y?6>Y40:^R241" M7YH&^U>-87K@U1#;5JRE4MAF-$6BZ>XO>K\9YV#G1S7F>#@*/!K;,OH]=W7X M7K8(+]Z@*1C2#GWO<#1(*,J:U%6H]*ZRS'2^.*AY6E9HN=8%'$39,+']XD N M3#2X0G)L7=$HP9>P7R@02;U'F5P.]OMAD9OT#'H!KXZ2IX=L3KM7.GM5C,0_ MR/KO3S<$OJ>E7N#'QY@X0?B%^*CMI^<;HPC"@7T4SS2Z$U2+/1'IZ!)_Q^CY MGJ"?#\TAS7 6HZ5O4] 6QE]3_RNNO:WIA5JAW0LB/V'C]FH^'8V?B/EB-'\B M%CCAB7@7OR @!O#0_3N2R8ULN =[3),HWJ:C!6I4-.E4_Z'7'R_8DFI/DD$[ M9M2F<$\\[CE+RW5]R\ ;FTC)B-@5TF$.^97F,60[).^G0:&"V^NPF]JVSP.@ MN6+ N=U:[>2MKFEXBQ )I4"8! ^F4/[3$_J6I8K!'2>-! )AU#C:EWK?)K$P M$9UU@H?B)'2CCRHY:L^9A;/[B;DG"Y\//\#9:\@?8FG01@^6#'?O-%9B%4I0 M>(0,B-E/2(]Z>"Z;_%B15NOR8,IWY!ZX:;W;N2DC3LLZ JT^MSR(;J$OZ&S0 M9U\=Q6EM.#0,7@;S"AXDPTU*/W,XGD/&CZ!"@!2JVA)8;CQ[9*@PL$;UZ-YM M'M+U-'U_!?,Z4>.2P8-8]9+J#AS 'W-+0Q!^XQP)P+-LM[90-?E-L !J'C_Y M&Q[@!C1^VCM@U/J9IU?TVZ&BOS3J#$YURDC0QP8!6&4:C*!3:YUS9P7P4\.# MI4N0OQ"%#[KHFX=.S62C6UEP+XDMNKK%H36J)O2J8QY KL;MHK"P@ MRWPBEF.!UAK-LN*ZF<-+(=?6#7.>SI/9>"+22;(:CT4Z2U)@WPW::.Y MZJ" MIQ2N'LDIU.EK0R[/IM-DMEJ(R64R7T*<5;)$S_EW'F$]J#UTTY=).B..9Y-D M"37@QS1)%RMQZHO#B\&GH:4R6_X UH)D5[7N*]%X-WYC>^4^+>V7NP]TT31L M-0*H4!MLI6]#SMP+FG#1U@U_:+JNV[8N^>=.2> F+<#S35VWX8(.B%\>O_X/ M4$L#!!0 ( #&"3UA.?=X.?P0 /(+ 9 >&PO=V]R:W-H965T^ZY5]Y\I\V3S0$<>RZDLHL@=ZZ\Z/=M MFD/!;4^7H/#/6IN".]R:3=^6!GCFA0K93Z)HW"^X4,%R[K_=FN5<5TX*!;>& MV:HHN-E?@=2[11 '+Q_NQ"9W]*&_G)=\ _?@'LI;@[M^BY*) I056C$#ZT5P M&5]<#>F\/_"7@)WMO#.R9*7U$VT^98L@(D(@(76$P''9PGN0DH"0QI<&,VA5 MDF#W_07]H[<=;5EQ"^^U?!29RQ?!-& 9K'DEW9W>_0&-/2/"2[6T_LEV]=E! M%+"TLDX7C3 R*(2J5_[<^*$C,#TED#0"B>==*_(LK[GCR[G1.V;H-*+1BS?5 M2R,YH2@H]\[@7X%R;GF#65O/"Z2LXB7D/:8X,X9$F4#,[@#5H[!QYO< +O S=* MJ(T]6,G^N5Q99S M_CUF< TW/ Y'I7)A2Y["(L!:L&"V$"Q_^2D>1[^?(3ML MR0[/H;\Y*#^.PAZ!X9>R,*902M52)4M9+"852BEJ M<'O,4)^P!\\4<3X;J_\3ZY T MR\K_++4#Y00&;E\;@-VXB9 NJ4/;KR/U8$,F 1/BV^A5%NJDP8O(5F;? #5I MB*:UV>*/'<@?-#?TUZ^3!;]A/R>^:Z.+[_'KL3\1?:TQ&7?>YHW++MC?P$W=1QEV0?#,7SHA/1)ZQ.Q7+$JTMK+("AT% MSRF4KH.;X77P&[NI"HR?T^:"W?Q8(OS,XF@4#F=C_Q:'R71*;W$2CK#=7X/2 MZ-X:^?'K9&FXWU. MSH2BE'H/W\TA-@WC:<)F83R9(6XXB*,W$SY1:*\IQW$X&2:>ZFP\9G%"ZZ#K M[D-0WN+X*^\E='4O2G")>K-1O4QJ-R ?OQWZ!9WDEQF5!28!5AOU7TK>(QEX MKG.$C*:D;RN?HH8)-NO%.(!(*=I:.>WR$TUA3YD-QS,[]#"3WJ!50OMA;W1" MZ1D5]H2.Q$-2\814YR7XB5#N0[PW4DXMY="M$*O @;*2&AK^S,U&H)D2UB@:]2:C M@)EZPJPW3I=^JEMIAS.B?\UQ* =#!_#_6F._;3:DH!WSE_\!4$L#!!0 ( M #&"3UCL1A*L\PH 'P< 9 >&PO=V]R:W-H965TEW5RZO56RXDV[^C*-X]GE3NIFZ43]9 MX=K=3MK[=ZHVMV\FR:2_\5%OMIYN7%Z]WLN-^J3\Y_U/%E>7@Y1*[U3CM&F$ M5>LWD[?)RW<%OVAUZT;?!7FR,N8+77Q7O9G$9)"J5>E)@L2?&W6MZIH$ MP8S?.YF3025M''_OI7]@W^'+2CIU;>I?=>6W;R:+B:C46K:U_VAN_ZDZ?PJ2 M5YK:\:>X#6NS;"+*UGFSZS;#@IUNPE]YU\5AM&$1/[(A[3:D;'=0Q%:^EUY> MO;;F5EA:#6GTA5WEW3!.-Y243][B5XU]_NJ[IC0[)7Z6=\J]OO202/.W3GS;5*HZ%G )4P9[TMZ>=^F3$M^KN[(VKK5*_.?MRGD+1/SWG,]!8GY>(IV2EVXO2_5F@F/@E+U1 MDZMO_I',XE=/V)L/]N9/2?]J/O[\;O'S5HD*E\[K4LBF$CC" &DCL&9O&M5X M)\Q:Z+!GI>CG_LJSA%N%.])A8XW#ZUZ*?RMI0ZH%$J5V*V6'9-%'2A^)N-"- M\%O3.FAUS\7[WHAG(DF+:+9,Z%LRBQ9S_I;.HBQ>B ^=>1=)E&3Y0J.;S=\-SN?IIZE8JTI960=_7HKKUEJD!T[D<93. M"GS)E@A*2G>BV;R @K7"FDI<4$"3#'%*%U&2(E#P>@:OC8>\A\)% @%%BCA% M<1*+933/$_')2Z].E<^C8DD+BJ00691#^4AI-,L+Z"RB+.B>(U]!I3O(@JW+ MO, G_(:(I#CD^$17,1-9+&#)0442I=D,HO/9DC[S6:]@/1;!8&&8Y!FOBXM^ MW=Z:&\VU@U)]"IA%E">,ESR:SS.&2Y0O<_%.;733()_8T26?TDS\<=WBP! 2 M_F563KPM/6$@C2%&U1K4#+\=+[94"80WJ Y5BV7$$M*66]Y^GXMHT M&]QQ8@OJX ,#_$%,C="Z6G(Q]EOI4:_;FLQ RMF]3F-8T3G"UL$@[,.J3M^J M]41+"/^9$\L9&&TF*QKCX1*,WIE*K[6JILA?:6R%1-?W$>*)9?"OE'L-[ 2O M6_N5>+DS6>-@H"/H$+0%%&!=*=U6[*6N^O64(,=$+"DT<'"/+'<.3@_'X BV MZ%>HF6$/&_1K3&?K-6YQ++P"K5MT5@(^8K]J2FQ:*7_+Z=J2>];>DV6(=-O1 MOW1.=;BNM5SI6GO=^;4&IIM2XRQ9M:?48.> 3MK0)8U%M4Y5)R=M6#P5GX ^ M!+Z4B-UQ^:$P5[V[M*DWZ"^7GO2]8&I*)!H<:UD]] ?.":( M#-05Z':Q2,7U"!='F-A#!+OD8/(212R)EDER?OW1&9LET7P6BVP6Y>#WC_V: M$O9KB (]SZ!W&2UG&>C9E%]>4.]9QI@Z-8UY\H59OP!V@D9QD<54^W&^;%WD^,= 18MF<%G]>: M*A?Q+O,3U1/#T#GKT,^FJU!\'FXY-):S+,]Y%PUJL:YN*RHM0VO6%3[4$6=J M7;$%W*(P]8(SNE[PN$#BZG:KD5_7XJ,/0-!+OLM*3;D9/&/.8&TE5O?B63)- M,&O5-=9$=+7LKSBMN)$/-_Y"&SETD:<%\^UCI8RS69TF_IBM JGCYUMI*Q;T MK"BFLX/](2@H/T6\ ,%B[$AH%L,T M, >WATEAW)5$ 2_KP9">.[)HL9SC,TMC0;UU(7XPS8O0$FL*Z%$IRZ)T2:-" M5N1BB;GCT9J'V6-9)&S1DAM_3"@S6!K*VD4^YWDDIH*T'&:!)QK^7Y6@9U<> M_Q\T0"VHP?(OW,T8I\D$%_"Q U^T=N DJ!]56\W]^XVI;]2A!V88_=96&]Y# M4:>Q>-=Q$2ZIY\%BG+L6209)[TRCDM7TC"#*4^H*EI@Q"1/S*)\G5%5"Q3K--V-AU)]#0"J*#-U11J;P M)O?U74 E /G-/Q9IDKX:_O8"SN\_,!.S6#C;'#X:.7WWR\6\B!]*?MJ?LAN] M P]'>4ZG- $=HYN<95\QZVCSJ=[^+W)U$O6/HH-T+C=FJ&Y8.=#L0<7BTM=];-BC8 MLE)]^X;3*[NCT)^$,UT(*M_YYL0-%'4X]6 >7(?R--(\ZMA&%?+L@ 7_@IU4 M?9^,UI18DHHN:B5/>&XTSHUGR;*T+4^M:+Z(E;B=,,-]L+BLF1M'9C[! (_A MXJB;8N,JPUY0!UF&;OD)M)@^%917B_D6N>5G'&&POO.H#42]?@NJ_W6K:X(+ M]M<:O<708J.?Q"3!P.!'354W_U*C?'1BHB%$%'GK YMS)EHPE0W5HNPA P+E M9QT058?91/89IR<6%,9.\LE##/)Z>.CE""X7/= MTJ"*1?=]M"2E#=+54+=48&EJK477![<@:%OS0X9>/BT!XGQ-X+6AAMQJFO^4 MHP)9A=)Q30]#FGMFC_DK1]1)KXDX4+^U5KM*EWTS3YH^HS3V@P'R],'8<2\T M>B!S:,\9-WYK3;O9AKH13A&UNZ$"NW;U&S]B,=W#8MG/$$'#YT^'0#ZB(LZ/ M583YD3#VYY4Q0+8=02$0/'[V>OD!S@$YTW-O'2Y';X1VRF[XO1>#K/'AY=!P M=WBU]C:\43HL#^_EOI<6)=0!C&ML19=?3,+DWE]XL^?W2ROCO=GQUZT")"PM MP.]K8WQ_00J&%XY7_P-02P,$% @ ,8)/6)]85G7)!P P1$ !D !X M;"]W;W)K&ULI5C;]O4CD#+IQNOOT:8!G M&^>_AA51%'>UL>%\M(JQ>3.=!K6B6H:):\CB3>5\+2.^^N4T-)YDF8QJ,UW, M9J^FM=1V='&6GMWXBS/71J,MW7@1VKJ6?GM%QFW.1_-1_^"+7JXB/YA>G#5R M2;<4?V]N/+Y-!R^EKLD&[:SP5)V/+N=OKHYY?5KP-TV;L/=9<"2%C MUR-14B5;$[^XS4_4Q7/"_I0S(?T5F[SV9#$2J@W1U9TQ$-3:YO_RKLO#GL'K MV1,&B\Y@D7#GC1+*=S+*BS/O-L+S:GCC#RG49 UPVG)1;J/'6PV[>''MZEI' M9#D&(6TIKIV-VB[)*DWA;!JQ!2^,+=?"$^P<,JB/>VI/*^@RFP M#0 7/<"KQ;,>WY&:B*/Y6"QFBZ-G_!T- 1\E?T?_2\#BG0[*N-!Z$G^_+$+T M8,T_'DM#WN3X\4VXD]Z$1BHZ'Z%5 ODUC2Z^_V[^:O;VF1".AQ".G_/^W]?L M_W G/DG;5LA"Z_%,7"X]45[Z!XF57!-,A.R?@KQQ)9PE$5?:EX>-]'$+NO8N MR(OH( !-8_!85]1X#8I;&L. NA85S4JBWQ2U42MI!/;U5&IV?_#]=Z\7B]G; MRYL/Z=/\[4N\%K\X;[;U.*&/&R=D66KN>1@_A2,PD,:[LE64[ H7HZ'.E8BR M, 2U$Y=!N$J A%070-\3<2PV''XII'@QFYPB%F.R3+$0-2[U+[XF@R&P*'&^PQ M$;_).Y#FB:R)\8#-DW(>"B&LLX>J]9Y1QF3P@M5:1 MCT@UVXC&A00*:?E(2T"[\4X1.&.7@1/%W,)NVG*VE&M]2-Z+-J 50HZXEEM1 M<,Z*?Z)0O(=)KI21NLZ-X6G9 H&#$YEJB=JM9&2/INR: 7XB>0U#6:Z)-Z*J M8H>P*/J (38:U?0 3[BH90EJ U8V+R NO,%H6VFCP #&'5JT$+%J9 M410 A(IL_V+B<;#P%W3*81M12DKE6$NO71O@*G;,'-\+"1$&XB9(G94-F _FRY6UV"/ZQ-^TS$)S*M4EI\')"G_6YW:#];"!58*N;'3+7Y M#Q #YFWC/+L)!(K!&(E /0$]UX]IWJ"^+%PRH!X&:W7FR^]6L^5M!(XT%Z+7 M*.,URH(60O5XT:]POR)O=^^1YVMI-!98+;DPOVJUP)M7U$3Q M&YS()@D>$Q:M > Y66A8:29C> V\WT2GB\.-/O[P4!XRE MD\;>^Z[*O5).>)N]D*VL$6";N=VW$_ S\>@.&4MB[%A#6"\1 DX[9$N9!@5( MZGE,B+5&>)F',+ZEKC/FLX/B97*]F!W(E_R.4;Z_@Y1@N(A+)(O??FG!GOFL M.#QA,M6M6>8>1T:HQ1G"IU72H!NIZS?VLP>EEB6)2IJ06=@W8)HPP>"@RB@# MUW$WXRJ9:@V^E7GBT]"OK+%85*!U[G7L6. D[+M(V0?@A@;AAF\3FW,3$@.Q M+6M,X$,, 7Y[2-N=^,LP4I\JN57%DB4YA B1CS-$MPTS8YW$Q.V*T@# MC@/ 43!]0+\L/U7+C[:)?3J-]&[@?WN*> [6,&#EOJK3'6YS@1Z@R1K@,(9# MXS(WT\Z83]D5P&T?6@'LY]P4,'B??8=^U%WO<^"V[S]VP@J'U'1IKYAY*X$! M *WV_!Z%7^#HI50:VDNS_28BV\V/'4+V MW3X6W)4TR<$M7\-R7^1V6L(Q+VBX0^M\_D"+>;?&L.L4\9$"\B;]X2[-,S[? M5<[@!LV(.^(PMW3YH")\#@P*5PKTTQZ!$)2N"S[Z),WO:#81-SM^2KO%0UOR MV2/V\$H*>FE3F-EM&ON=?@W",30^GVG,?Q(C#^@5R72KX%+EH+A>-5SL$$\T\XG@SI7$!9AFW_C+?4( MKS]23KP,Z(K=BT51XL>/I$C/]S[!NV9>P"*IV-;%M6X_&+TBKCBN4\ZZ[#=VN(-TK?N.O"N'%"TL>BB\0X";A;%Y>1B-9/[^<)?!O?Q M1 :)9.W]K6P^Z$4Q%D+88DV"H'C9X1ML6P%B&G<'S&)P*8:G\A']78Z=8UFK MB&]\^]UH:A;%>0$:-RJU],7OW^,AGN>"5_LVYB_L^[O5JP+J%,G;@S$SL,;U MJ[H_Y.'$X'S\"X/J8%!EWKVCS/)*D5K.@]]#D-N,)D(.-5LS.>.D*#<4^-2P M'2UOTCKB74)'\';'WS@OB6'EL*P/$*L>HOH%Q*2"3]Y1$^&MTZA_!BB9ST"J M.I):54\B7F$]@NGD#*IQ-7T";SH$.2S>'FWV.)JT MR47L5(V+@OL@8MAAL?SSV>3%^/437&<#U]E3Z+]7D/\) 9\=?%0N<=?!><[J M[ Q\"K#R*FCP&[@R@=O$APBJZX+?H08%+&R#LJ 2-3Z8?XW; C7(O=BE4#?< M"V*:.B /?_ 4X/?9MM)JK!7TVEO+.W[#]>T(K@\V$1(_D\!()@XNK'J -?*B M$8S+7F3NL"+<(IV)K@MFIPC;!W"X]618UL U=%'E!H_@ WBV#'L3<01?&8., M%=+*<3C6)TX(4U/NX22$R W7MN)<(V'@^PPK?WL%$YA;WK8V3:LPOGB5W>)L2 MR7 %3W.971XSYC7;H3[CLC_3/ZFP-5R9%C=L.AZ]?%Y Z.=D MOR'?Y=FT]L23+HL-_UHPR 4^WWA/QXTX&'Y6R_\ 4$L#!!0 ( #&"3UBO MH(F56P( ($& 9 >&PO=V]R:W-H965T<0[(1]5 :#14U5R-?4*K>L;C%560$752-3 S+ ]R>XHHQ[2>SV%C*)1:-+QF$AD6JJBLKG&91B-_6(M]^X9YM"VPV< MQ#7=P!+T0[V0)L(]2\XJX(H)CB2LI]XMN4DCF^\2?C'8J8,ULI.LA'BTP?=\ MZOFV(2@ATY:!FL<6YE"6ELBT\:?C]/J2%GBXWK-_=;.;6594P5R4OUFNBZEW M[:$R1FE1=6#30<5X^Z1/G0X' #(Y M 0@Z0/ 2$)T A!T@O!00=0 G-6Y'<3JD5-,DEF*'I,TV;';AQ'1H,S[C]MJ7 M6II39G Z6=!GM%5H =*]0CP#E#*5E4(U$M!']+!,T;NK]^@*,8Y^%J)1E."ZT*A+SR'_)@ FZ;[SH-]Y[/@+&,*V0B%Y ,* M_" <:&A^.3P8@*>7P\F9:<+^'D+'%_[//0S)W=)%PW36+&Y433.8>L8-%,@M M>,G;-V3B?QZ2ZC7)TEJC&41B)R?9R6#J218$R"/JV= !_\.2N0&V=R"F6BX;I]V_O=WD=OG7V\ MV)\9?VWM\!]-:\YW5&X85ZB$M:'T1Y],4[(UO#;0HG86L!+:&(I;%N8; =(F MF/.U$'H?V +]5R?Y"U!+ P04 " Q@D]83DT@'D0" "+!@ &0 'AL M+W=O&6RY8!4M)N M6AXZ16FW/3MP *O&9K8)[;^O;0C+IH1*>0';G//Y.T8V(HEX MHRAAL!5(-E6%Q>L:*&]CQW>."SM2E,HLN$E4XP(>0?VLMT+/W(&2D0J8))PA M 7GLK/SE>F'B;< O JT\&2-3R9[S9S/99+'C&2&@D"I#P/IV@#N@U("TQI^> MZ0Q;FL33\9'^S=:N:]EC"7><_B:9*F/GDX,RR'%#U8ZWWZ&O9V9X*:?27E'; MQ8:?'90V4O&J3]8&%6'=';_TYW"2X,\O) 1]0F"]NXVLY3U6.(D$;Y$PT9IF M!K94FZWE"#,OY5$)_93H/)5L]/%F(-"3P!EA!5H)@5D!^MB5C%RE=S!Q;MK3 MUATMN$#S _3 F2HE^LHRR/X%N%IM\ N.?NM@E'@/Z02%_@T*O" AYJ/IREK'$*L:._# GB $[R\8,_][Z, M*$\'Y>D8/=DU%)#O[6>W_JDV6F6\5O\?^Y+0:WQ=4'-^XWSKWHYYXTB I$8=N@1"EO MF.IZQ; Z=-I5UV#^AG=M^@&+@C")*.0ZU9LL].L47>OK)HK7MMWLN=+-RPY+ M_;< 80+T\YQS=9R8#8;_3_(&4$L#!!0 ( #&"3UCI@2 (JAH )-0 9 M >&PO=V]R:W-H965T[+XE, MSG17U^M3+\WOMLY_""MKA^KCNNO#]R>K8=@\>_0HU"N[-N',;6Q/WRR<7YN! M_NF7C\+&6]/P2^ONT>7Y^=>/UJ;M3UY\QY]=^Q??N7'HVMY>^RJ,Z[7QNY>V M<]OO3RY.X@?OVN5JP >/7GRW,4M[8X?WFVM/_WJ45FG:M>U#Z_K*V\7W)U<7 MSUY>?(T7^(E_MG8;BK\K'&7NW ?\XTWS_A_M_:5[3JL1'3\ MKHN>I#WQ8OEW7/U'/CP=9FZ"?>6Z7]MF6'U_\LU)U=B%&;OAG=O^N]4#/<%Z MM>L"_[?:ZK/G)U4]AL&M]66B8-WV\G_S41GQ.2]\>&E"&RJWJ*Z]#;8?C/"J;ZH;D1.^ MNVF7?;MH:],/U55=N[$?VGY97;NNK5L;J@?QKX??/1J(*"S]J%8"7@H!E_<0 M<'%9O77]L K5#WUCF^D"C^@TZ4B7\4@O+X^N^-K69]7CBUEU>7[Y^,AZCQ.+ M'O-ZC^]9[]")__-J'@9/*O5?ATXLZWUU>#W8V;.P,;7]_F0#IOM;>_+BKW^Y M^/K\^1%JOTK4?G5L]<,"/43D%RQ3_;*R5>WZ0&QHS&";:M'VIJ];TU6!'K%D MKD.H5N;65G-K^XK.MS&>GFMA?[7S#3UM2<6'5?7^[.:L6MK>>M-U.WQM-UC2 M9'9O?$N+;SJHV%__\LWEY?ES?NMO5U?7_.^+YP_/CO#L2>+9DZ.'O<[[T(E? MI0/>P[DO7JSZQ^@_@W_T?CTX:QR1,)VYR> BQM!UVA1E H4FFOX\M"9;8V%- Q!O5X.A?'VQE MT[Y@H@D41#?"PV%EALHL%A3E6$IF#>L)M!J)KY#>IXGCE6N5&LRO=[0A2;8> M1GHRJAQ99]=434M;^B1QTJ:%)Z485BX4U)Y5OUIZT=Z:;J1_L_+=?Q1K2)M^ M'PV1[6=J!:!#%O6V8]J))=[>VG[$1[6CR(2W9^4_>.6U-6'TPD82#C1Z339E M/F)/J^?M6C-O.WK)!NQ(RPX.AD G=D17ST^\J.] MLU0D'D>>NWX,\J#I9E5-RD7!M"-C@ CTL=F.PI%,K\ACURCE>3WS6Q"34:+9X MKK&D3>1;1)$B@:00YB"5,]#4$8BD;WT86/J_CPZ*1]$(^M!&**EDBH:T#;W, M0BU/'*/6W^F$775!WVW&(:305;U9D)%5TV\K"IB5N35M9^:=97I@N[2!KQZT M#^]2T[O^]',I>DY+T!H''@_D@#OC[SQ,3RM=HN[D;_H]&O Z6)M??UZ*%>-U"X8[J*T0$1D4% MS%S:.\+C_2,<,?EODLE_<]127YFP8EGP'S]0@"']3][^+=/-9[ZQ]>C9>1UR M!__KF\!5)*U>4>9$8NA:>K-A+QP&L1_6AVTKT(+ 1H$\F\D[$X)M2;!7#]&HMYK:9D1(9K/Q[B,K M!&M'[<+ L4Z(9TK6YC?G$>:!T>B9Q=@W;*_KS)"0&#*#CM W+3$B02^)P#/! M"+]X=K4[9NK2W5K?LQ(15.CKW60I#G 41.H/P'>9Z7B3@LJ:L!DC2@*(GLFN M.WJE7>R8T(/TP0Z24SHEBS\-9N\!AJ4 '<)SDMP"<4(<+KVNRKXO!55WB%*? M.$A >JQ7CA=P1A%FQ6GP3'!5A MC3WSKVG_1GTM#MB=AWQ&'$M!FC,2!EW Q M*63X-Z9OV)U5[^Y]%W\2^PBK00B-15 7?ZP'9FW-Z^O9&!E#13* 4&3RP'Y$ MM+1#I MP>R.30IT.ZR!Q-&5[9B;"[:H2?QNAY&],2LTGJ7$YC=&Q:ZJA1Q/FXNK<$K MYVW-2R)#&?C%B8=R>];IYEV[U'P,"\*YG2Z]:6QAUXV=#Q'^'K145F'V;!QO M3?7XZU-V>>((X5;,D!T>Z4)T>&?(3(*=$ EN-!3P/=EXBQ2;=FXM_,Q/H6C4[1HQII"Q%6%J +EVEAH+AU%2:.DXQ\;%N8K$M>,X$M] MEHB3;S)]M ?[BJ!D8N\-T<72!AP;B9NZ7 L])#(;2Z\TG%2"D8Q6R,.] 3#O M$6.)L![R8NE(+K/#PG&S0WL!#+,*=BR3GJ0AP >'DMP'<92694X&2Z$\+H/8 MKC3F\R1H6.RB'ITLG!BG7%Z3^ A2D601N4BGTHMLWZ+/>% 7J<:-Z\L/P,R+ MI\^1*->VW0P1US5^7)ZQ@^(O&!$&%76HI/2-))NVO*5P[;!3H9@;LR,S8V]_ M03X\"I?@1V\79$F2VWM.$J3PJ1>K>PG"-)_7X MQ0%M2QHBQD].0Y:W>QM []1?2(P\%I@NSG.!^OQH*'D3LW*-)H%%=4,^^V!< M^O+5*-@O1P(-_"4 'L4%]JQBO,A+&@[# 9I ;+1^():>52]M;0#TXX.%=]8>#A NL'R MP7+ECN, *[;L,HI IF$%DZ"L$.(D&;T="XR$5:JNUNPPV&J)6_#2C^^OII) MLK]$":-!)+&A]CD4VGFT/-E::APVX+#\IMZ*E)7\E)*^?F+'=V='1*^J;52)]:D5:XCJDZ')-C 3H S3&*$<#)%B02\"]R=W(>\:;K@(N0/1PQ3 M5+2L$<8J:IC= W*RJN,\%,LYV('&X"CH=D4V@0"R0HSBYV>5E!(U]O7C>B[* M'X,P!*.8(17_,[^TT(J,DKX@55=VL3B()1$DH#K2+V=D6TM"/V@YL/T42&B: M9DYL*"-11>ML5 CY)(N+RY3J2WR>Y'H"8L.AJ(_O,H^1CJ$AE <>.2W,C]6%(\!_1Q@K@< MWDD/)_&0["/0O'F=0>9QG9@$"?QQ\UIA1$*E9_A,;&,+*\_Y#. \*6^M]@3G M)KY"EH;5PZ^IR'<4K\GZ1G]<"&))CMLQCI-54XV( M*Q?)!C@PH;"J/GL7LV[N[PKT9&JD&V^]UE#3XUBRS/J*+AQWO. (]%4*\(WU ML1_#&\0BZWZPD6_MI&,F!=?G4E@%\*JA_BR%_8.=B"\#1P2(31I M=8&R,PJGS^DI,_' K=W#&G0[>/ $Q!7N61N.6F:F)=:Z9X:0KDC4$H^E0_+ M'[%FBJ&488,1G*8OM2.2=G!B)!&F5_,#H'YF%Y2IQC:5%FB'6ZN>'* MXH/Y0_@!;6HE.=!1L"29+\Y)'Z\W0^(WR[E^6.GL@@2/(C93O.ICYR]BU#!I M81:>X[!KH1W&3:/*O9:49$NRDBDD"'=N$8*+FJ3D;'F3 1V@MH=0I+[ )V+[ M P.E-R?^A>2_E!H*I2V<%1$$X^6Y0Q,;G]KR3/6CM!>+TC2_C6&X\P4;%;&? M=@C)S^VI I^7?!QZ5)%Q7$=%]SR^JVU/-*JQ5M0OYBFL5 MOI^VVUV-6(B#MQ'5R7*TZ=^RLKP3Y7@6]1IPD?P$,X;5(9;6YSL&F@2=B MW)D8'Y>! +GI!88+W"&7E(PU.*7&HJC).# '$9V\\H*SM#(8LX>11";5"]:I @Q7@0TQ&J4!5!*8#IZ-XX-TM,FY MEC@OVO2 PPMK'#FWD([-FES$W%*_7,;GB>^"G+6UQWU!F5.1X1YN@FL&&3Y= MID<.H<@L=LZY54+HP$*C5$SDT[/O>E9==91( ?QL[3ZT40R"ML-(7[!VS$A@ M4A[%MP5W;$PP)@<%7*%%0P0R1&,4#)=5%>-@&?'4O)/J$].^2^E%]JIS?$C< M9\.#EU4_RC&K>J B@7@@5OI'3:&=BZJQ8Y(XD+N;!5?XC'"F24(I#TZVFC)Q M.L%=X_]U&HE*T!2AF.I%&4@(S=.FY<4H2CK XP:1[5GUALL0C' P4ZF5B3YY5I0CR/>B6Q%S MH5$K045IFDR)&:' I>@(%4")GDMA)/GM+<\49?2WB9.=7.1$TT:YVW)1%'K) M""R/2B7FE[JA(P-I;Y;&TCLNZK%,#JE6?GZ;SR)F%[FQDQ!2%/:8OU[)@AIX];O,V"7=3"=MC@LL[ LOJ31CX0)4EHEYW0]5ZW1:4-_ M*5:OA=*5[3:%1& QF=C>(H!J7)<4AYQ%K,"\&L.*>)'+,[N^\5R3^345%*+B M)ZG%!# 4=73IWR@BAS/@ZE:3W+&6([BZH<.JTKAK,%/$90<$BFA1$VU4Q16] M9E /E]\SS_EP61 \LTC_768$J9PF<@0W.QEZY0[D"EU!S]T_)'< ,-9II>>B FD[7.">8D?F@O%@800"UQ&1X5&#%Q)59630:07Y1@C M>HSJR3$1W>EV,MUF\I99!$7#)FZ>NC:<=8<\RG^T%G:9:V&71ZM8[\IFPNO< M3#A8$/NRI:IWGVI83*JN6AR-630#,2U=\(0EH0[+XX#(*=%[F^1 M11B)6D7<*2L$@ZU7O4/5U<;Q!:TD8_*L$>=V#^^XI"O]',ZRIS:8AE)Y_%59 MN$NK,;?VF27S15-^)6A45B=P4825^WY(G0L\>0[ KCH"@*:>BSO7== MER+1QH3A#M"*PXO<[=?^Z+0<$(.!M%.*"9KL0-A5I;I?XIOS2]-KTI4E@'[ M&&*5!DV6S)H)E^_&BH+(8Q:8KZ=<'+U/\N+&+M5*M MTT/3^X!I3E#(=WPCR M<)CV%K:&J_G*+CMI_L_$936V;D-BHW:VBH)DGK9 @?C.AJE&&>UA?/Y]R/T"5+:0 M&JC--:!@85LD:+0W8">W:7!-[A1GUO8A1%B6'AIQK-HJI?.0FW [RWUEQ9X" M9!1E(>V)H]#VHY3+$FCD R+'MM6M-*GB-G&,%P\\%-\;P[8FE07YD2BYD8.Y M<+VFP <&NEF0,I)2H54Q4];=MC)^6M8#VT4>KN Q(]R^H4/EC#3@&2-7+B84 M2/6QB-_'[EQ,$XQB#I/[=H523&TX/9-YI\5:RC;Z09%%[G>_Q*C7Z4V]YR-D?5-,D_J(P-A75<WJ]<"J#:[3U#U&#V;*KZY@K75.BG6SIAYOK=*=-TB.>)';I]HYL M+%])^T.GS9E5R4I6C/-7,C]/D--)E2&0\R.NY')([D1A9S88.%TH<.Z4I;2N M$6QY_[9M$!5A7;)@A[0%8!N\]]U*#/;5H6DZ&M\ATCL[!Y16TC;F\D1CLUZ6 M+R3U;PIEK3NY,")U8XW(9WY M@2;2&M'U7XK]I'/8VU-F.@27E?ZLN@I2&!N[H5@EY4]SBX?3+2]"DDW@AV&CC/]L^I])_;3[6;*B\)<&(\F MHV^2^\6QQ8UP3BA5HX/"Y4AG^K( <40PRDZ47W=L)SK4*@03\VY()7]V]/33 M&6ZPDB? 8<7^^')S,>VM6_+%A6>YRQT,)"/@H1\B73B^,70]_(G/$%I>M?VZN95]?2K M2MI$=MY_ERXI0!XPHF=19N185]N$G&.LS84[%$D3\BL!_7OV6.DHVS+*?0Y- M$[\QD.=R'O?;)5!P+C&WPQ9)\C"Y>)M'?QC\TP98B4]PST[9Y^!IKPE(9>66 M9N0-6SU]G&8L= *&:XB9JA!O/'H,=TO-H0SO&.CB8BKY%DRI?[#<:3(])_V3 M[CD^D"+6@%+/8H&2)SH1YJ->?!(U@0'HI'I,'47R'^/Y P_6=[PL6 M/9QIX8CV;7%[J)(KHER=3!.E;K& 14=F:I7FT,B0TBOE-TDHI"QN>M/M #/O M'Y3CWHOD*WMW1DOJ;=#FJK"X73G7),86[%JGUG0Q(8K >8A543K:*"\[+3*N M7=P*TD2ZJ'XG4:H1[8EQ>FW[9A!P^$/>0V00[^;R?)A5YWU8'K&]!5M2C_16#%JVA,@=7])$Y;+HR"26.9;"B"VAU2X/C$U8@$.+0+BQ#CHMR MVX?-C'/><9"[H,[?P^38GI_@()<;%7%P%'2F@JPFKL13'O=*YY9Y+\)H=;ZE)*Z,G#B2 MN5BTXIL=[-;- G:;M.+B"4_H?C6+D[0>/_;32/F);]"VPV!EX@*A01PA?2WX M#0WN=+M(<'DJM&$D&#ONSP0_25%29Q?0D\L!AN$#GS!D0N)<1]J/,8'6HC_/ MOW&!Z&=*[/>M@10\*38Q."LK):>8:%CS99E4TX[BC.JI_-_335%:O:BZ+'[! MI6F\W"&B3"O$KG=6*T9W6L7"CY'L:]9]YE'NE TDM;WW=?M/4*'',PWX:'&M MTVMZ4:#0B\_0QO\[9?SJ_TD9#P6A1\7OQ*TM!>)7/.W&OE9^,BY]FGYQ[TI^ M9RX_+C_7]Y;B.&[$=W9!KYZ?/7UR4GGY!3SYQ^ V_*MS&ULE5;;;N,V$/V5@5H4#B!$$B7YDMH& MXJ27?5C 2-+VH>@#+8TM(I*HDI2]Z==W1I)=+^HUDA?Q.F?.F1F2FA^T>;4% MHH,O55G;A5.)8#EOY Z?T?W6K V- M@A-*KBJLK=(U&-PNO/OH;I7P_F[#[PH/]JP/K&2C]2L//N4++V1"6&+F&$%2 ML\<'+$L&(AI_#YC>R24;GO>/Z#]WVDG+1EI\T.4?*G?%PIMZD.-6MJ5[TH=? M<="3,EZF2]M]X3#L#3W(6NMT-1@3@TK5?2N_#'%XCX$8#$3'NW?4L7R43B[G M1A_ \&Y"XTXGM;,FP-FBQ=K*/59W#]>?,-])."S MKEUAX:,EE/#YD=[:1&2Z\AD-N]N@M?_@N&H<_7F&;G-@FU]"79TF[ M+^G R3I#2AE5OG)O\*G.RI;"#*J&%R-SA"?,4.V[[!U7[9DE'7IXU.W&;=OR MF'GK4ZWHJG&PEF_P(&T!C\KV2UWA/!32[' CLU=[*3Q7!5P.STO!5)@5I\$Q MW>$64?\07WG41[)09@6K=V32&)VWF:.[8X]UBR!/NICF@ Z9=+C3AO/*N%7_0>34V7EJ/0;@C9PHMVLH01<7.% M;BW9V1M8R;(GXO[G((3O(1K'])WY"9T/;M-)RD'?J^$N+ DY!Z?IAC"&G35H ME,[!2DYD/$L@COU).(,X\:,POFS;D(GYVG(D9C69ND"HMK)6].E@R/=@XR2R93LXM"?A2%W(C_FF2MJ(TA#B"(_FB3<")%\ M0&B:3B">^I,D)QF'XDD2IVD*)6S(-;R>I!Z9_A_N!TTWW]FVTHY>TZQ;TZX*&-]#Z5FMW'+"# MT\_0\E]02P,$% @ ,8)/6#_G*L\\! YPH !D !X;"]W;W)K&ULM59M;]LV$/XK!W4H;$")1;W:J6W 29MV0 H$==)] M&/:!EFF;B"2J)&4W^_4[4K)J.XXR#-@7B3P>GWL_WG@GY)/:,*;A9YX5:N)L MM"ZO!@.5;EA.U:4H68$G*R%SJG$KUP-52D:7]E*>#7S/BP:$,83,H]^:VU'6Q94L1N1_<&7>C-QA@XLV8I6F?XF=E]88X]5 M,!69LE_8-;R> VFEM,B;RZA!SHOZ3W\V?O@W%_SF@F_UK@59+3]23:=C*78@ M#3>BF84UU=Y&Y7AA@C+7$D\YWM/3V9;RC"XR!AA@F%-0PP0%M:@_R]0==^)^)'EEY"0%SP/3_HP M:!P46+WC30;=[!QUX M9=;AE3]G"Z4EIMU?Y_Q22PW/2S6E>*5*FK*)@[6FF-PR9_K^'8F]#QTVA:U- M81?Z=%Y7((@5Z V#FXPJQ5<\I;90D-H:?8%9<7%J-"_@1F"X"L669J5$QI=4 MX^::9K1(D=GDHSIG=J=BY\U^0!7ID4+***2.%!*5[%(%J$00A4F>81M25X!I MPO(%DVVJF(\//832&U$I3'?5AQNJ-L!^5'R+$DU,?X-1XI+$PT40N\'00WPA M]85F,L>R; OG0#D_\-T8;P1QY 9A '>B6'?Q1T9 #*$["A-X$)IFKS"B"L/$ M]4B,J]"+K9".Y(C:Y(BZDP/[_K)"46_EP;GP=D*_'MXZ++Q80VVE/37^-F'M MCOU:BJK$>"^>,;X*7S']7+*KPZ)\&>I3B@^S'*/(_[;YK#1\ED(I>"SPF9J=0I9"(A,LL!P5W+$MR\#'=""^YT;> MT*2(E^#W_;NA3_P/S+1T>GO=B/^O;,<\,P1 EYSF3*,0=+6J+# M]B(2S&7$]SWHC?IV1T9 L"1(X+=X^_^>_G@YOX2UV#)9F X)^.@7Z?-A,/?P MIPBG?S]R"<&2#8XH00PSDP(7"YH^H>?^ S 91F=I5O4':=O[&8T)C (WCB*( M"?3"OMDE^+1%0S="I?9 /1+Z?4,,1J%Y]MAS4]FPJG[%C^Q;S*D>#=GTG63T MXK0AO]4PL$V$Q*Y,=O1(T#_I(XD;DA!7Z%L\3^*D_T9[&1P,'Y@L:SMB*4A% M5>AZ#FFI[10WJX>77^SU"(B3Q]H41<96>-6[3+"=R'JLJC=:E':460B-@Y%= M;G 29=(PX/E*"+W?& 'M;#O]!U!+ P04 " Q@D]8.\G$?Z<# !!" M&0 'AL+W=OTRP:4*JZ16EJ)4'C8AI8@9#2.>X/]ZA?_&Y4RYS8?!:-=_KRJZF01% MA0O1-?9!;7[!;3Z>8*D:XW]AT]MF/("R,U:U6V=BT-:R_XJ7[3GL.13Q.PY\ MZ\ ][SZ09WDCK)A-M-J =M:$Y@8^5>]-Y&KI1'FTFG9K\K.S:]6NE:G]":D% M7*.VI"1W* MP&=98?46("+& VV^HWW%CR+>8'D."0N!QSPY@I<,QY!XO.0=O+?Y/F C+%9P M4YNR4:;3:.#/R[FQFHKHKT/Y]^CI871WL2[,6I0X#>CF&-3/&,P^?F"C^-,1 M[NG /3V&/GNDBUIU#7K]WLIY*Y]16J5?#W$^BGJ8\X '?Z#0O9I 6F [1SWH MX7XXG%(9V97JC)"5.8/O=#F!EM9:+0G/P D4(4\2^N9AP7/X4LN:ZKB"I5*5 MH<4\93 .>9S"-V5%0\Z[X"P+QWD*+ _CA,%7A^:TL;BLRSVSLA'&U(N:,(4! MJ>1/9:>G<4XB&6!%F(X*8"R,QP45*2$@6/%"6VOQ MZEX98&'!4BC&0Q1ZR"G)I2=/[>,)K9N5REC""_.<09JD@_6=D-V"+FNGG=7U MUBK-,LH$/K^4M?$!]\+%>0$?/Q2<\4]444NJA@42GRSEP,-1GL"]5@NJ-$IR MMY<0/4X9]KJ-LA3R4;(M)7'TK$\@8^&(%S1(XC ?CP^64K3WK+>HE[YY436J M3MK^A1]6A_YXV;>%'^9]<[T3>EE+ PTNR#4^SZE\=-^P^HE5:]\DYLI2R_'# M%?5XU,Z ]A=*V=W$!1C^-QS4J4S![J"A7M%-I(YFAJUK&M#+(\.$D1IX/!)):, MJV@^#6M+,Y_JV@FN<&G UE(R-O3<&G\E*ZY]^\CZ?10-/" 5FSB,P M^EWC*0KA@8C&KQ8SZD)ZQ_OC+?I9R)UR63&+IUI\Y;DK9]%1!#D6K!;N4F_> M89M/()AI8<,7-JWM((*LMD[+UID82*Z:/[MIS^%_'-+6(0V\FT"!Y1OFV'QJ M] :,MR8T/PBI!F\BQY4ORI4SM,O)S\W/D5*R\.(36PFT>]/8$:C?BK,6X*0! M2/\"D*1PH94K+;Q5.>8/ 6)BTU%*MY1.TE[$-Y@=PC#9AW20#GOPAEV*PX W M[$_Q^V)EG2$5_-B59 ,QV@WA.^/85BS#6432MVBN,9H_?Y),!J]["(XZ@J,^ M]/D5=5I>"P1=P'O5-)I7+$U;[@MKJ3^9RN&$LHM* 6)JUP!:[4M24WNP]XDV'ER,H# M$P"[1D/M#$SJ6CF[=PS?D)E&'4"U1;E"T]77?U(X9;:$BO&<@AB@&\?0":CU M#C)/(=T?ODK"/YV,X1(SO59\>UZ/LP-B2Q1+IHB31W^(>>N17KT,>$?)!+ZV M:1QLTS#HK[8[,@Z-A G(1O/=X)%?SFWF#P H%82CPP$\@Y'_]@AFW EF_-^" M.:M=3?6Y((ZREHU@8,ENZ>*DRM9TZ@8^:'5PRE1&):8NAX_=^3;RVB6D7@*[ M^V%A/9]'%=Z'HJ$H6XK-.58/*2JBF-U1_$,"_Q A:8PBC:B(R7@,G[1CXI&( MNGC>Y!RM!2ZKV@N6*ZHI6@PJZ#QO1M9HEF' M=\="4$1S.7>KW=.V:&[T._/F7;Q@9LV5I? %N0X.7U)I3//6-!.GJW"_K[2C MUR(,2WJ>T7@#VB^T=MN)#] ]^//?4$L#!!0 ( #&"3UCEI&KK@@4 ,T. M 9 >&PO=V]R:W-H965TOV1+ ME?4N.TL,Y*U=@74-DJ[#,.P#+9UM(I+HDK2=[-?OCI*5M';W-K%\6!@\CE6PGAJ@36-3)6NA*6NG@W,0J,H MW*2J'(2^GPXJ(>O>^,1]N];C$[6TI:SQ6H-95I70#^=8JO5I+^AM/MS(V=SR MA\'X9"%F>(OV]\6UIMZ@0REDA;61J@:-T]/>67!\GK&],_@D<6V>M($]F2AU MQYUWQ6G/9T)88FX90=#/"B^P+!F(:'QN,7O=DCSQ:7N#_L;Y3KY,A,$+5?XA M"SL_[0U[4.!4+$M[H]:_8.M/PGBY*HW[#^O6UN]!OC165>UD8E#)NOD5]VT< M7C(A;">$CG>SD&-Y*:P8GVBU!LW6A,8-YZJ;3>1DS9MR:S6-2IIGQ]<4!-0: M"[BU*K\#4;>MN2H+U.8GN/J\E/8!#C^*28GFZ&1@:5F>/,C;)*]J.S=P51=8? DP(+X=Z7!#^CS%$7A,CA1<_@M2[^ M=38Q5E.>_+W+R08BW@W!VCDV"Y'C:8_$85"OL#?^\8<@]7_>0S#N",;[T,>W MC61 3=MMNBY%#6>+O9?IPC3%5),I7U#"QO=ZM5^0\:4(M'&7&T MEK29&BQ-"GW:8F9T#!^6UEC*(4;XX"88^&U9342;Q%2U'"KW**<#:;:9P)B_".1B15BQP^B7*) M<"AKHJ>6AOB8(]=]0*';YI.1*K3\%'(;]*$F.>'[@Q5EGD?.*94D6K#@JKE.4C'>8 M)@%;AX$7I/N81+ZBP4LA5EJI"N0->QD)\:W;21)>E?5HE0/B W8I=0D M2J7-+A'LY_R-?.=\7F]\$:TOXBM?=.?+E'U9.5\FSI?J:U_4EX74@S\IW9H; MPJY:YTJQ'P:/ =U%8@?P,=Q(<_=ZJA%!T@<6+FB6 *?6 03>B/[[5*H.Z!C: MU#34%:1>UFB 6G'7BMI69[M2I;"R9.G3?C?YN7#'6!)Y_@$DJ9<<0$HK'-#^ MK&2!'"DF0(/-WY9/CCL4;+0ODO JB+R4)$=G"ZZL7IQ77Y6YV^=6S<5"6E$2O8+RB?Y6M*BB8%$Q\=U-8.B["I11O"C5."<$ M79PA"8%.:ZI]I'BBE,^=9 I<8/*GC\3GS9N'WGNA M9W3T0(E3FDJZH--9-X^GIF/5PCU8)LK2\\1,T&-#Y5RFXZO$#W@AW_ M"U!+ P04 " Q@D]8UX>_ $@# !8!P &0 'AL+W=OZ4?3(%IX;H4TRZBQMILGB2D; M;)D9J XE_:F5;IFEI=XEIM/(*N_4BB1/TW'2,BZCU<+OW>O50O56<(GW&DS? MMDQ_7Z-0^V641<>-![YKK-M(5HN.[7"#]F-WKVF5G% JWJ(T7$G06"^CFVR^ M'CI[;_")X]Z5LLH=8108&D= J/A"6]1" =$-/X]8$:GD,[Q M?'Y$_]OG3KELF<%;)3[SRC;+:!I!A37KA7U0^W_PD,_(X95*&/^%?; =DG'9 M&ZO:@S,Q:+D,(WL^Z'#F,$U?<,@/#KGG'0)YEG?,LM5"JSUH9TUH;N)3]=Y$ MCDMW*!NKZ2\G/[MZ3^?^5I:J1;A'#9N&:817']A6H'F]2"R%<(9)>8!;![C\ M!;@LAW=*VL; &UEA]3- 0MQ.!/,CP75^%?$.RP$460QYFA=7\(I3PH7'*U[ M>\.TY')GSM+]>K,U5M/]^'8IX0 WO SG:F9N.E;B,J*B,*B?,%K]\5LV3O^Z M0G9X(CN\AK[:4 U6O4!0-=RJMNLM\W>9EI<.[A+]JP$NT__0(-1*4+V24&#= M70#3J+T!2W_*GWE(XL$#CXYX&*\H-0M 5C9NBZMJ#E^0Z7 E@ X4VRV9'@_5 M?7+WR> 5EQ1#]8;)RL2 SR5V]@RWHBO^&M[W+6IFE9Y[%0[1F;6:;_M URK' MLR6*5$'E8Z-$A=K [Y"EHW@X&_M9%N?3J9ME>3RBFWN'4E&)!>3/OIZQ^I,] M4; =!@8&>D,Y!'B2 5U+X.7_53C&]J2SM(A'XY3&<3R93BC<*!Z/"KCCHG3&>'&19;^ M,N'*A:6MJY2S+)X,! M!=;DF@XFHPATZ.-A857G>^=66>K$?MK0TX?:&=#_6BE[7+@ I\=T]1]02P,$ M% @ ,8)/6*#/.5>2!@ U!$ !D !X;"]W;W)K&ULK5A=;]LX%OTK%YZB< V%O5II4F )IG9G8>9*9)V%HO%/M R90N5 M1"])-^W\^CVD9-E.%3=;[(L^R7//Y3WW7DJ7CTI_,FLI+7UIZM9<3=;6;BYF M,U.L92/,N=K(%F]*I1MA<:M7,[/14BS]I*:>A4&0SAI1M9/K2__LO;Z^5%M; M5ZU\K\ELFT;HKS>R5H]7$S[9/;BO5FOK'LRN+S=B)1^D_;AYKW$W&U"652-; M4ZF6M"RO)N_XQ_5X]]E M[T_B\ I5&W^DQWYL,*%B:ZQJ^LE@T%1M=Q9?^G5XR82PGQ!ZWITAS_).6'%] MJ=4C:3<::.["N^IG@US5NJ \6(VW%>;9ZU_;0C62/H@OTM#T@UC4TIQ=SBR@ MW8!9T&?FZ7-%W':6[RA2U,ELMZ5_O%L9J2./?8SYWB/$XHDN7"[,1A;R:(!^, MU)_EY/KU3SP-WI[@&P]\XU/HUP](O^6VEJ1*ZKDO)))0TMX31G>X,K8J2+1+ M@DPAPG;,DY.VQCWYL):T/(0O.WB"]8UJ96N-XU8=<>OOK)?3H\0383"Q1NZ; M"_JG%+H3""&\LEE(/838'4)WX#2M6K)KM36P:L[V/KXB'B8LS;F[XBF;9_XJ M3%D4S'?>TY0S'L5G-$WGP9F[BX+P[,D2'M%T$#%+DJR'Y9T!F$)AHQ.A3(90 M)B\.Y>W1XAV(=2;/' M<\3G"$ MWX#@R5Z;3VPE*44!@!&=AE (Z3G-WC-.=@?(0PHO516LSE'*6I0%%*8N12_>[,07X5X!"*J2PF[,\C9 *JOCTQFUO MEG[Q4"N$WS5U9D.,S5+B&*,@KG ?V!$J$I94F6 M(2]YF/7:' L"#S ./#)WBNE/46\[R\)%1;2%A-@3+%7FBCG6R@G^* X[\Q5\ M?DI-NTW9&U6^V1K96:1I%/BR$9R-L3H$.QCY.R:.L7^%B+ T<*4*R^W6^40F M94,F92_.I'N)VEN 4;@J:U5^NN@M(,NXBO"KH'[EH_>'P=!]R1,.-V_%LWF[9W//>6%O,N8*5(F">;0!+H2=UL, M-(L,AWU7[!BYNX;E;T*/LBUB8 MNTX2)3'E:$O/IBE:4YYPSRCW?0$-+ 73+A.G<>;;5>!R*!]:Q8_U@_F@XOG+ M=SUKT:X0"$3J1M0^J?'T;QJED#ZV3CBHW7_U7:'?"(WVA9,FGU>M6*VT7+D@ MB;;=PO5B3\@I;[$GM?*DMH>DG$[[^/U(TQ@3Z8U<56WKTFAGVNT]61RZ2I)C M#^""DK$8.UQDM_:UK/+-GS;*5"[FQC?XC:YP['9S'%]A282*&CDJ?I+Y_BS( M HIX_=,\Y.';X;P#&)^//E-IT=UCS;KD\LM75PW:4O=FFB7!M\BG_2GZK9'C MYA(D=FG"HP1=+TVC[] ZFOS4[NZ,6#U9]XBY,'T3@+$G@Z_+-YU7^K[X=W_CM^$A@8,&E6)J<%YADV^[OXA=#=6;?QW^T)9 MJQI_N98"Y<0-P/M2*;N[<0:&'SG7_P502P,$% @ ,8)/6"FD=S4U! M;A( !D !X;"]W;W)K&ULK9AM;^(X$,>_BI63 M3JU4-0]0^G" 5)H]W4JW%8)[>'&Z%R89B-7$SMD.;*7]\#=V0B#=D 4I;R!Q M/'][?AE/QA[OA'Q3"8 F7[.4JXF3:)T_N:Z*$LBHNA4Y<'RR%C*C&F_EQE6Y M!!I;HRQU \\;N1EEW)F.;=M<3L>BT"GC,)=$%5E&Y?L,4K&;.+ZS;UBP3:)- M@SL=YW0#2]!_YG.)=VZM$K,,N&*"$PGKB?/L/X7^P!C8'G\QV*FC:V)<60GQ M9FX^QQ/',S."%")M)"C^;>$%TM0HX3S^JT2=>DQC>'R]5__5.H_.K*B"%Y'^ MS6*=3)P'A\2PID6J%V+W&U0.W1F]2*3*_I)=U==S2%0H+;+*&&>0,5[^TZ\5 MB".#X=T)@Z R"#X8^,,3!H/*8'"NP; R&%HRI2N60T@UG8ZEV!%I>J.:N; P MK36ZS[AY[TLM\2E#.SV=4<44$6LREZ" :UJ^#1Z391D)YMF2;3A;LXAR39ZC M2!1<,[XAX#6Y"D%3EJIK$HDLQZXQ89S\D8A"H:H:NQIG M;<9VHVJ&LW*&P8D9^@'Y(KA.%/G$8XB; BZZ6_L<['V>!9V*(42W9.#?D, + M!D3!!N-8X[\TOM2S5@E%)"WS?3E?/6@Q#\\W]SN<'=0O>&#U!B?TVM[7/[]C M)_)90Z;^;7LAI>*P7=%DHB>5TP@F3FZ"1F[!F?[\DS_R?FFCU:=8V)-8@^2P M)CGL4I^^%MD*I%D/5:C8*YO MH!Q(S53N'XS$13L=CMWM,;C.V5P*KB>Q!KB[&MS=F>#VBPM31B8D$)U0?HV8]NUMH.Z^ ^5_ M -4Y^J6@>A)K@!K5H$9G@L+ONDFHN&BK]%0&D[UL@S3Z(:3.D2^%U)-8 ])] M#>F^$]("E)8LTH"?*"VB-_*\H])$U&+YK$PP?5K.YVV,.F4OS6I]BH4]B35P M/M0X'WK_/CST2;)/L; GL0;)QYKD8V=@EM$HH/KTS,YY9O60CL<3$A8W[&0(T2LHBC.2%C!(L M[F-RA;5D69B9E7ZR1)M5PW8EQ.Z978JQ+[4FQZ,JWN^./9KBNEW %G@!-^05 M-XS?R(O=/B#>%\$C_'#(LKA?,/6&3YZ] MJH5]J36Q!P?L0>_)LY+L"V>?:F%?:DV M$H.DW)_6K?6AR;,]*OC0/C.'*7:#?Y I3V*^4+EA7*'G:Y3T;N^Q8)7EX49Y MHT5NM_LKH7'UV\L$: S2=,#G:R'T_L8,4!\Q3?\'4$L#!!0 ( #&"3UBT M/<@O+04 )X8 9 >&PO=V]R:W-H965TR)EFB;B"1Z)&TW#_OO(R5%%XI6 M8\3K2ZS+^0YY/O*[B)D=&7\26T(D^):EN;@=;:7K-F M/,-2W?+-6.PXP4EAE*5CY#C!.,,T'\UGQ;,EG\_87J8T)TL.Q#[+,'^^)RD[ MWH[@Z.7! ]ULI7XPGL]V>$,>B?RZ6W)U-ZY9$IJ17%"6 T[6MZ,[>!,AI T* MQ)^4'$7K&F@I*\:>],WGY';DZ!F1E,124V#U)6!5WBFE%+X(<(2 MSV><'0'7:,6F+PIG%M9*/LWUNC]*KMY292?G]UA0 =@:+#D1))>X7(T\ 8_E M3M#O'NDFIVL:XUR"NSAF^US2? .6+*4Q)0*\;V'O4K651T1BFJJK*_#U,0+OWWT [XKQMVPO%%S, MQE*Y3SMA'%>NNB]=A4ZX"B+PA>5R*\"ON5+3)1@KO]?.1R_.OT>#C!&)KX$+ M/P+D(-V@VPHA+PN*NJC MIG[HUZ".(K]6Y \J4C%]H%412;%424(RE?C_JVD5=[<0F;G1 O+]T!1G89J> M2"6P:?+@8(/SEI)6,7=R]<1L12R@T,R2-B(T/:&LZ:W@<'/UIJ)6<7>GU*MI M-I3G^Z8\&^I418--IP6'6ZUS:AKLMT,((5.-!62&860!M<*P*Z5IJ^!P7_4; M.Q">ZS5267BE=J%]OPV2G)US+\D678JMZ\"F?X/A#ZQM@\WBV7Z^)%MT*;:N MGYLV$KZZCWQM;;.U@,ZTER9M,!B:GVP6V-2#Z$3\-0TE'.XHWU;AIOV,@";( M-Q7V8>XD]'K)T@)S0^=$-4!-]X<&NYZWU+F*N9._?3/++VRHP*QT-A!TO/"$ MNJ;G0L,]UYMJ'>IW35>>-W7,#LR&4TOHNZ9(&\YI\W55-HT8&F[$SJEX%57G M#&3BF0NRL,'ZX1E98>WP+!6-6P>W&5$?:?H 7( B"9?'B/73^I#]KCA:-I[? MPYNH/"IO:,J3^R_JVX_F J1DK2B=ZU#-B9>'X>6-9+OB>'C%I&19<;DE:B]P M#5#OUXS)EQL]0/TOB?E_4$L#!!0 ( #&"3UA:C3#@/0( &$% 9 M>&PO=V]R:W-H965T<1.?YO_]C9UQNE/ZP52( M!$^UD&825$3-;1B:O,*:F8%J4-J5K=(U(SO496@:C:SPHEJ$211=AS7C,LA2 M/[?26:I:$ESB2H-IZYKIYQD*M9L$<7"8N.=E16XBS-*&E;A&^MZLM!V%O4O! M:Y2&*PD:MY-@&M_.QB[>!_S@N#-'?7"9;)1Z<(-E,0DB!X0"[S[C/QP/F M2AC_A5T7.QH'D+>&5+T76X*:RZYE3_MS.!+$YP3)7I!X[FXC3[E@Q+)4JQUH M%VW=7,>GZM46CDMW*6O2=I5;'65K7DJ^Y3F3!--2(]H#)P/OX"O3FKD3@S<+ M),:%>9N&9'=TNC#?N\\Z]^2,>PQW2E)EX*,LL'BI#RUICYL<<&?)1<-I6PY@ M&%]!$L4W%_R&??I#[SM(?N+P9QIO(*ES >G_TJOHX^7 <]8 C[SX\ [C C;T86_0? ML,<]]OCBN2XE)\X$L ,N-*BY*DYQ7G8:PS,R;4XQA4>_?8VZ],5M(%>MI*X" M^MG^_9AV9?,OO'M\[I@NN30@<&NET>#&0NFNH+L!J<87T4:1+4G?K>P;B-H% MV/6M4G08N WZ5S7["U!+ P04 " Q@D]8BG\ '%<# "T#0 &0 'AL M+W=O:9F5J+UYMRV591 2M69V$"&3U9"IE3C5*YMM9% X\(IY;;G.(&=4I99 MX;18NY'A5.2:LPQN)%%YFE+Y]Q*XV,TLUWI%.7!ND#".WQ6H5>]I')OC1_3/!7DDLZ0*YH+_8+%.9M;8(C&L:,[UK=A] M@8K0T.!%@JOBE^PJ6\ZZ#7SGX M!=$RLH+6%=4TG$JQ(])8(YH9%+DIO)$-RTP9%UKB4X9^.KS84L;ID@-!29 % MQ<$W*A] %VL+B'+)- -%:!:3SY1)?N>O#7NWQ.1*XQ136V-:3'D[*A*P669 N^)%%Q!=$9\ M]P/Q',_O<)\_W]UKN]M8C+HB7ET1K\#SG\1;ZD;B/Y"+P]3]O$8G\E5#JGYU M$2YW&'3O8$Z&<[6A$OA):986 M0MAKKXMPB3(L4,S)M0W]\PS&3V!M9(1U,D(>I%GB1(T=#<9 MN0W9E4P.K?S 'S\ASE$=XNAHB(M$2'VJ0:;XV:@/]OW9VQ7N4<27UJ9C)[ 6LF8U,F8]"+6R8$,/=\+#M1Z:.8'0W_@=\O5=?8-B7,T MS&N1K5^HU^.(+ZU17VAM_HV&S'UUS59;])60GM#:"=GW0^[1#N/9NJU@FE_W M(9ZR__< '6:#R6#TGVSM1DMM[C/8%*]9I@B'%;HY9R/TE^45H9QHL2FZ[*70 MV+,7PP2O52"- 3Y?":$?)Z9QKR]JX3]02P,$% @ ,8)/6#7HF/L9!@ MCB8 !D !X;"]W;W)K&ULM5I=;]LV%/TKA%<, M+=#$(JD/NW,,I,G:%6B!HFZZAV$/LDW'0B31HVBG&?;C1\F**(D4+2'T2V+) MEY?G7E+G'EYK]DC90[8EA(.?29QF5Z,MY[MWXW&VVI(DS"[ICJ3BFPUE2/5 M"(Z>;WR+[K<\OS&>SW;A/5D0?K?[RL35N/*RCA*29A%- 2.;J]$U?'?C>OF MPN)'1!ZSVF>0A[*D]"&_^+2^&CDY(A*3%<]=A.+?@=R0.,X]"1S_E$Y'U9SY MP/KG9^\?BN!%,,LP(SB%%WBUOP^M4;\ I$*?B^I?M,S)+-QEP$EL,;K\H@WA^# M0!U!W)+5)<#P+4 .PIKA-_V'H^;PL4AGE5-4Y105_G"GOR6OA?RVE9$LS\A? MG\4@\(F3)/M;%_!Q!E<_0_YLO\MVX8IZ^JT:5/ "([R/C&89 MN$M%S8X+E!]%K=9R9J"!.6EA5&UR M7AFU3X)L/P?1;71 MPHDQ^ 7$+H,8F M\ ,]Q&D%<6J%DJ::!&HH234S41)T9&5V7DA*X#^Q1]F.LMQJ247M%'<^DP.) M =)64>.$0Q]26]Z:Z:D)%WAVTBJGL)402]Z:"9&J QKK> _B*AW4MRI$CN>T M64%GYT''GW9L::D%H%D,]">OTE'CX7."-D[5J.NIDTH FJ7 /XJ/>FG+Q&J M)A<^\CI RGH-C16P-X.5;EH+/H%>&Z;&SG-!%:Z:2TV5""J9J;%1K63O+FF]N*ON\O%);BG!\+2XDYX3]+5 M$\ADT\-(:&8(@\_ZYSCL(UGA$3Y_[\,H(@8GQ)*W9D*DGD!F/7&:T-!I&:$Q M01Z$'4YCCN"2+K@"B+*C(7U5XL=BWRRB^6X>I!A-*;NXP3#WY4+7EK MIDE6=C0]/W<9QG$ M+^W*/XNO[ZRXI]5<4!N3U=Z]+6_-/,DJCL_?OL=6^_>VO#43(D4#?FD+'ZM" M8(I]K]T7T9AY$Z^K(&.I&;"M)CY6)8'?_J%!8]-%#E(R8&MM?*SIT;MMB+I> MO]MQ/,.R8F,[G7RLGK*G.("HC5(U\R9XVM$%_H$;C1I(I1UV[73Q2_=>*=6 M6C73K?2X]K)0_J;6EY#=BY4#,=F(<P5+I!S-'M/!8"FF&T=S:ZCR.33['DIDC5:&D)U.E2V9IJF>QJ32RPH-* M$6=)THM+QF4T&OBU.ST:J-H*+O%.@ZG+DNFG2Q1J.8S2Z'GA"Y_-K5N(1X.* MS7""]FMUIVD6-RP%+U$:KB1HG ZCB_1\G'8=P._XQG%IML;@I-PK]> F-\4P M2IQ%*#"WCH+1WP+'*(1C(CO^6Y-&S9D.N#U^9K_VXDG,/3,X5N([+^Q\&)U& M4."4U<)^45Z;Q)!7ANKRC68+"BY7/VSQ[4CM@!I[P5 MM@9DOP*.7P!TUP#ON7AEF9=UQ2P;#;1:@G:[B$98+\XY6OTZNX.V;=_ &N(1;+@0%S@QB2W:[T^-\;>/ERL;L M!1O3#&Z5M',#_\@"BUV"F 0WJK-GU9=9D/$*\R/HIAW(DJS;8M#X]? L8$ZW M"4+7\W5?X-OXM0.73#"9D^M]$G_4JJZXG'7@FDM:YTS Q#+K'0]C5KE<,/#C M,S'"#2V;GVW^71U_W'Z\JQ3GIF(Y#B,J!0;U J/1WW^EO>1#FV\.1+;CJ>/& M4\M(8>A(T])8]\K(N*56MRZ GJ%!S5;39&";*^E#ZE[\M%$'HGJ'H-0I[ M^RCL@)DK;=]3G$HP3?UH$Q[F3^$)F6Y3'<3MJ;K?J.X'K?KNOPM8 %N@IN_< M:P(<9@S%-XC<4^EIH_0T'%\N77S;! 6!OUM.#D2VH_<7CV9POOV2$]=2"R M'4^ER>:BD 3?A\]*SL!G=;FY(&P2O$,EV5T;R6=-3K1^ZL.GI-U .H2Q^WI@ MZZJ4OJ;BM:H*(G\WT(=BV]69;71F?S8KUNR>*M;J)$/?--EH%!GD^5LL\3=T#3WH[^!U!+ P04 M " Q@D]8<>!,0M0" #H!P &0 'AL+W=OICVXR=?6PK$SVVGA MW^]S$K)>THI)>VGM^)SCNJ],EY%2?RP($ MCLRERJG!KEJXNE! LXJ47I6+Y5<5[]DW6 ]AZ2E-C)OR.@@ M9Z+^IR]-'38(?G2 $#2$X+V$L"&$5=#:615K0@U-ADJNB;)H5+.-JC85&],P M85=Q:A2.,N299"SS0FI6E53.R1B4P:4GUY13D0*95COIUD"NR1G9 =^*%0@C MU2LYG0#2N/Z$H,?IA)R>?"(G!'4>EK+45&1ZZ!IT:^=TT\;9=>TL..!L NDY M"?W/)/""L(,^?C\]V*:[6*.V4$%;J*#2"P_H;5?D'C@UD)$)TRF7NE2@R<^K MF38*]^6OKK"U>M2M;L_JI2YH"B,'#Z,&M0(G^?C![WM?NJ+_)[&M0H1M(<)C MZLD3'DN[M(62"U3O7-E:H5Z'?[:[?NNL?=?<-5Y+8[6M@P=*_-DG*J=9LSK"F5!,AQ5E: M*H6#70'Z>];.!D&T&Z #Y7L7AQ+$;8+X7^J[8_R(Z7A_'\:AM^-Y']3W/6_' ML;MQ#]LW\#M5"R8TX3!'FG<>(U_5[TK=,;*HKN:9-'C15\TE/L6@+ #'YU*: MMXZ][=O'/?D#4$L#!!0 ( #&"3UBQ!MO"? , /0* 9 >&PO=V]R M:W-H965T0"ES7A(!V=*Z:QW\UL%O M CV1-6&MJ:+)0O C$=H:U?1#DYO&&Z/)2[V,]TK@UQS]5++B1<5EWJ249V0% M0N':DVO*:)D"N6^VTHV"0I+WY*O:@R!7:2IJV)+/.=WD#%U!DK=K0#\FWZ'5 M]_LU>?OF'7E#4.C;GM>2EENYL!7BZDGMM$6[/J%Y9]#6D%X0W_V#>([G&]Q7 MKW?W7KK;F*0N4UZ7*:_1\\_HO4S)'3"J, GK7*:,RUI@$GY<;:02N#%_FH(] MJ0=F=5VME[*B*2PM+$<)X@!6\OMO;N3\:0K]?Q)[D0B_2X0_I9X\K7^*6P?K MF>J]8PKXI!(V*KJ;'!(O#,)X81_ZD8RMW#!TW<[J!6+0(0:3B!_Y 42)W49A MJ]G@0AFWWTDCZD\]"Z+9 -!@Y3KSF1DP[ ##2<";$K,'1-%'W#<5_44W#$R( MH0'1#0:$8Z/9W(P7=7C1JY88VRU^VA$L8&PZX@&4'J5<*F-"HS%M'+L#VK%1 MX =FW+C#C5^%^X66=8;U5PN-N3J'&8\Q@S <8(Z-/,=,.>LH9Y.4?SVFN6S6 M?&K%9V,X)Q[NR;'1&;9YQS:?9/L,.\I(!N9"F8^F"P-O@#2V\:+8-U.YSO/I MY$QRW0J>@=1WA@F\5J,_M]^K@/:P&!MYY]J,VSL]W4F^YD0T,KFCZ:)P6+@& MHS@ZE[/G<\J=[/[)-ZXP6;2M"5VZO#FWV?-Y;23V1ITX="-ON/4,9KX3SX<- MQ^Y=2?1]\ L5N[R4A$&&?LY%C +B=,4Z#12OFEO*ABN\\S2/>[R6@M &^#WC M7#T-],6GN^@F_P%02P,$% @ ,8)/6'("B(I$ @ .@4 !D !X;"]W M;W)K&ULK53!;MLP#/T50BN&%MABQTZSK7,,M F& M]5"L:-#M,.R@.$PL5+8\44FZOQ\E.T8"I$,/N]BBR/=$/E',=L8^48GHX+G2 M-4U$Z5QS%454E%A)&I@&:_:LC*VD8].N(VHLRF4 53I*XG@<55+5(L_"WKW- M,[-Q6M5X;X$V527MGQO49C<10['?>%#KTOF-*,\:N<8YNL?FWK(5]2Q+56%- MRM1@<341U\.K:>KC0\!WA3LZ6(.O9&',DS=NEQ,1^X108^$\@^3?%J>HM2?B M-'YWG*(_T@,/UWOV+Z%VKF4A":=&_U!+5T[$1P%+7,F-=@]F]Q6[>BX]7V$T MA2_LNMA80+$A9ZH.S!E4JF[_\KG3X0 P'+T 2#I \EI V@&"Q3B73TW5&%)!4K."*5K'5P\W4LNZ0)B' M3KIU6!&\AV^N1 O71.@(SF?(H9HNV/$XG\'YV06< 6/OE-9,1UGD.$%_3%1T MR=RTR20O)#/#8@#I\!TD<9*>@$]?#T^.X1'+TFN3]-HD@2]]@>]8A ?4TN$2 M9HH*;6ACD>#G]8*^/T&Y1Y&_?#,?QYU.E M_R>R(R'27HCT7^PL;.@1 IX:4+!7%5*#LTKJD[?\.^G'Y?Y7U!+ P04 " Q@D]8_#DEU7H# #B#@ &0 M 'AL+W=O M>00@T%,2IWQB1$)DIZ;)@P@2S ]I!JF\,ZN^&S8=TUS$)(4;AGB>))@]SR"FJXEA&R\=MV01"=5A3L<97L =B/OL MALF66:F$)(&4$YHB!O.)<6:?^K8.T"-^$ECQVC525AXH?52-RW!B6"HCB"$0 M2@++OR6<0QPK)9G'WU+4J.94@?7K%_4+;5Z:>< 0&.N?]&J&#OT#!3D7-"D#)89)"0M_O%3":(68(^V!#AE@+,> ML&T&MPQPWQK@E0&>)E-8T1Q\+/!TS.@*,35:JJD+#5-'2_LD5>M^)YB\2V2< MF%Z!A,;1 'W#C&&U!FC?!X%)S#_)WOL['^WO?4)[B*3H1T1SCM.0CTTAIU8" M9E!.,RNF<;9,8SOHFJ8BXNA+&D+8%#!ESE7BSDOB,Z=3T8?@$+GV 7(LQVU) MZ/SMX4Y+N/_V<+O#C5LM@ZOUW*W+P#G =++<8!\X $CF7XS?E_)L>A20,+_ MM($OA+UV8;5MG/(,!S QY+[ @2W!F'[\8(^LSVW0^A3S>Q)K /4JH%Z7^O1[ M!NIQ3A!:8W-91]0RQO;M6YXN&'8<=<'^2V#[-J@AI%19634 M:>1&L4D%6N(X!T3GB*XYBPE^(#$1!%JWI-&&.WMHKYGKS![XGL0:LHPK6 M42>LBUSD#-0109(\03RB3 P$L*1DE>%G>5P+KK^-AZ$QB5UX] MB35X'5>\CCMYG04!S5/],-T)>:AA%G)TGX58@"1DCP96V[$PZQ3==;?M4\SO M2:P!\Z2">?)>Q]=)GT#[%/-[$FL M:W7[S+K'0ZP4K3^$F_LU>?=,^^*J2^U M)J?:]ZO]KH=$*3_L)M:9P\[$>E(KB)FUC_\$V$(741SIW:WXG*YZJT+M3)25JL**B*AJ"9+C$>J) %B[Z,9!$* M3 V0]^>4BI>&FJ J:Z?_ %!+ P04 " Q@D]8HXG)0_ " A" &0 M 'AL+W=O/ M,D-4\%3D3(Z=3*GRRG5EG&%!9)>7R/27%1<%47HH4E>6 DEB047N!IX7N@6A MS(E&=NY61".^5CEE>"M KHN"B.&+>2[M+VSK6,^!>"T5+VJP5E!05CW)4YV'/8 ?O@((:D!P#.B_ NC5 M@)XU6BFSMN9$D6@D^!:$B=9LYL7FQJ*U&\K,+MXIH;]2C5/1->H<2.B W;\. M7W76$F$B)2H)A"6PP)PH3.":DB7-J:(Z^GR.BM!^3I51"G]X?;3FJ*/KM%.9&7\F2 MQ#AV])65*#;H1&_?^*'WHF6F)N?##=C-A8R8\:>;! MEC!,.F2CLZ_U"C1E_647%(JB3?!IVA *>T_;3MR_( ^\#1MOP[_SEE 9\S53 MH,\9MIFJ^"[W,NQUO8NC;6@-ZA]M@[M7;0L4J6U"$NSR575J9IL^-['E_6A^ MJOM?U:Y>:*KF>4-$2IG4^[32E%YWJ$^&J!I2-5"\M#5]R97N$/8UTSTW.3:6#AV9E]:^/8[.R'J1JCVDOAL__Z.%!E0RCT2@)*RY4D*5^;F&R M5#+D'JW2P8!Z\3]V)3HIL(L[3F&U@"/M8+0U'8LQ2B F6% M5LS >A99!BQO+.JJ Y.#2JCVSY^[<]@#1-$[@*@#1-YW*^1=SCGR+#5ZQXS; M36QNX%/U:#(GE"O*$@VM"L)A=@N4DF6G[+K!Q@"[$TI43<7\/%OP%RH 6G8\ M!^1"VA-VQ(1B#Z5N+%>%34,D$XXJS#O!RU8P>D=P#OD9FXP_L6@43=CCVYCG, KK@%LP6 M@NSCAW$R^GK X*0W.#G$GE&^TR%/+2KV*-="VVP0;;EL@.GUFZ.0@J^$%"A@\#22@9*,_[$4[O6<>[[NN-D( M94E@3:C1V6>"F_9): /4M6_#E49J:C\LZ14%XS;0^EIK? U<9_?O&PO=V]R:W-H965TO^K991> M]199MO[4[Z?3A5P%Z<=X+:/\+\]QL@JR_-=DWD_7B0QFY4RK9=\>#-S^*@BC MWO5E>=]]O]=H;[?,8L;]VUN=E@\^?S!/02KO MXN5OX2Q;7/4F/3*3S\%FF3W$KUS6#\@IO&F\3,O_D]=ZVD&/3#=I%J_JF?,U M6(51]3/X7C\1>S.,WIO!KF>P3YUA6,\P/)S!>6>&43W#Z-0E./4,SJDSN/4, M[L$,MOW.#.-ZAO&I,TSJ&2:GSG!1SW!1QJ'Z]RO_\;T@"ZXOD_B5),74N5;< M*!-4SIW_FX=1$?;'+,G_&N;S9=?W>;9DDL@9>S()PF?Y,?B)]DBZ"1*8DC,C7*,S2L_S._/:OBWB3 MYEIZV<_R]2R6UI_6ZW17K9/]SCI9Y',<98N4^-%,SEKF]X[,;QN ?OX$[9XE M>_LLW=I&\6:=?"0#YXS8 WM(OCYZY,-/VH.O?K0]5#/LR>E'8E6PU0GV3H"' MUL$:KY=!=)+NGZ[;G5:;G@YW>SZ8&?X<),WGHX7A9N9+_)(S WW]6AAQ.C-H M9[2<#G>OYF'I#M]Q'XMGIW[E;E^X__I'/A$1F5RE_VY9T]M*'+6+Q7OMIW0= M3.55+W\S367R(GO7?_V+Y0[^WI9V).8A,1^)423&D!A'8@*$:5$>[:(\,NE[ M;TQI\79TMMT !)ML$2?A?_(_?,C?9JI[?R8_WM\RW!H7U#7A2,RK,+?$BF'I MR[4UJ/Z[[+_LI_?4"2ER]1@2XTA,@# MF@=K"ZAQ>5T#BL2\"AOOY6[P<3"P#M)YTE04N6(,B7$D)D"8 M%DUW%TWW?]IHYGNY:98/QL-H?O)6T[BDKJ%$8I[;V!@>;BZ/3D&1*\20&$=B M H1I81SOPC@VAE&DZ2:(II+$SV0:KU9Q5*62;-;Y3?E=)M,P+?\:KXL#'^G) MT30NMVLTD9@W;@3/'CI.\_T##FVE&E:YW[W4DC+HR\O,LT*)Y\P?QQ9$DZS[?:A3E[+XGS"VO@'KP@6J:R+==U#C;;;9/9D^'!9 SY #@2$R!,"_'%+L07 MQA#_&F?!DH11GJDH#:?UF'5O^[L-8MLQMUNCW35A2,R[:&QTAVYSD]N3!\:$T2!,FK$JMFCMF3)S74,%U;Q: MVX_"R&X$QF^;;&@WDYD$U'ZI1J,:@&H=J J7I(;95B&WX ?J:1(4:J7E0S8=J%*HQJ,:A MFD!I>JA5Z609BX#K+W%T7NS35#LIY\6Y![-BCW\MHV)7J=S#*6[+UG1#^R>H MYM7:_INV-6J,!GWH0BE48U"-0S6!TO38JH+),C=,OY4GPLC9>? BDV N\]WM MXNR@8M][NP^^EDD8MX]AF_25F?U'._2::+?*M,[I=!U)IF: ,%U3RH MYD,U"M485.-03: T/="JU[)<_+@9VF!!-0^J^5"-0C4&U3A4$RA-#[7JQRQS M05:&^ORV'"[?[0^7;Y(DB.957_#T1O:GNP_>RKMO7H-D=D8^!]_#U69%U 9_ M\Y1.D[ J%AZ"K'W,#2W0H)I7:Q?:R02')QQ %TFA&H-J'*H)E*8'7I5HEKE% M.SR$5Z4X)1\>'F_2MM,H;\U@YZ1"BRVHYD,U"M485.-03: T/=*J4K,N\ ,3 M:)4&U3RHYD,U"M485.-03: T_<,.JL:SS37>'SJ@9[:[IANJ>7:SA6MV=7[+ M5,U"#[IB#*IQJ"90FAY&U?O9YMZO&BG\4G?)OZ@S&5O#!RT H9H'U7RH1J$: M@VHE95*V>;6ZW M'JM//&0RRC>Q4CM?=QJG67F*[=$3=]/.9^Z>'&AH;PC5O%K;C]^Y9;5!-H#0]SJK,L\V?4MN5%47@O#RMTSS&9'\_KS5CT#H/ MJGE0S8=J%*HQJ,:AFD!I>JQ5G6>/\;MVT"8.JGE0S8=J%*HQJ,:AFD!I>JA5 M96>;*[NO4;YYCN=1><&%DP\!0UL[J.;9S8^0N>/&V[P/72B%:@RJ<:@F4)H> M5U7'V>:/N!V-ZQEY/3SM\_C)GN:%=LXSM+ [\H1L3_8<;4_V=-\]UQ.Z7A2J M,:C&H9I :?H5GU19-S27=?; LK?##1%-\[V\XA)MY9D5[Y[O:2:[!AJJ>5#- MAVH4JC&HQJ&:0&EZJ%7I-[3@8^DAM/N#:AY4\Z$:A6H,JG&H)E":'FK5_0V- M-%I] *ZX*&-*?I0_6W,-K?^@FE=KVH7)#D;2T 52J,:@ M&H=J J7I8=V[DJ2YT_.WK=TZ":>2!.4%S8K113%DSB/\K'W4?[_U.R-13,HC MS-GBG41CKSF)O>ADI5V8$HV]EB3V8I+8JTEB+R?Y9S2#0]4,#LW-H/]]'2;5 MSN#[NWIFHW,TH?WT"CSSN M;70)=,0K5&%3C4$V@-#W:JB\<'JG'CH]+/N=)7VU6K=F&]H)0 MS8-J/E2C4(U!-0[5!$K3OT)#=8.C 7PX,H)V@U#-@VH^5*-0C4$U#M4$2M-# MK;K!T2D?"*P_27)VPA#$['5.-+08//)8K7((TAI>: <(U1A4XU!-H#0]O*H# M')D[P%,&'-4U75J3#*T"H9H'U7RH1J$:@VH(T/6@4(U!-0[5 M!$K3TZLZQ-&1:X$^WM^WU"O'K[UE=CNG&-H70C4?JE&HQJ :AVH"I>G)5J7B M"']1T!&T081J'E3SH1J%:@RJ<:@F4)H>:M4@CHY<%+3S8 -:'T(U[\AC-1S= M@#:%4(U!-0[5!$K3PZN:PI&Y,5-G.!>CBNJ" ?F HSAK20;3175R$EG7ER/O M\ W.T!(1JGFU9CH%&KI "M485.-03: T/K>E?+N6,[,G!X &Z5%IK MVD7K!F.GKD''PGYT [.:CF034? MJE&HQJ :AVH"I>FA5IV<8^ZI;C;9(D[*:\H%JW@39:TIAO9P4,V#:CY4HU"- MU=K^L*1Y=(.W3&4U/VPN4*NFQTZU:8ZY3:L__9_([H69TRREW+:KKM^U3%@^ M$XTI/?/*=LX0M!*#:@RJ<:@F4)H>256).>9*[*[X"H5U/D*MFMPBCK-XN2P^ M);F[MTCF3Z1O2N=%X^5GVX?!K*:9: RZH1J$:@VHL!5Y^7BO[;.A79?4,V# M:CY4HU"-034.U01*TT.MNB_7?(G+DW;KS4;G%$/++JCF0S4*U1A4XU!-U-K! MUP7O[T#K^50UEFNNL?[ _K]9[IQ::*L%U7RH1FM-^ZK&B[9OJX,NED,U@=+T MV*I>RSW6:R&.$9@7TCG!T*8+JOE0C=::=MS$_CB9'.876F%!-8'2]/RJ"LLU M7ZNRT]$$:'4%U3RHYD,U6FOZV0/-LQ"A"^503:"T*J7]="%EY@59<'VYDLE< MWLGE,B738EAZU2OVTW;WY@."YSS%UJ<;N]=OW.]9GZA5W-]7S/7E.IC+ST$R M#Z.4+.5S3A;'4GLD*:[LM_TEB]=7O7P_\RG.LGA5WES((-_E*R;(__X&PO M=V]R:W-H965T,/XDE M@$3/69J+B;.4OB2"% M2&H35#W6< UIJBTICI^U4:<94W?5RX@P=%,.< M%JF\8YN_H'8HT/8BEHKR%VWJMGT'1860+*L[*X(LR:LG?:X#L=/![^I Z@ZD MY*X&*BEOJ*33,6<;Q'5K94V_E*Z6O15Z_5DD\@6=H_MJXA";UVUG*2'&V4_'ODA5"C:,J3UZ5QZY4'FDN-ZKIKRIZTD&/"?K*50_+2%X3>:\< MR>L8Z9\B>P2NH_EMI1>HT?W*A&\VH7?LA5C1"":.VI("^!J^_X;#_IP70 M;P!]F_7I%2R2/$_RA5KV:J8C0*=JMBK_/Z'_C)&HJ"N[86E7IX7UE'AX-!R[ M:P-.T. $5IPZ2FC!:2[5>CT4)MB#\?"@@R5L6,*#6. 9>)2(#]"$>S3GQ L" M,\Z@P1D\,WF\T<=I#LZ@:WIZELAA:35;-;49^A'*7H0GZ/+-7"EXNBVWA%H MQI,(C(#X%^0T3%H_R!%9+69I2KE *Y61R]CJ(+=9W^A'-QU!+J5 M!6Q-ZL8\=PQ>-0K&KQ9"KW,AM*J [;)@SGW'$/K[A!CW_$$'82L4^#"EL*3# M8W #0T!Q#X<=N*V68+N8&%+D,7BA(9IA=S1;;<&'B0S[[(5$I:\2)V\=K2(UK3\X8^VJ%/.^C?L1Z@%]"S-$)9]8F/?133 M%]NG-VG5C%A5YB/H9\BP XS^V(>L_;'AMR)&[")V%/Z[F\/HE!UD;Y*\=^>H M%4)B/R!=+A8<%E0"^J)<2G*11.@[30MS\'_%28FTHDCLHMBR)@WK6K/JS&+D MK>P%N\>2@8])ASR35OS(8>*WFZZ[& Q'(^(-<4=:(ZVBD<..1^^GXRZRT! = M@H.WQS9WY^(C [XHKW>4\+,BE]4=2%/;7"%=5AK#4* 4YJIK MOS=0@_/J2JF90L*U^70&/@NH'Z?\Z8W!;T ,W%VO1_4$L#!!0 M ( #&"3UA:2X48' 0 )$/ 9 >&PO=V]R:W-H965T-JYJVUWESYOHK7D!+5 M$QO@YI^ED"G1IBM7OMI(($DNE#(_#(*1GQ+*O?DT'[N3\ZG(-*,<[B1269H2 M^7H-3.QF'O;V _=TM=9VP)]/-V0%#Z ?-W?2]/Q*2T)3X(H*CB0L9]X"7UV' M@17(9SQ1V*E&&]FM/ OQ8CNWR HMZ?RH*7YEQHY/;\S1@ I(4$/6L0OB/"RM18L :E^01^^9E2_HDOT4!P< M$DMT#TI+&NM*;&&-:Z>=WX FE*D+(W PZPSY2*V)!(4H1X^<:O6N,?#G6F3* M )C!LS?]J:_-5BVP'Y?;NBZV%79L"X?HL^!ZK= 'GD#R5H%O;%09*MP;ZCIT M:KR!N(?Z^!T*@["/'A]NT/G917-'Q<>Q4K\ZDGZ^4K]CI4624'MC"4,W5,5, MJ.Q <4%U'>YUL> [<1 2UV1";HCA'>!NO4>**-1Q7OR'D3_LC29Y!M#M=&.OH? M2,<5Z=AIV6M849X?_C,QAHP!G1L'+ESB OW5ZAP%=:%WE.NU*60['PR'4W_; M A-5,)$3IF$LE<>=E23<]OXM4W3 -!I.VIDF%=/D.*:M&3@":7* =(FC03L3 M#NK@'QQ'%=NS8\ST;2(P27\)]!C, M;DRDR4UI;5KGM=9]%.M$#;N&_=X$=UBV3BG8'?J=CGL*9[$Y\TN+PI^"- M#^_IH-=U3>OT@J,?]$##SD1UJL/7.0>[D\Y_>*-]1_/^D195C[3^]QYI89V5 M0G=66JQ6$E8VG-YR>!MLJ6_8?$1,7!155CV]*%8_$VE"J4(,ED8TZ(W-TK*H_XJ.%IN\YGH6VE1P M>7-M:F:0=H+Y?RF$WG?L E45/O\;4$L#!!0 ( #&"3UBO\/X?F@, + M 9 >&PO=V]R:W-H965T(AIX*T2I)][2F.K&]W6VQ(+IGJRPI#=SJ0IF:*H6OJX4LMPY%<*/ M@B#Q"\9+;SIV:X]J.I8K(WB)CPKTJBB8VLY0R,W$"[W=PA-?+(U=\*?CBBWP M&=F.?%&'N0X M9RMAGN3F7VSX#"Q>)H5V_[!I; ,/LI4VLFB<*8*"E_63O34Z[#E$@Q,.4>,0 M7>H0-P[QI0[]QJ'OE*FI.!U29MATK.0&E+4F-#MP8CIOHL]+F_9GH^@M)S\S M?22942G,X=G([!58V8R64N2H]%]P_WW%S1:NX+FN#)!S^.;DQ/SJ=HV*J@-N M-=5-93.I'<03:A*>E08^,:[@*Q,KO)I1?G)X0*97"JETC :J6_C2^/VCR)X, MC(3[HA)RBUB#I5Q1E4BEX7V*AG&A/U X[\ 'O60*]=@WI(3EXV<-ZUG-.CK! M.HS@099FJ>&^S#$_!/!)PE;':*?C+#J+F&+6@SC\"%$0Q1T!W5WN'G6XIY>[ MAV?8Q&U5Q XO/H'7YI?LIBL%]2?ZW9^PQ]F-KEB&$X_. M*XUJC=[TSS_")/B[2[[?"9;^)K #:?NMM/USZ-,GKE^OY@H1."E'^ 84,]@E M8 T4UDFWY_=Z&O2">#0<^^M];;KMPNLCN[3;+A@FK=T!HT'+:'"6T?U;1=O3 M;EQ411>/\^X);)'1WAY!46])VIPYVW;MZKO+D/H[I*A_"BF]#"EN8QIU(!VH ME;1J)9>IM9:"&2[LV4HGJG:G;Z5XUED*->;U0>8&\5$=)%WY'23]Z_W?44UT M^B3!L+LDABW)X5F2*5_S'.GH/E7:PU_Y')'Y7XOTG,5!U*,VZM'9J'\Y]=SI M1HDW"'-[C:W=-?;BKK'BYS4&[WD)N13"EDR%JKZ6/G3QK@,8[<4&ULS5A-;^,V$/TKA+IH=X$D^K1LI[:!.$K1!;J M$>^VAZ('1AI;1"122]+VIK^^I*3(ED(+2:%#+I9(S3S.F^'0PYD=&'\4*8!$ M/_*,BKF52EE5:SQ/W9)M*/6$O9@7>PAKDMV+%U4>:R@-CCWKP.9E;CK8(,HBEAL#J ML8=;R#*-I.SX7H-:S9I:\?3]&?VWDKPB\X %W++L+Y+(=&Y-+)3 !N\R><\. MOT--:*3Q8I:)\A<=:EG'0O%.2);7RLJ"G-#JB7_4CCA1<,,S"EZMX'45@C,* M?JW@OU8AJ!5*5]L5E=(/$99X,>/L@+B65FCZI71FJ:WH$ZKCOI9VX-G%9F>B=,='U MT!=&92K0'4T@:0/8BF]#VGLFO?1Z$2.(KY#O7B#/\7R#0;>O5_<,ZM'KU=T> M-GX30K_$\\_@W>5%QIX T!KXGL3JF6(.EP\OHG.!;K*,Q56D5!3O(69;2OY5 M8BO@A&EI(07Z^P^U OHL(1?_F,)5F1.8S=$'U;4H< QS2YU$0MD$UN+GG]S0 M^=7DZB'!HH' 6F$(FC $?>B+*BG.1'C@DBVN$T'@#(P'4Z_Z6W?ZD M0& MMXT;MXW?UX$S'C(,0X)% X&UPC!IPC 9."$G+Y)HU,FSVY=)UC'>>\ MKZ2L[1DH$H.B14.AM6-Q4E.[ V=F#7B:5.XH<+K9:1)3?_[=##6)!:X3FK/4 M]8Z\O/X21UW/"-U>H"U0X(JBSE>Z^L]K=';1X'Q0M&@JM'8MC_>[V%_#_(VM?EMF^'TS";M8:JO'I:-PM<4UB MDW'8S5K[Y+*? ]^631.A;-U165V!F]FF,7-3MB,Z\TO=L"F;"$>8JMOS!?,M MH0)EL%&0SM58V<2K!DHUD*PH6PH/3$J6EZ\IX 2X%E#?-XS)YX%>H&EC+?X# M4$L#!!0 ( #&"3UA?#!0.Z , %L. 9 >&PO=V]R:W-H965TZK*]O:S(0-$ M3>*<[<#NO[^Q$U)(#>W>P0>(G7F#W_/SV![ON'B6&P!%ON=9(2?.1JGRSG7E M<@,YDSU>0H%O5ESD3&%3K%U9"F") >69ZWM>Z.8L+9SIV/0]B.F85RI+"W@0 M1%9YSL2/&61\-W&HL^]X3-<;I3OBH?!+;<-DN2YE#(E!=$P&KB M?*1W,34 $_%W"CMY\$PTE07GS[KQ.9DXGAX19+!4.@7#GRW<0Y;I3#B.?YJD M3ON?&GCXO,_^R9!',@LFX9YGW])$;2;.R"$)K%B5J4>^^P,:0H'.M^29--]D MU\1Z#EE64O&\ >,(\K2H?]GW1H@# U/ /P&X'@0,\6F8\%W1.AHS*8?C)@&C?330L_[7 E\FR).3?]":WTNECP'\@""S#=, M +DE<_174F5 ^(K<\[RL%#/3A,T#Q/6?7,J; ^!U#(JE&?;=DJ=Y3*ZO;L@5 M<8G4;R5)"_)4I$I^..CXNN&59$6"G5='[;&KD)\>I;MLN,QJ+OX)+M0G7WBA M-I+\7B20'"=P49A6'7^OSLP_FS&&98_TZ0?B>W[?,J#[]\-]"SQ^/YR>8=-O MY[IO\O5/S765@V"*BSN;MC5V8,?J\G,G2[:$B8/U18+8@C/]]1<:>K_9=+ED MLOA"R8XT&[2:#%X@0[)2"LGJWS M!R:_KL+;*?6"012.W>VA8K8PZH]&QV&Q)8SZ ?7;L".606D M-X)+>N.2R>(+)3M2+6Q5"\]ZXYO95""Y95M<5VO85[5*0M(8! LGZ'TI79+B MQ4DE%LR]>^JZF39/\L8F?SV,\,@;_2#T.A:RA87#T;!C(4L8#<*@;[?0L!5C M>%:,.,TJO8436*UP3]<[!>1EQG\ U$N$\%)O(9)@<2=5L06)TI''^9-\B_[P MU8!'=.1WR+\.BN@PZE!_'81"4L_.?-0R'[W+!N0-&R1:(>SZ'T886::.#@== M+6QA011V2DYL"?,Q[(01HE:.Z/PNIK;YITHT.I[KG=6UCB?)Z4=!QC3UJ:#<-/3B'TK?K M!ZZ.GR!%;0/I1T>?+D4;YE6%M$=%'8KNP:D;#U9KG_P)02P,$% @ ,8)/6!/:_& 5 P = L M !D !X;"]W;W)K&ULS59M;YLP$/XK%I.F5MI" M(&];ER UI=,JK5W4:.N':1]P M!/T]7TB0:AI,I=@2::R1S0RLF!:-X3-NTK[4$G<9 MXG1P@S?KBDDQLJ)349(2CZY%EPGBESR&.(F@8M!U)'XNTCF_E'&$*(>&7CO MB-_W!RT.73P?[K? P^?#O2/1#.J\#"S?X #?.=YS?%>L?%KU)OC8 MP\NTV=?XJ.,OU;@CLH;&HUKCT5&-EUI$#^1;):P69%'(*,$2;FYUAFI:@S:= MCO*^],YV219V1-;0WK% 9><%W^H=>K=>MX;CNF)^MS;"G+ M#O ?3=F/7E.Y9BAO"BND[/.5$RURV_7<"XT]E!TFV!:#- :XOQ)" M[R;F@+K1#OX"4$L#!!0 ( #&"3U@EW1J+U0( #D( 9 >&PO=V]R M:W-H965TN:#C@PH#JR@T\+W%K3*B33LW:'4^G MK)45H7#'D6CK&O,_5 M,+]HU\=Z#LI;(5G=@Y6"FM#NB9_Z/!P _.0%0- #@C$@>@$0]H#PM8"H!T0F M,YT5DX<,2YQ..=LAKJ,5FQZ89!JTLD^HOO:EY&J7*)Q,;VC.:D /^ D$.D=+ M]5H5;06(K=&"U0VC0*70,S($HM,Y4%@3>89.,Y"85.),01^7&3H].4,G*A0] ME*P5F!9BZDJE4I_EYKVB>:$&1'Z!;1F4IT&=:0/&6.#9Z^'^$3?A<&.AX0O_>V,H(R*OF&@YH!_7*R&Y M^HI^VC+>,49V1EU9KD2#QDG']4%;@]S80GSD\GE*"RSL26A-QG"GNF/ M!_WQ4?VJ\*FR1FWR.V!R<."Y[X?12+TE*IEX(^TVJM +[-*307IR5'K_$J] M-2[8UQ:IBY#-36))7Q3'ER,[EC _\<=WEMG88M4E1X[<@Z): ]^8YB10SEHJ MN]HSK [][]J4_='Z7/7%KHW]H^F:ZBWF&T(%JF"M*+V+2R6*=XVJFTC6F-*] M8E(U C,L56\'K@/4_IHQN9_H X9_"^E?4$L#!!0 ( #&"3UA.-F)RWP, M .8/ 9 >&PO=V]R:W-H965TD.7/F4W/M4.5RF" M:JHJ#Z[P!+*(J*2>OXMR%UVF=6@>?';^Q_&?/:S N5L.3% MSSQ5VYDS=E *&=T7Z@<__@V-(2-PS0MI?M&QP7H.6N^EXF43K!64.:O_Z6N3 MB+, '%T)\)L OQM K@0$34#PW@#2!!"3F=J*R4-"%9U/!3\B4:$U6W5@DFFB MM?V<5>N^4D+?S76J*O(-%GM.3ECC-@2B*>H=--=+< !EFN[M%= M HKFA;S7\.=5@NX^W:-/*&?H:$KC:4NO+?_.U\ <9$UB/4(#_0+[G!Q9!R_>'^Y;PY/WA>,!-T*Y2 M8/B"*WS/H]4(99""H 52U5H]V))E%D5Q^UZJ-!]4]U_^[:W$2]YV,2A1V52PL*>]CK>.FC)C'!=B]QZR4> MK,"5H@H&2B^^9>G=DBRY$=E%UL9MUL8?+;UQ;Y'B<-)9R64?- EQISR3/B@@ M9]5Y(7S2"I]\N/ FEHJ*2'?3L*#"H%N=B8TK)G;MV#M]T[UW%)X\O;+6+[+7 M>S:9]&S84/JCUK%A004X'%_Q<=:;X,&BTYV=[MO80-DU!#>JNYNR);=BNTR> M?TJ>_]'::R(O=ONHN_!]3-#=:"V8:_LL/K4Z>+ 9&"R])O2B7K ?]+1;8"2: M=-7;4.3*-P^?N@T\W&[4Q9>=O[I6*\1B!8^[.Z -1H*>%1O*N])\X%/W@8?; MC]K*3O!#;N8\;4HW^F8FN.XK[/5!>$QPW/5E@9$X[NZ/-IBOMZF.,_=L "I! M;,P@*=&:[YFJ9X;V:CNL?C4C6N?ZHAIBS6!UHJDGX.]4;'(F40&9IO1&L=8D MZJ&R/E%\9\:L%Z[TT&8.MWH0!U$!]/V,<_5V4CV@'>WG_P-02P,$% @ M,8)/6'?RQ7[& P :@T !D !X;"]W;W)K&UL MK9=M;]LV$,>_"J$50PO,D:AG9;:!UD'1OM@6Q&GWFI%HFXA$:B0=I_OT.\JV M[(BTE@)Y8XO2_TZ_NR-YU'0GY*/:4*K1MI*3JC)K:#X,@]1O"N#>?=O=NY7PJMKIFG-Y*I+9-0^2/3[06 MNYF'O>.-.[;>:'/#GT];LJ9+JK^UMQ)&?N^E8@WEB@F.)%W-O(_X>H$38] I MOC.Z4V?7R(3R(,2C&7RM9EY@B&A-2VU<$/A[H@M:U\83J:FO =*\ MRB\/0)_V0.$%H!M:7J$(_X;"((PT*:N\E=GLQ:_%:M:2D,P\6FZ+RB7KS7W_!:?"[*\0W*PF<"V(8EF?(UJ 4EPUG7O-^G\FMWC:1X5,=3@Z3PT M6Q3G^4GT CGND>-1Y 5IF28U^Q?*9!)"9+GI^%O AXE<"J6=Q'NWZ1E,$>0# M8%N#"XS=P$D/G/P\,'V&K;EB>BO=Z4TLD!1G:3# M551&J>)FS?M>=-1WKLC M8PDK@;ESF=IYPFD^++^M*HHTZ9 M11'B-$L'K+8*9T62NF'S'C8?A?WKM) H$*.:D0=6,_W#Q9G;QD.E"Z>P9V"2#8%L48+#S$V$@U.7"D:9[@6L%].>AYNQL\$$=N6" M-+$FHT.7@2R^ 'O64O$H['=2;_6IM^"=ZVW$B,O?N@]^TP;V5MY>!GUH<'N]QPT4HS5EO(E:3+0RZ>>5,0637 M(1KNOR[1Q16)3QT.C[W_Z$$\-KUVIB'0B* M( V2(:@M2['=U_RS@[#Y"OF#R#7C"LJ\ KO@*@,'&PO=V]R:W-H965T2P=CS?;"?E9Y0":/)0%5W,OUWI]X?LJR:&DZDRL@>.=3,B2:AS*E:_6$FAJ MG4<6\QLW,W2J$U94OEX"878S;W0>YJX9:MB2%C&X*?2MVOT--R :8B$+9;[*K;0./)!NE15D[8P0EX]4O?:B%.' ( MQR\X1+5#]-QA^(+#H'88O-9A6#L,K3(5%:M#3#5=S*38$6FL$G'-$U$"^9,^@"(_DX]42FK^"?(F!DU9H=[B[/U=3-[\^';F M:US1^/E)C7Y9H40M@%\#+6)-WJ*]S+J1(PA.2.#\!V) M@FC@".CJ]>Z1PSU^O7O8P6;0J#^P>(/7J/_/'WB77&LHU;\NJ2NHH1O*Y(<+ MM:8)S#U, KD%KS%3S^$X^ 7ETQ]@L4]@;4D'#82#KO0C828[Q00QLF6%AM: MI9,"$QKE";B$K !'%M#DQ>TB# /SF?G;0XT<=N<.N]AA-VS;M9B-&F:C3F;W M7$(B5IS]#RG1]($L@4/&M"(ZIQKSZ:9("2M164T@R\!F4&N(K["3>+7>^##0 M('(Q[PSLU*>C)["6AN-&P_'W:[@$(K),X2:[?"24)#GEJU.>I_&1K-'4I6IG MJ*>JVA-82]5)H^KDVU1]A_MX(CSEAK44+S4"Y2$V_2FIZE":>D^JR:)$Z;TB==Y*ZH@7#VI S2N[T"TFA$^'4 M;:5/L+@GL)9R8; OC(+^]N8:JR<5>T6+^T)KZWA08(:=S^!'S*MX3#%E)5^1 M0BA%$JPR'_&YW%&9.E^F&O+P;1J-QJZD)KR[4OGL/.PG+Q M2><@J\3FEJ77BKE7M+@OM+9T^Z(Y'/:8W#HK\)-U[!,M[@NMK>.^1 ^[:_1O M2FZCHVU^XGQ7>ZW"^T*KA/(/.@XER)7MW"!WL>&Z.LPWLTUWZ+WMB3R;OS1= M(]O)V,-4+::@C0&>#\3 M0C\-S )-+VWQ!5!+ P04 " Q@D]8*4:\8*X# "Q"P &0 'AL+W=O MF_KR0;!XQ"\M 7L.2SQWMVM:L=[QA_$"L B1[K MBHJ)LY)R?>FZ(E]!C<6 K8&J-R7C-99JR9>N6'/ A3&J*S?PO*%;8T*=Z=CL MW?+IF&UD12C<5,+]HUV(]!^4;(5G=&BL/:D*;?_S8!N+ P!\^8Q"T!D'?('K&(&P- MPM<:1*U!9"+32#%QR+#$TS%G.\0U6K'I!Q-,8ZWD$ZKS/I=(4'2W8AN!:2'&KE3.:Q?,91/T#? M&94K@3[3 HIC E>I[J0'>^G7P5G&#/(!"OV/*/""T.+0S>O- XMY]GIS_XR: ML$MD:/C"%Q.),B+RBHD-!_3?U4)(KHKK?UO$&\;(SJ@[SJ58XQPFCFHI O@6 MG.F[-_[0^V2+UM\DR_X2V5$DHRZ2T3GVZ?U@/D!E>]BE*0PLD>CJ@*LC;HMF MPQH;5MUNM]-@Z,?)V-T>ALF"BB+/.T9E-JX@]CO4D;"X$Q:?%39[A^OUIPRI M D1,KH"CG$-!I+4:&ZKA@0<7OA][HYX<"RSU_:@GQX)*XB2URQEVC. M!*JKF'-O\O014753JJ:US]X"*)1$VO0-3UP*1VD_6190&/1S=0H*HC2V:TLZ M;J&ZW$8UU44%2$E4%[TP3=DF)CGU,SAPH1%S"HK"N)^I4U":>G8M MHT[+Z(4\L?SA0E_.Q8M"1J<'10GQ>THLJ"0=]?-B0:7Q<&07DW9BTK-B_M5U M8_,\/?U:E(0]QRV@P.L=NLP">NXX^=[3->^=]?N.254/:\ZVQ(QL:F(\*AWK MA>R=="%_%/G](K'!HJ2O/;/!5*%$/67NP2Q3 U^:F5"H@[.ALKG;N]UN[KPR MTU9O_UK/HV9&>J)IAMGOF"\)%:B"4E%Z@T3YQ)OYL%E(MC83TX))-7^9QY6: MJ8%K@'I?,B;W"_V!;DJ?_@%02P,$% @ ,8)/6+_5ZHVA P &@P !D M !X;"]W;W)K&ULK9=;;]LV%,>_"J$50PNTT=5R MDMD&8JO;^E @<)KN8=@#(QW;1"52(ZG8W:?O(:6HUL5.L/;%$LES_CH_'EZ. M9WLAOZ@=@":'(N=J[NRT+J]=5Z4[**BZ$"5P'-D(65"-3;EU52F!9M:IR-W M\V*WH(P[BYGMNY6+F:ATSCC<2J*JHJ#RZQ)RL9\[OO/4L6;;G38=[F)6TBW< M@;XO;R6VW%8E8P5PQ00G$C9SY\:_3GS/.%B+SPSVZNB=&)0'(;Z8QH=L[G@F M(L@AU4:"XN,15I#G1@GC^+<1==IO&L?C]R?UWRT\PCQ0!2N1_\4RO9L[EP[) M8$.K7*_%_D]H@"9&+Q6YLK]DW]AZ#DDKI471.&,$!>/UDQZ:B3AR\.,3#D'C M$/0=HA,.8>,0OM0A:APB.S,UBIV'A&JZF$FQ)])8HYIYL9-IO1&?<9/W.RUQ ME*&?7GS@J2B ?*('4.0=6>THW^(;XV1)<\I3(&)#_I!"*7+/):1BR]E_D!D' ML@0.&Z85>9V IBQ7;U#A_BXAKU^](:^,QJ>=J!3EF9JY&H,UGW33)K!E'5AP M(C _(!\%USM%WO,,LJZ BY0M:O"$N@S.*B:07I#0?TL"+PA' EJ]W#T8<4]> M[NZ?H0G;Q(56+SRAM\9<\)3EC-K]@UDZF9^WY/TAS:N,\2VY*43%,66W(#%E MW'1I@>,4UU;CM@9=2:[(WVN1YP1WUY[*[)^Q#-811N,1FA/K6I4TA;F#1Y(" M^0C.XM=?_-C[;6SV?Z98\I/$.IF)VLQ$Y]072]@R;F?VH=Y"8U-72TRLA#F; M'Q>^'P63F?MX/"=#JZL@G':-DJ'1-)KZK5&'8=(R3,XRX+& MX@"LXDUKHE2 M*&;6F2)XU9!2,OS]"E2.;NQ:.NZP!3VRH).)SV8U="HCWO.HH-[V>)>_L#:3"LI@6N;Q3&JRT$X013UJ4:,_+"7 MZ61HY,?QB05ZU;)=_4 JGV.[>BX9JV&>A\ )_YC1L!#K' M86BOV4[T8V;#4S,9,>LU0T%2"WMOA4)#7W8UU4M+UM@7MCR[I>_](4 MOK88^RY35\T?J<2K0)$<-BCI74PQ)%D7HG5#B]*69@]"8Z%G7W=8O(,T!CB^ M$4(_-&ULM9M;;]LV&(;_"N$-0P=TL20?DSD&TNC4 MH=V"9MTNAEW0,F,+E427HNT$Z(\?=8AE.3(C86]SD4@ROX>4^$2B/IJS/1=? MTC5CDCS&49)>]]92;J[Z_318LYBF%WS#$O7) QS[P*5RM97:@/Y]M MZ(K=,_EYC7GE6\,L("_Q5\CVZ=$VR4YEP?F7 M;.?]\KIG9"UB$0MDAJ#JSX[=LBC*2*H=7TMH[U!G%GB\_4QW\Y-7)[.@*;OE MT=_A4JZO>],>6;('NHWD)[[W67E"HXP7\"C-?Y-]479L]4BP326/RV#5@CA, MBK_TL;P01P'F\$R 5098;0,&9<#@-&!T)F!8!@Q/ \9G D9EP*AMD\9EP+AM MP*0,F+0-F)8!T[QWB^[(^]*FDLYG@N^)R$HK6K:1"Y%'JRX,D\S=>RG4IZ&* MD_-;'L>A5#+*E-!D26YY(L-DQ9(@9"GYA?Q.A:"97N2-S20-H_1G=?3SO4W> M_/CSK"]5$S)0/RBKLXOJK#/5#$[;*'"IWGXH.EZZ,-M%ER0@9F'6TV7HWUX M4^WN_ZO=:Q]N-H3[+:Y\&3[4].3@H/(@YPU>59G,HV6+@[-[[0XKKJ@(39ERT[SVE;T+UL>ZM'GH%M */2C-1]'J M@AUE%\T6@FT$WX59MKN0C.;&5:X%S8IIR9T50])L*,TI:5K%D!5Z4)J/HM45 MLRK%+*UB'UFT#8*0?"/W^(6DVE.9 :2Z4YD%I/HI65[!* M/)O?,?-L0E//4)H-I3E0F@NE>5":CZ+5?:PRT.8K*6CZE,M(]U0LU0U1ETHS8/2?!2M+EB5L3;U*>NV"4L]IK-6T%2UV39Y[$#K=:$T M#TKS4;2Z5E4:W-3GP3OG0_6\SGY!4^)0FF.V37F[T'H]*,U'T>I^5>EV4Y]O M[YQ@U?,Z^P7-N$-ICMDV@>]"Z_6@-!]%J_M5Y>]-?0+_?KM(V==M-K9W=NIW MHU+0I#V49D-I#I3F0FD>E.:C:/5O2%;3!);Q_?(;%G2J $JSH30'2G.A- ]* M\U&TNH_5K(*EGU5H^14[/:6S>= 9!"C-@=)<*,V#TOR2=CR,&)R,(NI25?,( MEGX>X?392KZ1KE,+^AHZ"P>=6H#2'"C-A=(\*,U'T>I65E,+UG><6K"@4PM0 MF@VE.5":"Z5Y4)J/HM5]K*86K%93"\5$?L16-#K* #>FZ*RVDP&W^JH["P:= M6H#27"C-@])\%*T0K'^T-"UF8I4O4\R^^[%-9+%(ZW#TL!3R)E\ >'+<,:^\ M8D%CA2G65WZD8A4FJ;+Q02&-BXE2311+%HL=R3?Y K@%EY+'^>::T24360'U M^0/G\GDGJ^"P<'3^'U!+ P04 " Q@D]8@!25]FD" #X!P &0 'AL M+W=O+:1<.G 0KV*:V"=U^_6Q#4#)1E&CA OQQWI?S'(P=EEQL90J@ MT#/-F)PXJ5+YV'5EG +%LL=S8'IFS07%2G?%QI6Y )Q8$8UNT%+Q>(L6D!=4/O/=5V UZ7,[0U>OKT%4Z M,^/OQG46]U46_@M9?,:LA[S;M\CW_&&+?-HM_\9W/33PK-P[EKNZ'DU1_*8H MOO4;G%@4]/.+CD /"JC\U497V0W;[%2KD@?R!!F/*"J3;:3HMS:2NSD34S6\XNTAM0=87NK@5EV* , M.U'^_8AM))T.YY)7)+^0V1%YT) '_[]B@Q,66872^;)S M4=R#?=F_UWNF,1'7.5!W%<[M5K[C2&[]MIOIH!F$"]/R: M<[7OF-V_.>RCOU!+ P04 " Q@D]8R%(G"$H# #*% #0 'AL+W-T M>6QEUY-B9 MX[*67X^OG:8?^%8=#Z,L%<2^Q^?<8_NF,?0KO>3T;D:I#A8%%]4@G&E=?HZB M:C*C!:DN9$F%07*I"J)-5TVCJE249!60"AYU6JTD*@@3X; OYL5-H:M@(N=" M#\)N$PK<[5LV"-O)91@XN9',Z"!\./OX>R[U]8? W4\^G9RT'LZO=^-G%C@/ M(Z_HU0&B%ZT6+@P@)IX<)KY/&Y/N;DO;X:=&R!%/,5KO($=[#&'"J<>/L;^V M!!V$W&UYR1M42XSJ,AGV+&=.Q@&WP!!77[?ED:AU-%ENW.5;@FV)M),I8JHZI)TPY7H6&?TQSL M*#:=P5W+,@)0:UF81L;(5 IB/:P8=ODHW*-FCU%_G9CK"]J%"Z:VB.5O8_B)O#&#J;5R=E"5? M?N%L*@KJ)G]PPF&?K'C!3"KV9+)!J4Q,@*HP>*1*L\EFY(\BY3U=Z%4Y+7+< M<^<=>OZWZSRE@BK"-TV;VC_F57ZUX_I]^!:>[=?*KF.OR;A[_![K,\"QFTS> M@\EWL=V]XS<9I\?OL3[S';G)[IM]L^\U&=4GH8WCUM9AJXD&<*@=A#_A>,S7 M28/QG''-1-V;L2RCXL69R\AK,C9_J&WIF_$9SOV=YA>.VE.U"87$QE=T&Q4=]5T;)N!:9BL]06$7>3&7GX$XSC,CP"& MY<$<8!S'PO+\3_/IH?-Q&.:MYT5Z**>',X2; 5 M'8V\#D;8NB4)_/C5,&_ P/) IK];:WRW\0K97P?8GNZK$&RF>"5B,\77&A#_ MN@$C3?V[C>4!!K8+6.U ?G\>J"D_)XYA5S%OV!.,(VF*(5"+_AI-$F1U$OCX M]P=[2N(X3?T(8'X'<8PA\#3B".8 /&!('-OWX,[[*%J]IZ+U?R^'SU!+ P04 M " Q@D]8EXJ[', 3 @ "P %]R96QS+RYR96QSG9*Y;L,P#$!_ MQ=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+ MJ1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D M5XA-/E_G;@ M2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/ M['X 4$L#!!0 ( #&"3UAD+A>/P@0 ! F / >&PO=V]R:V)O;VLN M>&ULQ9I;<]HX%(#_BH:G[@,+OB5MIG2& -DPDP 3,WWM"%N )K;$2C)I^NM[ M;$HC$_;,OISR9%L6XK-NWY'LSR_:/*^T?F;?RT+906?KW.ZFU[/95I3<_JUW M0L&=M38E=W!I-CV[,X+G=BN$*XM>V.]?]4HN5>?+YV-9"]/S+[03F9-:06*= M\%6*%_MVO[YD>VGE2A;2O0XZS7DA.JR42I;RA\@'G7Z'V:U^N==&_M#*\2+- MC"Z*028_1U,/Q>*C$&_-_JE&OUS(38YU5I5#N M4(]&%#6@LENYLQVF>"D&G9'>"\,6?"/JAX)_F>:'!W1 YE67N9%PPTSSAI&. M9UCETK&I.OP8[GI8(8(5TF*-YK-T_C =#Y>3,;L=/@QGHPE+[R>39>H!1@A@ M=#% ]F'!/<@8@8S_(&2ZA,/C9 : \SLVG8WF'F2"0"87@QS-'Q<>Y!4">75! MR&^A!WF-0%Y?#G*8WGN0'Q'(CQ>#3)?SD0?Y"8'\1 MYRZVT3*_9P@@+69L< MC*NN7D6KDGSY_$ ,TU K1I=[K2530M#BX\@^( B-WR@JM,,!\3\TU +)P' MP:UHM2TFEH#8+$]UHL@AD#'NE2T-5Y8W86&+$+-*0*P5&+EK80PPIDYGSX?! M6Y]M=9$+XV-B7@F(Q3(3=?25Z5*P!02&Z9:;5F2(Z20@]LDOKB7_WNYXF#T" M:GWHLI2NF>>:)AW! @)B>:$RV8;$[!$0ZR.M5E;\6T$F-MF?3,DA)HR06!@+ M_LKVMNYIS<_K^6TL;59H6[6Z78AY(R3VQE19"2.TGE5R:%HV-#"];-ZY+427 M)\320 .$5CP88M((B:6!8T8^)F:3D-@F:*30KDU,*2'U2@6+%-J8F%)"8J4< M(@7V85G7GOW+Q\)L$A+;!!5RN_8PP83$@CDGY+-UB0DF)!:,;^9SZ[(9!R\Z'Q/=#B,V#3Z%^Z:),--$ M%S5-JV]BIHF(38-CMOHF9IJ(>E<,%6*KT3'S1-3[8BAFJ]$Q\T3T2QL$L]7H MF'LB8O?\"B^.$Y#<@Q['T#-ET5)0C"DH)E;0;\8GN=FZKEYW*RO8T%K1+!M] M3$Q!,;&"?F/>50X68.RQ?D=6E:Q)9_[6=XPI*"96$!ZY^<,\QA04$RL(Q_2' M>8R^DR%6$([I#_,84U!\R?VS;U<^)J:@F%A!..:UCXDI*"96T-E519>E4'1> M%?[62XPI*+[$XN=MIO@?0 MJ6^A!+-00K[?UJY-;\%Q6IN8A1)B"YU@GD8?/B9FH8380B>83R+3*I.%/"PO MM8^)62@AMM!IW]S66ZR6'>--'Q/]-H!^R^V_M_M9U\?$+)006^C=AO_9D#C! M#)0T!NH=OT#*Q5HJD<^@> OI&2^RA6'UX?#"-$[J-QSKJBA&D#97#YKGQP^: MCA]C??D)4$L#!!0 ( #&"3UCS((MYZ0$ !(B : >&PO7W)E;',O M=V]R:V)O;VLN>&UL+G)E;'/-VCM.PT 4A>&M1%X D_N8\%!"14.+V( 5)@^1 MQ)9G$,GNB4(1CD5!@^94UMCR]5]]LL:>OZ1=6[;=(6^V?9X<][M#7C2;4OJ' M$/)RD_9MONGZ=#A?677#OBWGY; .?;M\;]NI3W^9 MV*U6VV5ZZI8?^W0HOPP.G]WPGCBGHK@=Z*>BN!WCIZV2;06U%O)=!;46\ET%M1;R706U%O)=!; M46\ET%M1;R706U%O)=#;4&\CT-M0;R/0VU!O(]#;1ILE!'H;ZFT$>AOJ;01Z M&^IM!'H;ZFT$>AOJ;01Z&^IM!'H[ZNT$>COJ[01Z.^KM!'H[ZNT$>OMHLYM M;T>]G4!O1[V=0&]'O9U ;T>]G4!O1[V=0.^(>D<"O2/J'0GTCJAW)- [HMZ1 M0.^(>D<"O>/H8R6!WA'UC@1Z1]0[_J?>N9QV*5][OM?X_/^DNISO3=?'7Y;? M)T?L7' .\ O(XQ=02P,$% @ ,8)/6+)H2=C5 0 OR$ !, !;0V]N M=&5N=%]4>7!E&ULS=I=3X,P% ;@O[)P:T;7K_D1YXUZJU[X!RJ<#3*@ M3=O-^>\M3$TT2EQFXGL#@;;G/;3)<\7EXXNC,-FU31<6616CNV L%!6U)N36 M49=&EM:W)J9'OV+.%&NS(B9FLSDK;!>IB]/8U\BN+F]H:39-G-SNTNM0VVZ1 M>6I"-KG>3^RS%IEQKJD+$],XVW;EEY3I6T*>5@YS0E6[<)(F9.S;A'[DYX"W M=?=;\KXN:?)@?+PS;9K%=@T+\:6AD(^7^*9'NUS6!96VV+1I21Z<)U.&BBBV M3;XO>C*>'-,.T_[*C\X?RHP%IID/WKJ03LS3X7'O1]*OGKI4B'RLQS_Q(S&5 M/OK[J#_MDLI?9J?M?;9^/9Q'8,/M^#W^?,8?]0_L0X#T(4'Z4"!]:) ^YB!] MG(+T<0;2QSE('WR&T@B*J!R%5(YB*D=!E:.HRE%8Y2BNN3M>N__J6@O^>MJ;OW?#;\MW'U"E!+ 0(4 Q0 ( M #&"3U@'04UB@0 +$ 0 " 0 !D;V-0&UL4$L! A0#% @ ,8)/6'1<,MCO *P( !$ M ( !KP &1O8U!R;W!S+V-O&UL4$L! A0#% @ ,8)/6)E&PO=V]R:W-H965T&UL4$L! A0#% @ ,8)/6(?^._P\ M @ OP4 !@ ("!_@\ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ ,8)/6%QXF7_)!0 TQ< !@ M ("!'1T 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0# M% @ ,8)/6,E=@"#>"0 8S$ !@ ("!L2D 'AL+W=O M&UL4$L! A0#% @ ,8)/6$S4'?$J!P :!( !D M ("!=&( 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ ,8)/6)-DCDPI @ )04 !D ("!4G, 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ ,8)/6.Q& M$JSS"@ ?!P !D ("!QXD 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ ,8)/6*^@B95; @ @08 !D M ("!0: 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ ,8)/6*=QE_S+ P & D !D ("! M+\ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ ,8)/6*W-Q!Q/ P _ < !D ("!@LP 'AL+W=O&UL4$L! A0#% @ ,8)/6*#/.5>2 M!@ U!$ !D ("!0-D 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ ,8)/6%J-,. ] @ 804 !D M ("!V>D 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ ,8)/6&,^^3B/ P Z@X !D ("!*_8 M 'AL+W=O!, M0M0" #H!P &0 @('Q^0 >&PO=V]R:W-H965T&UL4$L! A0#% @ M,8)/6'("B(I$ @ .@4 !D ("!KP ! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ ,8)/6%I+A1@&PO=V]R:W-H M965T&UL4$L! M A0#% @ ,8)/6%\,% [H P 6PX !D ("!EBP! 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ ,8)/ M6$XV8G+? P Y@\ !D ("!#3&PO=V]R:W-H965T&UL4$L! A0#% @ ,8)/6"E&O&"N P L0L M !D ("!34,! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ ,8)/6( 4E?9I @ ^ < !D M ("!8%$! 'AL+W=O&PO/P@0 ! F / M " 5Y8 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " Q@D]8 M\R"+>>D! 2(@ &@ @ %-70$ >&PO7W)E;',O=V]R:V)O M;VLN>&UL+G)E;'-02P$"% ,4 " Q@D]8LFA)V-4! "_(0 $P M @ %N7P$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 00!! +X1 ( !T80$ ! end XML 74 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 75 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 77 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 139 326 1 false 45 0 false 8 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.corcept.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Document - Audit Information Sheet http://www.corcept.com/role/AuditInformation Audit Information Cover 2 false false R3.htm 0000003 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS CONSOLIDATED BALANCE SHEETS Statements 3 false false R4.htm 0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETSParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 4 false false R5.htm 0000005 - Statement - CONSOLIDATED STATEMENTS OF INCOME Sheet http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFINCOME CONSOLIDATED STATEMENTS OF INCOME Statements 5 false false R6.htm 0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Sheet http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Statements 6 false false R7.htm 0000007 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) Sheet http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) Statements 7 false false R8.htm 0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 8 false false R9.htm 0000009 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 9 false false R10.htm 0000010 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies Basis of Presentation and Summary of Significant Accounting Policies Notes 10 false false R11.htm 0000011 - Disclosure - Significant Agreements Sheet http://www.corcept.com/role/SignificantAgreements Significant Agreements Notes 11 false false R12.htm 0000012 - Disclosure - Available for Sale Marketable Securities and Fair Value Measurements Sheet http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurements Available for Sale Marketable Securities and Fair Value Measurements Notes 12 false false R13.htm 0000013 - Disclosure - Composition of Certain Balance Sheet Items Sheet http://www.corcept.com/role/CompositionofCertainBalanceSheetItems Composition of Certain Balance Sheet Items Notes 13 false false R14.htm 0000014 - Disclosure - Leases Sheet http://www.corcept.com/role/Leases Leases Notes 14 false false R15.htm 0000015 - Disclosure - Related Party Transactions Sheet http://www.corcept.com/role/RelatedPartyTransactions Related Party Transactions Notes 15 false false R16.htm 0000016 - Disclosure - Preferred Stock and Stockholders' Equity Sheet http://www.corcept.com/role/PreferredStockandStockholdersEquity Preferred Stock and Stockholders' Equity Notes 16 false false R17.htm 0000017 - Disclosure - Net Income Per Share Sheet http://www.corcept.com/role/NetIncomePerShare Net Income Per Share Notes 17 false false R18.htm 0000018 - Disclosure - Income Taxes Sheet http://www.corcept.com/role/IncomeTaxes Income Taxes Notes 18 false false R19.htm 0000019 - Disclosure - Commitments and Contingencies Sheet http://www.corcept.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 19 false false R20.htm 0000020 - Disclosure - Subsequent Events Sheet http://www.corcept.com/role/SubsequentEvents Subsequent Events Notes 20 false false R21.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 21 false false R22.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 22 false false R23.htm 9954471 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies Basis of Presentation and Summary of Significant Accounting Policies (Policies) Policies http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies 23 false false R24.htm 9954472 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables) Sheet http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables Basis of Presentation and Summary of Significant Accounting Policies (Tables) Tables http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies 24 false false R25.htm 9954473 - Disclosure - Available for Sale Marketable Securities and Fair Value Measurements (Tables) Sheet http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsTables Available for Sale Marketable Securities and Fair Value Measurements (Tables) Tables http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurements 25 false false R26.htm 9954474 - Disclosure - Composition of Certain Balance Sheet Items (Tables) Sheet http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsTables Composition of Certain Balance Sheet Items (Tables) Tables http://www.corcept.com/role/CompositionofCertainBalanceSheetItems 26 false false R27.htm 9954475 - Disclosure - Leases (Tables) Sheet http://www.corcept.com/role/LeasesTables Leases (Tables) Tables http://www.corcept.com/role/Leases 27 false false R28.htm 9954476 - Disclosure - Preferred Stock and Stockholders' Equity (Tables) Sheet http://www.corcept.com/role/PreferredStockandStockholdersEquityTables Preferred Stock and Stockholders' Equity (Tables) Tables http://www.corcept.com/role/PreferredStockandStockholdersEquity 28 false false R29.htm 9954477 - Disclosure - Net Income Per Share (Tables) Sheet http://www.corcept.com/role/NetIncomePerShareTables Net Income Per Share (Tables) Tables http://www.corcept.com/role/NetIncomePerShare 29 false false R30.htm 9954478 - Disclosure - Income Taxes (Tables) Sheet http://www.corcept.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.corcept.com/role/IncomeTaxes 30 false false R31.htm 9954479 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative) (Details) Sheet http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails Basis of Presentation and Summary of Significant Accounting Policies (Narrative) (Details) Details http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables 31 false false R32.htm 9954480 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Summary of Allowance Activity Included in Trade Receivables Includes Allowance for Doubtful Accounts, Prompt Pay Cash Discounts and Chargebacks) (Details) Sheet http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesSummaryofAllowanceActivityIncludedinTradeReceivablesIncludesAllowanceforDoubtfulAccountsPromptPayCashDiscountsandChargebacksDetails Basis of Presentation and Summary of Significant Accounting Policies (Summary of Allowance Activity Included in Trade Receivables Includes Allowance for Doubtful Accounts, Prompt Pay Cash Discounts and Chargebacks) (Details) Details http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables 32 false false R33.htm 9954481 - Disclosure - Significant Agreements - Narrative (Details) Sheet http://www.corcept.com/role/SignificantAgreementsNarrativeDetails Significant Agreements - Narrative (Details) Details 33 false false R34.htm 9954482 - Disclosure - Available for Sale Marketable Securities and Fair Value Measurements - Summary of the classification of available-for-sale securities in condensed consolidated balance sheets (Details) Sheet http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsSummaryoftheclassificationofavailableforsalesecuritiesincondensedconsolidatedbalancesheetsDetails Available for Sale Marketable Securities and Fair Value Measurements - Summary of the classification of available-for-sale securities in condensed consolidated balance sheets (Details) Details 34 false false R35.htm 9954483 - Disclosure - Available for Sale Marketable Securities and Fair Value Measurements - Schedule of Available-for-Sale Securities (Details) Sheet http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails Available for Sale Marketable Securities and Fair Value Measurements - Schedule of Available-for-Sale Securities (Details) Details 35 false false R36.htm 9954484 - Disclosure - Available for Sale Marketable Securities and Fair Value Measurements - Narrative (Details) Sheet http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsNarrativeDetails Available for Sale Marketable Securities and Fair Value Measurements - Narrative (Details) Details http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsTables 36 false false R37.htm 9954485 - Disclosure - Composition of Certain Balance Sheet Items - Composition of Inventory (Details) Sheet http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsCompositionofInventoryDetails Composition of Certain Balance Sheet Items - Composition of Inventory (Details) Details 37 false false R38.htm 9954486 - Disclosure - Composition of Certain Balance Sheet Items - Other Accrued Liabilities (Details) Sheet http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsOtherAccruedLiabilitiesDetails Composition of Certain Balance Sheet Items - Other Accrued Liabilities (Details) Details 38 false false R39.htm 9954487 - Disclosure - Composition of Certain Balance Sheet Items - Other Assets (Details) Sheet http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsOtherAssetsDetails Composition of Certain Balance Sheet Items - Other Assets (Details) Details 39 false false R40.htm 9954488 - Disclosure - Leases - Narrative (Details) Sheet http://www.corcept.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 40 false false R41.htm 9954489 - Disclosure - Leases - Right-of-use Assets and Related Liabilities (Details) Sheet http://www.corcept.com/role/LeasesRightofuseAssetsandRelatedLiabilitiesDetails Leases - Right-of-use Assets and Related Liabilities (Details) Details 41 false false R42.htm 9954490 - Disclosure - Leases - Future Minimum Lease Payments (Details) Sheet http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails Leases - Future Minimum Lease Payments (Details) Details 42 false false R43.htm 9954491 - Disclosure - Preferred Stock and Stockholders' Equity - Narrative (Details) Sheet http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails Preferred Stock and Stockholders' Equity - Narrative (Details) Details 43 false false R44.htm 9954492 - Disclosure - Preferred Stock and Stockholders' Equity - Summary of Stock Plan Activity (Details) Sheet http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofStockPlanActivityDetails Preferred Stock and Stockholders' Equity - Summary of Stock Plan Activity (Details) Details 44 false false R45.htm 9954493 - Disclosure - Preferred Stock and Stockholders' Equity - Summary of Restricted Stock Activity (Details) Sheet http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofRestrictedStockActivityDetails Preferred Stock and Stockholders' Equity - Summary of Restricted Stock Activity (Details) Details 45 false false R46.htm 9954494 - Disclosure - Preferred Stock and Stockholders' Equity - Summary of Weighted-Average Assumptions and Resultant Fair Value-Based Measurements for Options Granted to Employees and Directors (Details) Sheet http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofWeightedAverageAssumptionsandResultantFairValueBasedMeasurementsforOptionsGrantedtoEmployeesandDirectorsDetails Preferred Stock and Stockholders' Equity - Summary of Weighted-Average Assumptions and Resultant Fair Value-Based Measurements for Options Granted to Employees and Directors (Details) Details 46 false false R47.htm 9954495 - Disclosure - Preferred Stock and Stockholders' Equity - Summary of Stock-Based Compensation (Details) Sheet http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofStockBasedCompensationDetails Preferred Stock and Stockholders' Equity - Summary of Stock-Based Compensation (Details) Details 47 false false R48.htm 9954496 - Disclosure - Net Income Per Share - Schedule of Computation of Net Income (Loss) Per Share (Details) Sheet http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomeLossPerShareDetails Net Income Per Share - Schedule of Computation of Net Income (Loss) Per Share (Details) Details 48 false false R49.htm 9954497 - Disclosure - Net Income Per Share - Narrative (Details) Sheet http://www.corcept.com/role/NetIncomePerShareNarrativeDetails Net Income Per Share - Narrative (Details) Details 49 false false R50.htm 9954498 - Disclosure - Income Taxes - Schedule of Components of income Tax (Benefit) (Details) Sheet http://www.corcept.com/role/IncomeTaxesScheduleofComponentsofincomeTaxBenefitDetails Income Taxes - Schedule of Components of income Tax (Benefit) (Details) Details 50 false false R51.htm 9954499 - Disclosure - Income Taxes - Components of Income Tax (Benefit) (Details) Sheet http://www.corcept.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails Income Taxes - Components of Income Tax (Benefit) (Details) Details 51 false false R52.htm 9954500 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets (Details) Sheet http://www.corcept.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails Income Taxes - Significant Components of Deferred Tax Assets (Details) Details 52 false false R53.htm 9954501 - Disclosure - Income Taxes - Narrative (Details) Sheet http://www.corcept.com/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 53 false false R54.htm 9954502 - Disclosure - Income Taxes - Reconciliation of Statutory Federal Income Tax Rate to Effective Rate (Details) Sheet http://www.corcept.com/role/IncomeTaxesReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails Income Taxes - Reconciliation of Statutory Federal Income Tax Rate to Effective Rate (Details) Details 54 false false R55.htm 9954503 - Disclosure - Income Taxes - Changes in Balance of Gross Unrecognized Tax Benefits (Details) Sheet http://www.corcept.com/role/IncomeTaxesChangesinBalanceofGrossUnrecognizedTaxBenefitsDetails Income Taxes - Changes in Balance of Gross Unrecognized Tax Benefits (Details) Details 55 false false R56.htm 9954504 - Disclosure - Commitments and Contingencies - Narrative (Details) Sheet http://www.corcept.com/role/CommitmentsandContingenciesNarrativeDetails Commitments and Contingencies - Narrative (Details) Details 56 false false R57.htm 9954505 - Disclosure - Subsequent Events (Details) Sheet http://www.corcept.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.corcept.com/role/SubsequentEvents 57 false false All Reports Book All Reports cort-20231231.htm cort-20231231.xsd cort-20231231_cal.xml cort-20231231_def.xml cort-20231231_lab.xml cort-20231231_pre.xml cort-20231231_g1.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 79 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "cort-20231231.htm": { "nsprefix": "cort", "nsuri": "http://www.corcept.com/20231231", "dts": { "inline": { "local": [ "cort-20231231.htm" ] }, "schema": { "local": [ "cort-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "cort-20231231_cal.xml" ] }, "definitionLink": { "local": [ "cort-20231231_def.xml" ] }, "labelLink": { "local": [ "cort-20231231_lab.xml" ] }, "presentationLink": { "local": [ "cort-20231231_pre.xml" ] } }, "keyStandard": 292, "keyCustom": 34, "axisStandard": 23, "axisCustom": 0, "memberStandard": 29, "memberCustom": 14, "hidden": { "total": 4, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 139, "entityCount": 1, "segmentCount": 45, "elementCount": 579, "unitCount": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 731, "http://xbrl.sec.gov/dei/2023": 38, "http://xbrl.sec.gov/ecd/2023": 4 }, "report": { "R1": { "role": "http://www.corcept.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.corcept.com/role/AuditInformation", "longName": "0000002 - Document - Audit Information", "shortName": "Audit Information", "isDefault": "false", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "dei:AuditorFirmId", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:AuditorFirmId", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS", "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "longName": "0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "unique": true } }, "R5": { "role": "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF INCOME", "shortName": "CONSOLIDATED STATEMENTS OF INCOME", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "unique": true } }, "R7": { "role": "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical", "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical)", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "unique": true } }, "R9": { "role": "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "longName": "0000009 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "9", "firstAnchor": { "contextRef": "c-16", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-16", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies", "longName": "0000010 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.corcept.com/role/SignificantAgreements", "longName": "0000011 - Disclosure - Significant Agreements", "shortName": "Significant Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurements", "longName": "0000012 - Disclosure - Available for Sale Marketable Securities and Fair Value Measurements", "shortName": "Available for Sale Marketable Securities and Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "cort:AvailableForSaleSecuritiesAndFairValueMeasurementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "cort:AvailableForSaleSecuritiesAndFairValueMeasurementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.corcept.com/role/CompositionofCertainBalanceSheetItems", "longName": "0000013 - Disclosure - Composition of Certain Balance Sheet Items", "shortName": "Composition of Certain Balance Sheet Items", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.corcept.com/role/Leases", "longName": "0000014 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.corcept.com/role/RelatedPartyTransactions", "longName": "0000015 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.corcept.com/role/PreferredStockandStockholdersEquity", "longName": "0000016 - Disclosure - Preferred Stock and Stockholders' Equity", "shortName": "Preferred Stock and Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.corcept.com/role/NetIncomePerShare", "longName": "0000017 - Disclosure - Net Income Per Share", "shortName": "Net Income Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.corcept.com/role/IncomeTaxes", "longName": "0000018 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.corcept.com/role/CommitmentsandContingencies", "longName": "0000019 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.corcept.com/role/SubsequentEvents", "longName": "0000020 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R21": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true }, "uniqueAnchor": null }, "R22": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables", "longName": "9954472 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsTables", "longName": "9954473 - Disclosure - Available for Sale Marketable Securities and Fair Value Measurements (Tables)", "shortName": "Available for Sale Marketable Securities and Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsTables", "longName": "9954474 - Disclosure - Composition of Certain Balance Sheet Items (Tables)", "shortName": "Composition of Certain Balance Sheet Items (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.corcept.com/role/LeasesTables", "longName": "9954475 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.corcept.com/role/PreferredStockandStockholdersEquityTables", "longName": "9954476 - Disclosure - Preferred Stock and Stockholders' Equity (Tables)", "shortName": "Preferred Stock and Stockholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.corcept.com/role/NetIncomePerShareTables", "longName": "9954477 - Disclosure - Net Income Per Share (Tables)", "shortName": "Net Income Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.corcept.com/role/IncomeTaxesTables", "longName": "9954478 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails", "longName": "9954479 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative) (Details)", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "cort:NumberOfSeriesOfSelectiveCortisolModulators", "unitRef": "series", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "cort:NumberOfSeriesOfSelectiveCortisolModulators", "unitRef": "series", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesSummaryofAllowanceActivityIncludedinTradeReceivablesIncludesAllowanceforDoubtfulAccountsPromptPayCashDiscountsandChargebacksDetails", "longName": "9954480 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Summary of Allowance Activity Included in Trade Receivables Includes Allowance for Doubtful Accounts, Prompt Pay Cash Discounts and Chargebacks) (Details)", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Summary of Allowance Activity Included in Trade Receivables Includes Allowance for Doubtful Accounts, Prompt Pay Cash Discounts and Chargebacks) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-15", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "unique": true } }, "R33": { "role": "http://www.corcept.com/role/SignificantAgreementsNarrativeDetails", "longName": "9954481 - Disclosure - Significant Agreements - Narrative (Details)", "shortName": "Significant Agreements - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-75", "name": "us-gaap:LongtermPurchaseCommitmentPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-75", "name": "us-gaap:LongtermPurchaseCommitmentPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsSummaryoftheclassificationofavailableforsalesecuritiesincondensedconsolidatedbalancesheetsDetails", "longName": "9954482 - Disclosure - Available for Sale Marketable Securities and Fair Value Measurements - Summary of the classification of available-for-sale securities in condensed consolidated balance sheets (Details)", "shortName": "Available for Sale Marketable Securities and Fair Value Measurements - Summary of the classification of available-for-sale securities in condensed consolidated balance sheets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-76", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "unique": true } }, "R35": { "role": "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails", "longName": "9954483 - Disclosure - Available for Sale Marketable Securities and Fair Value Measurements - Schedule of Available-for-Sale Securities (Details)", "shortName": "Available for Sale Marketable Securities and Fair Value Measurements - Schedule of Available-for-Sale Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-94", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "unique": true } }, "R36": { "role": "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsNarrativeDetails", "longName": "9954484 - Disclosure - Available for Sale Marketable Securities and Fair Value Measurements - Narrative (Details)", "shortName": "Available for Sale Marketable Securities and Fair Value Measurements - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:InterestReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:InterestReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsCompositionofInventoryDetails", "longName": "9954485 - Disclosure - Composition of Certain Balance Sheet Items - Composition of Inventory (Details)", "shortName": "Composition of Certain Balance Sheet Items - Composition of Inventory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-4", "name": "cort:InventoryWorkInProcessCurrentAndNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "cort:InventoryWorkInProcessCurrentAndNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsOtherAccruedLiabilitiesDetails", "longName": "9954486 - Disclosure - Composition of Certain Balance Sheet Items - Other Accrued Liabilities (Details)", "shortName": "Composition of Certain Balance Sheet Items - Other Accrued Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsOtherAssetsDetails", "longName": "9954487 - Disclosure - Composition of Certain Balance Sheet Items - Other Assets (Details)", "shortName": "Composition of Certain Balance Sheet Items - Other Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-4", "name": "cort:DepositsForClinicalTrials", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "cort:DepositsForClinicalTrials", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.corcept.com/role/LeasesNarrativeDetails", "longName": "9954488 - Disclosure - Leases - Narrative (Details)", "shortName": "Leases - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "unique": true } }, "R41": { "role": "http://www.corcept.com/role/LeasesRightofuseAssetsandRelatedLiabilitiesDetails", "longName": "9954489 - Disclosure - Leases - Right-of-use Assets and Related Liabilities (Details)", "shortName": "Leases - Right-of-use Assets and Related Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails", "longName": "9954490 - Disclosure - Leases - Future Minimum Lease Payments (Details)", "shortName": "Leases - Future Minimum Lease Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails", "longName": "9954491 - Disclosure - Preferred Stock and Stockholders' Equity - Narrative (Details)", "shortName": "Preferred Stock and Stockholders' Equity - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "unique": true } }, "R44": { "role": "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofStockPlanActivityDetails", "longName": "9954492 - Disclosure - Preferred Stock and Stockholders' Equity - Summary of Stock Plan Activity (Details)", "shortName": "Preferred Stock and Stockholders' Equity - Summary of Stock Plan Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofRestrictedStockActivityDetails", "longName": "9954493 - Disclosure - Preferred Stock and Stockholders' Equity - Summary of Restricted Stock Activity (Details)", "shortName": "Preferred Stock and Stockholders' Equity - Summary of Restricted Stock Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-117", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-114", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "unique": true } }, "R46": { "role": "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofWeightedAverageAssumptionsandResultantFairValueBasedMeasurementsforOptionsGrantedtoEmployeesandDirectorsDetails", "longName": "9954494 - Disclosure - Preferred Stock and Stockholders' Equity - Summary of Weighted-Average Assumptions and Resultant Fair Value-Based Measurements for Options Granted to Employees and Directors (Details)", "shortName": "Preferred Stock and Stockholders' Equity - Summary of Weighted-Average Assumptions and Resultant Fair Value-Based Measurements for Options Granted to Employees and Directors (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofStockBasedCompensationDetails", "longName": "9954495 - Disclosure - Preferred Stock and Stockholders' Equity - Summary of Stock-Based Compensation (Details)", "shortName": "Preferred Stock and Stockholders' Equity - Summary of Stock-Based Compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomeLossPerShareDetails", "longName": "9954496 - Disclosure - Net Income Per Share - Schedule of Computation of Net Income (Loss) Per Share (Details)", "shortName": "Net Income Per Share - Schedule of Computation of Net Income (Loss) Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "unique": true } }, "R49": { "role": "http://www.corcept.com/role/NetIncomePerShareNarrativeDetails", "longName": "9954497 - Disclosure - Net Income Per Share - Narrative (Details)", "shortName": "Net Income Per Share - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.corcept.com/role/IncomeTaxesScheduleofComponentsofincomeTaxBenefitDetails", "longName": "9954498 - Disclosure - Income Taxes - Schedule of Components of income Tax (Benefit) (Details)", "shortName": "Income Taxes - Schedule of Components of income Tax (Benefit) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.corcept.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails", "longName": "9954499 - Disclosure - Income Taxes - Components of Income Tax (Benefit) (Details)", "shortName": "Income Taxes - Components of Income Tax (Benefit) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.corcept.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails", "longName": "9954500 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets (Details)", "shortName": "Income Taxes - Significant Components of Deferred Tax Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.corcept.com/role/IncomeTaxesNarrativeDetails", "longName": "9954501 - Disclosure - Income Taxes - Narrative (Details)", "shortName": "Income Taxes - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.corcept.com/role/IncomeTaxesReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails", "longName": "9954502 - Disclosure - Income Taxes - Reconciliation of Statutory Federal Income Tax Rate to Effective Rate (Details)", "shortName": "Income Taxes - Reconciliation of Statutory Federal Income Tax Rate to Effective Rate (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.corcept.com/role/IncomeTaxesChangesinBalanceofGrossUnrecognizedTaxBenefitsDetails", "longName": "9954503 - Disclosure - Income Taxes - Changes in Balance of Gross Unrecognized Tax Benefits (Details)", "shortName": "Income Taxes - Changes in Balance of Gross Unrecognized Tax Benefits (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-15", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "unique": true } }, "R56": { "role": "http://www.corcept.com/role/CommitmentsandContingenciesNarrativeDetails", "longName": "9954504 - Disclosure - Commitments and Contingencies - Narrative (Details)", "shortName": "Commitments and Contingencies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:PurchaseObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:PurchaseObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.corcept.com/role/SubsequentEventsDetails", "longName": "9954505 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-103", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-139", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "cort-20231231.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "cort_AccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "AccountingPoliciesLineItems", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Line Items]", "label": "Accounting Policies [Line Items]", "documentation": "Accounting Policies [Line Items]" } } }, "auth_ref": [] }, "cort_AccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "AccountingPoliciesTable", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Table]", "label": "Accounting Policies [Table]", "documentation": "Accounting Policies [Table]" } } }, "auth_ref": [] }, "us-gaap_AccountingStandardsUpdate201602Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingStandardsUpdate201602Member", "presentation": [ "http://www.corcept.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting Standards Update 2016-02", "label": "Accounting Standards Update 2016-02 [Member]", "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842)." } } }, "auth_ref": [ "r498" ] }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsNotesAndLoansReceivableLineItems", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesSummaryofAllowanceActivityIncludedinTradeReceivablesIncludesAllowanceforDoubtfulAccountsPromptPayCashDiscountsandChargebacksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesSummaryofAllowanceActivityIncludedinTradeReceivablesIncludesAllowanceforDoubtfulAccountsPromptPayCashDiscountsandChargebacksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Receivable Type [Axis]", "label": "Receivable Type [Axis]", "documentation": "Information by type of receivable." } } }, "auth_ref": [ "r27" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r20", "r715" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Trade receivables, net of allowances", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r242", "r243" ] }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "(Accretion) of discount and Amortization of premium on marketable securities, net", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r99" ] }, "cort_AccruedGovernmentRebateCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "AccruedGovernmentRebateCurrent", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsOtherAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsOtherAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government rebates", "label": "Accrued Government Rebate Current", "documentation": "Accrued government rebate current." } } }, "auth_ref": [] }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsOtherAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsOtherAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes payable", "label": "Accrued Income Taxes, Current", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": [ "r74", "r117" ] }, "us-gaap_AccruedIncomeTaxesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedIncomeTaxesNoncurrent", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term accrued income taxes payable", "label": "Accrued Income Taxes, Noncurrent", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent." } } }, "auth_ref": [ "r75", "r117" ] }, "cort_AccruedLegalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "AccruedLegalFeesCurrent", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsOtherAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsOtherAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal fees", "label": "Accrued Legal Fees Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to legal services. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 }, "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsOtherAccruedLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsOtherAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued and other liabilities", "totalLabel": "Total accrued and other liabilities", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r22" ] }, "cort_AccruedManufacturingCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "AccruedManufacturingCostsCurrent", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsOtherAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsOtherAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued Manufacturing Costs", "label": "Accrued Manufacturing Costs, Current", "documentation": "Accrued Manufacturing Costs, Current" } } }, "auth_ref": [] }, "us-gaap_AccruedMarketingCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedMarketingCostsCurrent", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsOtherAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsOtherAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued selling and marketing costs", "label": "Accrued Marketing Costs, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsOtherAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsOtherAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Professional fees", "label": "Accrued Professional Fees, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r22" ] }, "cort_AccruedResearchAndDevelopmentExpensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "AccruedResearchAndDevelopmentExpensesCurrent", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued research and development expenses", "label": "Accrued Research And Development Expenses, Current", "documentation": "Accrued Research And Development Expenses, Current" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income (loss)", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r29", "r30", "r88", "r148", "r571", "r590", "r594" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r12", "r30", "r458", "r461", "r517", "r585", "r586", "r825", "r826", "r827", "r833", "r834", "r835" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r767" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r80", "r715", "r925" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r400", "r401", "r402", "r607", "r833", "r834", "r835", "r904", "r926" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r773" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r773" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r773" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r773" ] }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "presentation": [ "http://www.corcept.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]", "label": "Accounting Standards Update [Axis]", "documentation": "Information by amendment to accounting standards." } } }, "auth_ref": [ "r133", "r134", "r135", "r136", "r137", "r182", "r183", "r184", "r185", "r194", "r245", "r246", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r307", "r400", "r401", "r402", "r433", "r434", "r435", "r436", "r445", "r446", "r447", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r479", "r480", "r484", "r485", "r486", "r487", "r496", "r497", "r499", "r500", "r501", "r502", "r513", "r514", "r515", "r516", "r517", "r559", "r560", "r561", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594" ] }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting of RSAs in connection with ESPP", "label": "APIC, Share-Based Payment Arrangement, ESPP, Increase for Cost Recognition", "documentation": "Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r58", "r59", "r364" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income to net cash provided by operations:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r737", "r749", "r759", "r785" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r740", "r752", "r762", "r788" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r773" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r780" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r744", "r753", "r763", "r780", "r789", "r793", "r801" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r799" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "calculation": { "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofStockBasedCompensationDetails": { "parentTag": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails", "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash stock-based compensation expense", "verboseLabel": "Total stock-based compensation", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r397", "r407" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesSummaryofAllowanceActivityIncludedinTradeReceivablesIncludesAllowanceforDoubtfulAccountsPromptPayCashDiscountsandChargebacksDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at beginning of period", "periodEndLabel": "Balance at end of period", "label": "Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r149", "r244", "r290", "r293", "r295", "r921" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableRecoveries", "crdr": "credit", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesSummaryofAllowanceActivityIncludedinTradeReceivablesIncludesAllowanceforDoubtfulAccountsPromptPayCashDiscountsandChargebacksDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Credit or payments made during the period", "label": "Accounts Receivable, Allowance for Credit Loss, Recovery", "documentation": "Amount of increase in allowance for credit loss on accounts receivable, from recovery." } } }, "auth_ref": [ "r294" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableRollforward", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesSummaryofAllowanceActivityIncludedinTradeReceivablesIncludesAllowanceforDoubtfulAccountsPromptPayCashDiscountsandChargebacksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for Doubtful Accounts Receivable [Roll Forward}", "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of cloud computing arrangements", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r8", "r44", "r45" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.corcept.com/role/NetIncomePerShareNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average options excluded from the computation of diluted net income per share (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r213" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.corcept.com/role/NetIncomePerShareNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r36" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.corcept.com/role/NetIncomePerShareNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.corcept.com/role/NetIncomePerShareNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r36" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.corcept.com/role/SignificantAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangements and Non-arrangement Transactions", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r448" ] }, "us-gaap_AssetBackedSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetBackedSecuritiesMember", "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset-backed securities", "label": "Asset-Backed Securities [Member]", "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans." } } }, "auth_ref": [ "r708", "r848", "r853", "r854" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r116", "r144", "r175", "r220", "r233", "r237", "r279", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r449", "r451", "r483", "r569", "r641", "r715", "r726", "r865", "r866", "r910" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r139", "r152", "r175", "r279", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r449", "r451", "r483", "r715", "r865", "r866", "r910" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://www.corcept.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Firm ID", "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r731", "r732", "r745" ] }, "cort_AuditorInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "AuditorInformationAbstract", "lang": { "en-us": { "role": { "label": "Auditor Information [Abstract]", "documentation": "Auditor Information" } } }, "auth_ref": [] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://www.corcept.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Location", "label": "Auditor Location" } } }, "auth_ref": [ "r731", "r732", "r745" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://www.corcept.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Name", "label": "Auditor Name" } } }, "auth_ref": [ "r731", "r732", "r745" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Unrealized Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r252" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross Unrealized Losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r253" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Amortized Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r249", "r299", "r568" ] }, "cort_AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "AvailableForSaleSecuritiesAndFairValueMeasurementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Available For Sale Securities And Fair Value Measurements [Abstract]", "label": "Available For Sale Securities And Fair Value Measurements [Abstract]", "documentation": "Available for sale securities and fair value measurements." } } }, "auth_ref": [] }, "cort_AvailableForSaleSecuritiesAndFairValueMeasurementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "AvailableForSaleSecuritiesAndFairValueMeasurementsDisclosureTextBlock", "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurements" ], "lang": { "en-us": { "role": { "terseLabel": "Available for Sale Marketable Securities and Fair Value Measurements", "label": "Available For Sale Securities And Fair Value Measurements Disclosure [Text Block]", "documentation": "Available for sale securities and fair value measurements disclosure." } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails", "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsSummaryoftheclassificationofavailableforsalesecuritiesincondensedconsolidatedbalancesheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Fair Value", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r250", "r299", "r562", "r840" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r796" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r797" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r792" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r792" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r792" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r792" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r792" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r792" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails", "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails", "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofRestrictedStockActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r367", "r368", "r369", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r391", "r392", "r393", "r394", "r395" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r795" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r794" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r793" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r793" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsSummaryoftheclassificationofavailableforsalesecuritiesincondensedconsolidatedbalancesheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsSummaryoftheclassificationofavailableforsalesecuritiesincondensedconsolidatedbalancesheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r64", "r65" ] }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetRelatedDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Related Disclosures [Abstract]", "label": "Balance Sheet Related Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r100" ] }, "cort_CashAndCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "CashAndCashEquivalentsAndMarketableSecuritiesPolicyPolicyTextBlock", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents and Marketable Securities", "label": "Cash And Cash Equivalents And Marketable Securities Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents and marketable securities, including the policy for determining which items are treated as cash equivalents and available-for-sale securities. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r34", "r142", "r693" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents, at beginning of period", "periodEndLabel": "Cash and cash equivalents, at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r34", "r97", "r173" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r97" ] }, "us-gaap_CashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashEquivalentsMember", "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsSummaryoftheclassificationofavailableforsalesecuritiesincondensedconsolidatedbalancesheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents", "label": "Cash Equivalents [Member]", "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r142" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r771" ] }, "cort_ChargebacksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "ChargebacksMember", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesSummaryofAllowanceActivityIncludedinTradeReceivablesIncludesAllowanceforDoubtfulAccountsPromptPayCashDiscountsandChargebacksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Chargebacks", "label": "Chargebacks [Member]", "documentation": "Chargebacks." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails", "http://www.corcept.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r132", "r145", "r146", "r147", "r175", "r199", "r203", "r210", "r212", "r218", "r219", "r279", "r316", "r318", "r319", "r320", "r323", "r324", "r328", "r329", "r332", "r335", "r342", "r483", "r598", "r599", "r600", "r601", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r629", "r650", "r670", "r682", "r683", "r684", "r685", "r686", "r808", "r830", "r836" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders Equity [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r145", "r146", "r147", "r218", "r328", "r329", "r330", "r332", "r335", "r340", "r342", "r598", "r599", "r600", "r601", "r706", "r808", "r830" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r772" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r772" ] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommercialPaperMember", "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial paper", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r103", "r721", "r722", "r723", "r724" ] }, "cort_CommitmentAndContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "CommitmentAndContingenciesLineItems", "presentation": [ "http://www.corcept.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commitment And Contingencies [Line Items]", "label": "Commitment And Contingencies [Line Items]", "documentation": "Commitment and contingencies." } } }, "auth_ref": [] }, "cort_CommitmentAndContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "CommitmentAndContingenciesTable", "presentation": [ "http://www.corcept.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commitment And Contingencies [Table]", "label": "Commitment And Contingencies [Table]", "documentation": "Commitment and contingencies." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 10)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r24", "r71", "r570", "r628" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.corcept.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r102", "r309", "r310", "r689", "r862" ] }, "us-gaap_CommitmentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsDisclosureTextBlock", "presentation": [ "http://www.corcept.com/role/SignificantAgreements" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Agreements", "label": "Commitments Disclosure [Text Block]", "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights." } } }, "auth_ref": [ "r102" ] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares available for future issuance (in shares)", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r25" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails", "http://www.corcept.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common\u00a0Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r717", "r718", "r719", "r721", "r722", "r723", "r724", "r833", "r834", "r904", "r924", "r926" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r79" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r79", "r629" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares, issued", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r79" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares, outstanding", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r13", "r79", "r629", "r647", "r926", "r927" ] }, "us-gaap_CommonStockValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValueOutstanding", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value $0.001 per share, 280,000 shares authorized and 134,344 issued and 103,405 outstanding as of December\u00a031, 2023 and 130,959 shares issued and 107,835 outstanding as of December\u00a031, 2022", "label": "Common Stock, Value, Outstanding", "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares." } } }, "auth_ref": [ "r79", "r629" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r777" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r776" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r778" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r775" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Total comprehensive income", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r31", "r158", "r160", "r166", "r564", "r579" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r37", "r39", "r69", "r70", "r241", "r688" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r37", "r39", "r69", "r70", "r241", "r595", "r688" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r37", "r39", "r69", "r70", "r241", "r688", "r810" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Credit and Concentration Risks", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r72", "r126" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of sales to one specialty distributor, less than", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r37", "r39", "r69", "r70", "r241" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r37", "r39", "r69", "r70", "r241", "r688" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r63", "r695" ] }, "us-gaap_CorporateBondSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateBondSecuritiesMember", "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate bonds", "label": "Corporate Bond Securities [Member]", "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)." } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r92", "r558" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesMember", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r91" ] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpensesAbstract", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.corcept.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails": { "parentTag": "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.corcept.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current", "label": "Current Federal Tax Expense (Benefit)", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r812", "r832", "r903" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentForeignTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.corcept.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails": { "parentTag": "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.corcept.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current", "label": "Current Foreign Tax Expense (Benefit)", "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r812", "r832" ] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.corcept.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails": { "parentTag": "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.corcept.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current", "label": "Current State and Local Tax Expense (Benefit)", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r812", "r832", "r903" ] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r38", "r241" ] }, "cort_DebtAndCreditAgreementsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "DebtAndCreditAgreementsLineItems", "presentation": [ "http://www.corcept.com/role/SignificantAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt And Credit Agreements [Line Items]", "label": "Debt And Credit Agreements [Line Items]", "documentation": "Debt and credit agreements." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails", "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsSummaryoftheclassificationofavailableforsalesecuritiesincondensedconsolidatedbalancesheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-Sale [Table]", "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of the Classification of Available-for-Sale Securities in Condensed Consolidated Balance Sheets", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r855" ] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.corcept.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails": { "parentTag": "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.corcept.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred", "label": "Deferred Federal Income Tax Expense (Benefit)", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r832", "r901", "r903" ] }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredForeignIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.corcept.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails": { "parentTag": "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.corcept.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred", "label": "Deferred Foreign Income Tax Expense (Benefit)", "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r115", "r832", "r901" ] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets, net", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r414", "r415" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r8", "r115", "r129", "r439", "r440", "r832" ] }, "us-gaap_DeferredIncomeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilities", "crdr": "credit", "calculation": { "http://www.corcept.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.corcept.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total deferred tax liabilities", "label": "Deferred Tax Liabilities, Gross", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences." } } }, "auth_ref": [ "r76", "r77", "r118", "r427" ] }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.corcept.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails": { "parentTag": "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.corcept.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred", "label": "Deferred State and Local Income Tax Expense (Benefit)", "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r832", "r901", "r903" ] }, "cort_DeferredTaxAssetsCapitalizedResearchExpenditures": { "xbrltype": "monetaryItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "DeferredTaxAssetsCapitalizedResearchExpenditures", "crdr": "debit", "calculation": { "http://www.corcept.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.corcept.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalized research expenditures", "label": "Deferred Tax Assets, Capitalized Research Expenditures", "documentation": "Deferred Tax Assets, Capitalized Research Expenditures" } } }, "auth_ref": [] }, "cort_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts", "crdr": "debit", "calculation": { "http://www.corcept.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.corcept.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalized research and patent costs", "label": "Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs", "documentation": "Deferred tax assets deferred expense capitalized research and development costs." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://www.corcept.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.corcept.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total deferred tax assets", "label": "Deferred Tax Assets, Gross", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r428" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.corcept.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.corcept.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net deferred tax assets", "label": "Deferred Tax Assets, Net of Valuation Allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r899" ] }, "us-gaap_DeferredTaxAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNetAbstract", "presentation": [ "http://www.corcept.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets:", "label": "Deferred Tax Assets, Net [Abstract]" } } }, "auth_ref": [] }, "cort_DeferredTaxAssetsOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "DeferredTaxAssetsOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.corcept.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.corcept.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability", "label": "Deferred Tax Assets, Operating Lease Liability", "documentation": "Deferred Tax Assets, Operating Lease Liability" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://www.corcept.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.corcept.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal and state net operating losses", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r62", "r900" ] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "calculation": { "http://www.corcept.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.corcept.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Deferred Tax Assets, Other", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": [ "r62", "r900" ] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "crdr": "debit", "calculation": { "http://www.corcept.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.corcept.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research credits", "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards." } } }, "auth_ref": [ "r61", "r62", "r900" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "calculation": { "http://www.corcept.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.corcept.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation costs", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation." } } }, "auth_ref": [ "r62", "r900" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://www.corcept.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.corcept.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r429" ] }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesAbstract", "presentation": [ "http://www.corcept.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liabilities", "label": "Deferred Tax Liabilities, Gross [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesLeasingArrangements", "crdr": "credit", "calculation": { "http://www.corcept.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.corcept.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Operating lease right-of-use asset", "label": "Deferred Tax Liabilities, Leasing Arrangements", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements." } } }, "auth_ref": [ "r62", "r900" ] }, "cort_DepositsForClinicalTrials": { "xbrltype": "monetaryItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "DepositsForClinicalTrials", "crdr": "debit", "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsOtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deposits for clinical trials", "label": "Deposits For Clinical Trials", "documentation": "Deposits For Clinical Trials" } } }, "auth_ref": [] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization of property and equipment", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r8", "r223" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Annual Report", "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r731", "r732", "r745" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Financial Statement Error Correction [Flag]", "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r731", "r732", "r745", "r781" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r766" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Documents Incorporated by Reference", "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r729" ] }, "cort_ESPPMember": { "xbrltype": "domainItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "ESPPMember", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails", "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ESPP", "label": "ESPP [Member]", "documentation": "ESPP" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic net income per share (in dollars per share)", "verboseLabel": "Basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r167", "r186", "r187", "r188", "r189", "r190", "r196", "r199", "r210", "r211", "r212", "r216", "r475", "r476", "r565", "r580", "r698" ] }, "cort_EarningsPerShareBasicAndDilutedEPSAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "EarningsPerShareBasicAndDilutedEPSAbstract", "presentation": [ "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Net income per share attributable to common stockholders", "label": "Earnings Per Share, Basic and Diluted EPS [Abstract]", "documentation": "Earnings Per Share, Basic and Diluted EPS" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted net income per share (in dollars per share)", "verboseLabel": "Diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r167", "r186", "r187", "r188", "r189", "r190", "r199", "r210", "r211", "r212", "r216", "r475", "r476", "r565", "r580", "r698" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.corcept.com/role/NetIncomePerShare" ], "lang": { "en-us": { "role": { "terseLabel": "Net Income Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r195", "r213", "r214", "r215" ] }, "cort_EmployeeAndDirectorStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "EmployeeAndDirectorStockOptionMember", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee and Director Stock Option", "label": "Employee And Director Stock Option [Member]", "documentation": "Employee and director stock option." } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsOtherAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsOtherAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r22" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "crdr": "debit", "calculation": { "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofStockBasedCompensationDetails": { "parentTag": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation capitalized in inventory", "label": "Share-Based Payment Arrangement, Amount Capitalized", "documentation": "Amount of cost capitalized for award under share-based payment arrangement." } } }, "auth_ref": [ "r398" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation expense", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r399" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation expense, weighted-average vesting period", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r399" ] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockMember", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Purchase Plan", "label": "Employee Stock [Member]", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.corcept.com/role/NetIncomePerShareNarrativeDetails", "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options Outstanding", "verboseLabel": "Stock Options to Purchase Common Stock", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r728" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r728" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r728" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r806" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "lang": { "en-us": { "role": { "verboseLabel": "Entity Public Float", "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r728" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r728" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r728" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r728" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Voluntary Filers", "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Well-known Seasoned Issuer", "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r807" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r13", "r135", "r162", "r163", "r164", "r179", "r180", "r181", "r183", "r191", "r193", "r217", "r283", "r289", "r343", "r400", "r401", "r402", "r435", "r436", "r456", "r458", "r459", "r460", "r461", "r463", "r474", "r488", "r490", "r491", "r492", "r493", "r494", "r517", "r585", "r586", "r587", "r607", "r670" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r774" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r737", "r749", "r759", "r785" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r734", "r746", "r756", "r782" ] }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimate of fair value measurement", "label": "Estimate of Fair Value Measurement [Member]", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": [ "r325", "r482", "r704", "r705" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r780" ] }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByBalanceSheetGroupingTable", "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]", "label": "Fair Value, by Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r66", "r67", "r68" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r325", "r355", "r356", "r357", "r358", "r359", "r360", "r478", "r529", "r530", "r531", "r704", "r705", "r708", "r709", "r710" ] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementBasisAxis", "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Basis [Axis]", "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": [ "r17", "r66", "r325", "r704", "r705" ] }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosureItemAmountsDomain", "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement [Domain]", "label": "Fair Value Measurement [Domain]", "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value." } } }, "auth_ref": [ "r325", "r704", "r705" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r325", "r355", "r360", "r478", "r529", "r708", "r709", "r710" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r325", "r355", "r360", "r478", "r530", "r704", "r705", "r708", "r709", "r710" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r325", "r355", "r356", "r357", "r358", "r359", "r360", "r529", "r530", "r531", "r704", "r705", "r708", "r709", "r710" ] }, "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations", "crdr": "debit", "calculation": { "http://www.corcept.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.corcept.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total U.S. federal taxes", "label": "Federal Income Tax Expense (Benefit), Continuing Operations", "documentation": "Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r176", "r416" ] }, "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.corcept.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. federal taxes:", "label": "Federal Income Tax Expense (Benefit), Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r291", "r292", "r296", "r297", "r298", "r300", "r301", "r302", "r326", "r340", "r464", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r578", "r703", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r855", "r856", "r857", "r858" ] }, "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignIncomeTaxExpenseBenefitContinuingOperations", "crdr": "debit", "calculation": { "http://www.corcept.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.corcept.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total foreign taxes", "label": "Foreign Income Tax Expense (Benefit), Continuing Operations", "documentation": "Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations." } } }, "auth_ref": [ "r176" ] }, "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.corcept.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign taxes:", "label": "Foreign Income Tax Expense (Benefit), Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r741", "r753", "r763", "r789" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r741", "r753", "r763", "r789" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r741", "r753", "r763", "r789" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r741", "r753", "r763", "r789" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r741", "r753", "r763", "r789" ] }, "cort_GovernmentRebatesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "GovernmentRebatesMember", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesSummaryofAllowanceActivityIncludedinTradeReceivablesIncludesAllowanceforDoubtfulAccountsPromptPayCashDiscountsandChargebacksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government Rebates", "label": "Government Rebates [Member]", "documentation": "Government rebates." } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "ICFR Auditor Attestation Flag", "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r731", "r732", "r745" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "calculation": { "http://www.corcept.com/role/IncomeTaxesScheduleofComponentsofincomeTaxBenefitDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.corcept.com/role/IncomeTaxesScheduleofComponentsofincomeTaxBenefitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Domestic", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": [ "r177", "r441" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.corcept.com/role/IncomeTaxesScheduleofComponentsofincomeTaxBenefitDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.corcept.com/role/IncomeTaxesScheduleofComponentsofincomeTaxBenefitDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r89", "r120", "r220", "r232", "r236", "r238", "r566", "r575", "r700" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "crdr": "credit", "calculation": { "http://www.corcept.com/role/IncomeTaxesScheduleofComponentsofincomeTaxBenefitDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.corcept.com/role/IncomeTaxesScheduleofComponentsofincomeTaxBenefitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile." } } }, "auth_ref": [ "r177", "r441" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r306", "r308", "r655" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r308", "r655" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://www.corcept.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority", "label": "Income Tax Authority [Axis]", "documentation": "Information by tax jurisdiction." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://www.corcept.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority", "label": "Income Tax Authority [Domain]", "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.corcept.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r178", "r410", "r418", "r424", "r431", "r437", "r442", "r443", "r444", "r603" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 }, "http://www.corcept.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.corcept.com/role/IncomeTaxesReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.corcept.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails", "http://www.corcept.com/role/IncomeTaxesReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Income tax expense", "totalLabel": "Total provision for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r122", "r130", "r192", "r193", "r224", "r416", "r438", "r581" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r161", "r412", "r413", "r424", "r425", "r430", "r432", "r597" ] }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "calculation": { "http://www.corcept.com/role/IncomeTaxesReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.corcept.com/role/IncomeTaxesReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. federal taxes at statutory rate", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r417" ] }, "cort_IncomeTaxReconciliationNondeductibleExpenseBenefitShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "IncomeTaxReconciliationNondeductibleExpenseBenefitShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.corcept.com/role/IncomeTaxesReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.corcept.com/role/IncomeTaxesReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Stock-based compensation", "label": "Income Tax Reconciliation Nondeductible Expense Benefit Share Based Compensation", "documentation": "Income tax reconciliation nondeductible expense benefit share based compensation." } } }, "auth_ref": [] }, "cort_IncomeTaxReconciliationNondeductibleExpenseCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "IncomeTaxReconciliationNondeductibleExpenseCompensationCost", "crdr": "debit", "calculation": { "http://www.corcept.com/role/IncomeTaxesReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.corcept.com/role/IncomeTaxesReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-deductible compensation", "label": "Income Tax Reconciliation Nondeductible Expense Compensation Cost", "documentation": "Income tax reconciliation nondeductible expense compensation cost." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationNondeductibleExpenseOther", "crdr": "debit", "calculation": { "http://www.corcept.com/role/IncomeTaxesReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.corcept.com/role/IncomeTaxesReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses." } } }, "auth_ref": [ "r897" ] }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "crdr": "debit", "calculation": { "http://www.corcept.com/role/IncomeTaxesReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.corcept.com/role/IncomeTaxesReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State income taxes, net of federal benefit", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)." } } }, "auth_ref": [ "r897" ] }, "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationTaxCreditsResearch", "crdr": "credit", "calculation": { "http://www.corcept.com/role/IncomeTaxesReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.corcept.com/role/IncomeTaxesReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "R&D and other credits", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit." } } }, "auth_ref": [ "r897" ] }, "cort_IncomeTaxesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "IncomeTaxesLineItems", "presentation": [ "http://www.corcept.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes [Line Items]", "label": "Income Taxes [Line Items]", "documentation": "Income taxes." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes paid", "label": "Income Taxes Paid, Net", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r35" ] }, "cort_IncomeTaxesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "IncomeTaxesTable", "presentation": [ "http://www.corcept.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes [Table]", "label": "Income Taxes [Table]", "documentation": "Income taxes." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 17.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Trade receivables", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r7" ] }, "cort_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued research and development expenses", "label": "Increase (Decrease) In Accrued Research and Development Expenses", "documentation": "Increase (Decrease) In Accrued Research and Development Expenses" } } }, "auth_ref": [] }, "cort_IncreaseDecreaseInAccruedSettlementLitigationLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "IncreaseDecreaseInAccruedSettlementLitigationLiabilities", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 19.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued settlement related to Melucci litigation", "label": "Increase (Decrease) in Accrued Settlement Litigation Liabilities", "documentation": "Increase (Decrease) in Accrued Settlement Litigation Liabilities" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccruedTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedTaxesPayable", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term accrued income taxes", "label": "Increase (Decrease) in Accrued Taxes Payable", "documentation": "The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes." } } }, "auth_ref": [ "r828" ] }, "cort_IncreaseDecreaseInInsuranceRecoveryReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "IncreaseDecreaseInInsuranceRecoveryReceivable", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Insurance recovery receivable related to Melucci litigation", "label": "Increase (Decrease) in Insurance Recovery Receivable", "documentation": "Increase (Decrease) in Insurance Recovery Receivable" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventory", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 18.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r811", "r828" ] }, "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued and other liabilities", "label": "Increase (Decrease) in Other Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Other assets", "label": "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomeLossPerShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dilutive effect of employee stock options and unvested RSUs (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r200", "r201", "r202", "r212", "r366" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r744", "r753", "r763", "r780", "r789", "r793", "r801" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r799" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r733", "r805" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r733", "r805" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r733", "r805" ] }, "us-gaap_InsuranceRecoveries": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InsuranceRecoveries", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.corcept.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Insurance recovery related to Melucci litigation", "terseLabel": "Insurance recoveries", "label": "Insurance Recoveries", "documentation": "The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses." } } }, "auth_ref": [ "r93" ] }, "us-gaap_InterestReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestReceivableCurrent", "crdr": "debit", "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest receivable, current", "label": "Interest Receivable, Current", "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r823" ] }, "cort_InventoryCurrentNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "InventoryCurrentNoncurrent", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsCompositionofInventoryDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsCompositionofInventoryDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsCompositionofInventoryDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total inventory", "label": "Inventory Current Noncurrent", "documentation": "Total inventory." } } }, "auth_ref": [] }, "cort_InventoryFinishedGoodsCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "InventoryFinishedGoodsCurrentAndNoncurrent", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsCompositionofInventoryDetails": { "parentTag": "cort_InventoryCurrentNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsCompositionofInventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory Finished Goods Current And Noncurrent", "documentation": "Inventory, finished goods, current and noncurrent." } } }, "auth_ref": [] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsCompositionofInventoryDetails_1": { "parentTag": "cort_InventoryCurrentNoncurrent", "weight": 1.0, "order": 2.0 }, "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsCompositionofInventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "verboseLabel": "Total inventory classified as current", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r151", "r694", "r715" ] }, "us-gaap_InventoryNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNoncurrent", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsCompositionofInventoryDetails_1": { "parentTag": "cort_InventoryCurrentNoncurrent", "weight": 1.0, "order": 1.0 }, "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsCompositionofInventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Strategic inventory", "negatedLabel": "Less strategic inventory classified as non-current", "label": "Inventory, Noncurrent", "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle." } } }, "auth_ref": [ "r821" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory and Cost of Sales", "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r123", "r141", "r150", "r303", "r304", "r305", "r557", "r696" ] }, "cort_InventoryWorkInProcessCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "InventoryWorkInProcessCurrentAndNoncurrent", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsCompositionofInventoryDetails": { "parentTag": "cort_InventoryCurrentNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsCompositionofInventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work in progress", "label": "Inventory Work In Process Current And Noncurrent", "documentation": "Inventory, work in process. current and noncurrent." } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.corcept.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Information of Leases Asset and Liabilities", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r907" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.corcept.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r507" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://www.corcept.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r507" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.corcept.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Leases", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r908" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r512" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r512" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r512" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.corcept.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r503" ] }, "cort_LesseeShortTermLeaseLiabilityToBePaidYearOne": { "xbrltype": "monetaryItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "LesseeShortTermLeaseLiabilityToBePaidYearOne", "crdr": "credit", "presentation": [ "http://www.corcept.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Future minimum short-term lease payments, 2024", "label": "Lessee, Short-Term Lease, Liability, to be Paid, Year One", "documentation": "Lessee, Short-Term Lease, Liability, to be Paid, Year One" } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r21", "r175", "r279", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r450", "r451", "r452", "r483", "r627", "r699", "r726", "r865", "r910", "r911" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r84", "r119", "r573", "r715", "r831", "r859", "r905" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r23", "r140", "r175", "r279", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r450", "r451", "r452", "r483", "r715", "r865", "r910", "r911" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseAxis", "presentation": [ "http://www.corcept.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Axis]", "label": "Litigation Case [Axis]" } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseTypeDomain", "presentation": [ "http://www.corcept.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Domain]", "label": "Litigation Case [Domain]" } } }, "auth_ref": [] }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationSettlementAmountAwardedToOtherParty", "crdr": "credit", "presentation": [ "http://www.corcept.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment awarded to other party", "label": "Litigation Settlement, Amount Awarded to Other Party", "documentation": "Amount awarded to other party in judgment or settlement of litigation." } } }, "auth_ref": [] }, "us-gaap_LitigationSettlementExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationSettlementExpense", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.corcept.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Settlement expense related to Melucci litigation", "verboseLabel": "Litigation settlement, expense", "label": "Litigation Settlement, Expense", "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees." } } }, "auth_ref": [] }, "us-gaap_LitigationStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationStatusAxis", "presentation": [ "http://www.corcept.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Status [Axis]", "label": "Litigation Status [Axis]", "documentation": "Information by status of pending, threatened, or settled litigation." } } }, "auth_ref": [ "r863" ] }, "us-gaap_LitigationStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationStatusDomain", "presentation": [ "http://www.corcept.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Status [Domain]", "label": "Litigation Status [Domain]", "documentation": "Status of pending, threatened, or settled litigation." } } }, "auth_ref": [ "r863" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "cort_LongTermMarketableSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "LongTermMarketableSecuritiesMember", "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsSummaryoftheclassificationofavailableforsalesecuritiesincondensedconsolidatedbalancesheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term marketable securities", "label": "Long Term Marketable Securities [Member]", "documentation": "Long Term Marketable Securities [Member]" } } }, "auth_ref": [] }, "cort_LongTermMarketableSecuritiesRemainingMaturity": { "xbrltype": "durationItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "LongTermMarketableSecuritiesRemainingMaturity", "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long term marketable securities, remaining maturity", "label": "Long Term Marketable Securities, Remaining Maturity", "documentation": "Long Term Marketable Securities, Remaining Maturity" } } }, "auth_ref": [] }, "us-gaap_LongtermPurchaseCommitmentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermPurchaseCommitmentPeriod", "presentation": [ "http://www.corcept.com/role/SignificantAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial agreement period", "label": "Long-Term Purchase Commitment, Period", "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_LossContingencyAccrualCarryingValueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyAccrualCarryingValueCurrent", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.corcept.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued settlement related to Melucci litigation (Note 10)", "verboseLabel": "Accrued liability, litigation", "label": "Loss Contingency, Accrual, Current", "documentation": "Amount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r311" ] }, "cort_LossContingencyAccrualOther": { "xbrltype": "monetaryItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "LossContingencyAccrualOther", "crdr": "credit", "presentation": [ "http://www.corcept.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other losses for contingent liability", "label": "Loss Contingency Accrual, Other", "documentation": "Loss Contingency Accrual, Other" } } }, "auth_ref": [] }, "cort_LossContingencyAccrualProvisionOther": { "xbrltype": "monetaryItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "LossContingencyAccrualProvisionOther", "crdr": "debit", "presentation": [ "http://www.corcept.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other provisions for a loss contingency", "label": "Loss Contingency Accrual, Provision, Other", "documentation": "Loss Contingency Accrual, Provision, Other" } } }, "auth_ref": [] }, "us-gaap_LossContingencyReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyReceivableCurrent", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.corcept.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance recovery receivable related to Melucci litigation (Note 10)", "verboseLabel": "Insurance recovery receivable", "label": "Loss Contingency, Receivable, Current", "documentation": "Amount of receivable related to a loss contingency accrual that is expected to be collected within one year or the normal operating cycle, if longer. For example, an insurance recovery receivable." } } }, "auth_ref": [ "r864" ] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]" } } }, "auth_ref": [ "r241", "r707", "r868", "r922", "r923" ] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term marketable securities", "label": "Marketable Securities, Current", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": [ "r822" ] }, "cort_MarketableSecuritiesMaximumMaturityPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "MarketableSecuritiesMaximumMaturityPeriod", "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum maturity period", "label": "Marketable Securities Maximum Maturity Period", "documentation": "Marketable securities maximum original maturity period." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesNoncurrent", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term marketable securities", "label": "Marketable Securities, Noncurrent", "documentation": "Amount of investment in marketable security, classified as noncurrent." } } }, "auth_ref": [ "r822" ] }, "cort_MarketableSecuritiesWeightedAverageMaturityPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "MarketableSecuritiesWeightedAverageMaturityPeriod", "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average maturity period", "label": "Marketable Securities Weighted Average Maturity Period", "documentation": "Marketable securities weighted-average maturity period." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsNarrativeDetails", "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "verboseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r312", "r313", "r314", "r315", "r361", "r556", "r582", "r619", "r620", "r677", "r678", "r679", "r680", "r681", "r690", "r691", "r702", "r706", "r711", "r716", "r867", "r912", "r913", "r914", "r915", "r916", "r917" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r772" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r772" ] }, "cort_MelucciMember": { "xbrltype": "domainItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "MelucciMember", "presentation": [ "http://www.corcept.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Melucci", "label": "Melucci [Member]", "documentation": "Melucci" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsNarrativeDetails", "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "verboseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r312", "r313", "r314", "r315", "r361", "r556", "r582", "r619", "r620", "r677", "r678", "r679", "r680", "r681", "r690", "r691", "r702", "r706", "r711", "r716", "r867", "r912", "r913", "r914", "r915", "r916", "r917" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r792" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r869" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r800" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]" } } }, "auth_ref": [ "r241", "r707", "r868", "r922", "r923" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r773" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r172" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided (used in) by investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r172" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r97", "r98", "r99" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 }, "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income", "terseLabel": "Net income", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r90", "r99", "r121", "r138", "r156", "r159", "r164", "r175", "r182", "r186", "r187", "r188", "r189", "r192", "r193", "r208", "r220", "r232", "r236", "r238", "r279", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r476", "r483", "r576", "r649", "r668", "r669", "r700", "r725", "r865" ] }, "us-gaap_NetIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAbstract", "presentation": [ "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Numerator:", "label": "Net Income (Loss) Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net income attributable to common stockholders, basic", "verboseLabel": "Net income attributable to common stockholders", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r168", "r186", "r187", "r188", "r189", "r196", "r197", "r209", "r212", "r220", "r232", "r236", "r238", "r700" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Net income attributable to common stockholders, diluted", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r168", "r198", "r204", "r205", "r206", "r207", "r209", "r212" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recently Issued Accounting Pronouncements Not Yet Adopted", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "cort_NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability", "crdr": "debit", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Recognition of right-of-use asset in exchange for lease liability", "label": "Non Cash Transaction, Recognition Of Right Of Use Asset And Lease Liability", "documentation": "Non Cash Transaction, Recognition Of Right Of Use Asset And Lease Liability" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r772" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r741", "r753", "r763", "r780", "r789" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r770" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r769" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r780" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r800" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r800" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Interest and other income", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r95" ] }, "cort_NumberOfCompounds": { "xbrltype": "integerItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "NumberOfCompounds", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of compounds (more than)", "label": "Number Of Compounds", "documentation": "Number Of Compounds" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r838" ] }, "cort_NumberOfSeriesOfSelectiveCortisolModulators": { "xbrltype": "integerItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "NumberOfSeriesOfSelectiveCortisolModulators", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of series of selective cortisol modulators", "label": "Number Of Series Of Selective Cortisol Modulators", "documentation": "Number Of Series Of Selective Cortisol Modulators" } } }, "auth_ref": [] }, "cort_NumberOfStockOptionPlans": { "xbrltype": "integerItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "NumberOfStockOptionPlans", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of stock option plans", "label": "Number Of Stock Option Plans", "documentation": "Number of stock option plans." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Income from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r220", "r232", "r236", "r238", "r700" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [ "http://www.corcept.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease expense", "label": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r906" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.corcept.com/role/LeasesFutureMinimumLeasePaymentsDetails", "http://www.corcept.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Present value of operating lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r505" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term operating lease liability", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r505" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.corcept.com/role/LeasesRightofuseAssetsandRelatedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for operating lease liabilities", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r506", "r508" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.corcept.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use asset", "verboseLabel": "Operating lease right-of-use asset", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r504" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash amortization of right-of-use asset", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r829" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.corcept.com/role/LeasesRightofuseAssetsandRelatedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average discount rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r511", "r714" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.corcept.com/role/LeasesRightofuseAssetsandRelatedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining lease term", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r510", "r714" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://www.corcept.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net operating loss carryforwards", "label": "Operating Loss Carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r61" ] }, "cort_OptimeCareIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "OptimeCareIncMember", "presentation": [ "http://www.corcept.com/role/SignificantAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Optime Care, Inc.", "label": "Optime Care Inc [Member]", "documentation": "Optime Care, Inc." } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsOtherAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsOtherAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r22" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r143" ] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss) on marketable securities, net of tax impact of $(353), $105, and $198", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r153", "r154", "r155" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation gain (loss), net of tax", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r3" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive loss, net of tax", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r13", "r18", "r157", "r160", "r165", "r488", "r489", "r494", "r563", "r577", "r825", "r826" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss):", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "crdr": "debit", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss) on marketable securities, tax", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax", "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r4", "r154" ] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r99" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r772" ] }, "cort_OtherStatesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "OtherStatesMember", "presentation": [ "http://www.corcept.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other States", "label": "Other States [Member]", "documentation": "Other States [Member]" } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r739", "r751", "r761", "r787" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r742", "r754", "r764", "r790" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r742", "r754", "r764", "r790" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r768" ] }, "us-gaap_PaymentsForLegalSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForLegalSettlements", "crdr": "credit", "presentation": [ "http://www.corcept.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments for legal settlements", "label": "Payments for Legal Settlements", "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period." } } }, "auth_ref": [ "r6" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repurchase of common stock", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r33" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash paid to satisfy statutory withholding requirement for net settlement of cashless option exercises and vesting of restricted stock grants", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r171" ] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of marketable securities", "label": "Payments to Acquire Marketable Securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": [ "r841" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r96" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r771" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r771" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r770" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r780" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r773" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r769" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails", "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails", "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails", "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails", "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895" ] }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Portion at fair value measurement", "label": "Portion at Fair Value Measurement [Member]", "documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": [ "r481" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r78", "r328" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r78", "r629" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r78", "r629", "r647", "r926", "r927" ] }, "us-gaap_PreferredStockValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValueOutstanding", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value $0.001 per share, 10,000 shares authorized and no shares outstanding as of December\u00a031, 2023 and December\u00a031, 2022", "label": "Preferred Stock, Value, Outstanding", "documentation": "Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders." } } }, "auth_ref": [ "r78", "r629" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r824" ] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of common stock under our incentive award plan, net of issuance costs", "label": "Proceeds from Issuance or Sale of Equity", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": [ "r5", "r598" ] }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from maturities of marketable securities", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r169", "r170", "r841" ] }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sales of marketable securities", "label": "Proceeds from Sale of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r32", "r169", "r247", "r278" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net of accumulated depreciation and amortization", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r9", "r567", "r574", "r715" ] }, "cort_ProvisionForDoubtfulAccountsCurrentPeriodSales": { "xbrltype": "monetaryItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "ProvisionForDoubtfulAccountsCurrentPeriodSales", "crdr": "debit", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesSummaryofAllowanceActivityIncludedinTradeReceivablesIncludesAllowanceforDoubtfulAccountsPromptPayCashDiscountsandChargebacksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision related to current period sales", "label": "Provision For Doubtful Accounts, Current Period Sales", "documentation": "Provision For Doubtful Accounts, Current Period Sales" } } }, "auth_ref": [] }, "cort_ProvisionForDoubtfulAccountsPriorPeriodSales": { "xbrltype": "monetaryItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "ProvisionForDoubtfulAccountsPriorPeriodSales", "crdr": "debit", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesSummaryofAllowanceActivityIncludedinTradeReceivablesIncludesAllowanceforDoubtfulAccountsPromptPayCashDiscountsandChargebacksDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Provision related to prior period sales", "label": "Provision For Doubtful Accounts, Prior Period Sales", "documentation": "Provision For Doubtful Accounts, Prior Period Sales" } } }, "auth_ref": [] }, "us-gaap_PurchaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseObligation", "crdr": "credit", "presentation": [ "http://www.corcept.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase obligation", "label": "Purchase Obligation", "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r768" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r768" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsNarrativeDetails", "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r312", "r313", "r314", "r315", "r354", "r361", "r392", "r393", "r394", "r532", "r556", "r582", "r619", "r620", "r677", "r678", "r679", "r680", "r681", "r690", "r691", "r702", "r706", "r711", "r716", "r719", "r861", "r867", "r913", "r914", "r915", "r916", "r917" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsNarrativeDetails", "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r312", "r313", "r314", "r315", "r354", "r361", "r392", "r393", "r394", "r532", "r556", "r582", "r619", "r620", "r677", "r678", "r679", "r680", "r681", "r690", "r691", "r702", "r706", "r711", "r716", "r719", "r861", "r867", "r913", "r914", "r915", "r916", "r917" ] }, "us-gaap_ReceivableTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivableTypeDomain", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesSummaryofAllowanceActivityIncludedinTradeReceivablesIncludesAllowanceforDoubtfulAccountsPromptPayCashDiscountsandChargebacksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Receivable [Domain]", "label": "Receivable [Domain]", "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates." } } }, "auth_ref": [ "r27" ] }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "presentation": [ "http://www.corcept.com/role/IncomeTaxesChangesinBalanceofGrossUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r734", "r746", "r756", "r782" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions [Abstract]", "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.corcept.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r518", "r519", "r520", "r521", "r522", "r604", "r605", "r606", "r653", "r654", "r655", "r674", "r676" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r73", "r409", "r918" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development", "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r408" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r735", "r747", "r757", "r783" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r736", "r748", "r758", "r784" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r743", "r755", "r765", "r791" ] }, "cort_RestrictedStockAwardsRSAsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "RestrictedStockAwardsRSAsMember", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails", "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Awards (RSAs)", "label": "Restricted Stock Awards (RSAs) [Member]", "documentation": "Restricted Stock Awards (RSAs)" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails", "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofRestrictedStockActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r36" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r81", "r107", "r572", "r589", "r594", "r602", "r630", "r715" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r135", "r179", "r180", "r181", "r183", "r191", "r193", "r283", "r289", "r400", "r401", "r402", "r435", "r436", "r456", "r459", "r460", "r463", "r474", "r585", "r587", "r607", "r926" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Product revenue, net", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r221", "r222", "r231", "r234", "r235", "r239", "r240", "r241", "r352", "r353", "r558" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Net Product Revenue", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r131", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r692" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.corcept.com/role/LeasesRightofuseAssetsandRelatedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recognition of right-of-use asset in exchange for lease liability", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r509", "r714" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r800" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r800" ] }, "us-gaap_SalesAndExciseTaxPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesAndExciseTaxPayableCurrent", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsOtherAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsOtherAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Excise tax payable", "label": "Sales and Excise Tax Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r20" ] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesRevenueNetMember", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales Revenue, Net", "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r241", "r809" ] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesSummaryofAllowanceActivityIncludedinTradeReceivablesIncludesAllowanceforDoubtfulAccountsPromptPayCashDiscountsandChargebacksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": [ "r27" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Accrued Liabilities", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.corcept.com/role/NetIncomePerShareNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r36" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails", "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsSummaryoftheclassificationofavailableforsalesecuritiesincondensedconsolidatedbalancesheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Line Items]", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Available-for-Sale Securities", "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://www.corcept.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Income Tax (Benefit)", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r112" ] }, "us-gaap_ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Allowance Activity Included in Trade Receivables Includes Allowance for Doubtful Accounts, Prompt Pay Cash Discounts and Chargebacks", "label": "Financing Receivable, Current, Allowance for Credit Loss [Table Text Block]", "documentation": "Tabular disclosure of allowance for credit loss of financing receivable, classified as current." } } }, "auth_ref": [ "r43", "r860" ] }, "cort_ScheduleOfDebtAndCreditAgreementsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "ScheduleOfDebtAndCreditAgreementsTable", "presentation": [ "http://www.corcept.com/role/SignificantAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Debt And Credit Agreements [Table]", "label": "Schedule Of Debt And Credit Agreements [Table]", "documentation": "Schedule Of Debt And Credit Agreements [Table]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.corcept.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Significant Components of Deferred Tax Assets", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r111" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.corcept.com/role/NetIncomePerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Computation of Net Income Per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r837" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://www.corcept.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of Statutory Federal Income Tax Rate to Effective Rate", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r110" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r57" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Stock-Based Compensation", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r57" ] }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "presentation": [ "http://www.corcept.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Income before Income Tax, Domestic and Foreign", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions." } } }, "auth_ref": [ "r832" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItemsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Composition of Inventory", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r19", "r85", "r86", "r87" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r363", "r365", "r367", "r368", "r369", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r391", "r392", "r393", "r394", "r395" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Stock Plan Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r15", "r16", "r56" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Weighted-Average Assumptions and Resultant Fair Value-Based Measurements for Options Granted to Employees and Directors", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r109" ] }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Restricted Stock Activity", "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r46", "r47", "r48", "r49", "r50", "r51", "r52", "r105", "r106", "r107", "r145", "r146", "r147", "r218", "r328", "r329", "r330", "r332", "r335", "r340", "r342", "r598", "r599", "r600", "r601", "r706", "r808", "r830" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r727" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r730" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r225", "r226", "r227", "r228", "r229", "r230", "r240", "r701" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r94" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_SettledLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SettledLitigationMember", "presentation": [ "http://www.corcept.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Settled Litigation", "label": "Settled Litigation [Member]", "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval." } } }, "auth_ref": [ "r863" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r7" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails", "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options, vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r712" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Disclosures", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Restricted stock cancelled and forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r384" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock cancelled and forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r384" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r382" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r382" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r379", "r380" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Restricted Stock", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in dollars per share)", "periodEndLabel": "Ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r379", "r380" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Grant Date Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails", "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted-average remaining vesting period", "terseLabel": "Weighted-Average Remaining Vesting Life", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r108" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Restricted stock vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r383" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r383" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofWeightedAverageAssumptionsandResultantFairValueBasedMeasurementsforOptionsGrantedtoEmployeesandDirectorsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average assumptions for options granted:", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofWeightedAverageAssumptionsandResultantFairValueBasedMeasurementsforOptionsGrantedtoEmployeesandDirectorsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividend rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r393" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofWeightedAverageAssumptionsandResultantFairValueBasedMeasurementsforOptionsGrantedtoEmployeesandDirectorsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility of stock price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r392" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofWeightedAverageAssumptionsandResultantFairValueBasedMeasurementsforOptionsGrantedtoEmployeesandDirectorsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r394" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r363", "r365", "r367", "r368", "r369", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r391", "r392", "r393", "r394", "r395" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate", "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan." } } }, "auth_ref": [ "r55" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails", "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of RSAs granted for each share purchased (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted", "documentation": "Net number of non-option equity instruments granted to participants." } } }, "auth_ref": [ "r14" ] }, "cort_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofStockPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofStockPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercisable (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r373" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofStockPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercisable (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r373" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total intrinsic value of options exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r386" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofStockPlanActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Options canceled and forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r377" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofStockPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r375" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofWeightedAverageAssumptionsandResultantFairValueBasedMeasurementsforOptionsGrantedtoEmployeesandDirectorsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average grant date fair value-based measurement (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r385" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofStockPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r55" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofStockPlanActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r371", "r372" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofStockPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofStockPlanActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in dollars per share)", "periodEndLabel": "Ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r371", "r372" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofStockPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Options, Weighted- Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofStockPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options fully vested and expected to vest (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r388" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofStockPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options fully vested and expected to vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r387" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofStockPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options fully vested and expected to vest (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r387" ] }, "cort_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofStockPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Remaining Contractual Life", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails", "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails", "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofRestrictedStockActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Award", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r367", "r368", "r369", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r391", "r392", "r393", "r394", "r395" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofStockPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r376" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofStockPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options canceled and forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r377" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofStockPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r375" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r362", "r370", "r389", "r390", "r391", "r392", "r395", "r403", "r404", "r405", "r406" ] }, "us-gaap_ShareRepurchaseProgramAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareRepurchaseProgramAxis", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails", "http://www.corcept.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Axis]", "label": "Share Repurchase Program [Axis]", "documentation": "Information by share repurchase program." } } }, "auth_ref": [] }, "us-gaap_ShareRepurchaseProgramDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareRepurchaseProgramDomain", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails", "http://www.corcept.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Domain]", "label": "Share Repurchase Program [Domain]", "documentation": "Name of the share repurchase program." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "crdr": "debit", "calculation": { "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofStockBasedCompensationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total stock-based compensation", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount", "documentation": "Amount of cost expensed and capitalized for award under share-based payment arrangement." } } }, "auth_ref": [ "r396" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "crdr": "debit", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding", "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r713" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofWeightedAverageAssumptionsandResultantFairValueBasedMeasurementsforOptionsGrantedtoEmployeesandDirectorsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r391" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofStockPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r55" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofStockPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining contractual life, Options exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r55" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofStockPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining contractual life", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r108" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofStockPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining contractual life, Options fully vested and expected to vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r388" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "crdr": "credit", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of options vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value", "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock." } } }, "auth_ref": [ "r386" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price as percentage of fair value of common stock, no less than", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "documentation": "Purchase price of common stock expressed as a percentage of its fair value." } } }, "auth_ref": [] }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises (in shares)", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "cort_SharesRepurchasedInNetSettlementOfCashlessOptionExercise": { "xbrltype": "monetaryItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "SharesRepurchasedInNetSettlementOfCashlessOptionExercise", "crdr": "debit", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise cost of shares repurchased for net settlement of cashless option exercises", "label": "Shares Repurchased In Net Settlement Of Cashless Option Exercise", "documentation": "Shares Repurchased In Net Settlement Of Cashless Option Exercise" } } }, "auth_ref": [] }, "cort_ShortTermMarketableSecuritiesMaximumMaturityPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "ShortTermMarketableSecuritiesMaximumMaturityPeriod", "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum maturity period, short-term securities", "label": "Short Term Marketable Securities Maximum Maturity Period", "documentation": "Short Term Marketable Securities Maximum Maturity Period" } } }, "auth_ref": [] }, "cort_ShortTermMarketableSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "ShortTermMarketableSecuritiesMember", "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsSummaryoftheclassificationofavailableforsalesecuritiesincondensedconsolidatedbalancesheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term marketable securities", "label": "Short Term Marketable Securities [Member]", "documentation": "Short Term Marketable Securities [Member]" } } }, "auth_ref": [] }, "cort_SpecialtyDistributorMember": { "xbrltype": "domainItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "SpecialtyDistributorMember", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Specialty Distributor", "label": "Specialty Distributor [Member]", "documentation": "Specialty Distributor" } } }, "auth_ref": [] }, "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperations", "crdr": "debit", "calculation": { "http://www.corcept.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.corcept.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total state taxes", "label": "State and Local Income Tax Expense (Benefit), Continuing Operations", "documentation": "Amount of current and deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r832", "r896", "r902" ] }, "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.corcept.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State taxes:", "label": "State and Local Income Tax Expense (Benefit), Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StateAndLocalJurisdictionMember", "presentation": [ "http://www.corcept.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "California State", "label": "State and Local Jurisdiction [Member]", "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity." } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails", "http://www.corcept.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r132", "r145", "r146", "r147", "r175", "r199", "r203", "r210", "r212", "r218", "r219", "r279", "r316", "r318", "r319", "r320", "r323", "r324", "r328", "r329", "r332", "r335", "r342", "r483", "r598", "r599", "r600", "r601", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r629", "r650", "r670", "r682", "r683", "r684", "r685", "r686", "r808", "r830", "r836" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r13", "r26", "r135", "r162", "r163", "r164", "r179", "r180", "r181", "r183", "r191", "r193", "r217", "r283", "r289", "r343", "r400", "r401", "r402", "r435", "r436", "r456", "r458", "r459", "r460", "r461", "r463", "r474", "r488", "r490", "r491", "r492", "r493", "r494", "r517", "r585", "r586", "r587", "r607", "r670" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r179", "r180", "r181", "r217", "r558", "r596", "r618", "r621", "r622", "r623", "r624", "r625", "r626", "r629", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r642", "r643", "r644", "r645", "r646", "r648", "r651", "r652", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r670", "r720" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r179", "r180", "r181", "r217", "r558", "r596", "r618", "r621", "r622", "r623", "r624", "r625", "r626", "r629", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r642", "r643", "r644", "r645", "r646", "r648", "r651", "r652", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r670", "r720" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r738", "r750", "r760", "r786" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails", "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofStockPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon exercise of options (in shares)", "negatedLabel": "Options exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r13", "r78", "r79", "r107", "r376" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon exercise of options", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r13", "r26", "r107" ] }, "cort_StockOptionsFiscalTwentyTwelvePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "StockOptionsFiscalTwentyTwelvePlanMember", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails", "http://www.corcept.com/role/PreferredStockandStockholdersEquitySummaryofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2012 Equity Incentive Award Plan", "label": "Stock Options Fiscal Twenty Twelve Plan [Member]", "documentation": "Stock options fiscal 2012 plan." } } }, "auth_ref": [] }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails", "http://www.corcept.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Authorized amount", "label": "Stock Repurchase Program, Authorized Amount", "documentation": "Amount of stock repurchase plan authorized." } } }, "auth_ref": [] }, "cort_StockRepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "StockRepurchaseProgramMember", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails", "http://www.corcept.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Repurchase Program", "label": "Stock Repurchase Program [Member]", "documentation": "Stock repurchase program." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r79", "r82", "r83", "r101", "r631", "r647", "r671", "r672", "r715", "r726", "r831", "r859", "r905", "r926" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock and Stockholders' Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r104", "r174", "r327", "r329", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r341", "r343", "r465", "r673", "r675", "r687" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.corcept.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Line Items]", "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r495", "r524" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.corcept.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.corcept.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r495", "r524" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://www.corcept.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Table]", "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r495", "r524" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.corcept.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.corcept.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r495", "r524" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.corcept.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.corcept.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r495", "r524" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.corcept.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r523", "r525" ] }, "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SummaryOfIncomeTaxContingenciesTextBlock", "presentation": [ "http://www.corcept.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Balance of Gross Unrecognized Tax Benefits", "label": "Summary of Income Tax Contingencies [Table Text Block]", "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months." } } }, "auth_ref": [ "r11", "r113", "r114" ] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": [ "http://www.corcept.com/role/CompositionofCertainBalanceSheetItems" ], "lang": { "en-us": { "role": { "terseLabel": "Composition of Certain Balance Sheet Items", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": [ "r820" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r779" ] }, "us-gaap_TaxCreditCarryforwardAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardAmount", "crdr": "debit", "presentation": [ "http://www.corcept.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development tax credits", "label": "Tax Credit Carryforward, Amount", "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r61" ] }, "us-gaap_TaxesPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxesPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://www.corcept.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Taxes payable", "label": "Taxes Payable", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes." } } }, "auth_ref": [ "r74", "r117", "r920" ] }, "cort_TenderOfferMember": { "xbrltype": "domainItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "TenderOfferMember", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tender Offer", "label": "Tender Offer [Member]", "documentation": "Tender Offer" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Axis]", "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r839", "r909" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Domain]", "label": "Title of Individual [Domain]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r771" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r778" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r799" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r801" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.corcept.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r326", "r340", "r464", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r578", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r855", "r856", "r857", "r858" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r802" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r803" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r801" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r801" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r804" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r802" ] }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockAcquiredAverageCostPerShare", "presentation": [ "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost per share (in dollars per share)", "label": "Shares Acquired, Average Cost Per Share", "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased." } } }, "auth_ref": [ "r53" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r53" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r53" ] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury stock; at cost; 30,938 shares of common stock as of December\u00a031, 2023 and 23,124 shares of common stock as of December\u00a031, 2022", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r28", "r53", "r54" ] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockSharesAcquired", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of treasury stock (in shares)", "terseLabel": "Shares repurchased (in shares)", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": [ "r13", "r79", "r107" ] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.corcept.com/role/PreferredStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of treasury stock", "terseLabel": "Aggregate purchase price", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r13", "r53", "r107" ] }, "cort_TreasuryStockValueAcquiredExciseTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "TreasuryStockValueAcquiredExciseTax", "crdr": "debit", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Excise tax related to net share repurchases", "label": "Treasury Stock, Value, Acquired, Excise Tax", "documentation": "Treasury Stock, Value, Acquired, Excise Tax" } } }, "auth_ref": [] }, "us-gaap_TypeOfAdoptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfAdoptionMember", "presentation": [ "http://www.corcept.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type of Adoption [Domain]", "label": "Accounting Standards Update [Domain]", "documentation": "Amendment to accounting standards." } } }, "auth_ref": [ "r133", "r134", "r135", "r136", "r137", "r182", "r183", "r184", "r185", "r194", "r245", "r246", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r307", "r400", "r401", "r402", "r433", "r434", "r435", "r436", "r445", "r446", "r447", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r479", "r480", "r484", "r485", "r486", "r487", "r496", "r497", "r499", "r500", "r501", "r502", "r513", "r514", "r515", "r516", "r517", "r559", "r560", "r561", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.corcept.com/role/SignificantAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type of Arrangement and Non-arrangement Transactions", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r448" ] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. government agency securities", "label": "US Government Agencies Debt Securities [Member]", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": [ "r697", "r708", "r919" ] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USTreasurySecuritiesMember", "presentation": [ "http://www.corcept.com/role/AvailableforSaleMarketableSecuritiesandFairValueMeasurementsScheduleofAvailableforSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. Treasury securities", "label": "US Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": [ "r697", "r708", "r710", "r919" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r798" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.corcept.com/role/IncomeTaxesChangesinBalanceofGrossUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r411", "r419" ] }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions", "crdr": "debit", "presentation": [ "http://www.corcept.com/role/IncomeTaxesChangesinBalanceofGrossUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease in tax positions for current year", "label": "Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions", "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return." } } }, "auth_ref": [ "r60" ] }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "crdr": "debit", "presentation": [ "http://www.corcept.com/role/IncomeTaxesChangesinBalanceofGrossUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Decreases in tax positions for prior years", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r420" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued", "crdr": "credit", "presentation": [ "http://www.corcept.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits, accrued penalties", "label": "Unrecognized Tax Benefits, Income Tax Penalties Accrued", "documentation": "Amount of statutory penalties accrued for a tax position claimed or expected to be claimed by the entity, in its tax return." } } }, "auth_ref": [ "r898" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://www.corcept.com/role/IncomeTaxesChangesinBalanceofGrossUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in tax positions for current year", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return." } } }, "auth_ref": [ "r421" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://www.corcept.com/role/IncomeTaxesChangesinBalanceofGrossUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in tax positions for prior years", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r420" ] }, "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued", "crdr": "credit", "presentation": [ "http://www.corcept.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits, accrued interest", "label": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued", "documentation": "Amount of interest expense accrued for an underpayment of income taxes." } } }, "auth_ref": [ "r898" ] }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "crdr": "debit", "presentation": [ "http://www.corcept.com/role/IncomeTaxesChangesinBalanceofGrossUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease in tax positions for expirations of statute of limitations", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations." } } }, "auth_ref": [ "r422" ] }, "cort_UnrecognizedTaxBenefitsThatWouldBeOffsetByAChangeInValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.corcept.com/20231231", "localname": "UnrecognizedTaxBenefitsThatWouldBeOffsetByAChangeInValuationAllowance", "crdr": "credit", "presentation": [ "http://www.corcept.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits that would be offset by a change in valuation allowance", "label": "Unrecognized Tax Benefits That Would Be Offset By A Change In Valuation Allowance", "documentation": "Unrecognized Tax Benefits That Would Be Offset By A Change In Valuation Allowance" } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "crdr": "credit", "presentation": [ "http://www.corcept.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits that would impact effective tax rate", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate." } } }, "auth_ref": [ "r423" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.corcept.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r40", "r41", "r42", "r124", "r125", "r127", "r128" ] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": [ "http://www.corcept.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in valuation allowance", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": [ "r426" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomeLossPerShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted average shares used to compute diluted net income per common share (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r198", "r212" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Denominator:", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomeLossPerShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.corcept.com/role/NetIncomePerShareScheduleofComputationofNetIncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted-average shares used to compute basic net income per common share (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r196", "r212" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [ "http://www.corcept.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average shares outstanding used in computing net income per common share", "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(1)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.3,4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "50", "Paragraph": "11B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "9", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r696": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r697": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r699": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r700": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r701": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47" }, "r702": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r703": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r704": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r705": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r706": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r707": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r708": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r711": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r712": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r713": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r714": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r715": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r716": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r717": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r719": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r723": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r724": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r725": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r726": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r738": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r744": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r771": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r772": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r773": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r774": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r775": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r776": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r777": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r778": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r779": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r780": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r781": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r782": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r783": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r784": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r785": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r786": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r787": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r788": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r789": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r790": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r791": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r792": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r793": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r794": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r795": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r796": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r797": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r798": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r799": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r800": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r801": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r802": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r803": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r804": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r805": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r806": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r807": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r808": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//210/tableOfContent" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 80 0001628280-24-005055-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-24-005055-xbrl.zip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�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�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

V@EMQ@P&XZ#'&..@.S*3 M2&"5%[P56V;]?O/W&N4_O)WPWNTPS,8T8XZ8(_HQZ'A26C('Y)BN+%JXSF&Q MX\>=1V3!,2:(L1# @!$ 801!SA $!".>\9PD,;9R?+ M. .MF3_C.L"F\FGL-S-=3Z=[Q\9E-!P[-\YT]"H.CLL*7W)R]+QAQQ*?F&B( M?:H#H"JR+M31Z*>B9!\W[+%:!&F8^&$0@IPP"B A4!Y34T"R+,213S.8&_DW M!_J;&U_4XM[4T7PR+F4GLO=#"NTIJ0VO1 UAKLVI'M^;A34D5[%J1S(;T8\AN.@QT/CH3LR M+?4".][-D.MP<\19AIU/2F%VP!PSFF4K=@3WC6V0X$KZ'JU+T4U[GH&$'>7' M<000C4+)9B% Q$]!@@*(0+?_Y8*BG]56S7T5&S04NIUX]T^RGK8 M$^4-'&D$G*<3="WG*V49' GNR\D'Q^K0(GD!_>?#ZLNJO&>K+VPEN_]0FB

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

Z:*<[[!B01X?R_;BPS_@J#\'[+@P0LTCI= "P:R-G!IL34:@B'@- MF E:&G_N?+1T#G,",2@M_2=#V5]+I]I>SPW"::16Q2[;B)ZZ@L< M"DPNHT5E^#';9KKM_6.N\G> .0.1F(_!5*6T5%XE)4X%:[*K-J7M,T2'"QH7 M[.=R#AX8I+EDB-V&V%W[O'+UU^CG@!W]'M?\1@^N M9=#[H+ R##EHB>W8N[_>N VRSEO1]Z0CJ]#[4MR]66^LL=\?31=1E2'4 M87C28\&6WG81 [HUK+[@=BC.B\1,2=R((J8\$+I6)"U6;J.K0^B^CA@V@_I" MM'I.8&Z%%*CPFP]G#+S7M@D]NM(7+7^V!+&335M'N&&0$^]7:5CYV-FHH.(%$ZM2MPQK1/,H'%MYR:"XW/ [D M>M$OY+K$&'^LLASV/_*.][:L?@!%.;JT#\046SMD].(B,27+5@6'_9G?T%- MF5ZL@Z% E46!D?BL+J_8'5?P%*&EGMF\HV_K57M, MD,#VJ;%^3>L8=[':09!6U'95UC4P(V-=; LP:HY[(TQ7& M9@S&6C!/*JH+DH8*SE+9G8&[O,D[GTJ=H3*%'(^GV%TB@M'2>UK1]T[UF#NZ M?QR8\;)?F-$6W@OPT7^L.*7DZ6RDBM8%::+$FCV[;DFOOQ:-P9I0I).\7E1W0QCF1R[$O K*F.BCJYU38?" R$X.V/0!Y!*#O0KLN:,CJ,1BI M(&@H:,@BF!+^.XI.!@G%5'AXJ5*ORPQIDD*Z_(.-;*R/SLW1B:^.F5KKI*:; M++^TA+*PE&7AV^7P:*5#E>V:RN1-I W-,:3-#DBP(=KEY3M]*8,.M0:0L70O M49&D.AF7RI>R(@+;41CIR@W[DO-U27M.)W-#TMYT+.=QP$=_*H,3?+A#O&AI M8_U'CD[1'!KCKG0>$7=]>VL3VO;7+5G'[-!\>;@&LQ8&WFKL<&<5+*B^R?<4 M W>UYV&F&-P_\3=W_LD]B]2Y[5\R@Z^P0J'Z6Q6/%^MT+LO)KP6C;W?Z#9[? MD_]P@BR*SCJI?> O<%,AJ^>F<8%+RQ5^051)7RXA>)YA8=%&90\7F+\R V*U M"Q7)!'K)8[IZ%5CB3@EQGBZ9X"UJ&)+C%10?K)V$R]>J&O!92E#D$1-%$0RJ M^$F+P!GE &(P_62Q,-RJF6P+66AZ51IFIIK$I6&U"U#4G@Q>M+O?;5=<3'@< MLKT_9;9)ME]540108(H'X-#O%.AA27;G!.;(5DW_\-B2 YUC8QIO%N8*=&H- MM(HZ*WYF!^XU(09_E*%?LX,W724$DKZ/)!HU[,]]6B+1O^/IT>W/#W+&QM(_ M55X],.=0_38"YY'$7\,@B$_PIVJ/8UIR'5GQ+T-875*$M$N\,HI5K?W;O4IW M4^D,0ZD&]E B;80$4RY>G; M0?/%.X0QF!' (2ZL#O)=F@)/+&^^;VW),J;=UZM+N(KA)6QF%CA3OQM*?*'Z ML1E*&"8>%V#$Q#M^ Q/X<_(-"8Z&.M8E'%ZTD9/ZU?#D^J-X>RZN+OY^>?Y. MO/T5WT8K\"6NIY>_NF#TE3C_G_.SGZ\O_GDN/KY_?W%V_OF*;EM!^X--W]5! MD^S-2VK7O53T-+K)S2Q5;$KV7RA?,"22L.77:X*6-\8JZB2B_6I<%:T+(3,7 M&1TA-8)(=N_?]->2!^P73H(,$R>TZRPR2I^YXU6Y/I5A_2MDP:SE8FU,EM M2#0:P*'1FGU!"TKV:%P8(E=H2,N"TB0X ERA@DD:G1NDHDH:_GI%R_^"6C*> MH)R20**4$CJ1ULNAVFCK;_XV;X=R1T8^($YPD*YR#JE\Y:16%E%;&R]\=OMC='QZN_'IO=[CRNW7=[N_N MOUC][>_ME29[M%&WSV@C>#-@NRW0WX]/#IXTFAI9R,?[TR]BV-82T&A>VG$S MO2=)^W;A[61NW6N6M"?HALQ7/^IV;$'U'SZG)_Z<(3=X5.R)@]T7+Y:FN:JQ M8S6\LX.MP>P L,)C.GDP1TXJ\B5H)FU=]YOL[2/8GE9.TV-B=3:-=)G^&0>_ MFN6?D=39Q.C]MW4,//]]CH%G^.X;^&]29NF;_P=02P$"% ,4 " Q@D]8 M.'0$AT # @#(NA0 $0 @ $ 8V]R="TR,#(S,3(S,2YH M=&U02P$"% ,4 " Q@D]8CJ%7A[D0 #WL@ $0 @ %O M P( 8V]R="TR,#(S,3(S,2YX9 P!C;W)T M+3(P,C,Q,C,Q7VQA8BYX;6Q02P$"% ,4 " Q@D]8SM.T)<&- !HJ08 M%0 @ &^H 0 8V]R="TR,#(S,3(S,5]P&UL4$L! A0# M% @ ,8)/6,"$SEG?*@ 7 8! !8 ( !LBX% &-O#,Q,BYH=&U02P$"% ,4 M " Q@D]8V>C%6?L$ #X% %0 @ '@; 4 8V]R=#(P M,C,Q,"UK97@S,C$N:'1M4$L! A0#% @ ,8)/6*'^(G?A! SQ0 !4 M ( !#G(% &-O#DW+FAT;5!+!08 #@ . *$# !.C04 ! end XML 81 cort-20231231_htm.xml IDEA: XBRL DOCUMENT 0001088856 2023-01-01 2023-12-31 0001088856 2023-06-30 0001088856 2024-02-06 0001088856 2023-12-31 0001088856 2022-12-31 0001088856 2022-01-01 2022-12-31 0001088856 2021-01-01 2021-12-31 0001088856 cort:TenderOfferMember 2023-01-01 2023-12-31 0001088856 cort:TenderOfferMember 2022-01-01 2022-12-31 0001088856 cort:TenderOfferMember 2021-01-01 2021-12-31 0001088856 cort:StockRepurchaseProgramMember 2023-01-01 2023-12-31 0001088856 cort:StockRepurchaseProgramMember 2022-01-01 2022-12-31 0001088856 cort:StockRepurchaseProgramMember 2021-01-01 2021-12-31 0001088856 2021-12-31 0001088856 2020-12-31 0001088856 us-gaap:CommonStockMember 2020-12-31 0001088856 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001088856 us-gaap:TreasuryStockCommonMember 2020-12-31 0001088856 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001088856 us-gaap:RetainedEarningsMember 2020-12-31 0001088856 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001088856 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001088856 us-gaap:TreasuryStockCommonMember 2021-01-01 2021-12-31 0001088856 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001088856 cort:StockRepurchaseProgramMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001088856 cort:StockRepurchaseProgramMember us-gaap:TreasuryStockCommonMember 2021-01-01 2021-12-31 0001088856 cort:TenderOfferMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001088856 cort:TenderOfferMember us-gaap:TreasuryStockCommonMember 2021-01-01 2021-12-31 0001088856 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001088856 us-gaap:CommonStockMember 2021-12-31 0001088856 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001088856 us-gaap:TreasuryStockCommonMember 2021-12-31 0001088856 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001088856 us-gaap:RetainedEarningsMember 2021-12-31 0001088856 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001088856 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001088856 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-12-31 0001088856 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0001088856 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001088856 us-gaap:CommonStockMember 2022-12-31 0001088856 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001088856 us-gaap:TreasuryStockCommonMember 2022-12-31 0001088856 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001088856 us-gaap:RetainedEarningsMember 2022-12-31 0001088856 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001088856 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001088856 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-12-31 0001088856 cort:TenderOfferMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001088856 cort:TenderOfferMember us-gaap:TreasuryStockCommonMember 2023-01-01 2023-12-31 0001088856 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0001088856 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001088856 us-gaap:CommonStockMember 2023-12-31 0001088856 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001088856 us-gaap:TreasuryStockCommonMember 2023-12-31 0001088856 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001088856 us-gaap:RetainedEarningsMember 2023-12-31 0001088856 cort:SpecialtyDistributorMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001088856 cort:SpecialtyDistributorMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001088856 cort:SpecialtyDistributorMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001088856 cort:ChargebacksMember 2020-12-31 0001088856 cort:GovernmentRebatesMember 2020-12-31 0001088856 cort:ChargebacksMember 2021-01-01 2021-12-31 0001088856 cort:GovernmentRebatesMember 2021-01-01 2021-12-31 0001088856 cort:ChargebacksMember 2021-12-31 0001088856 cort:GovernmentRebatesMember 2021-12-31 0001088856 cort:ChargebacksMember 2022-01-01 2022-12-31 0001088856 cort:GovernmentRebatesMember 2022-01-01 2022-12-31 0001088856 cort:ChargebacksMember 2022-12-31 0001088856 cort:GovernmentRebatesMember 2022-12-31 0001088856 cort:ChargebacksMember 2023-01-01 2023-12-31 0001088856 cort:GovernmentRebatesMember 2023-01-01 2023-12-31 0001088856 cort:ChargebacksMember 2023-12-31 0001088856 cort:GovernmentRebatesMember 2023-12-31 0001088856 cort:RestrictedStockAwardsRSAsMember cort:ESPPMember 2023-01-01 2023-12-31 0001088856 cort:OptimeCareIncMember 2017-08-01 2017-08-31 0001088856 us-gaap:CashEquivalentsMember 2023-12-31 0001088856 us-gaap:CashEquivalentsMember 2022-12-31 0001088856 cort:ShortTermMarketableSecuritiesMember 2023-12-31 0001088856 cort:ShortTermMarketableSecuritiesMember 2022-12-31 0001088856 cort:LongTermMarketableSecuritiesMember 2023-12-31 0001088856 cort:LongTermMarketableSecuritiesMember 2022-12-31 0001088856 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CorporateBondSecuritiesMember 2023-12-31 0001088856 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CorporateBondSecuritiesMember 2022-12-31 0001088856 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CommercialPaperMember 2023-12-31 0001088856 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CommercialPaperMember 2022-12-31 0001088856 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001088856 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001088856 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2023-12-31 0001088856 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:AssetBackedSecuritiesMember 2022-12-31 0001088856 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001088856 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0001088856 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MoneyMarketFundsMember 2023-12-31 0001088856 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MoneyMarketFundsMember 2022-12-31 0001088856 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0001088856 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-12-31 0001088856 srt:MinimumMember 2023-01-01 2023-12-31 0001088856 srt:MaximumMember 2023-01-01 2023-12-31 0001088856 us-gaap:AccountingStandardsUpdate201602Member 2023-12-31 0001088856 cort:TenderOfferMember us-gaap:CommonStockMember 2023-03-31 0001088856 cort:TenderOfferMember us-gaap:CommonStockMember 2023-04-05 2023-04-05 0001088856 cort:TenderOfferMember us-gaap:CommonStockMember 2021-11-30 0001088856 cort:TenderOfferMember us-gaap:CommonStockMember 2021-11-08 2021-12-15 0001088856 cort:StockRepurchaseProgramMember us-gaap:CommonStockMember 2020-11-30 0001088856 cort:StockRepurchaseProgramMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001088856 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001088856 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001088856 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001088856 cort:StockOptionsFiscalTwentyTwelvePlanMember 2023-01-01 2023-12-31 0001088856 srt:MinimumMember cort:StockOptionsFiscalTwentyTwelvePlanMember 2023-01-01 2023-12-31 0001088856 srt:MaximumMember cort:StockOptionsFiscalTwentyTwelvePlanMember 2023-01-01 2023-12-31 0001088856 cort:StockOptionsFiscalTwentyTwelvePlanMember 2023-12-31 0001088856 cort:EmployeeAndDirectorStockOptionMember 2023-12-31 0001088856 cort:EmployeeAndDirectorStockOptionMember 2023-01-01 2023-12-31 0001088856 us-gaap:RestrictedStockMember cort:StockOptionsFiscalTwentyTwelvePlanMember 2022-12-31 0001088856 us-gaap:RestrictedStockMember cort:StockOptionsFiscalTwentyTwelvePlanMember 2023-01-01 2023-12-31 0001088856 us-gaap:RestrictedStockMember cort:StockOptionsFiscalTwentyTwelvePlanMember 2023-12-31 0001088856 us-gaap:RestrictedStockMember 2023-01-01 2023-12-31 0001088856 us-gaap:EmployeeStockMember 2023-12-31 0001088856 cort:RestrictedStockAwardsRSAsMember 2023-01-01 2023-12-31 0001088856 cort:RestrictedStockAwardsRSAsMember 2022-01-01 2022-12-31 0001088856 us-gaap:CostOfSalesMember 2023-01-01 2023-12-31 0001088856 us-gaap:CostOfSalesMember 2022-01-01 2022-12-31 0001088856 us-gaap:CostOfSalesMember 2021-01-01 2021-12-31 0001088856 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-12-31 0001088856 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0001088856 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001088856 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-12-31 0001088856 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-12-31 0001088856 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-12-31 0001088856 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001088856 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001088856 us-gaap:StateAndLocalJurisdictionMember 2023-12-31 0001088856 cort:OtherStatesMember 2023-12-31 0001088856 us-gaap:SubsequentEventMember 2024-01-31 0001088856 cort:MelucciMember us-gaap:SettledLitigationMember 2023-02-08 2023-02-08 0001088856 cort:MelucciMember us-gaap:SettledLitigationMember 2022-10-01 2022-12-31 0001088856 cort:MelucciMember us-gaap:SettledLitigationMember 2023-12-31 0001088856 cort:MelucciMember us-gaap:SettledLitigationMember us-gaap:SubsequentEventMember 2024-01-04 2024-01-04 0001088856 cort:StockRepurchaseProgramMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-01-08 iso4217:USD shares iso4217:USD shares cort:series cort:compound pure cort:segment cort:plan false 2023 FY 0001088856 10-K true 2023-12-31 --12-31 false 000-50679 CORCEPT THERAPEUTICS INC DE 77-0487658 149 Commonwealth Drive Menlo Park CA 94025 650 327-3270 Common Stock, $0.001 par value CORT NASDAQ Yes No Yes Yes Large Accelerated Filer false false true false false 1827006147 103517388 <div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portions of the Registrant’s definitive proxy statement for its 2024 Annual Meeting of Stockholders are incorporated by reference in Items 10, 11, 12, 13 and 14 of Part III.</span></div> false false false false 42 Ernst & Young LLP San Mateo, California 135551000 66329000 232670000 365343000 41123000 31057000 14000000 14000000 7730000 6100000 27562000 16424000 458636000 499253000 8244000 10931000 120000 1143000 195000 633000 57176000 4947000 6541000 5058000 90605000 61465000 621517000 583430000 17396000 11976000 21330000 14573000 51628000 30799000 14000000 14000000 151000 1143000 104505000 72491000 10307000 9097000 114812000 81588000 0.001 0.001 10000000 10000000 0 0 0 0 0.001 0.001 280000000 280000000 134344000 103405000 130959000 107835000 133000 131000 30938000 23124000 635078000 456148000 738515000 662342000 609000 -869000 402526000 296386000 506705000 501842000 621517000 583430000 482375000 401858000 365978000 6481000 5385000 5281000 184353000 130991000 113864000 184259000 152848000 122356000 0 14000000 0 0 14000000 0 375093000 289224000 241501000 107282000 112634000 124477000 17275000 3557000 529000 124557000 116191000 125006000 18417000 14773000 12494000 106140000 101418000 112512000 105496000 105496000 101288000 101288000 112512000 112512000 1.02 0.95 0.97 0.94 0.87 0.89 103560000 106787000 115653000 111742000 115966000 125963000 106140000 101418000 112512000 -353000 105000 198000 1120000 -331000 -621000 358000 -311000 -21000 107618000 100776000 111870000 106140000 101418000 112512000 48940000 42442000 42931000 9128000 -1383000 -5083000 465000 477000 409000 577000 782000 1072000 -29493000 -33905000 4346000 1320000 2187000 1995000 0 0 -10000 10066000 3432000 1427000 0 14000000 0 -1265000 -1199000 -3444000 11603000 6557000 4006000 1483000 1975000 -1917000 5778000 4757000 -3597000 6757000 2131000 -1262000 17649000 2927000 6479000 0 14000000 0 1210000 8688000 11000 -1289000 -2199000 -2025000 127039000 120323000 167892000 139000 413000 469000 419793000 241152000 398937000 0 0 50463000 328748000 355066000 312805000 90906000 -114327000 136126000 5811000 4381000 16229000 145428000 0 207500000 0 0 88485000 9106000 21665000 22835000 -148723000 -17284000 -302591000 69222000 -11288000 1427000 66329000 77617000 76190000 135551000 66329000 77617000 47602000 39747000 9104000 25032000 24388000 15796000 297000 2816000 0 116735000 122000 516140000 -75795000 415000 82456000 523338000 4632000 5000 32041000 32046000 1560000 38631000 38631000 43168000 43168000 -642000 -642000 3867000 88485000 88485000 10000000 207500000 207500000 112512000 112512000 105940000 127000 591349000 -410411000 -227000 194968000 375806000 3741000 4000 28478000 28482000 1846000 45737000 45737000 42515000 42515000 -642000 -642000 101418000 101418000 107835000 131000 662342000 -456148000 -869000 296386000 501842000 3383000 2000 29126000 29128000 1203000 32424000 32424000 6610000 145428000 145428000 1078000 1078000 45977000 45977000 1070000 1070000 1478000 1478000 106140000 106140000 103405000 133000 738515000 -635078000 609000 402526000 506705000 Basis of Presentation and Summary of Significant Accounting Policies<div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Business and Basis of Presentation</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corcept Therapeutics Incorporated (collectively, “Corcept,” the “Company,” “we,” “us” and “our”) is a commercial-stage pharmaceutical company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. In 2012, the United States Food and Drug Administration (“FDA”) approved Korlym</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“mifepristone”) 300 mg tablets, as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. We have discovered and patented four structurally distinct series of selective cortisol modulators, consisting of more than 1,000 compounds. We are developing compounds from these series as potential treatments for a broad range of serious disorders.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in the State of Delaware in May 1998. Our headquarters are located in Menlo Park, California.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”).</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements include the financial position and results of operations of Corcept Therapeutics UK Limited, our wholly owned subsidiary, which we incorporated in the United Kingdom in March 2017. All material intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reevaluate our estimates and assumptions each quarter, including those related to revenue recognition, recognition and measurement of income tax assets and liabilities, inventory, allowances for doubtful accounts and other accrued liabilities, including our bonus accrual, clinical trial accruals and stock-based compensation.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We value financial instruments using assumptions we believe third-party market participants would use. When choosing which assumptions to make when determining the value of a financial instrument, we look first for quoted prices in active markets for identical instruments (“Level 1 inputs”). If no Level 1 inputs are available, we consider (i) quoted prices in non-active markets for identical instruments; (ii) active markets for similar instruments; (iii) inputs other than quoted prices for the instrument; and (iv) inputs that are not directly observable, but that can be corroborated by observable data (“Level 2 inputs”). In the absence of Level 2 inputs, we rely on unobservable inputs, such as our estimates of the assumptions market participants would use in pricing the instrument (“Level 3 inputs”).</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents and Marketable Securities</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider highly liquid investments that will mature in three months or less from the time we purchase them to be cash equivalents. Cash equivalents are valued using Level 1 inputs, which approximate our cost.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest the majority of our funds in marketable securities, primarily corporate notes, U.S. Treasury and government agency securities, asset-backed securities and commercial paper. We classify our marketable securities as available-for-sale securities and report them at fair value as “cash equivalents” or “marketable securities” on our consolidated balance sheet, with related unrealized gains and losses included in stockholders' equity. Realized gains and losses and permanent declines in value are included in “interest and other income (expense)” on our consolidated statements of income.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit and Concentration Risks</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash, cash equivalents and marketable securities are held in four financial institutions. We are subject to credit risk from our cash equivalents and marketable securities. We limit our investments to U.S. Treasury obligations and high-grade corporate debt and asset-backed securities with less than a 36-month maturity at the time of purchase. These investments are diversified and do not expose us to concentrations of credit risk. We have never experienced a loss in, or lack of access to, our operating or investment accounts.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an agreement with one third-party manufacturer to supply mifepristone, the active pharmaceutical ingredient (“API”), in Korlym.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a concentration of risk in regard to the distribution of our product. A single specialty pharmacy, Optime Care, Inc. (“Optime”), dispenses Korlym to patients for us. Optime is an independent third party. Its unwillingness or inability to dispense Korlym to patients in a timely manner would harm our business.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell Korlym that Optime dispenses directly to patients, with title to the medicine passing directly from us to the patient upon the patient’s receipt of the drug. Our receivables risk is spread among various third-party payers – pharmacy benefit managers, insurance companies, government programs and private charities. We monitor our exposure and record an allowance against uncollectible trade receivables as necessary. To date, we have not recorded an allowance for credit losses.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory and Cost of Sales</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory approval of product candidates is uncertain. Because product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained, we record the cost of manufacturing our product candidates as research and development expense at the time such costs are incurred. Once a product candidate is approved by the FDA, we begin capitalizing manufacturing costs. We capitalize to inventory manufacturing costs related to Korlym.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We value inventory at the lower of cost or net realizable value and determine the cost of inventory we sell using the specific identification method, which approximates a first-in, first-out basis. We assess our inventory levels at each reporting period and write down inventory that is either expected to be at risk of expiration prior to sale, has a cost basis in excess of its expected net realizable value, or for which there are inventory quantities in excess of expected requirements. We destroy expired inventory and recognize the related costs as cost of sales in that period’s statement of income.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales also includes the cost of manufacturing Korlym, including materials, third-party manufacturing costs and indirect personnel and other overhead costs, based on the number of Korlym tablets for which we recognize revenue, as well as costs of stability testing, logistics and distribution.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify inventory we do not expect to sell within 12 months of the balance sheet date as strategic inventory, a non-current asset.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Product Revenue</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell Korlym directly to patients through a single specialty pharmacy. We also sell Korlym to a specialty distributor (“SD”), for which we recognize revenue at the time the SD receives Korlym. SD sales were less than one percent of our net revenue in each of the years ended December 31, 2023, 2022 and 2021.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine our revenue from the sale of Korlym, we (i) identify our contract with each customer; (ii) identify the obligations of Corcept and the customer under the contract; (iii) determine the contracted transaction price; (iv) allocate the transaction price to the contract’s performance obligations, which in our case consists of delivering Korlym to the customer; and (v) recognize revenue once Korlym has been delivered, provided we deem it probable that we will collect the payment due to us.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Confirmation of coverage by private or government insurance or by a third-party charity is a prerequisite for selling Korlym to a patient.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine net product revenue, we deduct from sales the cost of our patient co-pay assistance program and our estimates of (a) government chargebacks and rebates, (b) discounts provided to our SD for prompt payment and (c) reserves for expected returns. We record these estimates at the time we recognize revenue and update them as new information becomes available. Our estimates take into account our understanding of the range of possible outcomes. If results differ from our estimates, we adjust our estimates, which changes our net product revenue and earnings. We report any changes in the period they become known, even if they concern transactions occurring in prior periods.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Korlym is eligible for purchase by, or qualifies for reimbursement from, Medicaid, Medicare and other government programs that are eligible for rebates on the price they pay for Korlym. To determine the appropriate amount to reserve against these rebates, we identify Korlym sold to patients covered by government-funded programs, apply the applicable government discount to these sales, then estimate utilization of such programs by government payors. We (i) deduct this reserve from revenue in the period to which the rebates relate and (ii) include in accrued expenses on our consolidated balance sheet a current liability of an equal amount.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Although we sell Korlym to the SD at full price, some of the government entities to which the SD sells receive a discount. The SD recovers the full amount of any related discounts by reducing its payment to us (this reduction is called a “chargeback”). Chargebacks sometimes relate to Korlym purchased by the SD in prior periods. We deduct from our revenue in each period chargebacks claimed by the SD for Korlym it purchased in that period. We also create a reserve for chargebacks we estimate the SD will claim in future periods against Korlym it purchased in the current period but has not yet resold. We determine the amount of this reserve based on our experience with SD chargebacks and our understanding of the SD’s customer base and business practices. We deduct this reserve from revenue and include in accrued expenses on our consolidated balance sheet a current liability of equal amount.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient Assistance Program and Charitable Support: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is our policy that no patient be denied Korlym due to inability to pay. We provide financial assistance to eligible patients whose insurance policies have high deductibles or co-payments and deduct the amount of such assistance from gross revenue. We determine the assistance we provide each patient by applying our program guidelines to that patient’s financial position and their insurance policy’s co-payment and deductible requirements for the purchase of Korlym. We donate cash to charities that help patients with financial need pay for the treatment of Cushing’s syndrome. We do not include payments from these charities in revenue, but as a deduction to selling, general and administrative expenses. We provide Korlym at no cost to uninsured patients who do not qualify for charitable support.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales Returns:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Federal law prohibits the return of Korlym sold to patients. Sales to our SD are subject to return. We deduct the amount of Korlym we estimate the SD will return from each period’s gross revenue. We base our estimates on quantitative and qualitative information including, but not limited to, historical return rates, the amount of Korlym held by the SD and projected demand. If we cannot reasonably estimate returns with respect to a particular sale, we defer recognition of revenue until we can make a reasonable estimate. To date, returns have not been significant.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity in each of the product revenue allowance and reserve categories for the years ended December 31, 2023, 2022 and 2021:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:60.043%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.365%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Government Rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,412 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,575 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to current period sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,709 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to prior period sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,047)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,076)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit or payments made during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(478)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,900)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,378)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,174 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,224 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to current period sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,745 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,302 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to prior period sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit or payments made during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(455)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,753)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,208)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,098 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,328 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to current period sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,825 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,171 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to prior period sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(555)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(643)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit or payments made during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(266)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,900)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,166)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,468 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,690 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense includes the direct cost of discovering and screening new compounds, pre-clinical studies, clinical trials, manufacturing development, submissions to regulatory agencies and related overhead costs. We expense nonrefundable payments and the cost of technologies and materials used in research and development as we incur them.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base our accruals for discovery research, preclinical studies and clinical trials on our estimates of work completed, milestones achieved, patient enrollment and past experience with similar activities. Our estimates include assessments of information from contract research organizations and the status of our own research, development and administrative activities.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our operating segments based on the way we organize our business, make decisions and assess performance. We have one operating segment, which is the discovery, development and commercialization of pharmaceutical products.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize stock-based compensation expense for stock options, restricted stock awards (“RSAs”) and restricted stock units (“RSUs”), net of estimated forfeitures, on a straight-line basis over the period during which an employee is required to provide services in exchange for the award (the vesting period of the award). We estimate future forfeitures during the first quarter of each fiscal year, and revise the estimates, if necessary, in subsequent periods if actual forfeitures differ significantly from those estimates.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the fair value of stock options based on the value of the award at the grant date, using the Black-Scholes model. We recognize stock-based compensation expense over the applicable vesting period, net of estimated forfeitures. If actual forfeitures differ from our estimates, we adjust stock-based compensation expense accordingly.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have issued RSAs in connection with our Employee Stock Purchase Plan (“ESPP”) that vest on the condition that the participating employee hold the corresponding shares purchased under the ESPP for one year from the purchase date. The participating employee is granted one RSA for each share purchased in the ESPP. We initially measure the fair value of these RSAs based on the grant date fair value determined using the closing price of our common stock on the date the purchase of the corresponding ESPP shares is made. This fair value of the RSA is amortized over the one-year holding period. As a result of the RSA’s being reported as liability-classified awards, they must be remeasured at each reporting date until settlement. Ultimately, the compensation cost recognized for the RSA award will equal the fair value of the Company’s common stock on the date the RSA is fully vested and settled. See Note 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred Stock and Stockholders’ Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regarding our ESPP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes in accordance with ASC 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASC 740”), which requires recognition of deferred tax assets and liabilities for the expected tax consequences of our future financial and operating activities. Under ASC 740, we determine deferred tax assets and liabilities based on the temporary difference between the financial statement and tax bases of assets and liabilities using the tax rates in effect for the year in which we expect such differences to reverse. If we determine that it is more likely than not that we will not generate sufficient taxable income to realize the value of some or all of our deferred tax assets (net of our deferred tax liabilities), we establish a valuation allowance offsetting the amount we do not expect to realize. We perform this analysis each reporting period and reduce our measurement of deferred taxes if the likelihood we will realize them becomes uncertain.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deferred tax assets that we record each period depend primarily on our ability to generate future taxable income in the United States. Each period, we evaluate the need for a valuation allowance against our deferred tax assets and, if necessary, adjust the valuation allowance so that net deferred tax assets are recorded only to the extent we conclude it is more likely than not that these deferred tax assets will be realized. If our outlook for future taxable income changes significantly, our assessment of the need for, and the amount of, a valuation allowance may also change.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also required to evaluate and quantify other sources of taxable income, such as the possible reversal of future deferred tax liabilities, should any arise, and the implementation of tax planning strategies. Evaluating and quantifying these amounts is difficult and involves significant judgment, based on all of the available evidence and assumptions about our future activities.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for uncertain tax positions in accordance with ASC 740, which requires us to adjust our consolidated financial statements to reflect only those tax positions that are more-likely-than-not to be sustained upon review by federal or state examiners. We recognize in the consolidated financial statements the largest expected tax benefit that has a greater than 50 percent likelihood of being sustained on examination by the taxing authorities. We report interest and penalties related to unrecognized tax benefits as income tax expense.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-09, which requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. This ASU is effective for public companies with annual periods beginning after December 15, 2024, with early adoption permitted. We plan to adopt this guidance for the fiscal year ending December 31, 2025. We are currently evaluating the effects adoption of this guidance will have on the consolidated financial statements.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU No. 2023-07, to improve the disclosures about a public entity’s reportable segments and address requests from investors for additional, more detailed information about a reportable segment’s expenses. The standard is effective for public companies with annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 with early adoption permitted. We plan to adopt this guidance for the fiscal year ending December 31, 2024. We are currently evaluating the effects adoption of this guidance will have on the consolidated financial statements.</span></div> 4 1000 <div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”).</span></div> <div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements include the financial position and results of operations of Corcept Therapeutics UK Limited, our wholly owned subsidiary, which we incorporated in the United Kingdom in March 2017. All material intercompany balances and transactions have been eliminated in consolidation.</span></div> <div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reevaluate our estimates and assumptions each quarter, including those related to revenue recognition, recognition and measurement of income tax assets and liabilities, inventory, allowances for doubtful accounts and other accrued liabilities, including our bonus accrual, clinical trial accruals and stock-based compensation.</span></div> <div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We value financial instruments using assumptions we believe third-party market participants would use. When choosing which assumptions to make when determining the value of a financial instrument, we look first for quoted prices in active markets for identical instruments (“Level 1 inputs”). If no Level 1 inputs are available, we consider (i) quoted prices in non-active markets for identical instruments; (ii) active markets for similar instruments; (iii) inputs other than quoted prices for the instrument; and (iv) inputs that are not directly observable, but that can be corroborated by observable data (“Level 2 inputs”). In the absence of Level 2 inputs, we rely on unobservable inputs, such as our estimates of the assumptions market participants would use in pricing the instrument (“Level 3 inputs”).</span></div> <div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents and Marketable Securities</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider highly liquid investments that will mature in three months or less from the time we purchase them to be cash equivalents. Cash equivalents are valued using Level 1 inputs, which approximate our cost.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest the majority of our funds in marketable securities, primarily corporate notes, U.S. Treasury and government agency securities, asset-backed securities and commercial paper. We classify our marketable securities as available-for-sale securities and report them at fair value as “cash equivalents” or “marketable securities” on our consolidated balance sheet, with related unrealized gains and losses included in stockholders' equity. Realized gains and losses and permanent declines in value are included in “interest and other income (expense)” on our consolidated statements of income.</span></div> <div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit and Concentration Risks</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash, cash equivalents and marketable securities are held in four financial institutions. We are subject to credit risk from our cash equivalents and marketable securities. We limit our investments to U.S. Treasury obligations and high-grade corporate debt and asset-backed securities with less than a 36-month maturity at the time of purchase. These investments are diversified and do not expose us to concentrations of credit risk. We have never experienced a loss in, or lack of access to, our operating or investment accounts.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an agreement with one third-party manufacturer to supply mifepristone, the active pharmaceutical ingredient (“API”), in Korlym.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a concentration of risk in regard to the distribution of our product. A single specialty pharmacy, Optime Care, Inc. (“Optime”), dispenses Korlym to patients for us. Optime is an independent third party. Its unwillingness or inability to dispense Korlym to patients in a timely manner would harm our business.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell Korlym that Optime dispenses directly to patients, with title to the medicine passing directly from us to the patient upon the patient’s receipt of the drug. Our receivables risk is spread among various third-party payers – pharmacy benefit managers, insurance companies, government programs and private charities. We monitor our exposure and record an allowance against uncollectible trade receivables as necessary. To date, we have not recorded an allowance for credit losses.</span></div> <div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory and Cost of Sales</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory approval of product candidates is uncertain. Because product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained, we record the cost of manufacturing our product candidates as research and development expense at the time such costs are incurred. Once a product candidate is approved by the FDA, we begin capitalizing manufacturing costs. We capitalize to inventory manufacturing costs related to Korlym.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We value inventory at the lower of cost or net realizable value and determine the cost of inventory we sell using the specific identification method, which approximates a first-in, first-out basis. We assess our inventory levels at each reporting period and write down inventory that is either expected to be at risk of expiration prior to sale, has a cost basis in excess of its expected net realizable value, or for which there are inventory quantities in excess of expected requirements. We destroy expired inventory and recognize the related costs as cost of sales in that period’s statement of income.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales also includes the cost of manufacturing Korlym, including materials, third-party manufacturing costs and indirect personnel and other overhead costs, based on the number of Korlym tablets for which we recognize revenue, as well as costs of stability testing, logistics and distribution.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify inventory we do not expect to sell within 12 months of the balance sheet date as strategic inventory, a non-current asset.</span></div> <div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Product Revenue</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell Korlym directly to patients through a single specialty pharmacy. We also sell Korlym to a specialty distributor (“SD”), for which we recognize revenue at the time the SD receives Korlym. SD sales were less than one percent of our net revenue in each of the years ended December 31, 2023, 2022 and 2021.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine our revenue from the sale of Korlym, we (i) identify our contract with each customer; (ii) identify the obligations of Corcept and the customer under the contract; (iii) determine the contracted transaction price; (iv) allocate the transaction price to the contract’s performance obligations, which in our case consists of delivering Korlym to the customer; and (v) recognize revenue once Korlym has been delivered, provided we deem it probable that we will collect the payment due to us.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Confirmation of coverage by private or government insurance or by a third-party charity is a prerequisite for selling Korlym to a patient.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine net product revenue, we deduct from sales the cost of our patient co-pay assistance program and our estimates of (a) government chargebacks and rebates, (b) discounts provided to our SD for prompt payment and (c) reserves for expected returns. We record these estimates at the time we recognize revenue and update them as new information becomes available. Our estimates take into account our understanding of the range of possible outcomes. If results differ from our estimates, we adjust our estimates, which changes our net product revenue and earnings. We report any changes in the period they become known, even if they concern transactions occurring in prior periods.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Korlym is eligible for purchase by, or qualifies for reimbursement from, Medicaid, Medicare and other government programs that are eligible for rebates on the price they pay for Korlym. To determine the appropriate amount to reserve against these rebates, we identify Korlym sold to patients covered by government-funded programs, apply the applicable government discount to these sales, then estimate utilization of such programs by government payors. We (i) deduct this reserve from revenue in the period to which the rebates relate and (ii) include in accrued expenses on our consolidated balance sheet a current liability of an equal amount.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Although we sell Korlym to the SD at full price, some of the government entities to which the SD sells receive a discount. The SD recovers the full amount of any related discounts by reducing its payment to us (this reduction is called a “chargeback”). Chargebacks sometimes relate to Korlym purchased by the SD in prior periods. We deduct from our revenue in each period chargebacks claimed by the SD for Korlym it purchased in that period. We also create a reserve for chargebacks we estimate the SD will claim in future periods against Korlym it purchased in the current period but has not yet resold. We determine the amount of this reserve based on our experience with SD chargebacks and our understanding of the SD’s customer base and business practices. We deduct this reserve from revenue and include in accrued expenses on our consolidated balance sheet a current liability of equal amount.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient Assistance Program and Charitable Support: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is our policy that no patient be denied Korlym due to inability to pay. We provide financial assistance to eligible patients whose insurance policies have high deductibles or co-payments and deduct the amount of such assistance from gross revenue. We determine the assistance we provide each patient by applying our program guidelines to that patient’s financial position and their insurance policy’s co-payment and deductible requirements for the purchase of Korlym. We donate cash to charities that help patients with financial need pay for the treatment of Cushing’s syndrome. We do not include payments from these charities in revenue, but as a deduction to selling, general and administrative expenses. We provide Korlym at no cost to uninsured patients who do not qualify for charitable support.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales Returns:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Federal law prohibits the return of Korlym sold to patients. Sales to our SD are subject to return. We deduct the amount of Korlym we estimate the SD will return from each period’s gross revenue. We base our estimates on quantitative and qualitative information including, but not limited to, historical return rates, the amount of Korlym held by the SD and projected demand. If we cannot reasonably estimate returns with respect to a particular sale, we defer recognition of revenue until we can make a reasonable estimate. To date, returns have not been significant.</span></div> 0.01 0.01 0.01 <div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity in each of the product revenue allowance and reserve categories for the years ended December 31, 2023, 2022 and 2021:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:60.043%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.365%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Government Rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,412 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,575 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to current period sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,709 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to prior period sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,047)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,076)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit or payments made during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(478)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,900)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,378)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,174 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,224 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to current period sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,745 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,302 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to prior period sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit or payments made during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(455)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,753)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,208)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,098 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,328 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to current period sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,825 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,171 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to prior period sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(555)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(643)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit or payments made during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(266)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,900)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,166)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,468 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,690 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 163000 9412000 9575000 394000 33709000 34103000 29000 1047000 1076000 478000 30900000 31378000 50000 11174000 11224000 557000 38745000 39302000 -78000 68000 -10000 455000 38753000 39208000 230000 11098000 11328000 346000 52825000 53171000 88000 555000 643000 266000 44900000 45166000 222000 18468000 18690000 <div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense includes the direct cost of discovering and screening new compounds, pre-clinical studies, clinical trials, manufacturing development, submissions to regulatory agencies and related overhead costs. We expense nonrefundable payments and the cost of technologies and materials used in research and development as we incur them.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base our accruals for discovery research, preclinical studies and clinical trials on our estimates of work completed, milestones achieved, patient enrollment and past experience with similar activities. Our estimates include assessments of information from contract research organizations and the status of our own research, development and administrative activities.</span></div> <div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our operating segments based on the way we organize our business, make decisions and assess performance. We have one operating segment, which is the discovery, development and commercialization of pharmaceutical products.</span></div> 1 <div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize stock-based compensation expense for stock options, restricted stock awards (“RSAs”) and restricted stock units (“RSUs”), net of estimated forfeitures, on a straight-line basis over the period during which an employee is required to provide services in exchange for the award (the vesting period of the award). We estimate future forfeitures during the first quarter of each fiscal year, and revise the estimates, if necessary, in subsequent periods if actual forfeitures differ significantly from those estimates.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the fair value of stock options based on the value of the award at the grant date, using the Black-Scholes model. We recognize stock-based compensation expense over the applicable vesting period, net of estimated forfeitures. If actual forfeitures differ from our estimates, we adjust stock-based compensation expense accordingly.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have issued RSAs in connection with our Employee Stock Purchase Plan (“ESPP”) that vest on the condition that the participating employee hold the corresponding shares purchased under the ESPP for one year from the purchase date. The participating employee is granted one RSA for each share purchased in the ESPP. We initially measure the fair value of these RSAs based on the grant date fair value determined using the closing price of our common stock on the date the purchase of the corresponding ESPP shares is made. This fair value of the RSA is amortized over the one-year holding period. As a result of the RSA’s being reported as liability-classified awards, they must be remeasured at each reporting date until settlement. Ultimately, the compensation cost recognized for the RSA award will equal the fair value of the Company’s common stock on the date the RSA is fully vested and settled. See Note 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred Stock and Stockholders’ Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regarding our ESPP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div> P1Y 1 P1Y <div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes in accordance with ASC 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASC 740”), which requires recognition of deferred tax assets and liabilities for the expected tax consequences of our future financial and operating activities. Under ASC 740, we determine deferred tax assets and liabilities based on the temporary difference between the financial statement and tax bases of assets and liabilities using the tax rates in effect for the year in which we expect such differences to reverse. If we determine that it is more likely than not that we will not generate sufficient taxable income to realize the value of some or all of our deferred tax assets (net of our deferred tax liabilities), we establish a valuation allowance offsetting the amount we do not expect to realize. We perform this analysis each reporting period and reduce our measurement of deferred taxes if the likelihood we will realize them becomes uncertain.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deferred tax assets that we record each period depend primarily on our ability to generate future taxable income in the United States. Each period, we evaluate the need for a valuation allowance against our deferred tax assets and, if necessary, adjust the valuation allowance so that net deferred tax assets are recorded only to the extent we conclude it is more likely than not that these deferred tax assets will be realized. If our outlook for future taxable income changes significantly, our assessment of the need for, and the amount of, a valuation allowance may also change.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also required to evaluate and quantify other sources of taxable income, such as the possible reversal of future deferred tax liabilities, should any arise, and the implementation of tax planning strategies. Evaluating and quantifying these amounts is difficult and involves significant judgment, based on all of the available evidence and assumptions about our future activities.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for uncertain tax positions in accordance with ASC 740, which requires us to adjust our consolidated financial statements to reflect only those tax positions that are more-likely-than-not to be sustained upon review by federal or state examiners. We recognize in the consolidated financial statements the largest expected tax benefit that has a greater than 50 percent likelihood of being sustained on examination by the taxing authorities. We report interest and penalties related to unrecognized tax benefits as income tax expense.</span></div> <div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-09, which requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. This ASU is effective for public companies with annual periods beginning after December 15, 2024, with early adoption permitted. We plan to adopt this guidance for the fiscal year ending December 31, 2025. We are currently evaluating the effects adoption of this guidance will have on the consolidated financial statements.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU No. 2023-07, to improve the disclosures about a public entity’s reportable segments and address requests from investors for additional, more detailed information about a reportable segment’s expenses. The standard is effective for public companies with annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 with early adoption permitted. We plan to adopt this guidance for the fiscal year ending December 31, 2024. We are currently evaluating the effects adoption of this guidance will have on the consolidated financial statements.</span></div> Significant Agreements<div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial Agreement</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2017, we entered into a distribution services agreement with an independent third party, Optime, to provide exclusive specialty pharmacy and patient services programs for Korlym beginning August 10, 2017. Under the terms of this agreement, Optime acts as the exclusive specialty pharmacy distributor of Korlym in the United States, subject to certain exceptions. Optime provides services related to pharmacy operations; patient intake, access and reimbursement; patient support; claims management and accounts receivable; and data and reporting. We provide Korlym to Optime, which it dispenses to patients. Optime does not purchase Korlym from us and it does not take title to the product. Title passes directly from us to the patient at the time the patient receives the medicine.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial term of our agreement with Optime was five years. In August 2022, we amended our agreement to extend its term to September 30, 2022. In September 2022, we amended our agreement to further extend its term to March 31, 2024, unless terminated earlier by us upon 90 days’ notice. The agreement contains additional customary termination provisions, representations, warranties and covenants. Subject to certain limitations, we have agreed to indemnify Optime for certain third-party claims related to the product, and we have each agreed to indemnify the other for certain breaches of representations, warranties, covenants and other specified matters.</span></div> P5Y Available for Sale Marketable Securities and Fair Value Measurements<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The available-for-sale securities in our Consolidated Balance Sheets are as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,170 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,380 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,670 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,343 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,176 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,947 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387,016 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406,670 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our available-for-sale securities grouped by asset type:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:15.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.542%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value<br/>Hierarchy<br/>Level</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120,508 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120,815 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151,069 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(625)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,444 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75,308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75,319 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136,132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136,132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,113 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93,655 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93,712 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,536 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,394 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97,170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97,170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">386,641 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">388 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">387,016 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">407,414 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(767)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">406,670 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of marketable securities classified as Level 1 using quoted market prices obtained from a commercial pricing service for these or identical investments. We estimate the fair value of marketable securities classified as Level 2 using inputs that may include benchmark yields, reported trades, broker/dealer quotes and issuer spreads.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically review our debt securities to determine if any of our investments is impaired due to the issuer’s poor credit or other reasons. If the fair value of our investment is less than our amortized cost, we evaluate quantitative and subjective factors – including, but not limited to, the nature of security, changes in credit ratings and analyst reports concerning the security’s issuer and industry, and interest rate fluctuations and general market conditions – to determine whether an allowance for credit losses is appropriate.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of our investments, including those with unrealized losses, are impaired. Unrealized losses on our investments are due to interest rate fluctuations. We do not intend to sell investments that currently have unrealized losses and it is highly unlikely that we will sell any investment before recovery of its amortized cost basis, which may be at maturity. Accordingly, we have not recorded an allowance for credit losses for these investments.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classified accrued interest on our marketable securities of $1.7 million and $1.8 million as of December 31, 2023 and 2022, respectively, as prepaid and other current assets on our consolidated balance sheets.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, all our marketable securities had original maturities of no more than 27 months and all our marketable securities classified as short-term have maturities of less than one year. The weighted-average maturity of our holdings was seven months. As of December 31, 2023, our long-term marketable securities had remaining maturities between 13 months and 22 months. None of our marketable securities changed from one fair value hierarchy to another during the year ended December 31, 2023.</span></div> <div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The available-for-sale securities in our Consolidated Balance Sheets are as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,170 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,380 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,670 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,343 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,176 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,947 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387,016 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406,670 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 97170000 36380000 232670000 365343000 57176000 4947000 387016000 406670000 <div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our available-for-sale securities grouped by asset type:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:15.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.542%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value<br/>Hierarchy<br/>Level</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120,508 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120,815 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151,069 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(625)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,444 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75,308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75,319 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136,132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136,132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,113 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93,655 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93,712 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,536 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,394 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97,170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97,170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">386,641 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">388 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">387,016 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">407,414 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(767)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">406,670 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 120508000 307000 0 120815000 151069000 0 625000 150444000 75308000 20000 9000 75319000 136132000 0 0 136132000 0 0 0 0 25113000 23000 0 25136000 0 0 0 0 185000 0 0 185000 93655000 61000 4000 93712000 58536000 0 142000 58394000 97170000 0 0 97170000 36379000 0 0 36379000 386641000 388000 13000 387016000 407414000 23000 767000 406670000 1700000 1800000 P27M P1Y P7M P13M P22M Composition of Certain Balance Sheet Items<div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,233 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,827 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,741 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,204 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,974 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,031 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less strategic inventory classified as non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,244)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,931)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory classified as current</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,730 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we rely on one manufacturer to produce Korlym’s API, we have purchased and hold significant quantities of API, included in work in progress inventory. We classify inventory we do not expect to sell within 12 months of the balance sheet date as “Strategic inventory,” a non-current asset.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other liabilities</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,457 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,511 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government rebates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,098 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,814 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued selling and marketing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,771 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued Manufacturing Costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,455 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excise tax payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,673 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued and other liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,628 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,799 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other assets</span></div>As of December 31, 2023 and 2022, other assets included $6.4 million and $4.9 million of deposits for clinical trials, respectively. <div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,233 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,827 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,741 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,204 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,974 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,031 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less strategic inventory classified as non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,244)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,931)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory classified as current</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,730 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 8233000 7827000 7741000 9204000 15974000 17031000 8244000 10931000 7730000 6100000 <div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other liabilities</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,457 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,511 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government rebates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,098 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,814 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued selling and marketing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,771 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued Manufacturing Costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,455 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excise tax payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,673 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued and other liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,628 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,799 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 25457000 15511000 18468000 11098000 1814000 89000 1771000 434000 1455000 20000 1078000 0 542000 2673000 389000 211000 654000 763000 51628000 30799000 6400000 4900000 Leases<div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease our office facilities in Menlo Park, California. On April 1, 2023, we signed an amendment to extend our lease through June 30, 2024. As a result of this amendment, we recognized an additional right-of-use asset and corresponding lease liability of $0.3 million in the year ended December 31, 2023. The right-of-use asset and lease liability recognized equals the present value of the remaining payments due under our amended lease.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the operating lease for our facilities does not expressly state an interest rate, we calculated the present value of remaining lease payments using a discount rate equal to the interest rate we would pay on a collateralized loan with monthly payments and a term equal to the monthly payments and remaining term of our lease. We recognize operating lease payments as expenses using the straight-line method over the term of the lease.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease expense for the years ended December 31, 2023, 2022 and 2021 was $2.4 million, $2.3 million and $2.1 million, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our right-of-use assets and related lease liabilities were as follows (in thousands, except weighted average amounts):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.213%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.454%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating lease liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,391 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,265 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of right-of-use asset in exchange for lease liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,816 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 months</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, future minimum lease payments under non-cancelable operating leases were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, future minimum lease payments under non-cancellable short-term leases were $1.1 million for 2024. We do not recognize right-of-use assets or lease liabilities for leases with a term of twelve months or less, rather, we recognize the associated lease payments in the condensed consolidated statements of income on a straight-line basis over the lease term.</span></div> 300000 300000 2400000 2300000 2100000 <div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our right-of-use assets and related lease liabilities were as follows (in thousands, except weighted average amounts):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.213%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.454%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating lease liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,391 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,265 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of right-of-use asset in exchange for lease liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,816 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 months</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 2391000 2265000 297000 2816000 P6M P6M 0.080 0.040 <div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, future minimum lease payments under non-cancelable operating leases were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 155000 155000 4000 151000 1100000 Related Party Transactions<div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no related party transactions during the years ended December 31, 2023, 2022, and 2021.</span></div> Preferred Stock and Stockholders’ Equity<div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors is authorized, subject to any limitations prescribed by law, without stockholder approval, to issue up to an aggregate of 10.0 million shares of preferred stock at $0.001 par value in one or more series and to fix the rights, preferences, privileges and restrictions granted to or imposed upon the preferred stock, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences. The rights of the holders of common stock will be subject to the rights of holders of any preferred stock that may be issued in the future. As of December 31, 2023 and 2022, we had no outstanding shares of preferred stock.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Treasury Stock</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, we announced that our Board of Directors approved a tender offer to purchase up to 7.5 million shares of our common stock. The tender offer commenced on March 6, 2023 and expired on March 31, 2023. On April 5, 2023, we purchased 6.6 million shares through the tender offer at a price of $22.00 per share for an aggregate purchase price of $145.4 million, excluding related fees and expenses. We recorded purchased shares as treasury stock on our condensed consolidated balance sheet at cost.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, we announced that our Board of Directors approved a tender offer to purchase up to 10 million shares of our common stock. The tender offer commenced on November 8, 2021 and expired on December 15, 2021. We repurchased 10 million shares through the tender offer at a price of $20.75 per share for an aggregate purchase price of $207.5 million, excluding fees and expenses relating to the tender offer. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, we announced that our Board of Directors approved a program to repurchase up to $200 million of our common stock (the “Stock Repurchase Program”). The terms of this program did not require us to acquire any shares and allowed for repurchases by a variety of methods, including open market purchases, privately negotiated transactions, block trades, accelerated share repurchase transactions or any combination of such methods. The Stock Repurchase Program expired by its terms on September 30, 2021. During the year ended December 31, 2021, we purchased 3.9 million shares of common stock under the Stock Repurchase Program in open market transactions at an average price of $22.88 per share, for aggregate purchase price of $88.5 million.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2023, 2022 and 2021, we issued 2.4 million, 3.7 million and 4.6 million shares, respectively, of our common stock upon the exercise of stock options. Some option holders exercised their options on a “net exercise” basis, pursuant to which they surrendered to us, and we purchased from them, at the then current market price, shares equal in value to the associated exercise price and tax withholding obligations. During the years ended December 31, 2023, 2022 and 2021, we purchased 1.2 million, 1.8 million and 1.6 million shares, respectively, in connection with such option net exercises and paid $7.4 million, $21.3 million and $22.8 million, respectively, to satisfy associated tax withholding obligations.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded purchased shares as treasury stock on our consolidated balance sheets, at cost. It has not been determined whether purchased shares will be retired or sold.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any dividends.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Incentive Award Plan</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have one stock option plan – the Corcept Therapeutics Incorporated 2012 Incentive Award Plan (the “2012 Plan”).</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012, our Board of Directors and stockholders approved the 2012 Plan. Under the 2012 Plan, we can issue options, stock purchase and stock appreciation rights, and restricted stock awards to our employees, officers, directors and consultants. The 2012 Plan provides that the exercise price for incentive stock options will be no less than 100 percent of the fair value of our common stock as of the date of grant. Options granted under the 2012 Plan carry a contractual term of ten years and are </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expected to vest over periods ranging from one year to four years. We assume the vesting period of the options that we grant under the 2012 Plan to be equal to the option grantee’s period of service.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, we had 7.7 million shares available for future issuance under the 2012 plan.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Option activity during 2023</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes option activity under the 2012 Plan:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.334%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding Options</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,198 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,178 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,355)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options cancelled and forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(651)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,370 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.79</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374,129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,924 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323,814 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options fully vested and expected to vest at<br/>December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,149 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,158 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of options exercised during the years ended December 31, 2023, 2022 and 2021 was $36.0 million, $63.4 million and $78.9 million, respectively, based on the difference between the closing price of our common stock on the date of exercise and the exercise price.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of options that vested during the years ended December 31, 2023, 2022 and 2021 was $42.4 million, $43.2 million and $40.4 million, respectively.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, we had $67.3 million of unrecognized compensation expense for options outstanding, which had a weighted-average remaining vesting period of 2.35 years.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RSA and RSU (collectively, “restricted stock”) activity during 2023</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restricted stock activity under the 2012 Plan:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.334%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding Restricted Stock</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Restricted Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Remaining Vesting Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.91 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.04 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock cancelled and forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.73</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,910 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, we had $14.9 million of unrecognized compensation expense for restricted stock outstanding, which had a weighted-average remaining vesting period of 2.66 years.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ESPP</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we adopted an ESPP that allows employees to set aside, by means of payroll deductions, up to ten percent of their annual compensation for the purchase of our common stock. Shares are issued to participating employees from the 2012 Plan on March 1st and September 1st of each year (or, if those dates fall on holidays or weekends, on the first business day thereafter) at the then-current fair market value of our stock, as determined at the close of trading on those days. Payroll deductions for participating employees began April 1, 2022, and the first purchase under the plan took place on September 1, 2022.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we increased the number of ESPP purchase dates to occur quarterly on March 1st, June 1st, September 1st and December 1st (or, if those dates fall on holidays or weekends, on the first business day thereafter).</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each purchased share, the participating employee will receive one matching share, also issued from the 2012 Plan, if certain conditions are met. There is no vesting requirement for shares issued pursuant to the ESPP purchase. The matching share will be granted in the form of a RSA that will vest on the one-year anniversary of the respective ESPP purchase date, net of applicable tax withholding. The vesting condition on the RSA is that the participating employee hold the corresponding share purchased under the ESPP for one year from the purchase date. Shares purchased pursuant to the ESPP and any matching shares issued upon satisfaction of the one-year holding requirement may be held, sold or transferred at the employee’s sole discretion.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023 and 2022, we recorded $3.2 million and $0.2 million, respectively, of stock-based compensation related to RSAs granted in connection with our ESPP in “Accrued and other liabilities” on our consolidated balance sheet.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Option Valuation Assumptions</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted-average assumptions and resultant fair value-based measurements for options granted.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:60.043%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.365%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average assumptions for options granted:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.87%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.97%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.76%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility of stock price</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.5%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.7%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value-based measurement</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$13.65</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.27</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.06</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term of options reflected in the table above is based on a formula that considers the expected service period and expected post-vesting termination behavior depending on whether the option holder is an employee, officer or director.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected volatility of our stock used in determining the fair value-based measurement of option grants to employees, officers and directors is based on the volatility of our stock price. The volatility is based on historical data of the price for our common stock for periods of time equal to the expected term of these grants.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate employee stock-based compensation expense using the number of options we expect to vest, based on our estimate of the option grantees’ average length of employment, and reduced by our estimate of option forfeitures. We estimate forfeitures at the time of option grant and revise this estimate in subsequent periods if actual forfeitures differ from our estimates.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our stock-based compensation by financial statement classification.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:60.043%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.365%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation capitalized in inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,402 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,106 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,486 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,572 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,766 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,148 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,722 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,168 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 10000000 0.001 0 0 7500000 6600000 22.00 145400000 10000000 10000000 20.75 207500000 200000000 3900000 22.88 88500000 2400000 3700000 4600000 1200000 1800000 1600000 7400000 21300000 22800000 1 1 P10Y P1Y P4Y 7700000 <div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes option activity under the 2012 Plan:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.334%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding Options</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,198 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,178 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,355)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options cancelled and forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(651)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,370 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.79</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374,129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,924 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323,814 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options fully vested and expected to vest at<br/>December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,149 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,158 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 23198000 15.13 3178000 23.49 2355000 11.47 651000 21.16 23370000 16.47 P5Y9M14D 374129000 17924000 14.41 P5Y 323814000 23149000 16.40 P5Y9M3D 372158000 36000000 63400000 78900000 42400000 43200000 40400000 67300000 P2Y4M6D <div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restricted stock activity under the 2012 Plan:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.334%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding Restricted Stock</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Restricted Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Remaining Vesting Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.91 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.04 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock cancelled and forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.73</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,910 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 455000 23.91 659000 24.04 184000 23.87 103000 23.26 827000 24.10 P2Y8M23D 4910000 14900000 P2Y7M28D 0.10 1 P1Y P1Y P1Y 3200000 200000 <div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the weighted-average assumptions and resultant fair value-based measurements for options granted.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:60.043%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.365%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average assumptions for options granted:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.87%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.97%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.76%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility of stock price</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.5%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.7%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value-based measurement</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$13.65</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.27</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.06</span></td></tr></table></div> 0.0387 0.0197 0.0076 P6Y8M12D P6Y4M24D P6Y3M18D 0.530 0.565 0.607 0 0 0 13.65 11.27 15.06 <div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our stock-based compensation by financial statement classification.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:60.043%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.365%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation capitalized in inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,402 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,106 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,486 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,572 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,766 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,148 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,722 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,168 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 208000 280000 237000 52000 70000 59000 15402000 12800000 14106000 33486000 29572000 28766000 49148000 42722000 43168000 Net Income Per Share<div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compute our basic and diluted net income per share in conformity with the two-class method required for companies with participating shares. Under the two-class method, net income is determined by allocating net income between common stock and unvested RSAs. We compute basic net income per share by dividing our net income attributable to common stockholders by the weighted-average number of common shares outstanding during the period. We compute diluted net income per share by dividing our net income attributable to common stockholders by the weighted-average number of common shares outstanding during the period, including potentially dilutive stock options and unvested RSUs, less unvested RSAs. We use the treasury stock method to determine the number of dilutive shares of common stock resulting from stock options and unvested RSUs.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the computation of net income per share for each period:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:60.043%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.365%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except per share data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to common stockholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,496 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,512 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used to compute basic net income per common share</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,787 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,653 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of employee stock options and unvested RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,182 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,179 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,310 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used to compute diluted net income per common share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,742 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,966 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,963 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to common stockholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.02 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.94 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.87 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.89 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We excluded from the computation of diluted net income per share, on a weighted-average basis, 9.1 million stock options and unvested RSUs outstanding during the year ended December 31, 2023, and 7.3 million and 4.5 million stock options outstanding during the years ended December 31, 2022 and 2021, respectively, because including them would have reduced dilution.</span></div> <div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the computation of net income per share for each period:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:60.043%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.365%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except per share data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to common stockholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,496 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,512 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used to compute basic net income per common share</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,787 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,653 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of employee stock options and unvested RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,182 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,179 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,310 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used to compute diluted net income per common share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,742 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,966 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,963 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to common stockholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.02 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.94 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.87 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.89 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 105496000 101288000 112512000 103560000 106787000 115653000 8182000 9179000 10310000 111742000 115966000 125963000 1.02 0.95 0.97 0.94 0.87 0.89 9100000 7300000 4500000 Income Taxes<div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The domestic and foreign components of income before income taxes were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:64.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.913%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,691 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,871 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,134)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(680)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,302)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,557 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,191 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,006 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax expense for the years ended December 31, 2023, 2022, and 2021 consisted of the following:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.868%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal taxes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,675 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,613)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,122)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,066 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total U.S. federal taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,652 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,010 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,741 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,590 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,515 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,432 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,645)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,313)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total state taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,945 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,202 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,158 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign taxes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,236)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(446)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total foreign taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,180)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(439)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(405)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,417 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,773 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,494 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2022, the Tax Cuts and Jobs Act of 2017 eliminates the right to deduct research and development expenditures for tax purposes in the period the expenses were incurred and instead requires all U.S. and foreign research and development expenditures to be amortized over five and fifteen tax years, respectively. Congress has considered legislation that would defer the amortization requirement to later years, but as of December 31, 2023, the requirement has not been modified. Accordingly, we have capitalized our research and development expenses for tax purposes, resulting in higher cash paid for taxes as compared to prior years.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets are as follows:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and state net operating losses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,942 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,882 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and patent costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,911 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,465 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,682 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,963 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,676 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,956 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,577 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,127 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,582 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,584 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,947)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,839)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,605 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,465 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each quarter, we assess the likelihood that we will generate sufficient taxable income to use our federal and state deferred tax assets. Except for the valuation allowances that offset our California net deferred tax assets, we have determined that it is more likely than not we will realize the benefit related to all other deferred tax assets. To the extent we increase a valuation allowance, we will include an expense in the Consolidated Statement of Income in the period in which such determination is made.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation allowance increased by $1.1 million, $1.9 million and $1.4 million for the years ended December 31, 2023, 2022 and 2021, respectively.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, we had California net operating loss carryforwards of $55.6 million, which will begin to expire in the year 2032, and net operating loss carryforwards from other states of $0.7 million, which will begin to expire in the year 2035 if not utilized.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, we also had California research and development credits of $16.8 million, which have no expiration date.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation from the statutory federal income tax rate to the effective rate.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:60.043%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.365%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal taxes at statutory rate</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,157 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,251 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D and other credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,508)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,579)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,897 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,320 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,495 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,295 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,354 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,951)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,980)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,568)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(473)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,417 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,773 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,494 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain liabilities for uncertain tax positions. The measurement of these liabilities involves considerable judgment and estimation and are continuously monitored by management based on the best information available, including changes in tax regulations, the outcome of relevant court cases, and other pertinent information.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate annual changes in the balance of gross unrecognized tax benefits are as follows:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:60.043%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.365%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,425 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,237 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,471 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in tax positions for prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases in tax positions for prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(205)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in tax positions for expirations of statute of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(750)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in tax positions for current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,440 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,135 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,663 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in tax positions for current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,022 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,425 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,237 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the amount of unrecognized tax benefits that would favorably impact the effective tax rate were approximately $10.2 million, and approximately $2.8 million of unrecognized tax benefits would be offset by a change in the valuation allowance. A valuation allowance is maintained on the remaining tax benefits related to California deferred tax assets and would not impact the effective tax rate. We had no or insignificant amounts of accrued interest and no accrued penalties related to unrecognized tax benefits as of December 31, 2023, 2022 and 2021. We do not expect our unrecognized tax benefits to change materially over the next 12 months.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe we have adequately provided for all tax positions, amounts asserted by tax authorities could be greater or less than the recorded position. Accordingly, our provisions on federal and state tax-related matters to be recorded in the future may change as revised estimates are made or the underlying matters are settled or otherwise resolved.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s primary tax jurisdiction is the United States. For federal tax purposes, the years 2022 through 2023 remain open and subject to tax examination. For US state tax purposes, the years 2004 through 2023 generally remain open and subject to tax examination by the appropriate state taxing authorities.</span></div> <div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The domestic and foreign components of income before income taxes were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:64.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.913%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,691 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,871 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,134)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(680)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,302)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,557 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,191 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,006 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 125691000 116871000 126308000 -1134000 -680000 -1302000 124557000 116191000 125006000 <div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax expense for the years ended December 31, 2023, 2022, and 2021 consisted of the following:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.868%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal taxes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,675 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,613)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,122)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,066 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total U.S. federal taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,652 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,010 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,741 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,590 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,515 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,432 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,645)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,313)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total state taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,945 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,202 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,158 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign taxes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,236)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(446)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total foreign taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,180)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(439)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(405)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,417 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,773 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,494 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 40265000 39132000 4675000 -25613000 -28122000 5066000 14652000 11010000 9741000 7590000 9515000 3432000 -2645000 -5313000 -274000 4945000 4202000 3158000 56000 30000 41000 -1236000 -469000 -446000 -1180000 -439000 -405000 18417000 14773000 12494000 Significant components of our deferred tax assets are as follows:<div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and state net operating losses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,942 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,882 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and patent costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,911 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,465 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,682 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,963 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,676 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,956 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,577 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,127 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,582 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,584 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,947)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,839)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,605 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,465 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div> 3942000 4882000 908000 1911000 61760000 36465000 11682000 9963000 21676000 17956000 37000 280000 6577000 5127000 106582000 76584000 15947000 14839000 30000 280000 30000 280000 90605000 61465000 1100000 1900000 1400000 55600000 700000 16800000 <div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation from the statutory federal income tax rate to the effective rate.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:60.043%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.365%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal taxes at statutory rate</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,157 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,251 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D and other credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,508)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,579)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,897 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,320 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,495 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,295 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,354 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,951)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,980)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,568)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(473)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,417 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,773 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,494 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div> 26157000 24400000 26251000 11508000 9114000 7579000 3897000 3320000 2495000 3295000 4354000 990000 2951000 7980000 9568000 -473000 -207000 -95000 18417000 14773000 12494000 <div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate annual changes in the balance of gross unrecognized tax benefits are as follows:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:60.043%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.365%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,425 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,237 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,471 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in tax positions for prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases in tax positions for prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(205)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in tax positions for expirations of statute of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(750)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in tax positions for current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,440 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,135 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,663 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in tax positions for current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,022 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,425 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,237 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div> 11425000 9237000 7471000 112000 53000 103000 205000 0 0 750000 0 0 2440000 2135000 1663000 0 0 0 13022000 11425000 9237000 10200000 2800000 0 0 0 0 0 0 Commitments and Contingencies<div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing Agreements</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an agreement with one third-party manufacturer to supply mifepristone, the active pharmaceutical ingredient (“API”) in Korlym, and two additional third-party manufacturers to produce and bottle Korlym tablets.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, we had a $0.7 million remaining obligation in connection with commitments to purchase API from these third-party manufacturers. In January 2024, to ensure we have sufficient API to meet future demand of Korlym tablets, we committed to purchase an additional $3.0 million of API. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Taxes</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2023</span><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we have recorded non-current taxes payable of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$10.3 million</span><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to uncertain tax positions.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we may be subject to legal claims and regulatory actions that could have a material adverse effect on our business or financial position. We assess our potential liability in such situations by analyzing the possible outcomes of various litigation, regulatory and settlement strategies. If we determine a loss is probable and its amount can be reasonably estimated, we accrue an amount equal to the estimated loss.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Melucci Litigation and Settlement</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 14, 2019, a purported securities class action complaint was filed in the United States District Court for the Northern District of California by Nicholas Melucci (Melucci v. Corcept Therapeutics Incorporated, et al., Case No. 5:19-cv-01372-LHK) (the “Melucci litigation”). The complaint named us and certain of our executive officers as defendants asserting violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder and alleges that the defendants made false and materially misleading statements and failed to disclose adverse facts about our business, operations and prospects. The complaint asserts a putative class period extending from August 2, 2017 to February 5, 2019 and seeks unspecified monetary relief, interest and attorneys’ fees. On October 7, 2019, the Court appointed a lead plaintiff and lead counsel. The lead plaintiff’s consolidated complaint was filed on December 6, 2019.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2023, we reached an agreement in principle (the “Proposed Settlement”) to resolve all claims in the Melucci litigation. Under the Proposed Settlement, we have agreed to make a one-time payment of $14.0 million, which will be covered in full by our insurers. In connection with the Proposed Settlement, we recorded a settlement expense of $14.0 million and corresponding insurance recovery of $14.0 million in Operating Expenses on our Consolidated Statement of Income in the fourth quarter of 2022. Accordingly, we recorded an accrued liability of $14.0 million for this settlement and a corresponding insurance recovery receivable of $14.0 million on our Consolidated Balance Sheet. The Court granted preliminary approval of the Proposed Settlement on January 4, 2024, following which we paid $14.0 million into escrow. Our insurers reimbursed us in full. Payment of any funds out of the designated escrow is pending the Court’s final approval of the Proposed Settlement, a hearing for which is scheduled for June 6, 2024.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other losses and no other provisions for a loss contingency have been recorded to date.</span></div> 700000 3000000 10300000 14000000 14000000 14000000 14000000 14000000 14000000 0 0 Subsequent Events<div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2024, our Board of Directors approved a program authorizing the repurchase of up to $200 million of our common stock. Purchases under this program may be made in the open market, in privately negotiated transactions or otherwise. The timing and amount of any repurchases will be determined based on market conditions, our stock price and other factors. The program does not require us to repurchase any specific number of shares of its common stock and may be modified, suspended or discontinued at any time without notice.</span></div> 200000000